AMERICAN PSYCHIATRIC ASSOCIATION
2000 ANNUAL MEETING
The Doctor-Patient Relationship

APA2000
chicago

MAY 13 - 18, 2000 ■ CHICAGO, ILLINOIS
Dear Colleagues and Guests:

Welcome to the 153rd Annual Meeting of the American Psychiatric Association, the first in the new century. The coming week will highlight the best in our profession in the largest psychiatric meeting in the world. Our meeting has become an outstanding international forum to discuss the latest scientific advances and traditional humane values in psychiatry and how we will continue to integrate these bodies of knowledge to provide excellent patient care into the future.

This year’s Annual Meeting theme is “The Doctor-Patient Relationship.” I chose this theme for the first meeting of the new millennium to highlight the timeless importance of this heart and soul of psychiatry. Many sessions throughout the week will highlight an important aspect of the theme. Please make a special effort to attend the Monday afternoon Presidential Symposium, from 2:00 p.m.-5:00 p.m., entitled, “Perspectives on the Doctor-Patient Relationship.”

I join our colleagues from North America in greeting the thousands of colleagues from other parts of the world who have joined us in Chicago. At the Opening Session, from 5:00 p.m.-6:30 p.m. on Sunday, we will officially welcome the leaders of the World Psychiatric Association and leaders from psychiatric societies in the U.S. and around the world. I look forward to seeing you there and to speaking with you in my Presidential Address.

Please also make sure to attend the Convocation on Monday night where we will honor all those being inducted as fellows and those receiving awards from the APA. A special treat will be the convocation lecture, presented this year by Dr. Bertrand Piccard, the internationally-known psychiatrist who last year completed the first circumnavigation of the earth in a hot air balloon.

Organizing a meeting like ours represents the best in collaboration between our members and our staff. Special congratulations go to Dr. Pedro Ruiz and the members of the Scientific Program Committee, Drs. Nada Stotland and Martin Fine and the members of the Local Arrangements Committee, and to Cathy Nash and her staff in the Office to Coordinate Annual Meetings. The Meetings Management staff have done their usual excellent work in assuring all the arrangements flow seamlessly.

Welcome to Chicago 2000.

Sincerely,

Allan Tasman, M.D.
President
American Psychiatric Association
American Psychiatric Association

1400 K Street, N.W.
Washington, DC 20005
Telephone 202.682.6237
Fax 202.682.6345
E-mail: apa@psych.org
Internet: www.psych.org

May 13, 2000

Dear APA Members and Guests:

Welcome to Chicago, IL, and the 153rd Annual Meeting of the American Psychiatric Association. This exciting city, with its vibrancy, cultural diversity and excitement, provides a perfect setting for the scientific presentations we have planned. As you read through the Program Book, you will notice a number of sessions related to the theme “The Doctor-Patient Relationship,” chosen by our President, Dr. Allan Tasman. I draw your attention to the Presidential Symposium scheduled on Monday at 2:00 p.m., entitled “Perspectives on the Doctor-Patient Relationship.”

The Local Arrangements Committee, under the excellent guidance of its Co-Chairpersons, Dr. Martin Fine and Dr. Nada Stotland, has developed a wide array of activities that will help you take advantage of Chicago. You will notice that a number of activities are designed especially for families and children.

The Business Meeting will be held on Sunday from 12:30 p.m. to 1:30 p.m.; all voting members are encouraged to attend. The Opening Session will be held on Sunday from 5:00 p.m. to 6:30 p.m. Exhibits will be open 11:00 a.m. to 5:00 p.m. on Sunday, 10:00 a.m. to 6:00 p.m. on Monday and Tuesday, and 10:00 a.m. to 3:00 p.m. on Wednesday. The Convocation will begin Monday, May 15, at 7:30 p.m. The Convocation speaker will be Bertrand Piccard, M.D., the French psychiatrist who made recent history by sailing around the world in a hot-air balloon. The Advances in Research session will be held on Monday at 10:30 a.m. This session highlights the latest research findings in psychiatry and summarizes their relevance to clinical practice. This session has become an excellent way to start off the Annual Meeting’s research programs, in conjunction with the Young Investigators’ Poster and Oral/Slide Sessions also on Monday. You will find an expanded number of small group sessions, including Discussion Groups; Research Consultations with selected experts in the field; and Master Educator Clinical Consultations, a series of clinically-based seminars with outstanding clinician educators, which will be offered to APA members only.

A special aspect of the 2000 scientific program will be a series of collaborative scientific sessions supported in part by the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Exciting research discoveries in the areas of alcohol abuse and alcoholism will be presented in these special sessions. Each session in this special track has NIAAA listed under the title of the session.

You will also note in the Program Book that we are continuing with our expanded series of noon Forums. This format allows us to schedule sessions that may not fit in the usual formats or that focus on late-breaking topics of importance to the field.

I strongly encourage you to fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year’s Annual Meeting.

Once again, welcome to Chicago. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Pedro Ruiz, M.D.
Chairperson
Scientific Program Committee
KEY LOCATIONS - McCormick Place Lakeside

Administrative Office: Room E259, Level 2
American Journal of Psychiatry: APA Resource Center
APA Communications Center: Rooms E270/271, Level 2
APA Resource Center: Exhibit Hall D, Level 3
AV Preview Room: Room E262, Level 2
CME Course Enrollment: Exhibit Hall D, Level 3
Daily Bulletin: Rooms E270/271, Level 2
Education Office: Room E250, Level 2
Exhibit Office: Lobby, Level 1
Information/Locator Center: Lobby, Level 2
Lost & Found: Room E258, Level 2
Meetings Management: Room E258, Level 2
Message Center: Lobby, Level 2
On-Site Job Bank and Placement Center: APA Resource Center
Psychiatric Services: APA Resource Center
Registration: Exhibit Hall D, Level 3
Scientific Program Office: Room E263, Level 2

FIRST AID
Located on Level 1, McCormick Place Lakeside. Hours of operation: Thursday, May 11, through Thursday, May 18, 7:00 a.m.-6:00 p.m. Information on emergency services may be found on page 4 of the Leisure Time Activities Brochure.

COURTESY SHUTTLE BUS SERVICE
Your registration badge is needed to ride the shuttle buses. Bus service will be available beginning at 7:00 a.m. on Saturday, May 13, operate daily throughout the meeting until 11:00 p.m., and conclude on Thursday, May 18, at 6:00 p.m. Route maps and schedules are included in the registration packet and published in the APA Exhibits Guide.

LOCAL ARRANGEMENTS COMMITTEE
HOSPITALITY CENTER
Located in the Lobby, Level 2, McCormick Place Lakeside. Hours of operation: Saturday, May 13, 12 noon-5:00 p.m.; Sunday, May 14, to Wednesday, May 17, 9:00 a.m.-5:30 p.m.; and Thursday, May 18, 9:00 a.m.-12 noon. Tickets for leisure time activities will be available at the Tour Desk also located in the Lobby, Level 2, McCormick Place Lakeside.

EXHIBITS
Commercial and educational exhibits are located in Exhibit Hall D, Level 3, McCormick Place Lakeside, along with the Publishers' Bookfair and the APA Resource Center. As a convenience to registrants, the APA Resource Center and Publishers' Bookfair will open on Saturday, May 13, 11:00 a.m.-5:00 p.m. Hours for commercial and educational exhibits: Sunday, May 14, 11:00 a.m.-5:00 p.m.; Monday and Tuesday, May 15-16, 10:00 a.m.-6:00 p.m.; and Wednesday, May 17, 10:00 a.m.-3:00 p.m. All exhibits will close on Wednesday, May 17. Please refer to the APA Exhibits Guide for additional information on participating companies.

INFORMATION/LOCATOR CENTER
Located in the Lobby, Level 2, McCormick Place Lakeside and staffed during registration hours. Up-to-date general information about the program, component meetings, the local area, and the locations of various activities and events can be obtained there. Meeting participants also can find out where colleagues who are registered for the meeting are staying.

MESSAGE CENTER
Located in the Lobby, Level 2, McCormick Place Lakeside and staffed during registration hours. Messages can be left and picked up at the Message Center. Message monitors will be strategically located in the Exhibit Hall and elsewhere at the McCormick Place Lakeside. Registrants whose names appear on these monitors should pick up their messages at the Center.

APA RESOURCE CENTER
Located in Exhibit Hall D, Level 3, McCormick Place Lakeside. Hours of operation: Saturday, May 13, 10:00 a.m.-5:00 p.m.; Sunday, May 14, 8:00 a.m.-5:00 p.m.; Monday and Tuesday, May 15-16, 10:00 a.m.-6:00 p.m.; and Wednesday, May 17, 10:00 a.m.-3:00 p.m. See the back cover of this book for APA programs and services in the APA Resource Center.

APA JOB BANK
Located in the APA Resource Center and open during the Center's hours of operation. The computerized Job Bank gives you the opportunity to walk away with information on hundreds of job openings available to psychiatrists throughout the country. Employers can list available positions onsite. Psychiatrists and employers should stop by the booth to find out how they can access information in the Job Bank database throughout the year.

PRESS OFFICE
Located in the APA Communications Center, Rooms E270/271, Level 2, McCormick Place Lakeside. Hours of operation: Saturday, May 13, 12 noon-5:00 p.m.; Sunday-Wednesday, May 14-17, 8:00 a.m.-6:00 p.m.; and Thursday, May 18, 8:00 a.m.-12 noon. The Press Office is for the use of registered press only. All Annual Meeting sessions are open to the press except CME Courses, the Business Meeting, Clinical and Continuous Clinical Case Conferences and Master Educator Clinical Consultations.

DAILY BULLETIN
The Daily Bulletin accepts written requests from APA members for publicity of component, committee and allied group events as space allows. Four issues are published. Since the issue for Saturday/Sunday is preprinted, information cannot be added on site. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off at the APA Communications Center. The deadlines are noon prior to the date of publication.
CENTER FOR INTERNATIONAL GUESTS
Bienvenidos, Wilkommen, Bienvenue, Welcome!
Located in the Grand Ballroom in the Palmer House Hotel. Hours of operation: Saturday, May 13, 11:00 a.m.-6:00 p.m.; Sunday, May 14-Wednesday, May 17, 8:00 a.m.-6:00 p.m.; and Thursday, May 18, 8:00 a.m.-10:30 a.m. All visitors from outside of the U.S. and Canada are invited. These activities are sponsored by Pfizer International Pharmaceuticals.

BUSINESS CENTERS
McCormick Place Lakeside
Location: Level 2, East Building
Hours of operation: Saturday-Thursday, 8:30 a.m.-5:00 p.m.
Chicago Hilton
Location: Lower Level
Hours of operation: Saturday, 7:00 a.m.-9:00 p.m., Monday-Thursday, 7:00 a.m.-11:00 p.m.
Palmer House
Location: 7th Floor
Hours of operation: Saturday, 7:00 a.m.-1:00 p.m., Monday-Thursday, 7:00 a.m.-7:00 p.m.

REGISTRATION
ADMISSION TO ALL SESSIONS BY REGISTRATION BADGE ONLY
Located in Exhibit Hall D, Level 3, McCormick Place Lakeside. Hours of operation: Saturday, May 13, 10:00 a.m.-5:00 p.m.; Sunday, May 14, 7:30 a.m.-5:00 p.m.; Monday through Wednesday, May 15-17, 7:30 a.m.-6:00 p.m.; and Thursday, May 18, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:
APA MEMBERS
Full-Time Registration ..............................................$185.00
Members-in-Training (Member Class MT) ..................70.00
Daily Registration .................................................95.00
(all "Member" categories except Medical Students)
Medical Students no charge

NONMEMBERS
Full-Time Registration ............................................$650.00
Nonmember Residents, Students, Advocacy
Group Members or Mental Health Chaplains ...............90.00
Daily Registration (all "Nonmember" categories) ..........330.00
Medical Students no charge

GUEST REGISTRATION
One only per full-time registrant ...............................95.00
Only one guest is allowed to register with each full-time meeting registrant. The guest must reside in the same household and be able to receive mail at the same address. APA members cannot register as a "guest"; they must register as an APA member.

On-site fees can be paid by cash, check, money order, American Express, VISA or MasterCard. Registration fees are waived only for CME Course Faculty, APA Honorary or Distinguished Fellows (does not include APA Life Fellows or Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification) and nonmember program participants (only for the day(s) they present).

NONMEMBER PSYCHIATRIC RESIDENTS AND OTHER FULL-TIME STUDENTS must present documentation of their qualifications to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hrs. per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

Note: There are no exemptions or reduced fees available for CME courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the Program Book, APA Exhibits Guide, New Research Program and Abstracts Book and Syllabus.

NAME BADGES
Badges are required for all sessions including the Opening Session and exhibit area. Only an APA member badge will admit you to the Business Meeting.

Badge Color Codes: Blue-Members, Yellow-Nonmembers, Silver-Press, Red-Exhibitors, Green-APA Staff, Black-Temporary Convention Personnel.

CME COURSE ENROLLMENT
TICKET PURCHASE REQUIRED FOR CME COURSES
Located in Exhibit Hall D, Level 3, McCormick Place Lakeside. Hours of operation: Saturday, May 13, 10:00 a.m.-5:00 p.m.; Sunday, May 14, 7:30 a.m.-5:00 p.m.; Monday through Wednesday, May 15-17, 7:30 a.m.-6:00 p.m.; and Thursday, May 18, 7:30 a.m.-2:00 p.m. Tickets for CME Courses #3-8 not sold by April 3 will be on sale to all registrants beginning at 10:00 a.m. on Saturday, May 13. You must show your registration badge before you can enroll in courses.

APA ART ASSOCIATION
Located in the APA Resource Center and staffed during the Resource Center's hours. The exhibit includes paintings, photography, ceramics and crafts done by APA members and/or their significant others. Please stop by the exhibit for information on joining the APA Art Association.

APA AUXILIARY BOOTH
Located in the Lobby, Level 2, McCormick Place Lakeside. Hours of operation: Saturday, May 13, through Wednesday, May 17, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Auxiliary's program schedule and information on membership.
APA PERIODICALS

The American Journal of Psychiatry and Psychiatric Services will be located in the APA Periodicals Exhibit in the APA Resource Center and staffed during Resource Center hours. Staff of both journals will be available to answer authors' questions and to receive papers submitted for publication. Each journal publishes only original material not published elsewhere in any form and not being considered for publication elsewhere. Five copies and a disk are required for The American Journal of Psychiatry; six copies and a disk are required for Psychiatric Services. Persons who wish to contact editors or reporters of Psychiatric News should inquire at the APA Administrative Office, Room E259, Level 2, McCormick Place Lakeside, where an editor can be paged. They may also leave written announcements, suggestions for articles or letters to the editor for the newspaper's consideration.

CONTINUING MEDICAL EDUCATION

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA takes responsibility for the content, quality and scientific integrity of this CME activity. The APA designates this educational activity for up to 66 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions of the official Annual Meeting program, with some exceptions, meet the criteria for Category 1 CME credit. Sessions in the following program formats are designated as Category 1: Advances in Research, Clinical Case and Continuous Clinical Case Conferences, CME Courses, Debates, Forums, Industry-Supported Symposia, most Lectures, some Media Sessions, Medical Updates, New Research Oral/Slide Sessions, Research Advances in Medicine, the Presidential Symposium, Review of Psychiatry, Scientific and Clinical Reports, Symposia, Telecommunication sessions and Workshops. Other program activities are designated Category 2: Research Consultations With, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, and some Media Sessions, Lectures and Workshops. Scientific sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

Please note: APA members are required to maintain their own records of CME hours. Reporting of CME credit is on an honor basis.

To document CME credit earned at the Annual Meeting, participants should record the sessions they attended on the Certificate of Attendance found in the front of the 2000 Annual Meeting CME Syllabus & Proceedings Summary Book. Credit is earned on an hour-for-hour basis.

The Certificate of Attendance (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires participation in a total of 150 hours of CME activities within a three-year reporting period. At least 60 hours must be in Category 1 activities.

CME report forms may be obtained from the Office of Education at the APA. Staff will be available at the Office of Education booth in the APA Resource Center to answer any of your questions about CME.

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year's Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. BEFORE YOU LEAVE THE MEETING, PLEASE COMPLETE YOUR FORM AND DROP IT IN ONE OF THE EVALUATION BOXES LOCATED THROUGHOUT THE MEETING SITES. You can receive a parchment Certificate of Attendance at the Annual Meeting by returning your completed form (to the APA Administrative Staff Office, Scientific Program Office, Information/Locator Center or APA Resource Center, all located in the McCormick Place Lakeside) or by completing the computerized general evaluation in the APA Resource Center.

SESSION CAPACITY

We expect "sell out" attendance for many of the scientific sessions. So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

• Please find seating as far forward as possible.
• Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
• Store materials under chairs to maximize seating capacity.
• Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
• If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

Thank you for your cooperation.

AUDIOTAPES

Audiotapes of most sessions are available shortly after each session concludes and may be purchased at the Mobiltape Booth located in the McCormick Place Lakeside.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use and by members of the media. Registrants are welcome to use their own small, portable audiotape recorders to record any session except the Master Educator Clinical Consultations, Clinical Case Conferences and the Continuous Clinical Case Conference, or unless prohibited by the presenters. Larger professional tape recorders, however, are not permitted other than those utilized by members of the media and personnel representing the professional taping firm authorized by APA to audiotape sessions. The badges of personnel representing this firm and members of the media will clearly identify them. Nonmedia registrants are not permitted to videotape any session because the intrusive nature of the recording may disrupt the session.

SMOKING POLICY

There will be NO SMOKING in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.
CHILD CARE SERVICE

For the convenience of meeting registrants and their families, the APA, with assistance from the Local Arrangements Committee, has made arrangements for child care during the meeting. The child care service will be located in Room E254, Level 2, McCormick Place Lakeside. Hours of operation will be Sunday, May 14, to Thursday, May 18, 7:30 a.m.-6:30 p.m. Staffing will be available for children ages six months to 12 years, and off-site activities for children 12 years of age and older.

GUIDE TO THE PROGRAM BOOK

Below, you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. NOTE: To make it easier for you to plan your day, we have prepared a separate "Days-at-a-Glance," which is included in your registration packet.

If you have any questions about this book or the scientific sessions, please feel free to stop by the Scientific Program Office in the McCormick Place Lakeside, and we will be glad to help you. Also, all central office APA staff members will be wearing green ribbons on their badges. Please feel free to direct your questions to them.

FUTURE APA MEETINGS

APA ANNUAL MEETINGS

2001 May 5-10 New Orleans, LA
2002 May 18-23 Philadelphia, PA
2003 May 17-22 San Francisco, CA
2004 May 1-6 New York, NY
2005 May 21-26 Atlanta, GA
2006 May 20-25 Toronto, Canada
2007 May 19-24 San Diego, CA
2008 May 3-8 Washington, DC
2009 May 16-21 San Francisco, CA

APA CLINICAL MEETINGS

THE INSTITUTE ON PSYCHIATRIC SERVICES

2000 October 25-29 Philadelphia, PA
2001 October 10-14 Orlando, FL
2002 October 9-13 Chicago, IL
2003 October 29-Nov. 2 Boston, MA
2004 October 6-10 Atlanta, GA
2005 October 5-9 San Diego, CA

Tentative program schedules and hotel information for the 2000 Institute on Psychiatric Services are available at the Future Meetings Booth in the APA Resource Center and the Information/Locator Center, both located in the McCormick Place Lakeside.

TABLE OF CONTENTS

Floor Plans for McCormick Place, Hyatt Regency and Chicago Hilton .................................................. VI-XVI
City Map ...................................................................... XVII
Special Acknowledgments ................................................ XVIII-XIX
Format Descriptions .................................................... XX-XXI
Disclosure Information ................................................ XXII-XXXIV
Saturday Sessions ....................................................... 1-3
Audiotape Sales Information ........................................ 4
Sunday Sessions .......................................................... 5-13
Sessions Presented in Collaboration with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) ... 14
Monday Sessions .......................................................... 15-37
Call for 2001 Annual Meeting Papers ................................ 38
Tuesday Sessions .......................................................... 39-62
Wednesday Sessions .................................................... 63-85
2000 Institute on Psychiatric Services ................................ 86
Thursday Sessions ........................................................ 87-102
Topic Index .................................................................. 103-114
Participant Index .......................................................... 115-125
American Psychiatric Publishing Group ......................... 126-127
Industry-Supported Symposia ........................................ 128-152
APA Resource Center ................................................... Back Cover

Refer to the APA Exhibits Guide for information on: Exhibits, Publishers' Bookfair, Hospitality Lounge and Dining Facilities in the McCormick Place Lakeside.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association nor does the American Psychiatric Association warrant the accuracy of any information reported.

©American Psychiatric Association.
McCormick Place Lakeside
Level 2
McCormick Place Lakeside
Level 3
SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

Abbott Laboratories: support of the Industry-Supported Symposia, "Bipolar Children and Adolescents: Controversies in Diagnosis and Treatment," Sunday, May 14, 1:30 p.m.; "Defining Bipolar Disorder: A Public Health Challenge," Tuesday, May 16, 7:00 p.m.; and the Industry-Supported Breakfast Symposium, "Lengthening the Fuse: Treatment of Aggression," Monday, May 15, and Tuesday, May 16, 7:00 a.m.

Alza Corporation: support of the Industry-Supported Symposium, "Advances in ADHD: From Research to Clinical Practice," Wednesday, May 17, 7:00 p.m.


American Association of Psychiatric Administrators: co-sponsorship of the Administrative Psychiatry Award Lecture, Tuesday, May 16, 7:00 p.m.

American Psychiatric Association: co-support of the APA Award for Research in Psychiatry; and support of the Disaster Psychiatry Fellowship.


Association of Mental Health Clergy: co-support of the Oskar Pfister Award Lecture, Tuesday, May 16, 9:00 a.m.

Association of Women Psychiatrists: co-sponsorship of the Alexandria Symonds Award Lecture, Monday, May 15, 9:00 a.m. and support of the joint AWP/APA Women's Career reception and meeting, Monday, May 15, 7:30 p.m.

AstraZeneca Pharmaceuticals: support of the Industry-Supported Symposium, "New Antipsychotics: From Practice to Theory," Sunday, May 14, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Managing Psychoses Across the Age Spectrum," Monday, May 15 and Tuesday, May 16, 7:00 a.m.; the APA/AstraZeneca Minority Fellowship Program and reception; and the George Tarjan Award.

Aventis: support of the Female Resident Travel Program, and the Luncheon for Women in Psychiatry, Monday, May 15, 12:30 p.m.

Bristol-Myers Squibb: support of the Industry-Supported Breakfast Symposium, "New Clinical Advances in Depression," Monday, May 15 and Tuesday, May 16, 7:00 a.m.; co-support of the Industry-Supported Symposium, "Schizophrenia and Bipolar Disorders: Evolving Therapeutic Concepts," Sunday, May 14, 7:00 p.m.; support of the Solomon Carter Fuller Award Lecture, Wednesday, May 17, 2:00 p.m.; the APA Auxiliary reception and tea, the Women's Resource Center, and the APA/Bristol-Myers Squibb Fellowship Program and reception.

Center for Mental Health Services: sponsorship of the APA/CMHS Minority Fellowship Program; and support of Practice Research Network (PRN) Annual Meeting activities.

Eli Lilly and Company: support of the Industry-Supported Symposium, "Pharmacotherapy of Dementia: Expanding the Boundaries," Sunday, May 14, 7:00 p.m.; and "Behavioral Disturbances in Dementia: Causes, Treatments and Impact," Wednesday, May 17, 7:00 p.m.

Eli Lilly and Company: support of the Industry-Supported Symposium, "Schizophrenia: From Social Isolation to Social Reintegration," Saturday, May 13, 7:00 p.m.; "Advances in Women's Mental Health: A Decade of Progress," Sunday, May 14, 7:00 a.m.; and "Violence and Its Prevention: The Role of Psychiatry," Sunday, May 14, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "The Interface of Neuropsychiatric Disorders in the Elderly," Wednesday, May 17 and Thursday, May 18, 7:00 a.m.; the Adolf Meyer Award Lecture, Monday, May 15, 11:00 a.m.; the Simon Bolivar Award Lecture, Wednesday, May 17, 2:00 p.m.; the APA/Lilly Resident Research Awards; the Daniel X. Freedman Congressional Fellowship, partial support of the New Research Abstracts and Program Book; and partial support of the Research Colloquium for Junior Investigators, Sunday, May 14.

Forest Laboratories, Inc.: support of the Industry-Supported Symposium, "Mind and Body in the Patient with Depression: Clinical Implications of the Interrelationship Between Psychiatric, Cerebrovascular, and Cardiovascular," Saturday, May 13, 7:00 p.m.; "Recurrent Depression: Challenges and Solutions," Sunday, May 14, 7:00 p.m.; and "Psychiatry in Uncharted Territory: Assessing and Treating Psychiatric Conditions in Medical Patients," Tuesday, May 16, 7:00 p.m.

Glaxo Wellcome Inc.: support of the Industry-Supported Symposium, "Depamine Beyond Schizophrenia, Tools for Treatment," Saturday, May 13, 7:00 p.m.; "Complexities of Treatment of Bipolar Disorder," Sunday, May 14, 1:30 p.m.; "Neurotransmitters and Depression: New Possibilities," Tuesday, May 16, 7:00 p.m.; and the APA/Glaxo Wellcome Fellowship Program and reception.

Harding Foundation: co-support of the Oskar Pfister Award Lecture, Tuesday, May 16, 9:00 a.m.

Ittelson Foundation, Inc.: support of the Blanche F. Ittelson Award for Research in Child Psychiatry.

Janssen Pharmaceutica and Research Foundation: support of the Industry-Supported Symposia, "The Many Faces of Psychosis," Saturday, May 13, 7:00 p.m.; "Treatment Practice and Promise for Schizophrenia in the New Millennium," Sunday, May 14, 9:00 a.m.; "Managing Patients with Acute Psychosis: An Interactive Program," Sunday, May 14, 1:30 p.m.; "Schizophrenia: Across the Life Cycle," Wednesday, May 17, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Breaking the Cycle: Novel Treatments in Bipolar Disorder," Wednesday, May 17 and Thursday, May 18, 7:00 a.m.; the Early Career Psychiatrists' Dinner Forum, Tuesday, May 16, 7:00 p.m.; and the American Psychiatric Institute for Research and Education/Janssen Scholars in Research on Severe Mental Illness Program.

Estate of Kun-Po Soo, M.D., Ph.D.: support of the Kun-Po Soo Award Lecture, Tuesday, May 16, 11:00 a.m.

Lilly Research Laboratories, a division of Eli Lilly & Company: support of the APA/Lilly Psychiatric Research Fellowship.


Merck & Co., Inc.: support of the Industry-Supported Symposium, "New Treatments for Depression," Sunday, May 14, 9:00 a.m.; the William C. Menninger Memorial Convocation Lecture, Monday, May 15, 7:30 p.m.; the "Office of the Future" exhibit; and an unrestricted educational grant in support of various scientific sessions.

National Institute of Mental Health: co-support of the Seymour D. Vestermark Award for Psychiatric Education Lecture, Monday, May 15, 7:30 p.m.; and the "Office of the Future" exhibit.

National Institute on Alcohol Abuse and Alcoholism: support of the APA Office of Research Annual Meeting activities for research trainees.

National Institute on Alcohol Abuse and Alcoholism: support of the APA Office of Research Annual Meeting activities for research trainees.
SPECIAL ACKNOWLEDGMENTS


Novartis Pharmaceuticals Corporation: support of the Industry-Supported Symposium, “From Neurobiology to Novel Treatments: Applications in Alzheimer’s Disease,” Sunday, May 14, 9:00 a.m.

Organon Inc.: support of the Industry-Supported Symposium, “Individualizing Management of Depressive Disorders,” Sunday, May 14, 9:00 a.m.; and the Industry-Supported Breakfast Symposium, “Evidence-Based Management of Refractory Depression,” Monday, May 15, and Tuesday, May 16, 7:00 a.m.


Parke-Davis: support of the Industry-Supported Breakfast Symposium, “Antiepileptic Drugs in Psychiatric Disorders,” Monday, May 15, and Tuesday, May 16, 7:00 a.m.

Professional Risk Management Services, Inc.: support of the Manfred S. Guttmacher Award Lecture, Sunday, May 14, 2:30 p.m.

Pfizer Inc.: support of the Industry-Supported Symposiums, “Sexual Dysfunction: Epidemiology, Etiology, Diagnosis and Management,” Saturday, May 13, 7:00 p.m.; “Family Violence: Victimization and Perpetration,” Sunday, May 14, 1:30 p.m.; “From Patients to People: Redefining Wellness in Psychosis,” Sunday, May 14, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “The Mental Health of Women and Children,” Wednesday, May 17 and Thursday, May 18, 7:00 a.m.; the Residents’ Session, “Meet the Experts: Sunny-Side Up,” Monday, May 15, 7:00 a.m.; the Abstracts-On-Disc Program; the APA Daily Bulletin newspaper; and the IMG Hospitality Suite.

Pfizer International Pharmaceuticals: support of the International Hospitality Suite, a daily visitor center for international delegates; and the APA Office of Research activities for research trainees.


Roche Laboratories, a member of the Roche Group: support of the Benjamin Rush Award Lecture, Thursday, May 18, 9:00 a.m.

Sheppard Pratt Health System: support of the Warren Williams Speaker’s Awards.

Shire Richwood: support of the Industry-Supported Symposium, “Adult ADHD: Research Findings and Clinical Practice,” Tuesday, May 16, 7:00 p.m.; and support of the Industry-Supported Breakfast Symposium, “Clinical Challenges and Choices in the Treatment of ADD/ADHD,” Wednesday, May 17 and Thursday, May 18, 7:00 a.m.

SmithKline Beecham Pharmaceuticals: support of the Industry-Supported Symposium, “Reproductive Psychiatry: An Update on Women’s Health,” Saturday, May 13, 7:00 p.m.; “Images of Anxiety,” Sunday, May 14, 9:00 a.m.; “Neurobiology of Disease: From the Lab to the Clinic,” Sunday, May 14, 7:00 p.m.; the annual contribution to the APA Presidential Fund; and the APA/SmithKline Beecham Junior Faculty Fellowship for Research Development in Biological Psychiatry.

Solvay Pharmaceuticals, Inc.: support of the Industry-Supported Symposium, “Novel Precipitants of Anxiety,” Sunday, May 14, 7:00 p.m.; “Manic-Depressive Illness: An Update,” Tuesday, May 16, 7:00 p.m.; and support of the beverage service in the exhibit hall.

van Ameringen Foundation, Inc.: support of the APA Office of Research Annual Meeting activities for research trainees and health services researchers; and the Arnold L. van Ameringen Award in Psychiatric Rehabilitation.

Wyeth-Ayerst Laboratories: support of the Industry-Supported Symposium, “Advances in the Treatment of Insomnia,” Sunday, May 14, 9:00 a.m.; “Controversies at the Interface of Sleep and Psychiatry,” Sunday, May 14, 1:30 p.m.; “Seven Habits of Highly Effective Psychopharmacologists,” Wednesday, May 17, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “Why Do Anxious People Become Depressed? The Role of Stress Supersensitivity,” Wednesday, May 17 and Thursday, May 18, 7:00 a.m.; the APA/Wyeth-Ayerst Psychiatric Research Fellowship; the Resident, Medical Student, Training Directors luncheon; the Alexandra Symonds Award Lecture, Monday, May 15, 9:00 a.m.; and the daily in-house TV program, “APA News Network.”
## FORMAT DESCRIPTIONS

### ADVANCES IN RESEARCH
This two-hour session is traditionally chaired by the Chairperson of the Council on Research and co-chaired by the Chairperson of the Scientific Program Committee. After a brief overview of major advances in research in psychiatry and a preview of selected research presentations scheduled at the Annual Meeting, leading clinical researchers presented the latest developments in four different, clinically-relevant areas of research.

### CLINICAL CASE CONFERENCES
During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. These sessions are open to APA members only. Blue registration badge or APA membership card required for admittance.

### CONTINUOUS CLINICAL CASE CONFERENCES
The presenters will review the progress of psychotherapy in two successive three-hour sessions on consecutive days (Monday-Tuesday, beginning at 9:00 a.m.). Audience participation will be encouraged throughout. Participants are requested to attend both sessions in their entirety. These sessions are open to APA members only. Blue registration badge or APA membership card required for admittance.

### COURSES
Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day) and six-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Enrollment is limited, and participants must purchase tickets to attend.

### DEBATE
Experts in the field, including psychiatrists and nonpsychiatrists, will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

### DISCUSSION GROUPS
This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the experts. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

### FORUMS
These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

### LECTURES
Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

### MASTER EDUCATOR CLINICAL CONSULTATIONS
These 90-minute, clinically-based seminars are presented by outstanding educators. Formats and subject matter will vary, but all will utilize clinical material offered by participants. These sessions are limited to 25 participants on a first-come, first-served basis. These sessions are open to APA members only. Blue registration badge or APA membership card required for admittance.

### MEDIA SESSIONS
In these sessions, a video or film of educational value is shown. Videos or films may illustrate innovation in: patient assessment, diagnosis, treatment and education; practice management, medical records, information systems and research; professional education; public awareness and education; psychiatric interpretations of meaning in media; assessment of the biopsychosocial effects of media on individuals; social/cultural issues and mental health/illness; and the human spirit as seen in the arts and humanities.

### MEDICAL UPDATES
These 90-minute sessions are designed to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.

### NEW RESEARCH
This format allows for presentation of the very recent findings obtained from ongoing research. The three types of presentations include: Oral/Slide, which are twelve-minute presentations with three minutes for discussion; Posters, which are visual, self-explanatory presentations; and Young Investigators' Sessions, with presentations from young investigators, residents, medical students, and research or clinical fellows.

### RESEARCH ADVANCES IN MEDICINE
This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.

### RESEARCH CONSULTATIONS WITH
This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it's one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.

### REVIEW OF PSYCHIATRY
There will be five, three-and-one-half hour sessions presented, based on the annual American Psychiatric Press Review of Psychiatry Series. Each session includes an abridged presentation by the senior author from each of the chapters in each volume. The topics were selected by the overall editors of the series to represent current areas of new research, new developments in clinical care, and special issues of importance to APA members.
SCIENTIFIC AND CLINICAL REPORT SESSIONS
Scientific and Clinical Reports (formerly Paper Sessions) are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

TELECOMMUNICATION SESSIONS
These three-hour sessions are presented in a computer software demonstration format (i.e., on computer and LCD projector provided for projection on a large screen), or a "hands-on" format limited to 30 participants. Topic areas include telepsychiatry, virtual reality, internet, electronic medical records and information technology.

SYMPOSIA
Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposium" in this Program Book.

WORKSHOPS
Workshops are 90-minute sessions, which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.
AMERICAN PSYCHIATRIC ASSOCIATION  
CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure of the existence of any and all significant financial interest(s) or other affiliation(s) a presenter has with any commercial supporter(s) of these educational activities, and/or with the manufacturer(s) of any and all commercial product(s) and/or provider(s) of any and all commercial service(s) discussed in the scientific program. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter’s affiliation with every commercial supporter by an acknowledgment in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if AV equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgements about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The following presenters have indicated a significant financial interest or other affiliation with a commercial supporter of the session and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial service(s). The presenter’s name, the manufacturer’s name, and the page number(s) the presenter appears on in this Program Book are listed below:

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carle G. Abel, M.D.</td>
<td>Abel Screening Inc</td>
<td>64</td>
</tr>
<tr>
<td>Hagop S. Akiskal, M.D.</td>
<td>Abbott Laboratories, Glaxo Wellcome Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company. SmithKline Beecham Pharmaceuticals; Synthelabo: BW.</td>
<td>10, 26, 53, 54, 67, 78</td>
</tr>
<tr>
<td>George S. Alexopoulos, M.D.</td>
<td>Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Lilly Research Laboratories; a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Eisai Inc.; National Institute of Mental Health</td>
<td>2, 11</td>
</tr>
<tr>
<td>John P. Allen, Ph.D.</td>
<td>Astra Biochemicals</td>
<td>71</td>
</tr>
<tr>
<td>Michael H. Allen, M.D.</td>
<td>Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories; a division of Eli Lilly and Company.</td>
<td>9</td>
</tr>
<tr>
<td>Lori L. Altschuler, M.D.</td>
<td>Abbott Laboratories; Eli Lilly and Company; Forest Laboratories, Inc.; Glaxo Wellcome Inc.; Janssen Pharmaceutica and Research Foundation; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.</td>
<td>10, 31, 63</td>
</tr>
<tr>
<td>Raymond F. Anson, M.D.</td>
<td>Dupont Pharma; Lipha Pharmaceuticals</td>
<td>56</td>
</tr>
<tr>
<td>Ralph Aquila, M.D.</td>
<td>Eli Lilly and Company</td>
<td>3</td>
</tr>
<tr>
<td>Richard Balon, M.D.</td>
<td>Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Glaxo Wellcome Inc.; Merck &amp; Co., Inc.; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Novartis Pharmaceuticals Corporation</td>
<td>24, 48, 73, 96</td>
</tr>
<tr>
<td>Jack D. Barchas, M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>59</td>
</tr>
<tr>
<td>Elizabeth A. Baxter, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>44</td>
</tr>
<tr>
<td>Alan S. Bellak, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>60</td>
</tr>
<tr>
<td>Elissa P. Benedek, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>9, 84</td>
</tr>
<tr>
<td>Katherine I. Benziger, Ph.D.</td>
<td>KBA The Human Resource Technology Company</td>
<td>68</td>
</tr>
<tr>
<td>Joseph Bederman, M.D.</td>
<td>Alza Pharmaceuticals; Eli Lilly and Company; Glaxo Wellcome Inc.; Novartis Pharmaceuticals Corporation; Shire Richardwood Pharmaceuticals; Wyeth-Ayerst Laboratories</td>
<td>60, 60, 83, 98</td>
</tr>
<tr>
<td>Renee L. Binder, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>3, 5, 22, 58</td>
</tr>
<tr>
<td>Sandra L. Bloom, M.D.</td>
<td>Universal Health Services Inc. (employer); U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Howard E. Book</td>
<td>American Psychological Association</td>
<td>9, 26</td>
</tr>
<tr>
<td>Soo Borson, M.D.</td>
<td>Pharmaca &amp; Upjohn Company</td>
<td>3</td>
</tr>
<tr>
<td>Charles L. Bowden, M.D.</td>
<td>Abbott Laboratories; Forest Laboratories, Inc.; Glaxo Wellcome Inc.; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company. Merck &amp; Co., Inc.; National Institute of Mental Health; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc</td>
<td>32, 54, 102</td>
</tr>
<tr>
<td>Kathleen T. Brady, M.D.</td>
<td>Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb Company</td>
<td>12, 31, 43</td>
</tr>
<tr>
<td>William Breitbart, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Purdue Frederick; Ortho-Biotech; Roxane Laboratories</td>
<td>57, 64</td>
</tr>
<tr>
<td>Gregory J. Brown, M.D.</td>
<td>Bristol-Myers Squibb Company; Eli Lilly and Company; Glaxo Wellcome Inc.; Organon Inc; Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>72</td>
</tr>
<tr>
<td>Thomas E. Brown, Ph.D.</td>
<td>American Psychiatric Press; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Shire Richardwood Pharmaceuticals; The Psychological Corporation</td>
<td>5, 18, 51</td>
</tr>
<tr>
<td>Peter F. Buckley, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation</td>
<td>12, 26, 32, 97, 98</td>
</tr>
<tr>
<td>Harold J. Bursztajn, M.D.</td>
<td>Informed Consent Systems; Risk Management Services</td>
<td>26</td>
</tr>
<tr>
<td>Marian I. Butterfield, M.D.</td>
<td>Glaxo Wellcome Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Organon Inc.; Wyeth-Ayerst Laboratories</td>
<td>28, 57, 66</td>
</tr>
<tr>
<td>Daniel J. Buysse, M.D.</td>
<td>Cephalon; Searle; Wyeth-Ayerst Laboratories</td>
<td>7</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Joseph R. Calabrese, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; Merck &amp; Co., Inc.</td>
<td>32, 63, 74, 87</td>
</tr>
<tr>
<td>Jose M. Canive, M.D.</td>
<td>Eli Lilly and Company; Otsuka Pharmaceuticals, Inc.; Merck &amp; Co., Inc.; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals</td>
<td>56, 89, 79, 98</td>
</tr>
<tr>
<td>Patrick J. Cases, Ph.D.</td>
<td>The Meadows</td>
<td>50</td>
</tr>
<tr>
<td>Stanley N. Caroff, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>97</td>
</tr>
<tr>
<td>William T. Carpenter, Jr., M.D.</td>
<td>Ortho-McNeil Pharmaceuticals</td>
<td>83</td>
</tr>
<tr>
<td>Rosalind Cartwright, Ph.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>9</td>
</tr>
<tr>
<td>Daniel E. Casey, M.D.</td>
<td>Abbott Laboratories; Hoechst Marion Roussel; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>13</td>
</tr>
<tr>
<td>F. Xavier Castellano, M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Donna S. Charny, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb Company; Marion-Merrell Dow; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Merck &amp; Co., Inc.; Mitsubishi Chemical; Novartis Pharmaceuticals Corporation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Schering-Plough Corporation; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories</td>
<td>8, 43, 46</td>
</tr>
<tr>
<td>Daniel D. Christensen, M.D.</td>
<td>Abbott Laboratories; Bayer Corporation, Pharmaceutical Division; Bristol-Myers Squibb Company; Eisai Inc.; Glaxo Wellcome Inc.; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>36</td>
</tr>
<tr>
<td>Leslie L. Citrome, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation</td>
<td>77, 95</td>
</tr>
<tr>
<td>Gordon H. Clark, Jr., M.D.</td>
<td>Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company</td>
<td>36</td>
</tr>
<tr>
<td>Anita L. Clayton, M.D.</td>
<td>Glaxo Wellcome Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Pharmacia &amp; Upjohn Company, Inc.; Forest Laboratories, Inc.; Bristol-Myers Squibb Company; SmithKline Beecham Pharmaceuticals</td>
<td>7, 11, 41</td>
</tr>
<tr>
<td>K.N. Roy Chengappa, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals</td>
<td>9, 12</td>
</tr>
<tr>
<td>James C.Y. Chou, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.; Hoechst Marion Roussel; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>8, 43, 46</td>
</tr>
<tr>
<td>Daniel D. Christensen, M.D.</td>
<td>Abbott Laboratories; Bayer Corporation, Pharmaceutical Division; Bristol-Myers Squibb Company; Eisai Inc.; Glaxo Wellcome Inc.; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>8, 44</td>
</tr>
<tr>
<td>Robert R. Conley, M.D.</td>
<td>Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Zenith Goldline Pharmaceuticals; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals</td>
<td>9, 32</td>
</tr>
<tr>
<td>Kathryn M. Connor, M.D.</td>
<td>Meds Biotechnical, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Eli Lilly and Company</td>
<td>12</td>
</tr>
<tr>
<td>Ian A. Cook, M.D.</td>
<td>Eli Lilly and Company; Wyeth-Ayerst Laboratories; Pharmacia &amp; Upjohn Company, Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>72</td>
</tr>
<tr>
<td>Barbara Comblatt, Ph.D.</td>
<td>Bristol-Myers Squibb Company</td>
<td>72</td>
</tr>
<tr>
<td>Francine Cournoy, M.D.</td>
<td>WW Norton</td>
<td>30</td>
</tr>
<tr>
<td>Joseph T. Coyte, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Abbott Laboratories; Merck &amp; Co., Inc.</td>
<td>20, 32, 57, 89, 98, 12, 15, 32</td>
</tr>
<tr>
<td>Jeffrey L. Cummings, M.D.</td>
<td>Bayer Corporation, Pharmaceutical Division; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; SmithKline Beecham Pharmaceuticals; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb Company; Eisai Inc.</td>
<td>26</td>
</tr>
<tr>
<td>Anthony M. D'Agostino, M.D.</td>
<td>Behavioral Health Systems, Inc.</td>
<td>1</td>
</tr>
<tr>
<td>Jonathan S. Davne, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>6, 26</td>
</tr>
<tr>
<td>John M. Davis, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Forest Laboratories, Inc.</td>
<td>27</td>
</tr>
<tr>
<td>Kenneth L. Davis, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Shire Richwood Pharmaceuticals; Mitsubishi TAK; Gliatech, Pharmacia &amp; Upjohn Company, Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Anne M. DeFelipo, J.D.</td>
<td>Psychiatry Compliance Services</td>
<td>74</td>
</tr>
<tr>
<td>Ovidio A. DeLeon, M.D.</td>
<td>Parke-Davis, Division of Warner-Lambert Company</td>
<td>15</td>
</tr>
<tr>
<td>Pedro L. Delgado, M.D.</td>
<td>Glaxo Wellcome Inc.; National Institute of Mental Health; Solvay Pharmaceuticals, Inc.; Organon Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb Company; Pharmacia &amp;</td>
<td>97</td>
</tr>
</tbody>
</table>

**DISCLOSURE INDEX**
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sylvia J. Dennison, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>59</td>
</tr>
<tr>
<td>Mantooth J. Dewan, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories</td>
<td>40, 67, 96</td>
</tr>
<tr>
<td>Ruth A. Dickson, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutical companies; AstraZeneca</td>
<td>55</td>
</tr>
<tr>
<td>Karl Doghrany, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Parke-Davis, Division of Warner-Lambert Company</td>
<td>8</td>
</tr>
<tr>
<td>P. Murali Borawarny, M.D.</td>
<td>Pfizer Inc.</td>
<td>60, 79</td>
</tr>
<tr>
<td>Jacques M. Dubuis, M.D.</td>
<td>Eli Lilly and Company; Glaxo Wellcome Inc.; SmithKline Beecham Pharmaceuticals; Bristol-Myers Squibb Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Organon Inc.; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>7, 11</td>
</tr>
<tr>
<td>David A. Dunier, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Parke-Davis, Division of Warner-Lambert Company</td>
<td>39</td>
</tr>
<tr>
<td>Stephen V. Faraco, Ph.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Organon Inc.; Bristol-Myers Squibb Company; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>60, 83, 96</td>
</tr>
<tr>
<td>Maurizio Fava, M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>98</td>
</tr>
<tr>
<td>Maureen Fawcett, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Lily Research Laboratories, a division of Eli Lilly and Company; Astra-Merck Group; Division of Merck &amp; Co.; Organon Inc.; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Sorrento Pharmaceuticals</td>
<td>3, 12, 78, 94</td>
</tr>
<tr>
<td>Jacqueline M. Feldman, M.D.</td>
<td>Janssen Pharmaceutical companies; Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>36, 74</td>
</tr>
<tr>
<td>Robert L. Findling, M.D.</td>
<td>Janssen Pharmaceutical companies; Eli Lilly and Company; AstraZeneca</td>
<td>6, 15</td>
</tr>
<tr>
<td>Richard J. Frances, M.D.</td>
<td>Homewood Health Centre Inc. (employer)</td>
<td>50</td>
</tr>
<tr>
<td>Andrew J. Francis, Jr., M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.</td>
<td>59, 73</td>
</tr>
<tr>
<td>Ellen Frank, Ph.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.</td>
<td>60</td>
</tr>
<tr>
<td>Alan Frazer, Ph.D.</td>
<td>Eli Lilly and Company; TAP Pharmaceuticals/Tap Holdings, Inc.</td>
<td>9, 84</td>
</tr>
<tr>
<td>Jean A. Frazer, M.D.</td>
<td>Eli Lilly and Company; National Institute of Mental Health; Bristol-Myers Squibb Company; Glaxo Wellcome Inc.; Eli Lilly and Company; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Theodore and Vada Stanley Foundation; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; AstraZeneca Pharmaceuticals; Merck &amp; Co., Inc.; Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.; Pharmacia &amp; Upjohn Company, Inc.; Solvay Pharmaceuticals, Inc.</td>
<td>60</td>
</tr>
<tr>
<td>Joshua E. Freedman, M.D.</td>
<td>Eli Lilly and Company; Mediconsult.com (employer)</td>
<td>26, 82</td>
</tr>
<tr>
<td>Mary A. Frenkel, Ph.D.</td>
<td>American Psychiatric Press Inc.</td>
<td>8</td>
</tr>
<tr>
<td>XXIV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page</td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Mark A. Frye, M.D.</td>
<td>Abbott Laboratories; Eli Lilly and Company; Glaxo Wellcome Inc.; Bristol-Myers Squibb Company; Parkes-Davis, Division of Warner-Lambert Company</td>
<td>31, 74</td>
</tr>
<tr>
<td>David R. Gastfriend, M.D.</td>
<td>Earlly Corporation; Bristol-Myers Squibb Company; DuPont Pharma; Central America, Inc.</td>
<td>35, 100</td>
</tr>
<tr>
<td>F. Moses Gavina, M.D.</td>
<td>Parke-Davis, Division of Warner-Lambert Company</td>
<td>6, 15, 39</td>
</tr>
<tr>
<td>Alan J. Gelenberg, M.D.</td>
<td>Bristol-Myers Squibb Company; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories; a division of Eli Lilly and Company; Janssen Pharmaceuticals and Research Foundation; Merck &amp; Co., Inc.; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; Hoechst Marion Roussel; Forest Laboratories, Inc.; Parkes-Davis, Division of Warner-Lambert Company; Eli Lilly and Company; Searle Nova Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Best Pharmaceuticals and Research Foundation; Lilly Research Laboratories; a division of Eli Lilly and Company; Dupont Pharma; Glaxo Wellcome Inc.; Solvay Pharmaceuticals, Inc.; Parke-Davis, Division of Warner-Lambert Company; SmithKline Beecham Pharmaceuticals; Mediphysics/Amscham; Picker International; Danlec; Neutonix, Inc.; Cytronics, Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>3, 10</td>
</tr>
<tr>
<td>Mark S. George, M.D.</td>
<td>Abbott Laboratories</td>
<td>17</td>
</tr>
<tr>
<td>Elliott Gershon, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation</td>
<td>21, 102</td>
</tr>
<tr>
<td>S. Nasser Ghaemi, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation; Eli Lilly and Company; Glaxo Wellcome Inc.; Abbott Laboratories</td>
<td>2, 87</td>
</tr>
<tr>
<td>Stuart Gilow, M.D.</td>
<td>Health Inc. (owner)</td>
<td>20</td>
</tr>
<tr>
<td>Alexander H. Glassman, M.D.</td>
<td>Glaxo Welcome Inc.; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Forest Laboratories, Inc.; Parkes-Davis, Division of Warner-Lambert Company</td>
<td>3, 58</td>
</tr>
<tr>
<td>William M. Glazer, M.D.</td>
<td>Lilly Research Laboratories; a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb Company; Watson Laboratories, Inc.</td>
<td>55</td>
</tr>
<tr>
<td>Ira D. Glitz, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation; Lilly Research Laboratories; a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Glaxo Welcome Inc.; Watson Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>12, 62, 84</td>
</tr>
<tr>
<td>Donald C. Goff, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceuticals and Research Foundation; AstraZeneca Pharmaceuticals, U.S. Pharmaceuticals, Pfizer Inc.; Cortez Pharmaceuticals</td>
<td>7</td>
</tr>
<tr>
<td>Robert M. Goleman, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td>17</td>
</tr>
<tr>
<td>Terry E. Goldberg, Ph.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation</td>
<td>83</td>
</tr>
<tr>
<td>Stephen M. Goodfier, M.D.</td>
<td>Eli Lilly and Company; Zenith Goldline Pharmaceuticals, U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceuticals and Research Foundation; AstraZeneca Pharmaceuticals</td>
<td>50, 74</td>
</tr>
<tr>
<td>Patricia Goldman-Rakic, Ph.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Toby D. Goldman, M.D.</td>
<td>Forest Laboratories, Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories; Glaxo Wellcome Inc.; Solvay Pharmaceuticals, Inc.</td>
<td>91</td>
</tr>
<tr>
<td>Michael G. Goldstein, M.D.</td>
<td>Bayer Corporation, Pharmaceutical Division; Glaxo Wellcome Inc.; McNeil Pharmaceuticals; SmithKline Beecham Pharmaceuticals; DuPont Pharma; Merck &amp; Co., Inc.; Lilly Research Laboratories; a division of Eli Lilly and Company; Sano Corporation</td>
<td>26</td>
</tr>
<tr>
<td>Karl Goodkin, M.D.</td>
<td>Pharmacia &amp; Upjohn Company, Inc.; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; Merck &amp; Co., Inc.; Advanced Immune</td>
<td>20, 32, 101</td>
</tr>
<tr>
<td>Frederick K. Goodwin, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Searle Nova Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.</td>
<td>59, 78, 99</td>
</tr>
<tr>
<td>Jack M. Gorman, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals; AstraZeneca Pharmaceuticals; Janssen Pharmaceuticals and Research Foundation; Organon Inc.; Forest Laboratories, Inc.; Lundbeck; Solvay Pharmaceuticals, Inc.; Parkes-Davis, Division of Warner-Lambert Company; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb Company</td>
<td>6, 9, 66</td>
</tr>
<tr>
<td>Robert P. Granacher, Jr., M.D.</td>
<td>Bristol-Myers Squibb Company</td>
<td>17</td>
</tr>
<tr>
<td>Michael F. Green, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>60</td>
</tr>
<tr>
<td>David J. Greenblatt, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>2</td>
</tr>
<tr>
<td>Laurence L. Greenhill, M.D.</td>
<td>Alza Pharmaceuticals; Glaxo Wellcome Inc.; Shire Richwood Pharmaceuticals; Novum Pharmaceuticals; Glaxol</td>
<td>63, 76, 87</td>
</tr>
<tr>
<td>Carlos M. Grilo, Ph.D.</td>
<td>National Institutes of Health; Eli Lilly and Company</td>
<td>71</td>
</tr>
<tr>
<td>George T. Grossberg, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Lilly Research Laboratories; a division of Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceuticals and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Parkes-Davis, Division of Warner-Lambert Company; Abbott Laboratories; Bayer Corporation, Pharmaceutical Division; Synthelabo</td>
<td>2</td>
</tr>
<tr>
<td>Mary T. Guardino, B.A.</td>
<td>SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>99</td>
</tr>
<tr>
<td>Robert E. Hailes, M.D.</td>
<td>Bristol-Myers Squibb Company</td>
<td>15, 39</td>
</tr>
<tr>
<td>Harriet L. Hall, Ph.D.</td>
<td>Jefferson Center for Mental Health (employer)</td>
<td>27</td>
</tr>
<tr>
<td>Ellen Haller, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>16, 48, 70</td>
</tr>
<tr>
<td>Mark H. Halman, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.</td>
<td>32</td>
</tr>
<tr>
<td>Thomas E. Hansen, M.D.</td>
<td>Hoechst Marion Roussel, Sanofi Pharmaceuticals, Inc.</td>
<td>64</td>
</tr>
<tr>
<td>Peter Hauser, M.D.</td>
<td>Forest Laboratories, Inc.; Schering Plough</td>
<td>45</td>
</tr>
<tr>
<td>David J. Hellerstein, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Glaxo Wellcome Inc.; Bristol-Myers Squibb Company; Wyeth-Ayerst Laboratories</td>
<td>54</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Robert L. Hendrie, D.O.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories; Glaxo Wellcome Inc.</td>
<td>10, 16</td>
</tr>
<tr>
<td>Marvin I. Herz, M.D.</td>
<td>AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>95</td>
</tr>
<tr>
<td>Robert A. Hirschfeld, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb Company; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Pharmacia &amp; Upjohn Company, Inc.; Glaxo Wellcome Inc.; Forest Laboratories, Inc.</td>
<td>9, 10, 60</td>
</tr>
<tr>
<td>Max Hirshkowitz, Ph.D.</td>
<td>Seele, Wyeth-Ayerst Laboratories; Merck &amp; Co., Inc.; Cephalon</td>
<td>1</td>
</tr>
<tr>
<td>Eric Hollander, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Abbott Laboratories; Bristol-Myers Squibb Company; Lilly Research Laboratories, a division of Eli Lilly and Company; SmithKline Beecham Pharmaceuticals</td>
<td>12, 39, 80, 100</td>
</tr>
<tr>
<td>Julie Holman, M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>95</td>
</tr>
<tr>
<td>Joseph P. Horrigan, M.D.</td>
<td>Shire Richmond Pharmaceuticals, Watson Laboratories, Inc.</td>
<td>6</td>
</tr>
<tr>
<td>Thomas D. Hurwitz, M.D.</td>
<td>Seele</td>
<td>1, 8</td>
</tr>
<tr>
<td>Michael Y. Hwang, M.D.</td>
<td>Eli Lilly and Company</td>
<td>50, 76, 77</td>
</tr>
<tr>
<td>Steven E. Hyman, M.D.</td>
<td>Ortho-McNeil Pharmaceuticals</td>
<td>47, 83</td>
</tr>
<tr>
<td>Navneet Iqbal, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation</td>
<td>50</td>
</tr>
<tr>
<td>Kay R. Jamison, Ph.D.</td>
<td>Abbott Laboratories, Solvay Pharmaceuticals, Inc.</td>
<td>59</td>
</tr>
<tr>
<td>Philip G. Jancai, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Glaxo Wellcome Inc.; Abbott Laboratories; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company, Genentech</td>
<td>27</td>
</tr>
<tr>
<td>Robert Jarvik, M.D.</td>
<td>Jarvik Heart, Inc. (employer)</td>
<td>95</td>
</tr>
<tr>
<td>James W. Jefferson, M.D.</td>
<td>Organon Inc.; Abbott Laboratories, Bristol-Myers Squibb Company; Eli Lilly Inc.; Forest Laboratories, Inc.; Glaxo Wellcome Inc.; Seele; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; AstraZeneca Pharmaceuticals; Searle; Lilly Research Laboratories, a division of Eli Lilly and Company; Glaxo Wellcome Inc.; Abbott Laboratories; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Genentech</td>
<td>10, 15</td>
</tr>
<tr>
<td>Peter S. Jensen, M.D.</td>
<td>Abbott Laboratories</td>
<td>10</td>
</tr>
<tr>
<td>Dilip V. Jeste, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>18, 39, 77, 83, 98</td>
</tr>
<tr>
<td>Thomas H. Jobe, M.D.</td>
<td>Parke-Davis, Division of Warner-Lambert Company</td>
<td>15</td>
</tr>
<tr>
<td>Hadine Joffe, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company</td>
<td>6, 31</td>
</tr>
<tr>
<td>Peter B. Jones, Ph.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>83</td>
</tr>
<tr>
<td>Ned H. Kahn, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation</td>
<td>87</td>
</tr>
<tr>
<td>John M. Kane, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>10, 13</td>
</tr>
<tr>
<td>Andras M. Karger, M.D.</td>
<td>Glaxo Wellcome Inc.; Abbott Laboratories; Parke-Davis, Division of Warner-Lambert Company</td>
<td>6, 15, 96</td>
</tr>
<tr>
<td>Laurence P. Karp, M.D.</td>
<td>Leigh Valley Hospital (employer)</td>
<td>47</td>
</tr>
<tr>
<td>Wayne J. Kato, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Forest Laboratories, Inc.</td>
<td>60</td>
</tr>
<tr>
<td>Herbert Katschirng, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>12</td>
</tr>
<tr>
<td>Walter H. Kaye, M.D.</td>
<td>Biognosia USA</td>
<td>54</td>
</tr>
<tr>
<td>Paul E. Keck, Jr., M.D.</td>
<td>Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation; Merck &amp; Co., Inc.; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>60, 97</td>
</tr>
<tr>
<td>Richard S. Keefe, Ph.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories</td>
<td>3</td>
</tr>
<tr>
<td>Samuel J. Keith, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation</td>
<td>7</td>
</tr>
<tr>
<td>Martin B. Keller, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Wyeth-Ayerst Laboratories; Merck &amp; Co., Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Organon Inc.; SmithKline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; AstraZeneca Pharmaceuticals; Chisuka Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Mitsubishi Pharmaceuticals; Sorex</td>
<td>7, 39</td>
</tr>
<tr>
<td>Kenneth S. Kendler, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories</td>
<td>2</td>
</tr>
<tr>
<td>James L. Kennedy, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Solvay Pharmaceuticals, Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>102</td>
</tr>
<tr>
<td>Justine M. Kent, M.D.</td>
<td>Bristol-Myers Squibb Company; Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals</td>
<td>6, 72</td>
</tr>
<tr>
<td>Terrence A. Katter, M.D.</td>
<td>Abbott Laboratories; Parke-Davis, Division of Warner-Lambert Company; Glaxo Wellcome Inc.; Shire Richmond Pharmaceuticals; R. W. Johnson</td>
<td>32, 74</td>
</tr>
</tbody>
</table>

**XXVI**
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinton D. Kilts, Ph.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; SmithKline Beecham Pharmaceuticals</td>
<td>11</td>
</tr>
<tr>
<td>Steven A. King, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories; Purdue Pharmaceuticals</td>
<td>28</td>
</tr>
<tr>
<td>Donald F. Klein, M.D.</td>
<td>U.S. Pharmaceuticals; Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; Pharmacia &amp; Upjohn Company, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Intervenex</td>
<td>78, 99</td>
</tr>
<tr>
<td>Martin R.J. Knapp, Ph.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals</td>
<td>3</td>
</tr>
<tr>
<td>Richard Kogan, M.D.</td>
<td>Bristol-Myers Squibb Company; U.S. Pharmaceuticals; Pfizer Inc.</td>
<td>45, 85</td>
</tr>
<tr>
<td>Thomas R. Koester, M.D.</td>
<td>Schering Pharmaceuticals; Reckitt Benckiser; Bristol-Myers Squibb Company; Cansta</td>
<td>34, 43, 48, 100</td>
</tr>
<tr>
<td>Athanasio Koukopoulos, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>54</td>
</tr>
<tr>
<td>Henry R. Kranizer, M.D.</td>
<td>U.S. Pharmaceuticals; Pfizer Inc.; Bristol-Myers Squibb Company; Takeda Pharmaceuticals</td>
<td>35</td>
</tr>
<tr>
<td>K Ranga R. Krishnan, M.D.</td>
<td>Merck &amp; Co., Inc.; U.S. Pharmaceuticals; Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals; Pfizer Inc.</td>
<td>7, 31</td>
</tr>
<tr>
<td>Stanley P. Kutcher, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Boehringer Ingelheim; Hoffman-LaRoche; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals; Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Glaxo Wellcome Inc.; Novartis Pharmaceuticals Corporation; Solvay, Nova Pharmaceuticals; Hoechst Marion Roussel; Janssen Pharmaceutica and Research Foundation; Ortho-McNeil Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>87</td>
</tr>
<tr>
<td>Jonathan P. Lacro, Pharm.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals; Pfizer Inc.</td>
<td>96</td>
</tr>
<tr>
<td>Isabel T. Lagomasino, M.D.</td>
<td>Organon Inc.</td>
<td>15</td>
</tr>
<tr>
<td>Raymond W. Lam, M.D.</td>
<td>U.S. Pharmaceuticals; Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; Lundbeck</td>
<td>54</td>
</tr>
<tr>
<td>Y.W. Francis Lam, Pharm.D.</td>
<td>Eli Lilly and Company; Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals; Pfizer Inc.</td>
<td>40</td>
</tr>
<tr>
<td>J. Steven Lambert, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>51</td>
</tr>
<tr>
<td>Brian A. Lawlor, M.D.</td>
<td>U.S. Pharmaceuticals; Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>63</td>
</tr>
<tr>
<td>William B. Lawson, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Otsuka Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Glaxo Wellcome Inc.; Abbott Laboratories</td>
<td>10, 27, 52</td>
</tr>
<tr>
<td>Barry L. Lebowitz, Ph.D.</td>
<td>Eli Lilly and Company; National Institute of Mental Health</td>
<td>63, 87</td>
</tr>
<tr>
<td>Henrietta L. Leonard, M.D.</td>
<td>Bristol-Myers Squibb Company; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals; Pfizer Inc.</td>
<td>53</td>
</tr>
<tr>
<td>Francois Leperneau, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Bristol-Myers Squibb Company; U.S. Pharmaceuticals; Pfizer Inc.; Forest Laboratories, Inc.</td>
<td>2</td>
</tr>
<tr>
<td>Alan J. Levenson, M.D.</td>
<td>Psychiatrists' Purchasing Group, Inc.</td>
<td>49</td>
</tr>
<tr>
<td>Lydia Lewis</td>
<td>Abbott Laboratories; Bristol-Myers Squibb Company; Glaxo Wellcome Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Johnson and Johnson; Eli Lilly and Company; Merck &amp; Co., Inc.; U.S. Pharmaceuticals; Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories</td>
<td>60, 16</td>
</tr>
<tr>
<td>Freda C. Lewis-Hall, M.D.</td>
<td>Eli Lilly and Company</td>
<td>16</td>
</tr>
<tr>
<td>Jeffrey A. Lieberman, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Hoechst Marion Roussel; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals; Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>3, 22, 83</td>
</tr>
<tr>
<td>Michael R. Liebowitz, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Merck &amp; Co., Inc.; U.S. Pharmaceuticals; Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Synthelabo; Wyeth-Ayerst Laboratories</td>
<td>85, 99</td>
</tr>
<tr>
<td>Russell F. Lim, M.D.</td>
<td>Eli Lilly and Company</td>
<td>8, 79</td>
</tr>
<tr>
<td>Jean-Pierre Lindenmayer, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>9</td>
</tr>
<tr>
<td>Paul S. Links, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td>102</td>
</tr>
<tr>
<td>Joel F. Lubin, Ph.D.</td>
<td>Stoelting Autogenic Corporation</td>
<td>64</td>
</tr>
<tr>
<td>R. Bruce Lydiard, M.D.</td>
<td>Bristol-Myers Squibb Company; Eli Lilly and Company; Glaxo Wellcome Inc.; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals; Pfizer Inc.; Roche Laboratories, a member of the Roche Group; SmithKline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; Wyeth-Ayerst Laboratories; Abbott Laboratories; AstraZeneca Pharmaceuticals; Hoechst Marion Roussel; Astra/Merck Group; Division of Merck &amp; Co.; Dupont Pharma; Novartis Pharmaceuticals Corporation; Merck &amp; Co., Inc.; Forest Laboratories, Inc.; Solvay Pharmaceuticals, Inc.; Organon Inc.; Ravizza Pharmaceuticals</td>
<td>11, 99</td>
</tr>
<tr>
<td>Constantine G. Lyketsos, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals; Pfizer Inc.; Bayer Corporation; Pharmaceutical Division; Parke-Davis; Division of Warner-Lambert Company; Abbott Laboratories; Bristol-Myers Squibb Company</td>
<td>48</td>
</tr>
<tr>
<td>XXVII</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Jose R. Maldonado, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Glaxo Wellcome Inc.</td>
<td>5, 11, 41, 54</td>
</tr>
<tr>
<td>Catherine L. Manoni, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.; SmithKline Beecham Pharmaceuticals; Bristol-Myers Squibb Company</td>
<td>96</td>
</tr>
<tr>
<td>Hussaini K. Manji, M.D.</td>
<td>AstraZeneca Pharmaceuticals, Abbott Laboratories; Eli Lilly and Company; Solvay Pharmaceuticals, Inc.</td>
<td>59</td>
</tr>
<tr>
<td>Lauren B. Marangell, M.D.</td>
<td>AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company, Forest Laboratories, Inc.; Bristol-Myers Squibb Company; Abbott Laboratories; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; Mearx Biosciences; Wyeth-Ayerst Laboratories</td>
<td>12, 50</td>
</tr>
<tr>
<td>Stephen R. Markey, M.D.</td>
<td>AstraZeneca Pharmaceuticals and Research Foundation, Eli Lilly and Company, Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; Lundbeck</td>
<td>12, 27</td>
</tr>
<tr>
<td>John C. Markowitz, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb Company; National Institute of Mental Health; Eli Lilly Research Laboratories, a division of Eli Lilly and Company; American Psychiatric Press, Inc.</td>
<td>5, 24, 74, 96, 99</td>
</tr>
<tr>
<td>Prakash S. Maran, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Janssen Pharmaceuticals and Research Foundation; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb Company; Hoechst Marion Roussel; Novartis Pharmaceuticals Corporation; Pharmacia &amp; Upjohn Company, Inc.; Searle; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Eisai Inc.; Abbott Laboratories</td>
<td>2, 11</td>
</tr>
<tr>
<td>Barbara J. Mason, Ph.D.</td>
<td>Lipha Pharmaceuticals, Inc.</td>
<td>33</td>
</tr>
<tr>
<td>Mary Jane Masse, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb Company</td>
<td>57</td>
</tr>
<tr>
<td>John D. Matthews, M.D.</td>
<td>Eli Lilly and Company</td>
<td>49</td>
</tr>
<tr>
<td>W. Vaughn McCall, M.D.</td>
<td>Wyeth-Ayerst Laboratories, Searle</td>
<td>7, 8</td>
</tr>
<tr>
<td>Christopher J. McDougie, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation, U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Solvay Pharmaceuticals, Inc.</td>
<td>7</td>
</tr>
<tr>
<td>David M. McDowell, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Bristol-Myers Squibb Company</td>
<td>50, 58, 65, 70, 78</td>
</tr>
<tr>
<td>Susan L. McEwen, M.D.</td>
<td>Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; Solvay Pharmaceuticals, Inc.; Glaxo Wellcome Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis; Division of Warner-Lambert Company; Janssen Pharmaceuticals and Research Foundation; PRI</td>
<td>15, 31, 39, 54</td>
</tr>
<tr>
<td>Bonson H. McFarland, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Parke-Davis; Division of Warner-Lambert Company</td>
<td>48</td>
</tr>
<tr>
<td>Ian G. McFarland, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceuticals and Research Foundation; Eli Lilly and Company</td>
<td>63, 87</td>
</tr>
<tr>
<td>Michael S. Mega, M.D.</td>
<td>Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>11</td>
</tr>
<tr>
<td>Thomas A. Mellman, M.D.</td>
<td>Bristol-Myers Squibb Company; Wyeth-Ayerst Laboratories</td>
<td>5</td>
</tr>
<tr>
<td>Jacqueline Melonas, J.D.</td>
<td>Professional Risk Management Services, Inc. (employer)</td>
<td>49</td>
</tr>
<tr>
<td>Herbert Y. Metzler, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Merck &amp; Co., Inc.; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Dupont Pharma; Janssen Pharmaceuticals and Research Foundation</td>
<td>50</td>
</tr>
<tr>
<td>Samantha E. Metzler-Brody, M.D.</td>
<td>Bristol-Myers Squibb Company</td>
<td>26, 30</td>
</tr>
<tr>
<td>Alan J. Mendelowitz, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>13</td>
</tr>
<tr>
<td>Wallace B. Mendelson, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>1, 9</td>
</tr>
<tr>
<td>Ricardo P. Mendoza, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation; Parke-Davis; Division of Warner-Lambert Company</td>
<td>52</td>
</tr>
<tr>
<td>Richard J. Meltzer, M.D.</td>
<td>Glaxo Wellcome Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Eli Lilly and Company</td>
<td>59</td>
</tr>
<tr>
<td>E.E. Mck. Sc D</td>
<td>Alza Pharmaceuticals</td>
<td>83</td>
</tr>
<tr>
<td>Alexander L. Miller, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Janssen Pharmaceuticals and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>35</td>
</tr>
<tr>
<td>Jacob E. Mintzer, M.D.</td>
<td>Abbott Laboratories; Eisai Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceuticals and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Parke-Davis; Division of Warner-Lambert Company; Elan Inc.</td>
<td>40, 63, 87</td>
</tr>
<tr>
<td>David Mischoulon, M.D,</td>
<td>Bristol-Myers Squibb Company</td>
<td>24</td>
</tr>
<tr>
<td>Shalla Misi, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td>2, 8, 97</td>
</tr>
<tr>
<td>James C. Mitchell, M.D.</td>
<td>Eli Lilly and Company; Roche Laboratories, a member of the Roche Group; Sanders</td>
<td>5, 35, 34</td>
</tr>
<tr>
<td>Richard C. Motte, Ph.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Bayer Corporation, Pharmaceutical Division; Ortho-McNeill Pharmaceuticals; Janssen Pharmaceuticals and Research Foundation</td>
<td>87</td>
</tr>
<tr>
<td>James C. Montgomery, M.D.</td>
<td>Bristol-Myers Squibb Company</td>
<td>50</td>
</tr>
<tr>
<td>David A. Mrazek, M.D.</td>
<td>Abbott Laboratories</td>
<td>10</td>
</tr>
<tr>
<td>Benoit H. Mulsant, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Janssen Pharmaceuticals and Research Foundation; AstraZeneca Pharmaceuticals</td>
<td>47</td>
</tr>
<tr>
<td>Michael D. Murphy, M.D., M.P.H.</td>
<td>Specialized Healthcare Programs (employer), Psychiatry Compliance Services (employer)</td>
<td>74</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Philip R. Musik, M.D.</td>
<td>Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories</td>
<td>30, 89</td>
</tr>
<tr>
<td>Dominique L. Musselman, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Wyeth-Ayerst Laboratories; National Institutes of Health; Dana Foundation; Schering Plough</td>
<td>11, 63</td>
</tr>
<tr>
<td>Donald L. Myrick, M.D.</td>
<td>Parke-Davis, Division of Warner-Lambert Company; Abbott Laboratories</td>
<td>31</td>
</tr>
<tr>
<td>Carol C. Nadelson, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Henry A. Nasserallah, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb Company; Eli Lilly and Company; Organon Inc.; Wyeth-Ayerst Laboratories; Bayer Corporation. Pharmaceutical Division; Ciba Geigy; Glaxo Wellcome Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>2</td>
</tr>
<tr>
<td>J. Craig Nelson, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb Company; Eli Lilly and Company; Organon Inc.; Wyeth-Ayerst Laboratories; Bayer Corporation. Pharmaceutical Division; Ciba Geigy; Glaxo Wellcome Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>39</td>
</tr>
<tr>
<td>Andrew A. Nierenberg, M.D.</td>
<td>Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; NARSAD. National Institute of Mental Health; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; AstraZeneca Pharmaceuticals; NAMI; Merck &amp; Co., Inc.; Sanofi Pharmaceuticals, Inc.; Mitsubishi; Neurocine; Otsuka Pharmaceuticals</td>
<td>7, 11, 22, 45</td>
</tr>
<tr>
<td>Vernon M. Neppe, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb Company; Eli Lilly and Company; Novartis Pharmaceuticals Corporation</td>
<td>96</td>
</tr>
<tr>
<td>Antonia S. New, M.D.</td>
<td>Eli Lilly and Company</td>
<td>32</td>
</tr>
<tr>
<td>John W. Newcomer, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; AstraZeneca Pharmaceuticals</td>
<td>60</td>
</tr>
<tr>
<td>Raymond S. Niaura, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Glaxo Wellcome Inc.</td>
<td>28</td>
</tr>
<tr>
<td>Andrew A. Nierenberg, M.D.</td>
<td>Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Glaxo Wellcome Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Lichver Pharma; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Sanofi Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories</td>
<td>2, 15, 39, 94</td>
</tr>
<tr>
<td>Philip T. Ninan, M.D.</td>
<td>Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Bristol-Squibb Company; Organon Inc.; Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>87</td>
</tr>
<tr>
<td>H. George Nurnberg, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Bristol-Myers Squibb Company; Abbott Laboratories; Glaxo Wellcome Inc.</td>
<td>2</td>
</tr>
<tr>
<td>John I. Nurnberger, Jr., M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>10, 79</td>
</tr>
<tr>
<td>Kristin J. O'Neill, M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>49</td>
</tr>
<tr>
<td>Stephanie S. O'Malley, Ph.D.</td>
<td>Dupont Pharma; Merck &amp; Co., Inc.; Lipha Pharmaceuticals; AstraZeneca Pharmaceuticals</td>
<td>33</td>
</tr>
<tr>
<td>Jessica R. Cestende, M.D.</td>
<td>Cytochrome Drug Interaction Program (designer)</td>
<td>5, 67</td>
</tr>
<tr>
<td>Lewis A. Opler, M.D.</td>
<td>Multi-Health Systems</td>
<td>51, 76, 77</td>
</tr>
<tr>
<td>Paula G. Panzer, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Robert D. Patterson, M.D.</td>
<td>Mental Health Connecitons, Inc. (employer)</td>
<td>87</td>
</tr>
<tr>
<td>William E. Pelham, Jr., Ph.D.</td>
<td>Shire Richwood Pharmaceuticals; Alza Pharmaceuticals; Abbott Laboratories; Noven Pharmaceuticals; Bristol-Myers Squibb Company</td>
<td>83</td>
</tr>
<tr>
<td>Diana O. Perkins, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Hoechst-Marion Roussel</td>
<td>15</td>
</tr>
<tr>
<td>Bruce D. Perry, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>87</td>
</tr>
<tr>
<td>Eric D. Peselow, M.D.</td>
<td>Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>78, 84, 99</td>
</tr>
<tr>
<td>Elaine Peskind, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Abbott Laboratories; Elian</td>
<td>6</td>
</tr>
<tr>
<td>Richard G. Petty, M.D.</td>
<td>Eli Lilly and Company; AstraZeneca Pharmaceuticals</td>
<td>3, 21</td>
</tr>
<tr>
<td>Katherine A. Phillips, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Gate Pharmaceuticals</td>
<td>68, 90, 98</td>
</tr>
<tr>
<td>Edmond H. Pi, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company</td>
<td>20, 33, 46, 52</td>
</tr>
<tr>
<td>Ronald W. Pees, M.D.</td>
<td>GME, Inc. (Psychiatric Times)</td>
<td>99</td>
</tr>
<tr>
<td>Daniel S. Pine, M.D.</td>
<td>Bristol-Myers Squibb Company; Solvay Pharmaceuticals, Inc.</td>
<td>12</td>
</tr>
<tr>
<td>Olavo D. Pinto, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories</td>
<td>54</td>
</tr>
<tr>
<td>Bruce G. Pollock, M.D.</td>
<td>National Institute of Mental Health; Solvay Pharmaceuticals, Inc.; SmithKline Beecham Pharmaceuticals; Pharmaceuticals &amp; Upjohn Company, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Glaxo Wellcome Inc.; Lundbeck; Parke-Davis, Division of Warner-Lambert Company</td>
<td>3</td>
</tr>
<tr>
<td>Charles W. Popper, M.D.</td>
<td>Abbott Laboratories; Shire Richwood Pharmaceuticals; Pharmaceutical &amp; Upjohn Company, Inc.; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb Company</td>
<td>5</td>
</tr>
</tbody>
</table>

XXIX
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>David W. Prven, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.</td>
<td>46, 68, 96</td>
</tr>
<tr>
<td>Annette Primm, M.D.</td>
<td>Eli Lilly and Company</td>
<td>19, 79</td>
</tr>
<tr>
<td>Jefferson B. Prince, M.D.</td>
<td>Organon Inc.</td>
<td>36</td>
</tr>
<tr>
<td>Andres J. Pumariega, M.D.</td>
<td>Forest Laboratories, Inc., Janssen Pharmaceuticals and Research Foundation</td>
<td>35, 79</td>
</tr>
<tr>
<td>Scott E. Purdon, Ph.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company, Janssen Pharmaceuticals and Research Foundation, AstraZeneca Pharmaceuticals</td>
<td>87</td>
</tr>
<tr>
<td>Paul M. Ramirez, Ph.D.</td>
<td>Multi-Health Systems, Inc.</td>
<td>51</td>
</tr>
<tr>
<td>Neal G. Ranen, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals, Richmond, Norvatis Pharmaceuticals Corporation; Astra Pharmaceuticals, Inc.</td>
<td>35</td>
</tr>
<tr>
<td>Judith H.L. Rapoport, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Janssen Pharmaceuticals and Research Foundation</td>
<td>83, 90</td>
</tr>
<tr>
<td>Natalie L. Rasgon, M.D.</td>
<td>Abbott Laboratories, Forest Laboratories, Inc., Solvay Pharmaceuticals, Ltd.</td>
<td>31</td>
</tr>
<tr>
<td>Murray A. Raskind, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Searle, Bristol-Myers Squibb Company, Eisai Inc.</td>
<td>8, 83</td>
</tr>
<tr>
<td>Jerroid F. Rosenbaum, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company, Merck &amp; Co., Inc.; Forest Laboratories, Inc.</td>
<td>40, 64</td>
</tr>
<tr>
<td>Charles F. Raymond III, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceuticals and Research Foundation; Eli Lilly and Company, Bristol-Myers Squibb Company</td>
<td>89, 99</td>
</tr>
<tr>
<td>Gary Richardson, M.D.</td>
<td>Wyeth-Ayerst Laboratories, Searle, Synthelabo</td>
<td>7</td>
</tr>
<tr>
<td>Margaret A. Richter, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td>101</td>
</tr>
<tr>
<td>Trevor Robbins, Ph.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>87</td>
</tr>
<tr>
<td>Laura W. Roberts, M.D.</td>
<td>Ortho-McNeil Pharmaceuticals</td>
<td>83</td>
</tr>
<tr>
<td>Robert G. Robinson, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>2, 35</td>
</tr>
<tr>
<td>Catherine A. Roca, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td>2</td>
</tr>
<tr>
<td>Elizabeth J. Rody, M.D.</td>
<td>Magellan Behavioral Health (employer)</td>
<td>28</td>
</tr>
<tr>
<td>Marijke T. Rooney, Ph.D.</td>
<td>American Psychiatric Press, Inc.</td>
<td>8</td>
</tr>
<tr>
<td>Steven P. Roose, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company</td>
<td>64</td>
</tr>
<tr>
<td>Jerold F. Rosenbaum, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company</td>
<td>9</td>
</tr>
<tr>
<td>Jenilyn Ross, M.A.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td>85</td>
</tr>
<tr>
<td>Kathryn M. Rost, Ph.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>60</td>
</tr>
<tr>
<td>Thomas Roth, Ph.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>9</td>
</tr>
<tr>
<td>Peter T. Roy-Byrne, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Forest Laboratories, Inc.</td>
<td>60</td>
</tr>
<tr>
<td>David R. Rubnow, M.D.</td>
<td>Dieta Products, TAP Pharmaceuticals, Ciba Geigy Corporation, Pharmaceutical Division, Upjohn-Smith, Eli Lilly and Company</td>
<td>6, 31</td>
</tr>
<tr>
<td>Neal D. Ryan, M.D.</td>
<td>Wyeth-Ayerst Laboratories, SmithKline Beecham Pharmaceuticals, U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company, Abbott Laboratories</td>
<td>60</td>
</tr>
<tr>
<td>Gary S. Sacks, M.D.</td>
<td>Abbott Laboratories, Glaxo Wellcome Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company, Janssen Pharmaceuticals and Research Foundation; Seis Nova Pharmaceuticals; Forest Laboratories, Inc., SmithKline Beecham Pharmaceuticals, Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>60, 63</td>
</tr>
<tr>
<td>Martha Sajatovic, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>64, 98</td>
</tr>
<tr>
<td>Carl Salzman, M.D.</td>
<td>Forest Laboratories, Inc., AstraZeneca Pharmaceuticals, Janssen Pharmaceuticals and Research Foundation, Wyeth-Ayerst Laboratories, SmithKline Beecham Pharmaceuticals, Glaxo Wellcome Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>2</td>
</tr>
<tr>
<td>Franklin R. Schneider, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.</td>
<td>7, 85</td>
</tr>
<tr>
<td>Nina R. Schoeler, Ph.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals</td>
<td>7, 32</td>
</tr>
<tr>
<td>R. Andrew Schultz-Ross, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Pfenum Press</td>
<td>59</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>S. Charles Schultz, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation, Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals</td>
<td>15, 39</td>
</tr>
<tr>
<td>Dean Schuyler, M.D.</td>
<td>Eli Lilly; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.</td>
<td>27</td>
</tr>
<tr>
<td>Jan Scott, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>12</td>
</tr>
<tr>
<td>R. Taylor Segraves, M.D.</td>
<td>Glaxo Wellcome Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories</td>
<td>55</td>
</tr>
<tr>
<td>Gabrielle L. Shapiro, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>15</td>
</tr>
<tr>
<td>Peter A. Shapiro, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>25, 93</td>
</tr>
<tr>
<td>Rajiv P. Sharma, M.D.</td>
<td>Parke-Davis, Division of Warner-Lambert Company; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>27</td>
</tr>
<tr>
<td>Jon A. Shaw, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>15</td>
</tr>
<tr>
<td>Shawn C. Shea, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td>1, 17</td>
</tr>
<tr>
<td>M. Katherine Shea, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; Hoffman-LaRoche; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>72</td>
</tr>
<tr>
<td>David V. Sheehan, M.D.</td>
<td>Abbott Laboratories; Boehringer Ingelheim; Boots Pharmaceuticals; Bristol-Myers Squibb Company; Charter Hospitals; Ciba Geigy Corporation; Pharmaceutical Division; Distal Products; Eli Lilly and Company, Excerpta Medica Asia; Glaxo Wellcome Inc.; Hospital Corporation of America, Humana; IC: Kali-Duphar Laboratories, Inc.; Marion Merril Dow; McKesson Pharmaceuticals; Merck &amp; Co., Inc.; Organon Inc., Novo Nordisk; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; Rhone-Poulenc Rorer Pharmaceuticals, Roche Laboratories; Roeng; Sandoz Pharmaceuticals; Shering Corporation; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; TAP Pharmaceuticals; TGH-University Psychiatry Center; Pharmacia &amp; Upjohn Company, Inc.; Warner Chilcott; Wyeth-Ayerst Laboratories; Layton Biocrise; Medical Outcomes Systems; Proctonetics On Line; American Medical Association; Anlotin Foundation; Eisa Inc.; Forest Laboratories, Inc.; International Clinical Research; Janssen Pharmaceutica and Research Foundation; National Institutes of Health; Novartis Pharmaceuticals Corporation; Quinlins; Sanofi Pharmaceuticals, Inc.; Synthelabo; Tampa General Hospital-University Psychiatry Center; Worldwide Clinical Trials; AstraZeneca Pharmaceuticals; Shire Richwood Pharmaceuticals; World Health Organization; Pierre Fabre, France; Lundbeck, Alza Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; National Anxiety Foundation; Philadelphia College of Pharmacy and Science; Lilly Research Laboratories, a division of Eli Lilly and Company; Connecticut and Ohio Academies of Family Physicians; CPC Coliseum Medical Center; USF Friends of Research in Psychiatry, Board of Trustees; National Anxiety Awareness Program; Anxiety Disorders Resource Center; APA Task Force on Treatment of Psychiatric Disorders; APA Task Force on Benzodiazepine Dependency; Pharmacia &amp; Upjohn Company, Inc.; National Depressive and Manic Depressive Association; Council on Anxiety Disorders; Division of Drugs and Technology; American Medical Association; National Institute of Mental Health; APA Working Groups to revise DSM III Anxiety Disorders; Anxiety Drug Efficacy Case; U.S. Food and Drug Administration; U.S. Congress-House of Representatives Committee</td>
<td>61, 83</td>
</tr>
<tr>
<td>Barbara B. Sherwin, Ph.D.</td>
<td>Proctor and Gamble Pharmaceuticals; Wyeth-Ayerst Laboratories; Solvay Pharmaceuticals, Inc.</td>
<td>31</td>
</tr>
<tr>
<td>Marjorie L. Shuer, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>40</td>
</tr>
<tr>
<td>Larry J. Siever, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation</td>
<td>32, 73</td>
</tr>
<tr>
<td>George M. Simpson, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation</td>
<td>27</td>
</tr>
<tr>
<td>Gary W. Small, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Bayer Corporation; Pharmaceutical Division; Eisa Inc. Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals</td>
<td>8, 76</td>
</tr>
<tr>
<td>Michael W. Smith, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>25, 96</td>
</tr>
<tr>
<td>Thomas E. Smith, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation, Eisa Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>83</td>
</tr>
<tr>
<td>Beth Smith-Bowin, M.S.</td>
<td>Janssen Pharmaceutica and Research Foundation, Eisa Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>26</td>
</tr>
<tr>
<td>Solomon H. Snyder, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>50, 52</td>
</tr>
<tr>
<td>Andrew Solomon</td>
<td>Forest Laboratories, Inc.</td>
<td></td>
</tr>
<tr>
<td>Paul R. Solomon, Ph.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td></td>
</tr>
<tr>
<td>Thomas J. Spencer, M.D.</td>
<td>Abbott Laboratories; Alza Pharmaceuticals; Bristol-Myers Squibb Company; Eisa Inc.; Glaxo Wellcome Inc.; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; National Institute on Drug Abuse; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Shire Richwood Pharmaceuticals; Wyeth-Ayerst Laboratories</td>
<td>60, 83</td>
</tr>
<tr>
<td>Margaret S. Spinhel, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>24</td>
</tr>
<tr>
<td>Thomas B. Stage, M.D.</td>
<td>Joint Commission on Accreditation of Health Care Organizations</td>
<td></td>
</tr>
</tbody>
</table>

XXXI
**DISCLOSURE INDEX**

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen M. Strakowski, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Janssen Pharmaceutica and Research Foundation; Bayer Corporation; Pharmaceutical Division; Boehringer Ingelheim; Yamanouchi; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb Company; Roche Laboratories, a member of the Roche Group; Ciba Geigy Corporation; Pharmaceutical Division; Novartis Pharmaceuticals Corporation; Pharmacia &amp; Upjohn Company; Hoehst Marion Roussel; Takeda Pharmaceuticals; Abbott Laboratories; Organon Inc.; Sanofi Pharmaceuticals; Inc.; Pierre Fabre; Loretex; Sumitomo; Synthélabo; Watson Laboratories, Inc.; AstraZeneca Pharmaceuticals</td>
<td>82, 83</td>
</tr>
<tr>
<td>Dan J. Stein, M.B.</td>
<td>South African Mental Health Information Centre (employer); Solvay Pharmaceuticals, Inc.</td>
<td>12</td>
</tr>
<tr>
<td>Murray B. Stein, M.D.</td>
<td>Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; Hoffman-LaRoche; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Janssen Pharmaceutica and Research Foundation; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>7, 12</td>
</tr>
<tr>
<td>Hans Steiner, M.D.</td>
<td>Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>6</td>
</tr>
<tr>
<td>Michael Sterman, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Hoffmann-LaRoche; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>18, 26, 57, 60</td>
</tr>
<tr>
<td>Donna E. Stewart, M.D.</td>
<td>Eli Lilly and Company; Forest Laboratories, Inc.</td>
<td>64</td>
</tr>
<tr>
<td>Nada L. Stollard, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Forest Laboratories, Inc.; Journal Watch Women’s Health (associate editor)</td>
<td>18, 26, 31, 36, 44, 50, 57, 78, 79, 99</td>
</tr>
<tr>
<td>Zachary N Stowe, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly Research Laboratories, a division of Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.                                                                                                                                 2, 6</td>
<td></td>
</tr>
<tr>
<td>Stephen M. Strakowski, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Otsuka Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>6</td>
</tr>
<tr>
<td>Bradley W. Strong, M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>31</td>
</tr>
<tr>
<td>David L. Sutizer, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Bayer Corporation; Pharmaceutical Division; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.</td>
<td>20</td>
</tr>
<tr>
<td>Trey Sunderland, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; AstraZeneca Pharmaceuticals</td>
<td>40</td>
</tr>
<tr>
<td>Patricia Suppes, M.D.</td>
<td>Abbott Laboratories; SmithKline Beecham Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Organon Inc.; Glaxo Wellcome Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Ortho-McNeil Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; CME, Inc.; SCP Communications</td>
<td>11</td>
</tr>
<tr>
<td>Norman Sussman, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Glaxo Wellcome Inc.; Bristol-Myers Squibb Company; Organon Inc.; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; AstraZeneca Pharmaceuticals</td>
<td>32, 83</td>
</tr>
<tr>
<td>Alan C. Swann, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Robert Wood Johnson Foundation; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; AstraZeneca Pharmaceuticals; Cephalon; Lilly Research Laboratories, a division of Eli Lilly and Company; Gisteltech</td>
<td>7, 18, 79, 99</td>
</tr>
<tr>
<td>James M. Swanson, Ph.D.</td>
<td>Alza Pharmaceuticals; Novartis Pharmaceuticals Corporation; Shire Richwood Pharmaceuticals; Cellgene; Medeva; Janssen Pharmaceutica and Research Foundation; Cephalon; Lilly Research Laboratories, a division of Eli Lilly and Company; Gisteltech</td>
<td>32</td>
</tr>
<tr>
<td>Sandra S. Swantek, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Merck &amp; Co., Inc.; Abbott Laboratories, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb Company; Lundbeck; Janssen Pharmaceutica and Research Foundation; Synthélabo; Pharmacia &amp; Upjohn Company, Inc.; Quintiles; Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation</td>
<td>63, 76, 87</td>
</tr>
<tr>
<td>Carol A. Tamminga, M.D.</td>
<td>Eli Lilly and Company; Pharmacia &amp; Upjohn Company, Inc.; Bristol-Myers Squibb Company; Organon Inc.; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; AstraZeneca Pharmaceuticals</td>
<td>64</td>
</tr>
<tr>
<td>Rajiv Tandon, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Shire Richwood Pharmaceuticals; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; AstraZeneca Pharmaceuticals</td>
<td>22, 92</td>
</tr>
<tr>
<td>Rosemary Tannock, Ph.D.</td>
<td>Novartis Pharmaceuticals Corporation; Shire Richwood Pharmaceuticals; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; AstraZeneca Pharmaceuticals</td>
<td>13, 15, 39</td>
</tr>
<tr>
<td>Pierre N. Taniot, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Shire Richwood Pharmaceuticals; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; AstraZeneca Pharmaceuticals</td>
<td>6, 76</td>
</tr>
<tr>
<td>Clifton R. Tennison, Jr., M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; Glaxo Wellcome Inc.; Merck &amp; Co., Inc.; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; Wyeth-Ayerst Laboratories; Parke-Davis, Division of Warner-Lambert Company; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Lippa Pharmaceuticals</td>
<td>39, 40, 83</td>
</tr>
<tr>
<td>Michael E. Thase, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; Glaxo Wellcome Inc.; Merck &amp; Co., Inc.; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; Wyeth-Ayerst Laboratories; Parke-Davis, Division of Warner-Lambert Company; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Lippa Pharmaceuticals</td>
<td>36, 54</td>
</tr>
<tr>
<td>Troy L. Thompson II, M.D.</td>
<td>Glaxo Wellcome Inc.; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; SmithKline Beecham Pharmaceuticals; AstraZeneca Pharmaceuticals; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; AstraZeneca Pharmaceuticals</td>
<td>25, 44, 54, 92</td>
</tr>
<tr>
<td>Martin G. Tracy, J.D.</td>
<td>Professional Risk Management Services, Inc. (employer)</td>
<td>49, 96</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Madhukar H. Trivedi, M.D.</td>
<td>Smithkline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Organon Inc.; Pharmacia &amp; Upjohn Company, Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories</td>
<td>15, 36, 72</td>
</tr>
<tr>
<td>Ming T. Tsuang, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>7, 20, 98</td>
</tr>
<tr>
<td>Phube M. Tucker, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Smithkline Beecham Pharmaceuticals; Eli Lilly and Company,</td>
<td>12</td>
</tr>
<tr>
<td>Larry E. Tune, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals; Pfizer Inc.; Eli Lilly; AstraZeneca Pharmaceuticals</td>
<td>83</td>
</tr>
<tr>
<td>Sam Tyano, M.D.</td>
<td>GEHA Psychiatric Hospital (employer)</td>
<td>44</td>
</tr>
<tr>
<td>Amy M. Ursano, M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>24</td>
</tr>
<tr>
<td>Jerome V. Vaconaro, M.D.</td>
<td>Pacificare (employer)</td>
<td>36</td>
</tr>
<tr>
<td>Michael A. Van Averwege, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb Company; Solvay Pharmaceuticals, Inc.; Parke-Davis, Division of Warner-Lambert Company; Smithkline Beecham Pharmaceuticals</td>
<td>48</td>
</tr>
<tr>
<td>Bessel A. Van Der Kolk, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Server</td>
<td>9, 32</td>
</tr>
<tr>
<td>Bruce S. Vido, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company, Forest Laboratories, Inc.; Bristol-Myers Squibb Company; Solvay Pharmaceuticals, Inc.</td>
<td>1</td>
</tr>
<tr>
<td>Adolfo C. Vignera, M.D.</td>
<td>Eli Lilly and Company; 21, 92</td>
<td>6, 79</td>
</tr>
<tr>
<td>Frank J. Vooc, Ph.D.</td>
<td>Reckitt and Colman Pharmaceuticals; National Institute on Drug Abuse</td>
<td>34</td>
</tr>
<tr>
<td>Suzanne E. Vogel-Scibilia, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company, Ortho-McNeil Pharmaceuticals</td>
<td>44, 83</td>
</tr>
<tr>
<td>Joseph R. Volpoei, M.D.</td>
<td>DuPont Pharma</td>
<td>39</td>
</tr>
<tr>
<td>Alan Wade, M.B.</td>
<td>Forest Laboratories, Inc.; Lundbeck; Smithkline Beecham Pharmaceuticals, U.S. Pharmaceuticals, Pfizer Inc.; Sanofi Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Merck Sharp &amp; Dohme; Synthélabo</td>
<td>12</td>
</tr>
<tr>
<td>Karen D. Wagner, M.D.</td>
<td>Smithkline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories, Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb Company; Organon Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>10, 83, 87</td>
</tr>
<tr>
<td>Art C. Wallaszek, M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>20</td>
</tr>
<tr>
<td>B. Timothy Walsh, M.D.</td>
<td>Eli Lilly and Company; Ortho-McNeil Pharmaceuticals</td>
<td>6, 36, 77, 83</td>
</tr>
<tr>
<td>Julia K. Warnock, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>2</td>
</tr>
<tr>
<td>Carole L. Warshaw, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Sandra L. Waugh, V.M.D.</td>
<td>Windsor Animal Hospital (co-owner)</td>
<td>88</td>
</tr>
<tr>
<td>Peter J. Widner, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Johnson and Johnson</td>
<td>13</td>
</tr>
<tr>
<td>Daniel R. Weinberger, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>22</td>
</tr>
<tr>
<td>Joseph S. Weiner, M.D.</td>
<td>Eli Lilly and Company; Bristol-Myers Squibb Company; Eli Lilly and Company</td>
<td>68</td>
</tr>
<tr>
<td>Richard D. Weiner, M.D.</td>
<td>Medica Corporation</td>
<td>8</td>
</tr>
<tr>
<td>Risa Weisberg, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>48</td>
</tr>
<tr>
<td>Robert L. Weissman, D.O.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Smithkline Beecham Pharmaceuticals</td>
<td>91</td>
</tr>
<tr>
<td>Margaret D. Weiss, M.D.</td>
<td>Smithkline Beecham Pharmaceuticals</td>
<td>5, 16, 51</td>
</tr>
<tr>
<td>Myrna M. Weissman, Ph.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Merck &amp; Co., Inc</td>
<td>7, 59, 99</td>
</tr>
<tr>
<td>Elizabeth B. Weiler, M.D.</td>
<td>Organon Inc.; Abbott Laboratories; Smithkline Beecham Pharmaceuticals; Forest Laboratories, Inc.; Wyeth-Ayerst Laboratories; Remeron</td>
<td>21, 92</td>
</tr>
<tr>
<td>Joyce C. West, M.R.P.</td>
<td>American Psychiatric Association (employer)</td>
<td>53</td>
</tr>
<tr>
<td>Thomas A. Widiger, Ph.D.</td>
<td>Co-author of the Structured Interview for Five Factor Model of Personality (published by Psychological Assessment Resources)</td>
<td>53</td>
</tr>
<tr>
<td>Timothy E. Wiens, M.D.</td>
<td>Abbott Laboratories; Alza Pharmaceuticals; Bristol-Myers Squibb Company; Eisai Inc.; Glaxo Wellcome Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Medeva; National Institute on Drug Abuse; National Institute of Mental Health; Novartis Pharmaceuticals Corporation Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Shire Richwood Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories</td>
<td>60, 71, 83</td>
</tr>
<tr>
<td>John W. Winkelman, M.D.</td>
<td>Eli Lilly and Company; Bristol-Myers Squibb Company; Cephalon; Wyeth-Ayerst Laboratories; Searle Products; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Roering; Smithkline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; Wyeth-Ayerst Laboratories</td>
<td>8</td>
</tr>
<tr>
<td>Daniel K. Winstead, M.D.</td>
<td>Abbott Laboratories; Boots Pharmaceuticals, Bristol-Myers Squibb Company; CoCensys; Distal Products; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Roering; Smithkline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; Wyeth-Ayerst Laboratories</td>
<td>21, 26, 41, 74</td>
</tr>
<tr>
<td>Donna A. Wrisning, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>12</td>
</tr>
<tr>
<td>Roy A. Wise, Ph.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Katherine L. Weiner, M.D.</td>
<td>Roering-Pfizer; Solvay Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Glaxo Wellcome Inc.</td>
<td>10, 97</td>
</tr>
<tr>
<td>Mark L. Wolraich, M.D.</td>
<td>Alza Pharmaceuticals; Shire Richwood Pharmaceuticals</td>
<td>83</td>
</tr>
<tr>
<td>Jesse H. Wright, M.D.</td>
<td>Mindstreet (medical software) (employer)</td>
<td>40</td>
</tr>
<tr>
<td>Joel Yager, M.D.</td>
<td>Eli Lilly and Company</td>
<td>5, 44, 54, 65, 72</td>
</tr>
</tbody>
</table>

XXXIII
### DISCLOSURE INDEX

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rachel Yetuda, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb Company</td>
<td>45, 61, 81</td>
</tr>
<tr>
<td>Kimberly A. Yonkers, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>79</td>
</tr>
<tr>
<td>Elizabeth A. Young, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>84</td>
</tr>
<tr>
<td>Larry Young, Ph.D.</td>
<td>Bristol-Myers Squibb Company; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>15</td>
</tr>
<tr>
<td>Stuart C. Yudofsky, M.D.</td>
<td>Bristol-Myers Squibb Company; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>15, 39, 101</td>
</tr>
<tr>
<td>John M. Zajacka, M.D.</td>
<td>Abbott Laboratories, Bristol-Myers Squibb Company; Eli Lilly and Company. Forest Laboratories, Inc.; Glaxo Wellcome Inc.; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia &amp; Upjohn Company; Inc.; Sanofi Pharmaceuticals, Inc.; Pfizer-Roering; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories</td>
<td>57</td>
</tr>
<tr>
<td>Mary C. Zannin, Ed.D</td>
<td>Abbott Laboratories, Eli Lilly and Company.</td>
<td>32, 78, 79</td>
</tr>
<tr>
<td>Mark Zeitin, M.D.</td>
<td>Glaxo Wellcome Inc.; Bristol-Myers Squibb Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Tail Tree Software (partner)</td>
<td>47</td>
</tr>
<tr>
<td>Sidney Zisook, M.D.</td>
<td>Glaxo Wellcome Inc.; SmithKline Beecham Pharmaceuticals; Bristol-Myers Squibb Company; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth-Ayerst Laboratories; Abbott Laboratories, Novartis Pharmaceuticals Corporation</td>
<td>47</td>
</tr>
<tr>
<td>Joseph Zohar, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Solvay Pharmaceuticals, Inc.</td>
<td>12, 80</td>
</tr>
</tbody>
</table>

**Voting members of the Board of Trustees, Assembly officers, and members of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participation in Industry-Supported Symposia. In accordance with this policy, the following member is participating in an Industry-Supported Symposium and will not receive any compensation:**

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul S. Appelbaum, M.D.</td>
<td>83</td>
</tr>
<tr>
<td>Steven E. Hyman, M.D.</td>
<td>83</td>
</tr>
<tr>
<td>William B. Lawson, M.D.</td>
<td>10</td>
</tr>
<tr>
<td>Carol C. Nadeison, M.D.</td>
<td>2</td>
</tr>
</tbody>
</table>

The following presenters on this year's scientific program failed to return the APA disclosure form. The presenter's name and the page number(s) the presenter appears on in this Program Book are listed below:

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohammed Abou-Saleh, M.D.</td>
<td>60</td>
</tr>
<tr>
<td>Tom G. Campbell, M.D.</td>
<td>49</td>
</tr>
<tr>
<td>Tanya R. Cheevers, M.D.</td>
<td>61</td>
</tr>
<tr>
<td>Judith H. W. Cross, M.D.</td>
<td>27</td>
</tr>
<tr>
<td>Gilla P. Davis, M.D.</td>
<td>27</td>
</tr>
<tr>
<td>James G. Donat, Ph.D.</td>
<td>27</td>
</tr>
<tr>
<td>Terence Dunlop, Ph.D.</td>
<td>27</td>
</tr>
<tr>
<td>Louise F. Fitzgerald, Ph.D.</td>
<td>27</td>
</tr>
<tr>
<td>Veena Greyak, M.D.</td>
<td>27</td>
</tr>
<tr>
<td>Lindsey George, M.D.</td>
<td>27</td>
</tr>
<tr>
<td>Diane Geraghty, J.D.</td>
<td>27</td>
</tr>
<tr>
<td>Bud Grace</td>
<td>27</td>
</tr>
</tbody>
</table>

David G. Ostrow, M.D.                 | 71             |
William J. Richardson, Ph.D.          | 49             |
David Rusin, M.D.                     | 91             |
Adel Sadek, M.D.                      | 61             |
Teresa Sanjuro, M.D.                  | 52             |
Mark E. Schneiderman, Pharm. D.       | 33             |
Sally E. Shaywitz, M.D.               | 76             |
Naotaka Shintaku, M.D.                | 56             |
Paul Spicer, M.D.                     | 73             |
Kenneth Steele                       | 73             |
Tony Strickland, Ph.D.               | 10             |
Peter Tyrer, M.D.                     | 43             |
SATURDAY, MAY 13, 2000

153rd ANNUAL MEETING

8:00 a.m. Sessions

COURSES 1-2
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 1 8:00 a.m. - 12 noon
Room N427 B/C, Level 4, McCormick Place North
THE PSYCHIATRIST AS EXPERT WITNESS
Director: Phillip J. Resnick, M.D.

COURSE 2 8:00 a.m. - 12 noon
Room S502 B, Level 5, McCormick Place South
AN INTRODUCTION TO CLINICAL NEURODYNAMICS
Director: William T. Prey, M.D.

9:00 a.m. Sessions

COURSES 3-8
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 3 9:00 a.m. - 4:00 p.m.
Room S102 B/C, Level 1, McCormick Place South
TRANSPERSONAL PSYCHIATRY: THEORY AND PRACTICE
Co-Directors: Bruce W. Scotton, M.D., Allan B. Chinen, M.D.
Faculty: Seymour Boorstein, M.D., Sylvia Boorstein, Ph.D., William W. Foote, M.D., John F. Hiest, M.D., Francis G. Lu, M.D., Elizabeth F. Targ, M.D., Bruce S. Victor, M.D.

COURSE 4 9:00 a.m. - 4:00 p.m.
Room S104 A, Level 1, McCormick Place South
MONEY IN THE DOCTOR/PATIENT RELATIONSHIP
Director: Cecilia M. Mikalac, M.D.

COURSE 5 9:00 a.m. - 4:00 p.m.
Room S501 A, Level 5, McCormick Place South
ADVANCED INTERVIEWING TECHNIQUES
Director: Shawn C. Shea, M.D.

COURSES 9-11
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 9 1:00 p.m. - 5:00 p.m.
Room N426 A, Level 4, McCormick Place North
PSYCHODYNAMIC TREATMENT OF PANIC DISORDER
Co-Directors: Fredric N. Busch, M.D., Barbara L. Milrod, M.D.
Faculty: Merianne B. Singer, M.D.

COURSE 10 1:00 p.m. - 5:00 p.m.
Room S101 B, Level 1, McCormick Place South
USE OF THE ARTS IN PSYCHIATRIC EDUCATION
Director: Paul R. Miller, M.D.

COURSE 11 1:00 p.m. - 5:00 p.m.
Room S502 B, Level 5, McCormick Place South
CLINICAL TOPICS IN SLEEP MEDICINE
Director: Thomas D. Hurwitz, M.D.
Faculty: Max Hirshkowitz, Ph.D., Wallace B. Mendelson, M.D.
SATURDAY

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIUM 1

MIND AND BODY IN THE PATIENT WITH DEPRESSION: CLINICAL IMPLICATIONS OF THE INTERRELATIONSHIP BETWEEN PSYCHIATRIC, CEREBROVASCULAR AND CARDIOVASCULAR DISEASE
Supported by Forest Laboratories, Inc.

Chp.: Carl Salzman, M.D.
A Prefrontal Dysfunction in Geriatric Patients
George S. Alexopoulos, M.D.
B Neuropsychiatric Consequences of Stroke
Robert G. Robinson, M.D.
C Cardiovascular Disease and Depression: Cause, Effect or Conundrum?
Francois Lesperance, M.D.
D Antidepressant Pharmacotherapy in the Elderly and Old-Old
Carl Salzman, M.D.
E Psychopharmacology in the Context of Comorbid Vascular Illness: Applying Knowledge of Drug Metabolism to Optimize Drug Therapy
David J. Greenblatt, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 2

SEXUAL DYSFUNCTION: EPIDEMIOLOGY, ETIOLOGY, DIAGNOSIS AND MANAGEMENT
Supported by U.S. Pharmaceuticals, Pfizer Inc.

Chp.: H. George Nurnberg, M.D.
Co-Chp.: Anita L.H. Clayton, M.D.
A Epidemiology, Classification and Assessment of Sexual Dysfunction
Anita L.H. Clayton, M.D.
B Prevalence Assessment of Antidepressant-Induced Sexual Dysfunction
Andrew A. Nierenberg, M.D.
C Management of Antidepressant-Induced Sexual Dysfunction
H. George Nurnberg, M.D.
D Hormonal Aspects of Sexual Function in Women: Improvement with Hormone Replacement Therapy
Julia K. Wamock, M.D., J. Clark Bundren, M.D., David W. Morris, M.A.
E Sexual Dysfunction in Men: Diagnosis and Treatment of Patients with Depression and Other Psychiatric Disorders
Matthew A. Menza, M.D., Raymond Rosen, Ph.D.

Discussant: Alan J. Gelenberg, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 3

REPRODUCTIVE PSYCHIATRY: AN UPDATE ON WOMEN'S HEALTH
Supported by SmithKline Beecham Pharmaceuticals

Chp.: Shaila Misri, M.D.
Co-Chp.: Meir Steiner, M.D.
A Premenstrual Dysphoric Disorder: New Research
Meir Steiner, M.D.
B Mood Disorders in Pregnancy and Lactation: Treatment Issues
Zachary N. Stowe, M.D., James R. Strader, Jr., B.S., Amy Hostetter, B.A.
C The Use of SSRIs in Pregnant and Lactating Women
Shaila Misri, M.D.
D Mood, Hormones and Menopause
Catherine A. Roca, M.D., Peter J. Schmidt, M.D., David R. Rubinow, M.D.

Discussant: Carol C. Nadelson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 4

THE MANY FACES OF PSYCHOSIS
Supported by Janssen Pharmaceutica and Research Foundation

Chp.: Prakash S. Masand, M.D.
A The Genetic Epidemiology of Psychosis
Kenneth S. Kendler, M.D.
B Psychosis Associated with Schizophrenia
Prakash S. Masand, M.D.
C Psychosis Associated with Major Depression
J. Craig Nelson, M.D.
D Psychosis Associated with Bipolar and Schizoaffective Disorders
S. Nassir Ghaemi, M.D.
E Psychosis Associated with Dementia
George T. Grossberg, M.D.
SATURDAY

INDUSTRY-SUPPORTED SYMPOSIUM 5
7:00 p.m. - 10:00 p.m.
Regency Ballroom, Second Floor, Hyatt Regency

NOREPINEPHRINE AND DEPRESSION IN THE ELDERLY
Supported by Pharmacia & Upjohn Company, Inc.

Chp.: Alan F. Schatzberg, M.D.
Co-Chp.: Soo Borson, M.D.

A Epidemiology and Clinical Presentation of Depression in the Elderly
Soo Borson, M.D.

B The Importance of the Prefrontal Noradrenergic Systems in Depression, Alzheimer's Disease and Psychosis
Kenneth L. Davis, M.D., Joseph I. Friedman, M.D., Vahram Haroutunian, Ph.D.

C Significance of Anergia and Anhedonia As Symptoms of Depression: Biological and Pharmacological Perspectives
Bruce G. Pollock, M.D.

D Efficacy and Safety of Noradrenergic Antidepressants in the Elderly
Alan F. Schatzberg, M.D.

E Treatment Options for Medical and Psychiatric Comorbidity with Depression
Dwight L. Evans, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 6
7:00 p.m. - 10:00 p.m.
Grand Ballroom, Second Floor, Chicago Hilton

DOPAMINE: BEYOND SCHIZOPHRENIA, TOOLS FOR TREATMENT
Supported by Glaxo Wellcome Inc.

Chp.: Alexander H. Glassman, M.D.
Co-Chp.: Patricia Goldman-Rakic, Ph.D.

A The Meso-Limbic Dopamine System in Motivation and Reward
Roy A. Wise, Ph.D.

B Smoking, Smoking Cessation and Antidepressants
Alexander H. Glassman, M.D.

C Dopamine in the Treatment of Depression
Maurizio Fava, M.D.

D Direct and Indirect Modulation of Cortical Circuits Involved in Cognition
Patricia Goldman-Rakic, Ph.D.

E Dopamine in the Etiology and Treatment of ADHD
F. Xavier Castellanos, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 7
7:00 p.m. - 10:00 p.m.
International Ballroom North, Second Floor, Chicago Hilton

SCHIZOPHRENIA: FROM SOCIAL ISOLATION TO SOCIAL REINTEGRATION
Supported by Eli Lilly and Company

Chp.: Jeffrey A. Lieberman, M.D.
Co-Chp.: Richard G. Petty, M.D.

A Impact of Early Identification and Treatment on First-Episode Schizophrenia
Jeffrey A. Lieberman, M.D.

B Cognitive Deficits and Everyday Functioning
Richard S.E. Keefe, Ph.D.

C Atypical Antipsychotic Agents: Expanding the Goals of Therapy to Improve Outcomes
Richard G. Petty, M.D.

D Improving Outcomes: Reintegration in Disadvantaged Populations
Ralph Aquila, M.D.

E Quality of Life and Economic Outcomes in Treatment
Martin R.J. Knapp, Ph.D.
American Psychiatric Association

Audiotapes
Recorded Live!

High Quality Continues for the 2000 Annual Meeting...

Live recordings will be available for most of the following:

• Lectures • Advances in Research
• Presidential Symposium • Medical Updates
• Scientific and Clinical Reports • Symposia
• Debates • Research Advances in Medicine

Tapes may be purchased on site at Mobiltape’s booth at McCormick Place

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 ♦ (800) 369-5718
Fax: (661) 295-8474
Website: www.mobiltape.com
SUNDAY, MAY 14, 2000

153rd ANNUAL MEETING

8:00 a.m. Sessions

COURSES 12-19
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 12
8:00 a.m. - 12 noon
Room N426 B, Level 4, McCormick Place North
MEDICAL AND PSYCHIATRIC IMPLICATIONS OF CYTOCHROME P450
Co-Directors: Scott C. Armstrong, M.D., Kelly L. Cozza, M.D.
Faculty: Jessica R. Oesterheld, M.D., Michael Cole, M.D., Jesus Almanza, M.D.

COURSE 13
8:00 a.m. - 12 noon
Room N427 B/C, Level 4, McCormick Place North
PSYCHIATRIC DISORDERS RELATED TO EPILEPSY
Director: Dietrich P. Blumer, M.D.
Faculty: John Barry, M.D.

COURSE 14
8:00 a.m. - 12 noon
Room S101 B, Level 1, McCormick Place South
USING HUMANITIES TO UNDERSTAND MOOD DISORDERS
Co-Directors: Steven D. Targum, M.D., Emilie Passow, Ph.D.

COURSE 15
8:00 a.m. - 12 noon
Room S102 A, Level 1, McCormick Place South
INTERPERSONAL PSYCHOTHERAPY
Director: John C. Markowit, M.D.

COURSE 16
8:00 a.m. - 12 noon
Room S103 A, Level 1, McCormick Place South
DELIRIUM AND OTHER ACUTE CONFUSIONAL STATES: DIAGNOSIS AND MANAGEMENT
Director: Jose R. Maldonado, M.D.

COURSE 17
8:00 a.m. - 12 noon
Room S103 B/C, Level 1, McCormick Place South
ADD IN ADULTS
Director: Thomas E. Brown, Ph.D.
Faculty: Margaret D. Weiss, M.D.

8:00 a.m. - 12 noon
Room S501 D, Level 5, McCormick Place South
SEXUAL HARASSMENT: PSYCHOLOGICAL AND LEGAL ASPECTS
Director: Gail E. Robinson, M.D.
Faculty: Renee L. Binder, M.D., Sharyn A. Lenhart, M.D., Michael Myers, M.D.

COURSE 19
8:00 a.m. - 12 noon
Room S503 A, Level 5, McCormick Place South
OUTPATIENT GROUP THERAPY FOR THE SERIOUSLY MENTALLY ILL
American Group Psychotherapy Association
Director: Walter N. Stone, M.D.

9:00 a.m. Sessions

COURSES 20-28
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 20
9:00 a.m. - 4:00 p.m.
Room N426 A, Level 4, McCormick Place North
MEDICAL ETHICS 101
Director: Edmund G. Howe, M.D.

COURSE 21
9:00 a.m. - 4:00 p.m.
Room N426 C, Level 4, McCormick Place North
THERAPEUTIC INTERVENTIONS IN EATING DISORDERS
Director: David C. Jimerson, M.D.
Faculty: W. Stewart Agras, M.D., Katherine A. Halmi, M.D., James E. Mitchell, M.D., Joel Yager, M.D.

COURSE 22
9:00 a.m. - 4:00 p.m.
Room S101 A, Level 1, McCormick Place South
PERSONNEL MANAGEMENT FOR CLINICIANS/MANAGERS
Director: Stephen M. Solity, M.D.
Faculty: Mark Binkley, J.D., William Noyes, M.P.A., Joseph J. Parks III, M.D., Brenda Ratliff, M.D., David Rosin, M.D.
COURSE 23
Room S102 B/C, Level 1, McCormick Place South
MIND AT THE MILLENNIUM: CONSCIOUSNESS AND MODERN SCIENCE
Director: Vincenzo R. Sanguineti, M.D.
Faculty: Stuart R. Hameroff, M.D., Alfred W. Kaszniak, Ph.D.,
Alwyn Scott, Sc.D.

COURSE 24
Room S103 D, Level 1, McCormick Place South
ADVANCED CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
Director: Charles W. Popper, M.D.
Faculty: Barbara J. Coffey, M.D., Robert L. Findling, M.D., Joseph P.
Horrigan, M.D., Martin H. Telcher, M.D., B. Timothy Walsh, M.D.,
Rosemary Tannock, Ph.D.

COURSE 25
Room S104 B, Level 1, McCormick Place South
PSYCHIATRY AND PRIMARY CARE: SHARING CARE
Director: Nick S. Kates, M.B.
Faculty: Marilyn Craven, M.D., Jonathan S. Davine, M.D., Richard
Segal, M.D.

COURSE 26
Room S501 A, Level 5, McCormick Place South
CLINICAL NEUROPSYCHIATRY: AN UPDATE (IN SPANISH)
Co-Directors: F. Moises Gaviria, M.D., Andres M. Kanner, M.D.
Faculty: Juan C. Rivas, M.D., Oscar Doval, M.D., Ignacio
Quemeda, M.D.

COURSE 27
Room S502 A, Level 5, McCormick Place South
DISORDERS OF THE SELF: DIFFERENTIAL DIAGNOSIS AND TREATMENT
Director: James F. Masterson, M.D.

COURSE 28
Room S502 B, Level 5, McCormick Place South
THE PRACTICAL MANAGEMENT OF PERSONALITY DISORDER
Director: John Livesley, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 8-14

INDUSTRY-SUPPORTED SYMPOSIUM 8
9:00 a.m. - 12 noon
Room E450, Level 4, McCormick Place Lakeside
ADVANCES IN WOMEN'S MENTAL HEALTH: A DECADE OF PROGRESS
Supported by Eli Lilly and Company
Chp.: Adele C. Viguera, M.D.
Co-Chp.: Lee S. Cohen, M.D.
A Effects of Gonadal Steroids on Brain and Behavior
  David R. Rubinow, M.D., Peter J. Schmidt, M.D.
B SSRIs in the Treatment of PMDD: A Critical Review
  Adele C. Viguera, M.D.
C Course and Treatment of Mood Disorders During Pregnancy
  and the Postpartum Period
  Lee S. Cohen, M.D.
D Psychopharmacology During Pregnancy and Lactation:
  Determining Infant Exposure
  Zachary N. Stowe, M.D., Lee S. Cohen, M.D., Amy
  Hostetter, B.A.
E Mood Disorders in Perimenopause: The Estrogen
  Connection
  Hadine Joffe, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 9
9:00 a.m. - 12 noon
Room E451, Level 4, McCormick Place Lakeside
FROM NEUROBIOLOGY TO NOVEL TREATMENTS:
APPLICATIONS IN ALZHEIMER'S DISEASE
Supported by Novartis Pharmaceuticals Corporation
Chp.: Murray A. Raskind, M.D.
Co-Chp.: Gary W. Small, M.D.
A Multidisciplinary Management of the Patient with Alzheimer's
  Disease: A Case History
  Murray A. Raskind, M.D.
B Etiology of Alzheimer's Disease: Evolving Theories
  Paul R. Solomon, Ph.D.
C Emerging Therapeutic Options in Alzheimer's Disease
  Gary W. Small, M.D.
D The Role of the Psychiatrist in Optimizing Outcomes in
  Alzheimer's Disease: Facilitating Cooperation Across
  Specialties
  Elaine Peskind, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 10
9:00 a.m. - 12 noon
Grand Ballroom A, Level 1, McCormick Place South
IMAGES OF ANXIETY
Supported by SmithKline Beecham Pharmaceuticals
Chp.: Jack M. Gorman, M.D.
A Advances in Neuroimaging
  Jack M. Gorman, M.D.
B Images of Fear in Panic
  Justine M. Kent, M.D.
C PTSD: A Mind's-Eye View
Murray B. Stein, M.D.

D Images of Social Anxiety Disorder: A Five-Year Video Case Study
Daniel D. Christensen, M.D.

E Social Anxiety Disorder: The Shy Brain
Franklin R. Schneier, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 11
9:00 a.m. - 12 noon
Grand Ballroom B, Level 1, McCormick Place South

TREATMENT PRACTICE AND PROMISE FOR SCHIZOPHRENIA IN THE NEW MILLENNIUM
Supported by Janssen Pharmaceutica and Research Foundation
Chp.: Ming T. Tsuang, M.D.

A Toward the Primary Prevention of Schizophrenia
Ming T. Tsuang, M.D.

B Childhood-Onset Schizophrenia
Christopher J. Mc Dougle, M.D.

C Therapeutic Implications of the Glutamate Model of Schizophrenia
Donald C. Goff, M.D.

D Optimal Use of Atypical Antipsychotics
Samuel J. Keith, M.D.

E Long-Term Outcome: Staying the Course
Nina R. Schooler, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 12
9:00 a.m. - 12 noon
Regency Ballroom, Second Floor, Hyatt Regency

ADVANCES IN THE TREATMENT OF INSOMNIA
Supported by Wyeth-Ayerst Laboratories
Chp.: W. Vaughn McCall, M.D.

A Prevalence, Phenomenology and Consequences of Insomnia
Daniel J. Buysse, M.D.

B Circadian Rhythm Disorders and Insomnia: Treatment with Melatonin, Phototherapy and Chronotherapy
Gary Richardson, M.D.

C Behavioral Intervention for Chronic Insomnia
Jack D. Edinger, Ph.D.

D Pharmacotherapy for Insomnia
W. Vaughn McCall, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 13
9:00 a.m. - 12 noon
Grand Ballroom, Second Floor, Chicago Hilton

NOVEL TREATMENTS FOR DEPRESSION
Supported by Merck U.S. Health
Chp.: Martin B. Keller, M.D.

A Current Status of Managing Depression: Is There a Need for New Treatment Strategies?
Alan F. Schatzberg, M.D.

B Substance P Antagonists: Mechanisms of Action and Clinical Implications
Dennis S. Charney, M.D.

C Transcranial Magnetic Stimulation: Magnets in Depression
K. Ranga R. Krishnan, M.D.

D Evidence-Based Psychotherapy: Improving Patient Outcomes
Myrna M. Weissman, Ph.D.

E Corticotropin-Releasing Factor Antagonists: Promising Therapy for Depression
Charles B. Nemeroff, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 14
9:00 a.m. - 12 noon
International Ballroom North, Second Floor, Chicago Hilton

INDIVIDUALIZING MANAGEMENT OF DEPRESSIVE DISORDERS
Supported by Organon Inc.
Chp.: Norman Sussman, M.D.

A Sexual Dysfunction Associated with Treatment of Major Depression
Anita L.H. Clayton, M.D., Elizabeth L. McGarvey, Ed.D., Gail Clavet, Ph.D.

B Weight Gain Associated with Long-Term Antidepressant Therapy
Norman Sussman, M.D.

C Management of Antidepressant Nonresponders
Jerrold F. Rosenbaum, M.D.

D Linking Antidepressant Therapy to Medical Outcomes
P. Murali Doraiswamy, M.D.
12:30 p.m. Session

BUSINESS MEETING
(Voting Members Only*)
12:30 p.m. - 1:30 p.m.
Room S406 A, Level 4, McCormick Place South

CALL TO ORDER
Allan Tasman, M.D., President

ANNOUNCEMENT OF ELECTION OF OFFICERS AND TRUSTEES; AND RESULTS OF BALLOTING ON AMENDMENTS TO THE CONSTITUTION AND BY-LAWS
L. Gordon Kirschen, M.D., Chairperson, Committee of Tellers

REPORTS TO THE MEMBERSHIP
Secretary: Michelle Riba, M.D.
Treasurer: Maria T. Lymberis, M.D.
Speaker, Assembly: Alfred Herzog, M.D.
Speaker-Elect, Assembly: Robert M. Pearce, M.D.
Chairperson, Constitution and By-Laws Committee: Robert J. McDevitt, M.D.
Chairperson, Elections Committee: Sheldon I. Miller, M.D.
Chairperson, Membership Committee: Bernard A. Katz, M.D.
Medical Director: Steven M. Mirin, M.D.
Chairpersons of the Eleven Councils

FORUM

ADJOURNMENT

*Courses in Training, General Members, Fellows, Life Fellows and Life Members. Badge or APA membership card necessary for admission. No cameras or tape recorders will be permitted.

1:00 p.m. Sessions

COURSES 29-37
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 29 1:00 p.m. - 5:00 p.m.
Room N426 B, Level 4, McCormick Place North
THE ADVANCED PRACTICE OF PSYCHOTHERAPY
Director: T. Byram Karasu, M.D.

COURSE 30 1:00 p.m. - 5:00 p.m.
Room N427 B/C, Level 4, McCormick Place North
PSYCHIATRIC DISORDERS IN PREGNANCY AND POSTPARTUM
Co-Directors: Shaila Misri, M.D., Kristin S. Sivertz, M.D.
Faculty: Diana Carter, M.B., Deirdre M. Ryan, M.B., Maria R. Corral, M.D.

COURSE 31 1:00 p.m. - 5:00 p.m.
Room S101 B, Level 1, McCormick Place South
DREAM TRANSLATION: ONE EMPIRICALLY-BASED APPROACH
Director: Milton Kramer, M.D.

COURSE 32 1:00 p.m. - 5:00 p.m.
Room S103 A, Level 1, McCormick Place South
ECT PRACTICE UPDATE
Director: Charles H. Kellner, M.D.
Faculty: Richard D. Weiner, M.D., W. Vaughn McCall, M.D., Richard L. Jaffe, M.D.

COURSE 33 1:00 p.m. - 5:00 p.m.
Room S103 B/C, Level 1, McCormick Place South
HOW TO PASS THE BOARDS! THE PART II ORAL EXAM
Director: James C.Y. Chou, M.D.

COURSE 34 1:00 p.m. - 5:00 p.m.
Room S104 A, Level 1, McCormick Place South
LEARN CHIPS: A NEW CHILDREN'S DIAGNOSTIC INTERVIEW
Director: Mary A. Fristad, Ph.D.
Faculty: Marijo T. Rooney, Ph.D.

COURSE 35 1:00 p.m. - 5:00 p.m.
Room S501 B/C, Level 5, McCormick Place South
OVERVIEW AND UPDATE OF SLEEP DISORDERS MEDICINE
Director: Karl Doghramji, M.D.
Faculty: Thomas D. Hurwitz, M.D., John W. Winkelman, M.D.

COURSE 36 1:00 p.m. - 5:00 p.m.
Room S501 D, Level 5, McCormick Place South
DSM-IV CULTURAL FORMULATIONS: DIAGNOSIS AND THERAPY
Director: Russell F. Lim, M.D.
Faculty: Francis G. Lu, M.D., J. Charles Ndlela, M.D., Candace M. Fleming, Ph.D., Roberto Lewis-Fernandez, M.D., Michael W. Smith, M.D.
SUNDAY

COURSE 37  1:00 p.m. - 5:00 p.m.
Room S503 A, Level 5, McCormick Place South

BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE CONFLICTUAL RELATIONSHIP THEME METHOD
Director: Howard E. Book, M.D.

1:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 15-21

INDUSTRY-SUPPORTED SYMPOSIUM 15
1:30 p.m. - 4:30 p.m.
Room E450, Level 4, McCormick Place Lakeside

FAMILY VIOLENCE: VICTIMIZATION AND PERPETRATION
Supported by U.S. Pharmaceuticals, Pfizer Inc.

Chp.: Elissa P. Benedek, M.D.
Co-Chp.: Paula G. Panzer, M.D.
A Domestic Violence: Context and Treatment
Carole L. Warshaw, M.D.
B Beyond PTSD: Adaptation to Domestic Trauma
Bessel A. Van Der Kolk, M.D.
C Creating Sanctuary: Toward the Evolution of Sane Societies
Sandra L. Bloom, M.D.
D PTSD and Addictive Disorders: Concurrent Treatment
Paula G. Panzer, M.D.
E Violent Children
Elissa P. Benedek, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 16
1:30 p.m. - 4:30 p.m.
Room E451, Level 4, McCormick Place Lakeside

MANAGING PATIENTS WITH ACUTE PSYCHOSIS: AN INTERACTIVE PROGRAM
Supported by Janssen Pharmaceuticals and Research Foundation

Chp.: Michael H. Allen, M.D.
A Neurobiology of Aggressive Behavior
Jean-Pierre Lindenmayer, M.D.
B Involuntary Treatment
Renee L. Binder, M.D.
C Initial Pharmacologic Management of Episodic Agitation
Michael H. Allen, M.D.
D The Impact of the Second-Generation Antipsychotics on Aggression Among Psychotic Patients
K.N. Roy Chengappa, M.D.
E Maximizing Long-Term Compliance and Functional Outcome
Robert R. Conley, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 17
1:30 p.m. - 4:30 p.m.
Grand Ballroom A, Level 1, McCormick Place South

CONTROVERSIES AT THE INTERFACE OF SLEEP AND PSYCHIATRY
Supported by Wyeth-Ayerst Laboratories

Chp.: Thomas A. Mellman, M.D.
A Sleep Disturbance in Mood and Anxiety Disorders
Thomas A. Mellman, M.D.
B Mood Regulation: Function of REM Sleep and Dreaming
Rosalind Cartwright, Ph.D.
C Medications for Sleep Disorders
Wallace B. Mendelson, M.D.
D Defining Optimal Sleep
Thomas Roth, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 18
1:30 p.m. - 4:30 p.m.
Grand Ballroom B, Level 1, McCormick Place South

PHARMACOTHERAPY OF DEPRESSION: NEW STRATEGIES
Supported by Pharmacia & Upjohn Company, Inc.

Chp.: Michael E. Thase, M.D.
A Mechanism of Action and Clinical Response
Alan Frazer, Ph.D.
B Anxiety and Depression
Jack M. Gorman, M.D.
C Sexual Dysfunction and Depression
Robert M.A. Hirschfeld, M.D.
D Sleep and Depression
Michael E. Thase, M.D.
E Compliance and Tolerability
Steven P. Roose, M.D.
SUNDAY

INDUSTRY-SUPPORTED SYMPOSIUM 19
1:30 p.m. - 4:30 p.m.
Regency Ballroom, Second Floor, Hyatt Regency

BIPOLAR CHILDREN AND ADOLESCENTS:
CONTROVERSIES IN DIAGNOSIS AND TREATMENT
Supported by Abbott Laboratories

Chp.: David A. Mrazek, M.D.

A Bipolar Spectrum Disorder: Genetic Hypotheses
David A. Mrazek, M.D.

B Controversies in Making the Diagnosis
Peter S. Jensen, M.D.

C Controversies in the Treatment of Difficult Bipolar Adolescents
Karen D. Wagner, M.D.

D Evaluation and Management of Violent Behavior in Bipolar Adolescents
Hans Steiner, M.D.

E Neuroimaging and Neuropsychological Testing
Robert L. Hendren, D.O.

Discussant: Frederick K. Goodwin, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 20
1:30 p.m. - 4:30 p.m.
Grand Ballroom, Second Floor, Chicago Hilton

COMPLEXITIES OF TREATMENT OF BIPOLAR DISORDER
Supported by Glaxo Wellcome Inc.

Chp.: William B. Lawson, M.D.

A Recent Genetic Findings in Bipolar Disorder
John I. Nurnberger, Jr., M.D., J. Raymond DePaulo, Jr., M.D., Theodore A. Reich, M.D., Mary Blehar, Ph.D., Tatiana Foroud, Ph.D., Elliott S. Gershon, M.D.

B Distinctive Mixed States of Bipolar I, II and Beyond
Hagop S. Akiskal, M.D.

C Ethics Issues in Bipolar Disorder
William B. Lawson, M.D.

D Women with Bipolar Illness: Special Issues
Katherine L. Wisner, M.D.

Discussant: Tony Strickland, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 21
1:30 p.m. - 4:30 p.m.
International Ballroom North, Second Floor, Chicago Hilton

SCHIZOPHRENIA AND BIPOLAR DISORDERS: EVOLVING THERAPEUTIC CONCEPTS
American Society of Clinical Psychopharmacology
Supported by Bristol-Myers Squibb Company

Chp.: James W. Jefferson, M.D.
Co-Chp.: John M. Kane, M.D.

A Can Schizophrenia Be Diagnosed and Treated Before It's Schizophrenia?
Barbara Comblatt, Ph.D., Michael O'bichowski, Ph.D., Keith S. Ditkowsky, M.D., Julia A. Becker, M.D., Todd Lencz, Ph.D.

B Long-Term Management of Schizophrenia: Improved Treatments, Promising Outcomes
John M. Kane, M.D.

C Acute Bipolar Disorders: State-of-the-Art Treatment
Lon L. Altshuler, M.D.

D Long-Term Management of Bipolar Disorders
Alan J. Gelenberg, M.D.

E Minimizing Risks to Maximize Benefits of Long-Term Treatment
James W. Jefferson, M.D.

2:30 p.m. Session

LECTURE 1
2:30 p.m. - 4:00 p.m.
Room E353 A/B, Level 3, McCormick Place Lakeside
AAPL/APA'S MANFRED S. GUTTMACHER
AWARD LECTURE

Thomas Grisso, M.D. and Paul S. Appelbaum, M.D.

Frontiers of Decision Making Competence

Chp.: Brian Crowley, M.D.
Co-Chp.: Bruce E. Harry, M.D.

Using concepts developed for the MacArthur Treatment Competence Study of patients' decision-making capacities, Thomas Grisso, Ph.D., and Paul S. Appelbaum, M.D., examine legal and ethical questions concerning the decisional capacities of children and of potential research subjects. Dr. Grisso and Dr. Appelbaum are the authors of Assessing Competence to Consent to Treatment: A Guide for Physicians and Other Health Professionals. Dr. Grisso is Professor and Director of Forensic Training and Research in the Department of Psychiatry at the University of Massachusetts Medical School in Worcester. He is also in the private practice of forensic clinical psychology and is a consultant to the Office of Forensic Mental Health of the Massachusetts Department of Mental Health. A Fellow of the American Psychological Association, Dr. Grisso has received the Saul Stahl Award from the National Association of State Forensic Mental Health Program Directors and has been recognized by the American Psychological Association for his distinguished contributions to research in public policy. Other books that he has written include Forensic Evaluation of Juveniles and Competency to Stand Trial Evaluations. In addition, he is the author of several dozen professional articles, book...
chapters and reviews. Dr. Grisso received his doctorate in clinical psychology from the University of Arizona in Tucson. Dr. Appelbaum is A. F. Zeleznik Professor and Chairman of the Department of Psychiatry at the University of Massachusetts Medical School, where he is also Director of the Program in Law and Psychiatry. A Fellow and current Vice-President of the American Psychiatric Association, Dr. Appelbaum has received the Isaac Ray Award from APA for his outstanding contributions to forensic psychiatry and has previously received the Manfred S. Guttmacher Award for Clinical Handbook of Psychiatry and the Law (with Thomas Gutheil, M.D.) in 1983 and for Almost a Revolution: Mental Health Law and the Limits of Change, in 1996. Dr. Appelbaum is a member of the Editorial Boards of Law and Human Behavior, Psychiatry, and Behavioral Sciences and the Law, a contributing editor to Psychiatric Services, and a consulting editor to Ethics and Behavior. He is the author of 300 papers and book chapters and the author or editor of several books. Dr. Appelbaum graduated from Harvard Medical School and completed his residency in psychiatry and a fellowship in mental health administration at Massachusetts Mental Health Center in Boston.

5:00 p.m. Session

OFFICIAL OPENING SESSION

5:00 p.m. - 6:30 p.m.
Room E354, Level 3, McCormick Place Lakeside

CALL TO ORDER
Allan Tasman, M.D.
President

INTRODUCTION OF STAGE GUESTS

INTRODUCTION OF CHAIRPERSONS OF THE SCIENTIFIC PROGRAM COMMITTEE AND THE TASK FORCE ON LOCAL ARRANGEMENTS

Pedro Ruiz, M.D.
Chairperson, Annual Meeting Scientific Program Committee

Martin Fine, M.D.
Co-Chairperson, Task Force on Local Arrangements

INTRODUCTION OF VISITING DIGNITARIES

PRESIDENTIAL ADDRESS
Allan Tasman, M.D.
To be introduced by Michelle Riba, M.D.

RESPONSE OF THE PRESIDENT-ELECT
Daniele B. Borenstein, M.D.
To be introduced by Herbert Sacks, M.D.

ADJOURNMENT

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 22-23

INDUSTRY-SUPPORTED SYMPOSIUM 22
7:00 p.m. - 10:00 p.m.
Room E450, Level 4, McCormick Place Lakeside

NEUROBIOLOGY OF DISEASE: FROM THE LAB TO THE CLINIC
Supported by SmithKline Beecham Pharmaceuticals

Chp.: Charles B. Nemeroff, M.D.

A Recent Advances in the Neurobiology of Mood and Anxiety Disorders
Dennis S. Charney, M.D.

B Novel Actions of Antidepressants
Charles B. Nemeroff, M.D., Michael J. Owens, Ph.D., Paul M. Plotzky, Ph.D.

C Use of Functional Brain Imaging in Understanding Major Psychiatric Disorders: Profiles and Promises
Clinton D. Kilts, Ph.D.

D Psychiatric Sequelae of Interferon Therapy and Its Management with Antidepressants
Dominique L. Musselman, M.D., David H. Lawson, M.D., Charles B. Nemeroff, M.D., Andrew H. Miller, M.D.

E Neurobiology of the Gut and Brain: Implications for Management of Irritable Bowel Syndrome
R. Bruce Lydiard, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 23
7:00 p.m. - 10:00 p.m.
Room E451, Level 4, McCormick Place Lakeside

PHARMACOTHERAPY OF DEMENTIA: EXPANDING THE BOUNDARIES
Supported by Eisai Inc., Pfizer Inc.

Chp.: P. Murali Doraiswamy, M.D.

A Can We Delay the Onset of Alzheimer's Disease?
P. Murali Doraiswamy, M.D.

B Pharmacotherapy of Cognition in Dementia
Trey Sunderland, M.D.

C Pharmacotherapy of Depression in Dementia
George S. Alexopoulos, M.D.

D Pharmacotherapy of Agitation in Dementia
Prakash S. Masand, M.D.

E Pharmacotherapy of Apathy in Dementia
Michael S. Mega, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 24
7:00 p.m. - 10:00 p.m.
Grand Ballroom A, Level 1, McCormick Place South
NEW ANTIPSYCHOTICS: FROM PRACTICE TO THEORY
Supported by AstraZeneca Pharmaceuticals
Chp.: Stephen R. Marder, M.D.
Co-Chp.: Ira D. Glick, M.D.
A The Efficacy Spectrum for Atypicals in Clinical Practice
   Ira D. Glick, M.D.
B Adverse Experiences with Newer Antipsychotics
   Donna A. Wirshing, M.D.
C Subjective Response to Atypical Antipsychotic Medication
   Stephen R. Marder, M.D.
D Combining New Antipsychotics with Psychosocial Treatments
   Heinz Katschnig, M.D.
E The Management of Treatment-Refractory Schizophrenia:
   Experiences from the Front Line
   Peter F. Buckley, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 25
7:00 p.m. - 10:00 p.m.
Grand Ballroom B, Level 1, McCormick Place South
RECURRENT DEPRESSION: CHALLENGES AND SOLUTIONS
Supported by Forest Laboratories, Inc.
Chp.: A. John Rush, M.D.
A Maximizing Acute-Phase Treatment
   Michael E. Thase, M.D.
B The Role of Psychotherapy in Chronic Depression
   Jan Scott, M.D.
C Managing Chronic Depression
   Lauren B. Marangell, M.D.
D Long-Term Prophylactic Studies of Depression: The Message Meets the Medium
   Alan Wade, M.B.
E Challenges in Depression: A Case-Based Problem-Solving Panel
   John Rush, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 26
7:00 p.m. - 10:00 p.m.
Regency Ballroom, Second Floor, Hyatt Regency
VIOLENCE AND ITS PREVENTION: THE ROLE OF PSYCHIATRY
Supported by Eli Lilly and Company
Chp.: Maurizio Fava, M.D.
A Personality Disorders and Impulsive Aggression
   Emil F. Coccaro, M.D.
B Depression and Anger Attacks
   Maurizio Fava, M.D.
C Impact of Newer Antipsychotic Agents on Violence in Psychosis
   K.N. Roy Chengappa, M.D.
D Violent Behavior and Substance Abuse: Preventive and Treatment Approaches
   Kathleen T. Brady, M.D.
E A Cycle of Trauma: Violence and PTSD
   Kathryn M. Connor, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 27
7:00 p.m. - 10:00 p.m.
Grand Ballroom, Second Floor, Chicago Hilton
NOVEL PRECIPITANTS OF ANXIETY
Supported by Solvay Pharmaceuticals, Inc.
Chp.: Eric Hollander, M.D.
A Precipitants of Anxiety in Response to Noncombat Trauma
   Phebe M. Tucker, M.D., Betty Pfefferbaum, M.D., Sara Jo Nixon, Ph.D.
B Precipitants of Anxiety in Children and Adolescents
   Daniel S. Pine, M.D.
C Anxiety Disorders Across Cultures
   Dan J. Stein, M.D.
D Repetitive Behaviors and the Regulation of Anxiety
   Eric Hollander, M.D., Concetta M. DeCaria, Ph.D., Suzanne Yoon, M.D., Charles Cartwright, M.D., Sherie Novotny, M.D., Carol Bienstock, B.A., Jared Finkell, B.A.
E Precipitants of Anxiety in Social Situations
   Murray B. Stein, M.D.
Discussant: Joseph Zohar, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 28
7:00 p.m. - 10:00 p.m.
International Ballroom North, Second Floor, Chicago Hilton
FROM PATIENTS TO PEOPLE: REDEFINING WELLNESS IN PSYCHOSIS
Supported by U.S. Pharmaceuticals, Pfizer Inc.
Chp.: Daniel E. Casey, M.D.
A Early Intervention in Schizophrenia
   John M. Kane, M.D.
B Assessment and Treatment of Acute Psychotic Agitation
   Alan J. Mendelowitz, M.D.

C Broadening Spectrum of Antipsychotic Efficacy
   Rajiv Tandon, M.D.

D Raising Standards and Switching Medications
   Peter J. Weiden, M.D.

E Atypical Antipsychotics: Enhancing Healthy Outcomes
   Daniel E. Casey, M.D.

MEDIA SESSIONS 1-2

MEDIA SESSION 1  7:00 p.m.-10:00 p.m.
Room E351, Level 3, McCormick Place Lakeside

PSYCHOANALYTIC PERSPECTIVES ON THE PIANO
The Forum for the Psychoanalytic Study of Film
Co-Chps.: Bruce H. Sklarow, M.D., Harvey R. Greenberg, M.D.

1 The Piano
   (120 minutes)
Distributor: Swank Motion Pictures, Inc.
   350 Vanderbuilt Motor Partway
   Hauppauge, NY 11787

In The Piano, director Jane Campion transports the audience to
another world and time immediately and with absolute precision. The
movie is a critically acclaimed, stunningly photographed Mid-
 Nineteenth Century romantic period fable about an unhappily married
mute woman who plays the piano to express herself. It tells a story
of love and fierce pride, and places it on a bleak New Zealand coast
where people live rudely in the rain and mud, struggling to maintain
the appearance of the European society they've left behind. It is a
story of shyness, repression and loneliness; of a woman who will not
speak and a man who cannot listen, and of a willful little girl who
causes mischief and pretends she didn't mean to. This haunting,
erotically charged, original drama pleases fans of offbeat, multi-
layered fare.

MEDIA SESSION 2  7:00 p.m.-10:00 p.m.
Room E352, Level 3, McCormick Place Lakeside

A JOURNEY HOME FOR A VIETNAMESE FILM MAKER
Chp.: Francis G. Lu, M.D.

2 Three Seasons
   (113 minutes)
Distributor: USA Films
   65 Bleecker Street, 2nd Floor
   New York, NY 10012

Three Seasons is a 1999 drama written and directed by 26-year-old
Tony Bui, a Vietnamese filmmaker. Winning the 1999 Sundance
Film Festival Grand Jury Prize, it is the first U.S. feature film shot in
Vietnam in 25 years. It introduces and then traces the steps of five
central characters: a cyco driver, a prostitute, an American GI, a
young girl and a little boy. The lives of these five are intertwined as
they try to find happiness. It is a film of despair, hope and healing.

Discussant: Phuong-Thuy Le, M.D.
A Special APA Annual Meeting Series in Collaboration with the National Institute on Alcohol Abuse and Alcoholism

“Alcohol Research: Achievements and Promise”

Monday, May 15

LECTURE 3 (page 18)
9:00 a.m. - 10:30 a.m.
Room E353 A/B, McCormick Place Lakeside

Alcohol Research: Achievements and Promise: Enoch Gordis, M.D.

ADVANCES IN RESEARCH (page 22)
10:30 a.m. - 12:30 p.m.
Room E451, McCormick Place Lakeside

New Developments in the Genetics of Alcoholism: Marc A. Schuckit, M.D.

MEDIA SESSION 5 (page 23)
11:00 a.m. - 2:00 p.m.
Room E351, McCormick Place Lakeside

Affliction

COMPONENT WORKSHOP 17 (page 26)
11:00 a.m. - 12:30 p.m.
Room 4K, Chicago Hilton

Alcohol and Drug Use in Late Life: Diagnosis and Treatment
APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly and APA Council on Aging in Collaboration with the National Institute on Alcohol Abuse and Alcoholism

FORUM 2 (page 27)
12 noon - 1:30 p.m.
Boulevard Room C, Chicago Hilton

Ethnic issues in Alcohol Research

SYMPOSIUM 3 (page 31)
2:00 p.m. - 5:00 p.m.
Room E203 C, McCormick Place Lakeside

Bipolar Illness and Alcohol Abuse: Course and Treatment

SYMPOSIUM 12 (page 33)
2:00 p.m. - 5:00 p.m.
Continental Ballroom B, Chicago Hilton

Frontiers in Alcoholism Treatment: Pharmacology

Tuesday, May 16

MASTER EDUCATOR CLINICAL CONSULTATION 7 (page 42)
9:00 a.m. - 10:30 a.m.
Room 4H, Chicago Hilton

Dual Diagnosis: Sheldon I. Miller, M.D.

LECTURE 15 (page 46)
11:00 a.m. - 12:30 p.m.
Room E353 C, McCormick Place Lakeside

Terry: A Life and Death Struggle with Alcoholism and Depression: The Honorable George McGovern
APA's Patient Advocacy Award Lecture

SYMPOSIUM 39 (page 56)
2:00 p.m. - 5:00 p.m.
Continental Ballroom B, Chicago Hilton

Are There Genes for Alcoholism?

Wednesday, May 17

ISSUE WORKSHOP 79 (page 91)
9:00 a.m. - 10:30 a.m.
Room S404 A, McCormick Place South

Child-Adolescent Substance Use Disorders

DISCUSSION GROUP 21 (page 92)
11:00 a.m. - 12:30 p.m.
Room 4L, Chicago Hilton

Emerging Issues in the Treatment of Addictive Disorders: Richard T. Suchinsky, M.D.

SYMPOSIUM 96 (page 100)
2:00 p.m. - 5:00 p.m.
Continental Ballroom B, Chicago Hilton

Frontiers in Clinical Alcoholism Treatment/Behavioral Therapies
### MONDAY, MAY 15, 2000

#### 153rd ANNUAL MEETING

**7:00 a.m. Sessions**

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 29-33</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 29, PART 1</strong></td>
</tr>
<tr>
<td><strong>7:00 a.m. - 8:30 a.m.</strong></td>
</tr>
<tr>
<td><strong>Room E450, Level 4, McCormick Place Lakeside</strong></td>
</tr>
</tbody>
</table>

**MANAGING PSYCHOSES ACROSS THE AGE SPECTRUM**

*Supported by AstraZeneca Pharmaceuticals*

- **Chp.:** Rajiv Tandon, M.D.
- **Co-Chp.:** S. Charles Schulz, M.D.

- **A Child and Adolescent Psychosis**
  - Robert L. Findling, M.D.

- **B Adolescent Psychoses and the First Episode**
  - Gabrielle L. Shapiro, M.D.

- **C Psychoses in Women: Across the Age Spectrum**
  - Diana O. Perkins, M.D.

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 30, PART 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>7:00 a.m. - 8:30 a.m.</strong></td>
</tr>
<tr>
<td><strong>Grand Ballroom A, Level 1, McCormick Place Lakeside</strong></td>
</tr>
</tbody>
</table>

**ANTIEPILEPTIC DRUGS IN PSYCHIATRIC DISORDERS**

*Supported by Parke-Davis*

- **Chp.:** F. Moises Gaviria, M.D.
- **Co-Chp.:** Andres M. Kanner, M.D.

- **A Antiepileptic Drugs in Psychiatric Disorders: An Overview**
  - Andres M. Kanner, M.D.

- **B Antiepileptic Drugs in Mood Disorders**
  - Ovidio DeLeon, M.D.

- **C Antiepileptic Drugs in Anxiety Disorders**
  - Thomas H. Jobe, M.D.

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 31, PART 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>7:00 a.m. - 8:30 a.m.</strong></td>
</tr>
<tr>
<td><strong>Regency Ballroom, Second Floor, Hyatt Regency</strong></td>
</tr>
</tbody>
</table>

**EVIDENCE-BASED MANAGEMENT OF REFRACTORY DEPRESSION**

*Supported by Organon Inc.*

- **Chp.:** Andrew A. Nierenberg, M.D.
- **Co-Chp.:** Madhukar H. Trivedi, M.D.

- **A Timing and Nature of Interventions for Nonresponders**
  - Madhukar H. Trivedi, M.D.

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 32, PART 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>7:00 a.m. - 8:30 a.m.</strong></td>
</tr>
<tr>
<td><strong>Grand Ballroom, Second Floor, Chicago Hilton</strong></td>
</tr>
</tbody>
</table>

**LENGTHENING THE FUSE: TREATMENT OF AGGRESSION**

*Supported by Abbott Laboratories*

- **Chp.:** Susan L. McElroy, M.D.

- **A Mechanisms of Aggression**
  - Larry Young, Ph.D.

- **B Biologies and Treatment of Intermittent Explosive Disorder**
  - Emil F. Coccaro, M.D.

- **C Psychopathology and Pharmacotherapy of Sexually Aggressive Offenders**
  - Susan L. McElroy, M.D.

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 33, PART 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>7:00 a.m. - 8:30 a.m.</strong></td>
</tr>
<tr>
<td><strong>International Ballroom North, Second Floor, Chicago Hilton</strong></td>
</tr>
</tbody>
</table>

**NEW CLINICAL ADVANCES IN DEPRESSION**

*Supported by Bristol-Myers Squibb Company*

- **Chp.:** Robert E. Hales, M.D.
- **Co-Chp.:** Stuart C. Yudofsky, M.D.

- **A The Time Course and Biology of Major Depression: Impact on the Clinical Manifestations of the Disorder**
  - Jerrold F. Rosenbaum, M.D.

- **B What Happens When in the Treatment of Depression: An Update on the Clinical Effects of the Newer Antidepressants**
  - John M. Zajecka, M.D.

**Discussant:** Paula J. Clayton, M.D.
MONDAY

RESIDENTS' SESSION
7:00 a.m. - 8:30 a.m.
Continental Ballroom A, Lobby Level, Chicago Hilton

MEET THE EXPERTS: SUNNY SIDE-UP
Chp.: Allan Tasman, M.D.
Co-Chp.: Daniel B. Borenstein, M.D.
Nationally recognized "experts" will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include child and adolescent psychiatry, minority issues, organizational psychiatry, private practice, psychiatry and the law, public and community psychiatry, research, writing and publishing, women's issues, issues related to managed care and many more.

8:00 a.m. Sessions

COURSES 38-46
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 38  8:00 a.m. - 12 noon
Room N426 A, Level 4, McCormick Place North
MUTUALITY IN THE DOCTOR/PATIENT RELATIONSHIP
Co-Directors: Odysseus Adamides, Jr., M.D., Judith V. Jordan, Ph.D.
Faculty: Mary D. Tantillo, Ph.D., Jessica S. Butzel, Ph.D.

COURSE 39  8:00 a.m. - 12 noon
Room N426 B, Level 4, McCormick Place North
RISK ASSESSMENT FOR VIOLENCE
Director: Phillip J. Resnick, M.D.

COURSE 40  8:00 a.m. - 12 noon
Room N426 C, Level 4, McCormick Place North
ADD IN CHILDREN AND ADOLESCENTS
Director: Thomas E. Brown, Ph.D.
Faculty: Margaret D. Weiss, M.D.

COURSE 41  8:00 a.m. - 12 noon
Room N427 B/C, Level 4, McCormick Place North
ALTERNATIVE APPROACHES TO UNDERSTANDING HUMANS
Director: Richard D. Chessick, M.D.

COURSE 42  8:00 a.m. - 12 noon
Room S501 D, Level 5, McCormick Place South
TREATING MEDICAL STUDENTS AND PHYSICIANS
Co-Directors: Michael Myers, M.D., Leah J. Dickstein, M.D.

COURSE 43  8:00 a.m. - 12 noon
Room S502 A, Level 5, McCormick Place South
INDIVIDUAL AND COMMUNITY INTERVENTIONS IN DISASTER
Co-Directors: Ann E. Norwood, M.D., Michael Blumenfield, M.D.
Faculty: Robert J. Ursano, M.D., Jon A. Shaw, M.D.

COURSE 44  8:00 a.m. - 12 noon
Room S502 B, Level 5, McCormick Place South
ECT IN NEUROLOGICAL DISORDERS
American Neuropsychiatric Association
Director: Max Fink, M.D.
Faculty: Charles H. Kellner, M.D., Georgios Petrides, M.D., Keith Rasmussen, M.D., Raymond A. Faber, M.D.

COURSE 45  8:00 a.m. - 12 noon
Room S503 A, Level 5, McCormick Place South
COGNITIVE-BEHAVIORAL TREATMENT OF SPECIFIC PHOBIAS
Co-Directors: Martin M. Antony, Ph.D., Richard P. Swinson, M.D.

COURSE 46  8:00 a.m. - 12 noon
Room S504 A, Level 5, McCormick Place South
TREATMENT ISSUES FOR WOMEN IN MINORITY GROUPS
Director: Susan R. Downs, M.D.
Faculty: Ellen Haller, M.D., Freda C. Lewis-Hall, M.D., Silvia W. Olarte, M.D., Elisabeth C. Small, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 1
9:00 a.m. - 10:30 a.m.
Williford Room C, Third Floor, Chicago Hilton
A CHILD WITH MEDICALLY UNEXPLAINED PHYSICAL SYMPTOMS
Moderator: Robert L. Hendren, D.O.
Presenter: Sasikala Ravi, M.D.
Discussant: David B. Herzog, M.D.
THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.
CONTINUOUS CLINICAL CASE CONFERENCE 1: PART 1
9:00 a.m. - 12 noon
PDR 2, Third Floor, Chicago Hilton

PATIENTS WITH MEDICALLY UNEXPLAINED PHYSICAL
SYMPTOMS: PSYCHIATRY AND FAMILY MEDICINE AS
PHYSICIAN PARTNERS
American Academy of Family Physicians

Moderators: Arthur J. Barsky III, M.D., Frank V. deGruy, M.D.
Presenters: Susan McDaniel, M.D., Tom G. Campbell, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE
REGISTRATION BADGE OR APA MEMBERSHIP CARD
REQUIRED FOR ADMITTANCE.

COURSES 47-53
Course descriptions are available in the CME
Course Brochure included in your registration
packet. Admission by ticket only.

COURSE 47 9:00 a.m. - 4:00 p.m.
Room E152, Level 1, McCormick Place Lakeside

BUILDING ELECTRONIC MEDICAL RECORDS (BASIC)
Psychiatric Society of Informatics

Director: Daniel A. Deutschman, M.D.
Faculty: Rodolfo J. Albuquerque, M.D., Sol Herman, M.D.,
Giovanni Torello, M.D.

COURSE 48 9:00 a.m. - 4:00 p.m.
Room N427 A, Level 4, McCormick Place North

ADVANCES IN NEUROPSYCHIATRY
American Neuropsychiatric Association

Co-Directors: C. Edward Coffey, M.D., Jeffrey L. Cummings, M.D.
Faculty: Mark S. George, M.D., James D. Duffy, M.D.

COURSE 49 9:00 a.m. - 4:00 p.m.
Room S501 A, Level 5, McCormick Place South

INTRODUCTION TO BEHAVIOR THERAPY
Co-Directors: Robert M. Goisman, M.D., Philip G.
Levendusky, Ph.D.

COURSE 50 9:00 a.m. - 4:00 p.m.
Room S501 B/C, Level 5, McCormick Place South

THE DELICATE ART OF THE INITIAL INTERVIEW: TRAPS,
ROADBLOCKS, STRATEGIES AND SOLUTIONS
Director: Shawn C. Shea, M.D.

COURSE 51 9:00 a.m. - 4:00 p.m.
Room S503 B, Level 5, McCormick Place South

ASSESSMENT AND TREATMENT OF PATIENTS WITH MENTAL
RETARDATION
Director: Ruth M. Ryan, M.D.

COURSE 52 9:00 a.m. - 4:00 p.m.
Room S504 B/C, Level 5, McCormick Place South

TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC
ASSESSMENT
Director: Robert P. Granacher, Jr., M.D.

COURSE 53 9:00 a.m. - 4:00 p.m.
Room S504 D, Level 5, McCormick Place South

BASIC HYPNOSIS: PRINCIPLES AND APPLICATIONS
Director: Jose R. Maldonado, M.D.
Faculty: David Spiegel, M.D.

DEBATE 1
9:00 a.m. - 10:30 a.m.
Joliet Room, Third Floor, Chicago Hilton

RESOLVED: RECOVERY MEMORIES CAN BE ETHICALLY AND
APPROPRIATELY INTERPRETED INTO THE TREATMENT OF
TRAUMA PATIENTS

Moderator: William H. Sledge, M.D.
Affirmative: David Spiegel, M.D., Alan W. Scheflin, LL.M.
Negative: Paul R. McHugh, M.D., Sally L. Satel, M.D.

THIS SESSION WILL BE AUDIOTAPED.

DISCUSSION GROUPS 1-4
9:00 a.m. - 10:30 a.m.
These sessions are limited to 25 participants on a first-come,
first-served basis.

1 Michael J. Vergare, M.D., on Career Development in
Administrative Psychiatry
Room 4G, Fourth Floor, Chicago Hilton

2 Henry G. Conroe, M.D., Terrence Dunlop, Ph.D., Dale N.
Cox, B.S., Bud Grace, on Social Security Disability Evaluation:
Let's Discuss the Issues.
Social Security Administration
Room 4H, Fourth Floor, Chicago Hilton

3 Jerry M. Wiener, M.D., on Psychotherapy and
Psychopharmacology: Combined Versus Divided Treatment (For
Residents Only)
Room 4I, Fourth Floor, Chicago Hilton

4 Carl C. Bell, M.D., on Health Promotion, Resiliency and
Prevention
Room 4L, Fourth Floor, Chicago Hilton
LECTURE 2

9:00 a.m. - 10:30 a.m.
Room E350, Level 3, McCormick Place Lakeside

Dilip V. Jeste, M.D.

Schizophrenia and the Third Age:
Old Controversies, New Insights

Chp.: David A. Casey, M.D.
Co-Chp.: Lesly T. Mega, M.D.

Dilip V. Jeste, M.D., discusses recent research involving several hundred middle-aged and elderly patients with schizophrenia and examines findings suggesting that schizophrenia with onset in middle age is a distinct subtype of the disorder and that the course of schizophrenia is usually not won with progressive deterioration. Dr. Jeste is Professor of Psychiatry and Neurosciences and Chief of the Geriatric Psychiatry Division at the University of California, San Diego. He is also Director of the Geriatric Psychiatry Clinical Research Center at the University of California, San Diego, and the Veterans Affairs San Diego Healthcare System. A Fellow of the American Psychiatric Association, Dr. Jeste is a member of the Board of Directors of the American Psychiatric Institute for Research and Education and serves on the Editorial Boards of the American Journal of Psychiatry and the International Journal of Geriatric Psychiatry. He is the author or editor of six books and more than 300 scientific articles and book chapters. Dr. Jeste graduated from the Medical College of the University of Poona, in Poona, India, and completed additional training in psychiatry at the University of Bombay, India. He completed residencies in psychiatry at the New Jersey College of Medicine and Dentistry and the Maryland Hospital in Newark, and New York Hospital—Cornell Medical Center in White Plains, and a fellowship in neurology at George Washington University Medical Center in Washington, DC.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 3

9:00 a.m. - 10:30 a.m.
Room E353 A/B, Level 3, McCormick Place Lakeside

Enoch Gordis, M.D.

Alcohol Research: Achievements and Promise
National Institute on Alcohol Abuse and Alcoholism

Chp.: Sheldon I. Miller, M.D.
Co-Chp.: Richard T. Suchinsky, M.D.

Enoch Gordis, M.D., was appointed Director of the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health in 1986. He also holds appointments as Professor of Medicine at Mount Sinai School of Medicine, Adjunct Professor at Rockefeller University and Visiting Physician at Rockefeller Hospital in New York City. A Fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences, Dr. Gordis received the Presidential Distinguished Executive Rank Award in 1999 and the Presidential Citation from the American Psychological Association in 1996. He is a member of the Editorial Board of the Journal of Studies on Alcohol and Molecular Psychiatry. His numerous scientific publications include many papers that address treatment of alcoholism and the implications of research on alcohol abuse for public health policy. He received his medical degree from Columbia University College of Physicians and Surgeons.

Frontiers of Science Lecture

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 4

9:00 a.m. - 10:30 a.m.
Room E353 C, Level 3, McCormick Place Lakeside

APA'S ALEXANDRA SYMONDS AWARD LECTURE

Nada L. Stotland, M.D.

Six Easy Lessons in the Care of Women Patients:
Using What You Already Know to Improve Your Practice

Chp.: Donna E. Stewart, M.D.
Co-Chp.: Cheryl F. McCartney, M.D.

The majority of psychiatric patients are women, and several issues that affect psychiatric illness and treatment are gender-specific. Nada L. Stotland, M.D., describes how clinical assessments and interventions can be tailored to, taken into account gender differences in anatomy, physiology, psychology, roles and life circumstances. Dr. Stotland is Professor of Psychiatry at Rush Medical College in Chicago and Chair of the Department of Psychiatry at Illinois Masonic Medical Center. She has served as President of the Association of Women Psychiatrists and the Women's Caucus of the American Psychiatric Association. She chaired the APA Joint Commission on Public Affairs for four years and received the Francis Braceland Award from APA in recognition of her leadership in public education about psychiatric disorders and treatments. The author or editor of six books and more than 60 papers, Dr. Stotland is Associate Editor of the American Journal of Psychiatry and a member of the Editorial Advisory Board of Psychiatric News. She graduated from the University of Chicago School of Medicine and was a resident in psychiatry and fellow in the psychiatric consultation-liaison service at the University of Chicago. She received her training in psychoanalysis at the Chicago Institute for Psychoanalysis and a master's degree in public health from the University of Illinois at Chicago.
1. **Robert M.A. Hirschfeld, M.D.**, on Depression and Bipolar Disorder
   Room 4E, Fourth Floor, Chicago Hilton

2. **Mina K. Dulcan, M.D.**, on ADHD in Children and Adolescents
   Room 4F, Fourth Floor, Chicago Hilton

**THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

4. **The D Files**
   (28 minutes)
   Distributor: Hands Across Cultures, Corp.
   Attn: Harry Montoya
   P.O. Box 2215
   Española, NM 87532-2215

   The people of Northern New Mexico share some of the tragedies brought about by drugs and drinking in their communities. While exposing the pain and waste of human potential, this video also puts forth possible underlying causes and show how to build sobriety to enhance the strong spiritual and cultural presence of this unique area.

5. **Familias Unidas Saben (in Spanish)**
   (37 minutes)
   Distributor: Theatron Productions
   Robert Concha
   7857 Convoy Court, #209
   San Diego, CA 92111

   This educational video is designed to target monolingual Spanish-speaking families and clients to teach them about mental illness. It addresses cultural factors, religious beliefs relating to mental illness and concerns about stigma, which impede access to professional care. This video also details the symptoms of major illnesses, including schizophrenia, depression and bipolar disorder. The family members featured in this video talk about their own experiences in facing the challenges of mental illness, and encourage those watching not to be afraid to seek help for themselves or their loved ones.

   **Discussant:** Luis M. Garcia, M.A.

---

**MEDIA SESSIONS 3-4**

3. **Black and Blue: Depression in the African-American Community**
   (22 minutes)
   Distributor: Annelle Primm, M.D.
   Department of Psychiatry
   Johns Hopkins
   600 N. Wolfe Street, Meyer 144
   Baltimore, MD 21287-7180

   Black & Blue is an educational videotape developed to educate African Americans about depression in an effort to address the disparity between need for and use of mental health care among this group. The specific aims of the videotape are to: 1) present the major symptoms and causes of depression as expressed by consumers and health professionals who have experience dealing with the illness; 2) emphasize the importance of recognizing depression and getting treatment from a health professional; 3) discuss standard treatments for depression, including antidepressant medication and psychotherapy; 4) emphasize the importance of treatment to avoid negative consequences such as poor physical health, loss of productivity, substance use disorders and suicide; and 4) provide information about how and where to get treatment.

   **Discussant:** Annelle Primm, M.D.

6. **Rabbit in the Moon**
   (85 minutes)
   Distributor: Transit Media
   22D Hollywood Avenue
   Hohokus, NJ 07423

   *Rabbit in the Moon* is a 1999 documentary memoir about the lingering effects of the World War II internment of Japanese-Americans. It is also the story of two sisters, both former internees, film-maker Emiko Omori and writer Chizuko Omori, who revisited the absence of this vital history in their lives while searching for the memory of their mother. Visually stunning and emotionally compelling, this film examines issues that ultimately created deep rifts within the community, reveals the racist subtext of the loyalty questionnaire and exposes the absurdity of the military draft within the camps. Winner of the Cinematography Award at the 1999 Sundance Film Festival.
NEW RESEARCH YOUNG INVESTIGATORS’
POSTER SESSION 1
9:00 a.m. - 10:30 a.m.
Hall E, Level 2, McCormick Place Lakeside

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

WORKSHOPS

COMPONENTS 1-12

COMPONENT WORKSHOP 1 9:00 a.m. - 10:30 a.m.
Room S403 A, Level 4, McCormick Place South
CYTOCHROME P450 AND THE MANAGEMENT OF MEDICALLY ILL PATIENTS
APA Commission on AIDS
Chp.: Marshall Forstein, M.D.
Participants: Francine Cournoy, M.D., Robert S. Stasko, M.D., Karl Goodkin, M.D., Stephen J. Ferrando, M.D.

COMPONENT WORKSHOP 2 9:00 a.m. - 10:30 a.m.
Room S403 B, Level 4, McCormick Place South
THE DOCTOR AS PATIENT: BOTH SIDES OF TRANSFERENCE
APA/GlaxoWellcome Fellows
Chp.: Bradley W. Strong, M.D.
Participants: Carol A. Bernstein, M.D., Art C. Walszek, M.D., Judith H. W. Crossley, M.D., Andrew B. Klafter, M.D.

COMPONENT WORKSHOP 3 9:00 a.m. - 10:30 a.m.
Room S404 D, Level 4, McCormick Place South
HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 1
APA Committee of Early Career Psychiatrists and APA Assembly Committee of Early Career Psychiatrists
Co-Chps.: William E. Callahan, Jr., M.D., Ann S. Maloney, M.D.
Participants: Barry W. Wall, M.D., Keith W. Young, M.D.

COMPONENT WORKSHOP 4 9:00 a.m. - 10:30 a.m.
Williford Room A, Third Floor, Chicago Hilton
OPEN ETHICS FORUM
APA Ethics Committee
Chp.: David S. Wahl, M.D.
Participants: Beverly J. Fauman, M.D., Robert M. Wettstein, M.D.

COMPONENT WORKSHOP 5 9:00 a.m. - 10:30 a.m.
Williford Room B, Third Floor, Chicago Hilton
BULLYING AND HARASSMENT: PATHS TO SCHOOL VIOLENCE
APA Committee on Psychiatry and Mental Health in the Schools
Chp.: Lois T. Flaherty, M.D.
Participants: Eugenio M. Rothe, M.D., Trina B. Allen, M.D.

COMPONENT WORKSHOP 6 9:00 a.m. - 10:30 a.m.
Room 4D, Fourth Floor, Chicago Hilton
SOLVING MANAGEMENT PROBLEMS IN VIVO
APA Committee on Psychiatric Administration and Management
Chp.: Philip E. Veenhuis, M.D.
Participants: W. Walter Menninger, M.D., Veena Garyali, M.D., Stuart B. Silver, M.D.

COMPONENT WORKSHOP 7 9:00 a.m. - 10:30 a.m.
Room 4K, Fourth Floor, Chicago Hilton
REDISCOVERING AUTHORITY IN AMERICAN LIFE
APA Alliance
Chp.: Jacquelyn M. Le Blanc
Participant: Sara C. Charles, M.D.

COMPONENT WORKSHOP 8 9:00 a.m. - 10:30 a.m.
Room 4M, Fourth Floor, Chicago Hilton
HOT ISSUES IN TELEPSYCHIATRY
APA Committee on Telemental Health Services
Chp.: David F. McMahon, M.D.
Participants: Charles L. Zaylor, D.O., Ellen N. Rothchild, M.D., Stuart Gitlow, M.D., Zebulon C. Taintor, M.D., Donald M. Hill, M.D., Scott L. Bienefeld, M.D., Beverly N. Jones, M.D.

COMPONENT WORKSHOP 9 9:00 a.m. - 10:30 a.m.
Lake Erie Room, Eighth Floor, Chicago Hilton
RESIDENCY TRAINING: ADDICTIONS TREATMENT ADVANCES
APA Committee on Training and Education in Addiction Psychiatry
Chp.: Richard S. Schottenfeld, M.D.
Participants: Jonathan River, M.D., William M. Greenberg, M.D., Peter R. Martin, M.D., Jeffrey A. Berman, M.D., Teresita Sanjurjo, M.D., Denise C. Bridgeford, M.D.

COMPONENT WORKSHOP 10 9:00 a.m. - 10:30 a.m.
Lake Huron Room, Eighth Floor, Chicago Hilton
CAREER LESSONS FOR ASIAN-AMERICAN EARLY CAREER PSYCHIATRISTS
APA Committee of Asian-American Psychiatrists
Co-Chps.: Jacqueline B. Chang, M.D., Edmond H. Pi, M.D.
Participants: Jambur V. Ananth, M.D., Albert C. Gaw, M.D., Norma C. Panahon, M.D., Ming T. Tsuang, M.D.

COMPONENT WORKSHOP 11 9:00 a.m. - 10:30 a.m.
Lake Michigan Room, Eighth Floor, Chicago Hilton
NEW TOOLS FOR ASSESSMENT AND DIAGNOSIS OF TODDLERS
APA Committee on Pre-School Children
Chp.: Harry H. Wright, M.D.
Participants: Helen L. Egger, M.D., Christopher Lucas, M.D., Margaret Briggs-Gowan, Ph.D.
MONDAY

COMPONENT WORKSHOP 12  9:00 a.m. - 10:30 a.m.
Lake Ontario Room, Eighth Floor, Chicago Hilton

IS HOMOPHOBIA A MENTAL DISORDER?
APA Committee on Gay, Lesbian and Bisexual Issues
Chp.: Leslie G. Goransson, M.D.
Participants: Howard C. Rubin, M.D., Ronald L. Cowan, M.D.,
Philip A. Blair, M.D., Mark H. Townsend, M.D., Kenneth B. Ashley, M.D.

ISSUES 1-12

ISSUE WORKSHOP 1  9:00 a.m. - 10:30 a.m.
Room E253 A, Level 2, McCormick Place Lakeside
CRIMINAL RESPONSIBILITY AND ALCOHOL INTOXICATION
Chp.: Norman S. Miller, M.D.
Participant: Anthony R. Derrico, D.O.

ISSUE WORKSHOP 2  9:00 a.m. - 10:30 a.m.
Room E253 B, Level 2, McCormick Place Lakeside
VOLUNTARY DISCLOSURE OF GENETIC FACTS
Chp.: Paul S. Appelbaum, M.D.
Participants: Lauren S. Wakschlag, Ph.D., Yehoshua Eichenstein,
Sander L. Gilman, Ph.D., Elliott S. Gershon, M.D.

ISSUE WORKSHOP 3  9:00 a.m. - 10:30 a.m.
Room E253 C, Level 2, McCormick Place Lakeside
THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY
UPDATE: A GUIDE PARTICULARLY FOR RESIDENTS TO
UNDERSTAND THE REQUIREMENTS TO SIT FOR THE ABPN
EXAMINATION
The American Board of Psychiatry and Neurology, Inc.
Chp.: Stephen C. Scheiber, M.D.
Participants: Glenn C. Davis, M.D., Michael H. Ebert, M.D., Larry R.
Faulkner, M.D., Pedro Ruiz, M.D., John E. Schowalter, M.D.,
James H. Scully, Jr., M.D., Elizabeth B. Weller, M.D., Daniel K.
Winstead, M.D.

ISSUE WORKSHOP 4  9:00 a.m. - 10:30 a.m.
Room E253 D, Level 2, McCormick Place Lakeside
SUBJECTIVITY: CRUCIAL KEY TO THE THERAPEUTIC
ALLIANCE
Co-Chps.: Alwyn Scott, Sc.D., Vincenzo R. Sanguineti, M.D.

ISSUE WORKSHOP 5  9:00 a.m. - 10:30 a.m.
Room E255, Level 2, McCormick Place Lakeside
PERSONALITY DISORDER PROBLEMS IN THE WORKPLACE
Association for Research in Personality Disorders and International
Society for Study of Personality Disorders
Chp.: James H. Reich, M.D.
Participants: Elsa F. Ronningstam, Ph.D., Cesare Maffei, M.D.,
Per Vaglum, M.D.

ISSUE WORKSHOP 6  9:00 a.m. - 10:30 a.m.
Room E256, Level 2, McCormick Place Lakeside
BLAMING THE PATIENT: BLIND SPOT FOR DOCTOR AND
PATIENT
Chp.: David R. Coursin, M.D.
Participant: Douglas B. Coursin, M.D.

ISSUE WORKSHOP 7  9:00 a.m. - 10:30 a.m.
Room S402 A, Level 4, McCormick Place South
THE INTERFACE OF ESTROGEN AND NEUROTRANSMITTERS
Chp.: Patricia L. Paddison, M.D.

ISSUE WORKSHOP 8  9:00 a.m. - 10:30 a.m.
Room S402 B, Level 4, McCormick Place South
CHILD CUSTODY EVALUATIONS: DILEMMAS AND SOLUTIONS
Chp.: Phyllis E. Amabile, M.D.
Participants: Alan J. Ravitz, M.D., Alan Childs, Psy.D., Rachelle
Hasson Miller, M.D.

ISSUE WORKSHOP 9  9:00 a.m. - 10:30 a.m.
Room S404 A, Level 4, McCormick Place South
A NONALGORITHMIC APPROACH TO INSOMNIA TREATMENT
Co-Chps.: Robert W. Bloom, M.D., Jane V. Dyonzak, Ph.D.

ISSUE WORKSHOP 10  9:00 a.m. - 10:30 a.m.
Room S404 B/C, Level 4, McCormick Place South
COMPLEMENTARY AND ALTERNATIVE MEDICINE
Chp.: Daniel A. Monti, M.D.
Participants: Howard L. Field, M.D., Marie Stoner, M.Med.,
Richard G. Petty, M.D., Bernardo A. Merizalde, M.D.

ISSUE WORKSHOP 11  9:00 a.m. - 10:30 a.m.
Boulevard Room A/B, Second Floor, Chicago Hilton
POEMS ON PSYCHIATRY
Chp.: Charles R. Joy, M.D.

ISSUE WORKSHOP 12  9:00 a.m. - 10:30 a.m.
Boulevard Room C, Second Floor, Chicago Hilton
MOVEMENT, RHYTHM AND AFFECTIVE STATES
Chp.: Marion E. Wolf, M.D.
Participants: Helen J. Conran, M.D., Susan Imus, M.A., Gina
Demos, A.D.T.R., Gail A. Bradshaw, M.A., Yael Barkai, M.S.
MONDAY

10:30 a.m. Session

ADVANCES IN RESEARCH
10:30 a.m. - 12:30 p.m.
Room E451, Level 4, McCormick Place Lakeside

RESEARCH ADVANCES IN PSYCHIATRY: AN UPDATE FOR THE CLINICIAN
APA Scientific Program Committee and APA Council on Research

Chp.: Herbert Pardes, M.D.
Co-Chp.: Pedro Ruiz, M.D.

Participants:
Marc A. Schuckit, M.D., on New Developments in the Genetics of Alcoholism
National Institute on Alcohol Abuse and Alcoholism
Jeffrey A. Lieberman, M.D., on Pathophysiology and Treatment of the Early Stages of Schizophrenia
Charles B. Nemeroff, M.D., on Cardiovascular Disease: Pathophysiology and Treatment Considerations
Carol A. Tamminga, M.D., on Schizophrenia: Directions in Pathophysiology Research

THIS SESSION WILL BE AUDIOTAPED.

11:00 a.m. Sessions

DISCUSSION GROUPS 5-7
11:00 a.m. - 12:30 p.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

5 Marc Galanter, M.D., on Network Therapy: Office Treatment for the Substance Abuser
Room 4G, Fourth Floor, Chicago Hilton

6 Lawrence Hartmann, M.D., on Physician-Assisted Suicide and Psychiatry
Room 4I, Fourth Floor, Chicago Hilton

7 Renee L. Binder, M.D., on Malpractice Issues
Room 4L, Fourth Floor, Chicago Hilton

LECTURES 5-7

LECTURE 5
11:00 a.m. - 12:30 p.m.
Room E350, Level 3, McCormick Place Lakeside
Meredith Small, Ph.D.
The Natural History of Babies

LECTURE 6
11:00 a.m. - 12:30 p.m.
Room E350 A/B, Level 3, McCormick Place Lakeside
APA'S ADOLF MEYER AWARD LECTURE
Daniel R. Weinberger, M.D.

Psychotherapy in the Post-Genome Era: A Potential Meyerian Renaissance in Schizophrenia

Chp.: Francisco Fernandez, M.D.
Co-Chp.: Geetha Jayaram, M.D.

In the post-genome era of human biology and medicine, the psychobiological perspective of Adolf Meyer is likely to have renewed influence as investigation of the relationship between genetic discoveries and psychiatric illness continues. Daniel R. Weinberger, M.D., highlights the use of psychobiological principles in defining the biology of vulnerability to schizophrenia, including genetic factors that influence patterns of reaction to the environment and account for individual variation in symptoms, illness severity, and treatment response. Dr. Weinberger is Chief of the Clinical Brain Disorders Branch of the Intramural Research Program at the National Institute of Mental Health, in Bethesda, Maryland. He is the recipient of many honors and awards, including the Research Prize of the World Federation of Societies of Biological Psychiatry, the Gold Medal Award of the Society of Biological Psychiatry, the Foundation's Fund Prize From the American Psychiatric Association, and the Lieber Prize of the National Alliance for Research on Schizophrenia and Affective Disorders.
He has published more than 300 scientific articles and is the coauthor of the book *Neuropsychiatric Disorders* and the coeditor of *The Neurology of Schizophrenia and Schizophrenia*. Dr. Weinberger graduated from the University of Pennsylvania School of Medicine and completed residencies in psychiatry at the Massachusetts Mental Health Center in Boston and in neurology at George Washington University Medical Center in Washington, D.C.

**LECTURE 7**
11:00 a.m. - 12:30 p.m.
Room E353 C, Level 3, McCormick Place Lakeside
Kaylie Jones
Celeste Ascending
Chp.: Karon Dawkins, M.D.
Co-Chp.: Molly T. Finnerty, M.D.

Kaylie Jones is the author of the novels *A Soldier’s Daughter Never Cries*, *Quite the Other Way*, and *As Soon As It Rains*. In her lecture, she discusses the theme and structure of her new novel, *Celeste Ascending*, and uses the example of the psychological development of the book’s protagonist, Celeste, to explore how denial manifests itself in the psyche. Ms. Jones is Associate Professor of English and Writing and Distinguished Author in the Master of Fine Arts Program at Long Island University, Southampton Campus, in Southampton, New York. She is also an instructor in creative writing at the Writer’s Voice at the West Side YMCA in New York City and a member of the Teachers and Writers Collaborative, through which she is a writer-in-residence in New York City schools.

She has written, in addition to her novels, numerous book reviews, essays and short fiction works that have been published in the *New York Times*, the *Pants Review* and other periodicals. Ms. Jones received her master of fine arts degree in writing from Columbia University in New York City.

**MEDIA SESSIONS 5-6**

**MEDIA SESSION 5**
11:00 a.m. - 2:00 p.m.
Room E351, Level 3, McCormick Place Lakeside

**ALCOHOLISM: A PORTRAYAL OF ITS IMPACT ON FAMILY RELATIONSHIPS**
National Institute on Alcohol Abuse and Alcoholism

Chp.: Harvey R. Greenberg, M.D.

7 Affliction
(113 minutes)

Distributor: Lions Gate Films
561 Broadway, Suite 12B
New York, NY 10012

*Affliction* was written and directed by Paul Schrader and based on the novel set in New Hampshire by Russell Banks. Actor Nick Nolte portrays Wade Whitehouse, the sheriff of a small New Hampshire town, whose uniform, gun and stature do not make up for a deep feeling of worthlessness. He drinks, he smokes pot on the job, he walks with a sad weariness, his ex-wife hates him and his young daughter looks at him as if he is crazy. Its characters are fleshed-out human beings capable of good and evil and in the grips of intense suffering, not the formulaic cardboard creations, which populate so many recent Hollywood productions.

**MEDIA SESSION 6**
11:00 a.m. - 12:30 p.m.
Room E352, Level 3, McCormick Place Lakeside

**A UGANDAN TRAGEDY: CHILDREN WHO KILL**

Chp.: Yvonne B. Ferguson, M.D.

8 Soldier Child
(60 minutes)

Distributor: Winghead Films
c/o Neil Abramson
2814 Haddington Drive
Los Angeles, CA 90064-4415

South African filmmaker, Neil Abramson, documents the atrocities of child abductions occurring in Northern Uganda. A rebel movement calling itself the Lord’s Resistance Army, led by a man named Joseph Kony, abducts children and turns them into child soldiers. Once stolen from their homes and put into military service, boys and girls as young as seven years in age are tortured, starved and forced to kill their countrymen. For children, and on the behalf of human rights everywhere, this is a film not to be missed.

**DISCUSSION:** Erin O’Brien
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 a.m.</td>
<td>INFANTICIDE IN AMERICA: MADNESS OR MALICE?</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>Treatment Issues with SSRIS</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>ISSUES IN ADOLESCENT PSYCHIATRY</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>SCIENTIFIC AND CLINICAL REPORT SESSION 1</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>SCIENTIFIC AND CLINICAL REPORT SESSION 2</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>SCIENTIFIC AND CLINICAL REPORT SESSION 3</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>SCIENTIFIC AND CLINICAL REPORT SESSION 4</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>PSYCHODYNAMIC ISSUES</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>DOCTOR-PATIENT RELATIONSHIPS</td>
</tr>
</tbody>
</table>

**MEDICAL UPDATE 1**

11:00 a.m. - 12:30 p.m.
Room S404 B/C, Level 4, McCormick Place South

INFANTICIDE IN AMERICA: MADNESS OR MALICE?

Chp.: Michelle Oberman, J.D.
Presenter: Margaret G. Spinelli, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-9

TREATMENT ISSUES WITH SSRIS

Chp.: Richard Balon, M.D.
Co-Chp.: Robert Jalousinski, M.D.

11:00 a.m.
2 SSRI-Associated Sexual Dysfunction: New Data from Prospective Trials
   David Michelson, M.D., Mark E. Schmidt, M.D., Robert Johnston, Ph.D.

11:30 a.m.
3 Sexual Dysfunction During SSRI Continuation Treatment
   Christina M. Dording, M.D., Kathryn A. Bottonari, B.A., Andrea C. Hutchins, B.A., Jonathan E. Alpert, M.D., Andrew A. Nierenberg, M.D., Maurizio Fava, M.D.

12 noon
4 A Pilot Study of the Effectiveness of Nefazodone in Depressed Outpatients With or Without a History of SSRI Treatment Failure
   David Mischoulon, M.D., Gudrun Opitz, B.S., Karen E. Kelly, B.A., Maurizio Fava, M.D., Jerrold F. Rosenbaum, M.D.
THIS SESSION WILL BE AUDIOTAPED.

ISSUES IN ADOLESCENT PSYCHIATRY

Chp.: Sidney H. Weissman, M.D.
Co-Chp.: Amy M. Ursano, M.D.

11:00 a.m.
5 Two-Year Stability of Personality Disorder Dimensions in Adolescents
   Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D., William S. Edell, Ph.D., Thomas H. McGlashan, M.D.

12 noon
6 Asking the Right Questions to Find Teenage Killers
   Kenneth G. Busch, M.D., Robert J. Zagar, Ph.D., Jack Arbitt, Ph.D., John R. Hughes, M.D., Judge Julia Quinn-Dempsey, J.D., Olu Olowe, M.D., Nancy Hablutzel, J.D., Scott Belford, J.D.

12 noon
7 Gender Differences: Youth Violence Exposure/Risk
   Dwain C. Fehon, Psy.D., Carlos M. Grilo, Ph.D., Deborah Lipschitz, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 3

11:00 a.m. - 12:30 p.m.
Room S402 B, Level 4, McCormick Place South

PSYCHODYNAMIC ISSUES

Chp.: John C. Markowitz, M.D.
Co-Chp.: David Im, M.D.

11:00 a.m.
8 Role of the Mother in Psychoanalytic Theories of BPD
   James F. Masterson, M.D.

11:30 a.m.
9 Termination of Psychotherapy: Residents' Perspective
   Vinay Kapoor, M.D., Anu Motorin, M.D., Pedro Ruiz, M.D.

12 noon
10 Doctor-Patient Post-Termination Issues
   Carl P. Malmquist, M.D., Malkah T. Notman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 4

11:00 a.m. - 12:30 p.m.
Room S403 B, Level 4, McCormick Place South

DOCTOR-PATIENT RELATIONSHIPS

Chp.: David A. Casey, M.D.
Co-Chp.: Samuel O. Okpaku, M.D.

11:00 a.m.
11 Assessing the Impact of Research on Patients
   Randall D. Marshall, M.D., Robert L. Spitzer, M.D., Susan C. Vaughan, M.D., Lisa A. Mellman, M.D., Roger A. MacKinnon, M.D., Steven P. Roose, M.D.

11:30 a.m.
12 Characteristics of Pre-Impaired Male Physicians
   Roy W. Meninginger, M.D.

12 noon
13 Patients' View of the Doctor-Patient Relationship
   Irene Jakab, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 5
11:00 a.m. - 12:30 p.m.
Boulevard Room A/B, Second Floor, Chicago Hilton

CROSS-CULTURAL AND GENDER ISSUES
Chp.: Francis G. Lu, M.D.
Co-Chp.: Cathryn A. Galanter, M.D.

11:00 a.m.
14 Gender Differences in Violence
Menahem Krakowski, M.D., Pal Czobor, Ph.D., Tovit Krakowski, M.A.

11:30 a.m.
15 Screening of Major Depression Among Chinese Patients in a Primary Care Setting
Albert Yeung, M.D., Shauna Howarth, B.A., Andrew A. Nierenberg, M.D., Raymond Chan, B.S., Jonathan E. Alpert, M.D., David Mishoulion, M.D., Maurizio Fava, M.D.

12 noon
16 Spirituality and Resilience to Torture
Lynne M. Gaby, M.D., James L. Griffith, M.D., Judy Okawa, Ph.D., Melissa E. Griffin, M.S.N.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 6
11:00 a.m. - 12:30 p.m.
Marquette Room, Third Floor, Chicago Hilton

PSYCHIATRIC ISSUES IN MEDICALLY ILL PATIENTS
Chp.: Troy L. Thompson II, M.D.
Co-Chp.: Linda L.M. Worley, M.D.

11:00 a.m.
17 Buspirone in Patients with Schizophrenia
Pinkhas Sirot, M.D., Bella Epstein, M.D., Rehoven Benatov, M.D., Michael Sosnovsky, M.D., Seth Kindler, M.D.

11:30 a.m.
18 Magnesium and Vitamin C Infusion in Fibromyalgia
Mohammad Z. Hussain, M.D., Zubaida A. Chaudhry, M.B.

12 noon
19 Psychoeducation in Oral Cancer
Mark R. Katz, M.D., Jonathan Irish, M.D., Gerald Devins, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 7
11:00 a.m. - 12:30 p.m.
Williford Room B, Third Floor, Chicago Hilton

THE IMPACT OF THE ENVIRONMENT ON MENTAL HEALTH
Chp.: Hagop S. Akiskal, M.D.
Co-Chp.: Claudio O. Cabrejos, M.D.

11:00 a.m.
20 Seasonal Variation of Violence and Latitude
Gunnar Morken, M.D., Olav M. Linaker, Ph.D.

11:30 a.m.
21 Mental Illness and Violence: Is the Public at Risk?
Heather Stuart, Ph.D.

12 noon
22 Mental Health Impact of Hurricane Mitch
Robert Kohn, M.D., Izhak Levey, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 8
11:00 a.m. - 12:30 p.m.
Room 4M, Fourth Floor, Chicago Hilton

TREATMENT AND OUTCOME ISSUES IN SPECIAL POPULATIONS
Chp.: Carol S. North, M.D.
Co-Chp.: Alexandra Obiora-Oputa, M.D.

11:00 a.m.
23 Outcome of Liver Transplants for Patients on Methadone
Kevin C. Hails, M.D., Geraldine F. Mayor, M.D., Kenneth Rothstein, M.D.

11:30 a.m.
24 Outcomes Assessment in a Schizophrenia Service
Thomas E. Smith, M.D., Kim Weiss, Ph.D., James W. Hull, Ph.D.

12 noon
25 Understanding Mental and General Medical Disability
Benjamin G. Druss, M.D., Steven Marcus, Ph.D., Robert A. Rosenheck, M.D., Mark Olsson, M.D., Terri L. Tanielian, M.A., Harold Alan Pincus, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 9
11:00 a.m. - 12:30 p.m.
Lake Michigan Room, Eighth Floor, Chicago Hilton

DEPRESSION AND THE HEART
Chp.: Peter A. Shapiro, M.D.
Co-Chp.: Cheryl McCullum-Smith, M.D.

11:00 a.m.
26 Is Depression a Risk for Coronary Artery Disease Onset? A Meta-Analysis
Lawson R. Wulsin, M.D., Bonita Singal, M.D.

11:30 a.m.
27 Depression in Elderly Patients with Congestive Heart Failure: Six-Month Follow-Up
George Fulop, M.D., James J. Strain, M.D., Glen Stettin, M.D.

12 noon
28 Depression, Hostility, Gender and Myocardial Infarction
Michael W. Kaufmann, M.D., Elliot J. Sussman, M.D., James Reed, Ph.D., John Fitzgibbon, M.D.

THIS SESSION WILL BE AUDIOTAPED.
MONDAY

WORKSHOPS

COMPONENTS 13-17

COMPONENT WORKSHOP 13 11:00 a.m. - 12:30 p.m.
Room S403 A, Level 4, McCormick Place South

DOCUMENTATION REQUIREMENTS AND CODING UPDATE
APA Committee on Codes and Reimbursements and APA
Committee on Resource-Based Relative Value Scale Study
Chp.: Chester W. Schmidt, Jr., M.D.
Participants: Tracy R. Gordy, M.D., Ronald A. Shellow, M.D.,
Melodie Morgan-Minott, M.D., Donald J. Scherl, M.D.

COMPONENT WORKSHOP 14 11:00 a.m. - 12:30 p.m.
Room S404 D, Level 4, McCormick Place South

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE:
PART 2
APA Committee of Early Career Psychiatrists and APA Assembly
Committee of Early Career Psychiatrists
Co-Chps.: William E. Callahan, Jr., M.D., Ann S. Maloney, M.D.
Participants: Barry W. Wall, M.D., Keith W. Young, M.D.

COMPONENT WORKSHOP 15 11:00 a.m. - 12:30 p.m.
Williford Room A, Third Floor, Chicago Hilton

OFFICE OF THE FUTURE
APA Committee on Information Systems
Co-Chps.: Bertram Warren, M.D., Ronnie S. Stangler, M.D.
Participants: Norman E. Alessi, M.D., Joshua E. Freedman, M.D.,
Cheryl A. Chessick, M.D., John Luo, M.D.

COMPONENT WORKSHOP 16 11:00 a.m. - 12:30 p.m.
Room 4D, Fourth Floor, Chicago Hilton

GENERATIONS OF MENTORING: FROM RECEIVING TO GIVING
APA Committee on Women
Co-Chps.: Deborah Spitz, M.D., Michelle L. Kramer, M.D.
Participants: Marian I. Butterfield, M.D., Cheryl F. McCartney, M.D.,
Donna E. Stewart, M.D., Diana L. Dell, M.D.

COMPONENT WORKSHOP 17 11:00 a.m. - 12:30 p.m.
Room 4K, Fourth Floor, Chicago Hilton

ALCOHOL AND DRUG USE IN LATE LIFE: DIAGNOSIS AND
TREATMENT
APA Committee on Access and Effectiveness of Psychiatric Services
for the Elderly and APA Council on Aging in Collaboration with
the National Institute on Alcohol Abuse and Alcoholism
Chp.: Mustafa M. Husain, M.D.
Participants: Julian Offsay, M.D., Daniel Weintraub, M.D., Sharon S.
Levine, M.D., Blaine S. Greenwald, M.D.

ISSUES 13-21

ISSUE WORKSHOP 13 11:00 a.m. - 12:30 p.m.
Room E253 A, Level 2, McCormick Place Lakeside

HOW TO DETECT DECEPTION
Chp.: Alan R. Hirsch, M.D.
Participants: Carl M. Wahlstrom, Jr., M.D., David E. Hartman, Ph.D.,
Peter M. Fink, M.D., Charles J. Wolf, M.D.

ISSUE WORKSHOP 14 11:00 a.m. - 12:30 p.m.
Room E253 B, Level 2, McCormick Place Lakeside

TEACHING BEHAVIORAL SCIENCES TO FAMILY DOCTORS
Chp.: Jonathan S. Davine, M.D.

ISSUE WORKSHOP 15 11:00 a.m. - 12:30 p.m.
Room E256, Level 2, McCormick Place Lakeside

A PRIMER ON THE NEW RRC ESSENTIALS FOR PSYCHIATRY
Co-Chps.: Daniel K. Winstead, M.D., Carol A. Bernstein, M.D.
Participants: Eva M. Szgethy, M.D., David G. Bienerfeld, M.D.,
Larry D. Sulton, Ph.D., Pedro Ruiz, M.D.

ISSUE WORKSHOP 16 11:00 a.m. - 12:30 p.m.
Room S402 A, Level 4, McCormick Place South

IMPLEMENTING THE RECOVERY PARADIGM AND BEST
PRACTICES FOR PERSONS WITH SERIOUS MENTAL ILLNESS
Chp.: Dale P. Svendsen, M.D.
Participants: Wilma Townsend, Lawrence P. Ackerman, B.A.,
Peter F. Buckley, M.D., Rodrigo A. Muhoz, M.D.

ISSUE WORKSHOP 17 11:00 a.m. - 12:30 p.m.
Room S402 A, Level 4, McCormick Place South

THE WORLD WIDE WEB: SAFETY NET OR TRAP?
Co-Chps.: Harold J. Bursztajn, M.D., Robert C. Hsiung, M.D.

ISSUE WORKSHOP 18 11:00 a.m. - 12:30 p.m.
Williford Room C, Third Floor, Chicago Hilton

EXECUTIVE SKILLS: ASSESSMENT, COACHING AND THEORY
Association of Organizational and Occupational Psychiatry
Chp.: Howard E. Book, M.D.
Participants: Jeffrey P. Kahn, M.D., Stewart Gabel, M.D.

ISSUE WORKSHOP 19 11:00 a.m. - 12:30 p.m.
Lake Erie Room, Eighth Floor, Chicago Hilton

SWOROES INTO PLOUGHSHARES: THE IMPORTANCE OF
DIALOOG
Chp.: Sasha L. Ferguson
ISSUE WORKSHOP 20  11:00 a.m. - 12:30 p.m.
Lake Huron Room, Eighth Floor, Chicago Hilton

OSKAR PFISTER'S IMPACT ON PSYCHIATRY AFTER 2000
Chp.: Hansjuergen W. Kienast, M.D.
Participants: Reverend Clark S. Aist, Ph.D., David A. Powell, M.D.

ISSUE WORKSHOP 21  11:00 a.m. - 12:30 p.m.
Lake Ontario Room, Eighth Floor, Chicago Hilton

MEDICAL STUDENT EDUCATION: CHALLENGE OR DILEMMA?
Co-Chaps.: David A. Baron, D.O., Ellen Sholevar, M.D.
Participants: Thomas Hardie, Ed.D., Paul Jay Fink, M.D., Howard B. Moss, M.D.

12 noon Sessions

FORUMS 1-3

FORUM 1  12 noon - 1:30 p.m.
Room E253 D, Level 2, McCormick Place Lakeside

PSYCHIATRIC PERSPECTIVES ON VIOLENCE
Chp.: Carl C. Bell, M.D.

FORUM 2  12 noon - 1:30 p.m.
Boulevard Room C, Second Floor, Chicago Hilton

ETHNIC ISSUES IN ALCOHOL RESEARCH
National Institute on Alcohol Abuse and Alcoholism
Chp.: William B. Lawson, M.D.
Participants: Bankole A. Johnson, M.D., Ting-Kai Li, Ph.D., Paul Spicer, M.D., John Franklin, M.D.

FORUM 3  12 noon - 1:30 p.m.
Joliet Room, Third Floor, Chicago Hilton

SCHOOL VIOLENCE AND ITS AFTERMATH
Chp.: Mohammad Shafii, M.D.
Participants: Harriet Hall, Ph.D., Robert S. Pynoos, M.D., Michael Breen, J.D.

12:30 p.m. Session

MEDIA SESSION 7
12:30 p.m. - 2:00 p.m.
Room E352, Level 3, McCormick Place Lakeside

A BLACK CHILD'S STRUGGLE WITH AIDS
Chp.: Cheryl A. Kennedy, M.D.

9  Travis
(56 minutes)

Distributor: First Run Icarus Films
153 Waverly Place
New York, NY 10014

Travis Jefferies is a ten-year-old African-American boy with a warm personality, an infectious smile and full-blown AIDS. When we first meet him, Travis is six and has been unable to eat for months due to intractable sores in his mouth, esophagus and stomach. This film documents the complex life of this vital child born with HIV/AIDS, who, with the help of experimental drug therapy and his grandmother's unwavering love and support, struggles to survive and pursue a dignified, happy life.

1:00 p.m. Sessions

COURSES 54-62
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 54  1:00 p.m. - 5:00 p.m.
Room N426 A, Level 4, McCormick Place North

RELATIONAL THEORY AND KEY CLINICAL APPLICATIONS
Director: Stella L. Blackshaw, M.D.
Faculty: Judith V. Jordan, Ph.D., Michael Myers, M.D.

COURSE 55  1:00 p.m. - 5:00 p.m.
Room N426 B, Level 4, McCormick Place North

ACHIEVING EFFECTIVE DUAL DIAGNOSIS TREATMENT
Co-Directors: Andrew P. Ho, M.D., John W. Tsuang, M.D.

COURSE 56  1:00 p.m. - 5:00 p.m.
Room N426 C, Level 4, McCormick Place North

DRUG TREATMENT OF SCHIZOPHRENIA
Director: Philip G. Janicak, M.D.
Faculty: John M. Davis, M.D., Stephen R. Marder, M.D., Rajiv P. Sharma, M.D., George M. Simpson, M.D.

COURSE 57  1:00 p.m. - 5:00 p.m.
Room N427 B/C, Level 4, McCormick Place North

COGNITIVE THERAPY: THE BASICS
Director: Dean Schuyler, M.D.
MONDAY

COURSE 58 1:00 p.m. - 5:00 p.m.
Room N427 D, Level 4, McCormick Place North

THE EVALUATION AND MANAGEMENT OF PAIN
Director: Steven A. King, M.D.

COURSE 59 1:00 p.m. - 5:00 p.m.
Room S501 D, Level 5, McCormick Place South

HOW TO TAKE THE PAIN OUT OF "DOC-TO-DOC" REVIEWS
Director: Gabriel Kaplan, M.D.
Faculty: Elizabeth J. Rody, M.D., Matthew M. Keats, M.D., Neal R. Setten, M.D.

COURSE 60 1:00 p.m. - 5:00 p.m.
Room S502 A, Level 5, McCormick Place South

DEALING WITH RESISTANCE IN ADDICTION PATIENTS
Director: David Mee-Lee, M.D.

COURSE 61 1:00 p.m. - 5:00 p.m.
Room S502 B, Level 5, McCormick Place South

ASSESSMENT AND TREATMENT OF NICOTINE DEPENDENCE
Co-Directors: Michael G. Goldstein, M.D., Raymond S. Niaura, Ph.D.

COURSE 62 1:00 p.m. - 5:00 p.m.
Room S504 A, Level 5, McCormick Place South

INTEGRATIVE PSYCHOTHERAPY SUPERVISION: BASIC TOOLS
Director: Paul Rodenhauser, M.D.
Faculty: Ramona Dvorak, M.D., Albert F. Painter, Psy.D., John R. Rudisill, Ph.D.

NEW RESEARCH YOUNG INVESTIGATORS' ORAL/SLIDE SESSIONS 2-3
1:00 p.m. - 2:30 p.m.

2 BRAIN IMAGING AND OTHER NEW TECHNOLOGIES
Room E255, Level 2, McCormick Place Lakeside

3 ANXIETY AND MOOD DISORDERS
Room E256 Level 2, McCormick Place Lakeside

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

2:00 p.m. Sessions

LECTURES 8-9

LECTURE 8
2:00 p.m. - 3:30 p.m.
Room E350, Level 3, McCormick Place Lakeside
Sherry Turkle, M.D.

Intimate Machines: From Digital Pets to Digital Personae
Chp.: Norman E. Alessi, M.D.
Co-Chp.: Anand Pandya, M.D.

New directions in computer technology include the development of computational toys and digital "pets" for children and recent work in building robots with emotional systems. Sherry Turkle, Ph.D., discusses how people's interactions with these objects may affect their way of thinking about themselves, their sense of human identity, and their sense of what makes people special. Dr. Turkle is Professor of the Sociology of Science and Member of the Laboratory for Computer Science in the Program in Science, Technology, and Society at the Massachusetts Institute of Technology in Cambridge, Massachusetts. She is the author of Life on the Screen: Identity in the Age of the Internet, The Second Self: Computers and the Human Spirit and Psychoanalytic Politics: Freud's French Revolution, as well as several articles and book chapters that address the psychological and cultural impact of the computer. A Fellow of the American Association for the Advancement of Science, Dr. Turkle is a member of the Editorial Advisory Board of Science, Technology, and Human Values and serves on the Advisory Board of Computer Professionals for Social Responsibility. Dr. Turkle received a joint doctorate in sociology and personality psychology from Harvard University. She is also a graduate of the Boston Psychoanalytic Society and Institute.

Frontiers of Science Lecture Series

LECTURE 9
2:00 p.m. - 3:30 p.m.
Room E353 A/B, Level 3, McCormick Place Lakeside

APA'S MARMOR AWARD LECTURE
Solomon H. Snyder, M.D.

Novel Neurotransmitters, Drugs and Psychiatry
Chp.: Donna M. Norris, M.D.
Co-Chp.: Joseph T. Coyle, Jr., M.D.

Solomon H. Snyder, M.D., highlights recent research on the neurotransmitter functions of nitric oxide, carbon monoxide and D-serine and discusses treatment advances.
MEDIA SESSIONS 8-9

MEDIA SESSION 8  2:00 p.m. - 5:00 p.m.
Room E351, Level 3, McCormick Place Lakeside

ADOLESCENT DEPRESSION AND SUBSTANCE ABUSE: TORONTO AND SAN FRANCISCO

Chp.: Richard E. D'Alli, M.D.

10 The Other Side of Blue: The Truth About Teenage Depression
(52 minutes)

Distributor: Elyse D. Dubo, M.D.
Department of Psychiatry
Sunnybrook/Women's HSC
2075 Bayview Avenue
Toronto, ONT, Canada M4N 3M5

This educational documentary video was designed to help increase public awareness about teenage depression. There is a widespread misconception that depression in adolescents is normal. It is usually dismissed as "teenage blues." Most people don't realize that eight to ten percent of teenagers suffer from true, clinical depression. Depressed teenagers often appear irritable rather than sad. They may get into trouble at home, school, or with the law, or they may turn to drugs and alcohol as a way of coping. This unique video uses contemporary-style imagery and special effects to portray the experience of teenage depression in a compelling and highly personal manner. It tells the emotional stories of four teenagers suffering from depression and their lengthy struggle with this debilitating illness.

Discussants: Elyse D. Dubo, M.D., Linda Conn, M.S.W., Marshall Korenblum, M.D., Boja Vasic, B.A.

11 Black Tar Heroin: The Dark End of the Street
(75 minutes)

Distributor: Farrall on Films
1400 Shattuck Avenue, #7-4
Berkeley, CA 94709

Filmmaker Steven Okazaki and sound recordist Jason Cohen spent two years in San Francisco's drug otherworld, chronicling the lives of five adolescent heroin addicts, Tracey, Jake, Jessica, Oreo and Alice, from diverse cultural backgrounds. This extraordinary documentary captures not only the pain and brutality of lives devastated by heroin, but also the addicts raw yearning to get their lives back.

MEDIA SESSION 9  2:00 p.m. - 5:00 p.m.
Room E352, Level 3, McCormick Place Lakeside

TRAUMA AND LOSS: HEALING THROUGH MUSIC AND DANCE

Chp.: Ian E. Alger, M.D.

12 Hope and Remembrance: Ritual and Recovery
(30 minutes)

Distributor: Knowledge Exchange
CMHS
5600 Fishers Lane, R15-99
Rockville, MD 20857

This video was developed and designed to assist government planners, mental health clinicians and other groups in helping a community in the healing process following a large-scale disastrous event. The video outlines the following points: 1) individual reaction to traumatic events; 2) an overview of rituals and ceremonial activities; 3) visual images of various ritualistic symbols; 4) the role of survivors and family members in planning a ceremony; 5) the role of mental health professionals in planning a ceremony; 6) the logistics of planning an event; 7) rescue worker recognition; and 8) children and rituals. It is about those who have survived and their journey to understand, comprehend, make sense of the event and memorialize their loved ones.

Discussant: Steven P. Shon, M.D.

13 Music Therapy and Medicine: Partnerships in Care
American Music Therapy Association
(25 minutes)

Distributor: American Music Therapy Association
8455 Colesville Road, Suite 1000
Silver Spring, MD 20910

This video is a documentary that communicates how music therapy plays a vital role in the treatment of children and adults with a wide range of diagnoses. The video, which has won two national awards, was filmed at major medical centers in Cleveland, Ohio and New York City, and captures actual music therapy sessions in progress. Interviews with patients, physicians, family members and other health care professionals provide testimony regarding the use of music therapy to decrease depression, pain and medication requirements, as well as increase relaxation, positive attitudes toward hospitalization and improve coordination and rhythmic gait.

Discussants: John S. McIntyre, M.D., Bryan C. Hunter, Ph.D.
Deborah Salmon has worked as a music therapist with the terminally ill since 1984. Featuring her work in the Palliative Care Unit of the Royal Victorian Hospital, On Wings of Song shows how a skilled music therapist may help a diverse group of patients find spiritual and emotional nourishment during their last days. By calling upon the knowledge of a wide range of musical instruments and styles, a music therapist is able to forge a strong emotional connection with patients. This poignant and inspiring film captures moments of humor, celebration and joy made possible through music.

15 Dancing Through Death: Monkey, Magic and Madness in Cambodia (56 minutes)

This is the story of Thavro Phim, who came of age under the Pol Pot regime and lost his father, brother and grandfather to the bloodthirsty Khmer Rouge. What kept him alive was his Buddhist faith and dedication to Cambodian classical dance where he performs the role of Hanuman, the magical white monkey. The film takes us back to the years 1975-79 when 90% of the dancers were executed or died of starvation or disease. Their story leads to Cambodia’s killing fields, the refugee camps and to Yale University’s Cambodian Genocide Project, which helps families access information about their loved ones.
<table>
<thead>
<tr>
<th>SYMPOSIUM 2</th>
<th>2:00 p.m. - 5:00 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room E253 B, Level 2, McCormick Place Lakeside</td>
<td></td>
</tr>
<tr>
<td>RELIGION AS A WEDGE BETWEEN DOCTOR AND PATIENT</td>
<td></td>
</tr>
<tr>
<td>Chp.: Nada L. Stotland, M.D.</td>
<td></td>
</tr>
<tr>
<td>A Domestic Violence: Psychiatry Versus Religion</td>
<td></td>
</tr>
<tr>
<td>Nada L. Stotland, M.D.</td>
<td></td>
</tr>
<tr>
<td>B Domestic Violence and Mental Health: Expanding the Conceptual Frame</td>
<td></td>
</tr>
<tr>
<td>Carole L. Warshaw, M.D.</td>
<td></td>
</tr>
<tr>
<td>C Religion, Ethics and Psychiatric Responsibilities</td>
<td></td>
</tr>
<tr>
<td>Martha B. Holstein, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>D The Forgotten Factor in Mental Health</td>
<td></td>
</tr>
<tr>
<td>David B. Larson, M.D., Byron R. Johnson, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>E Theology and Domestic Abuse</td>
<td></td>
</tr>
<tr>
<td>Don S. Browning, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>THIS SESSION WILL BE AUDIOTAPED.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIUM 3</th>
<th>2:00 p.m. - 5:00 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room E253 C, Level 2, McCormick Place Lakeside</td>
<td></td>
</tr>
<tr>
<td>BIPOLAR ILLNESS AND ALCOHOL ABUSE: COURSE AND TREATMENT</td>
<td></td>
</tr>
<tr>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td></td>
</tr>
<tr>
<td>Chp.: Mark A. Frye, M.D.</td>
<td></td>
</tr>
<tr>
<td>A Bipolar Disorder and Comorbid Alcoholism</td>
<td></td>
</tr>
<tr>
<td>Susan L. McElroy, M.D.</td>
<td></td>
</tr>
<tr>
<td>B Alcohol and Axis II Comorbidity in Bipolar Patients</td>
<td></td>
</tr>
<tr>
<td>Lori L. Altshuler, M.D., JoAnne Kay, M.A., Joseph Ventura, Ph.D., Jim Mintz, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>C Courses of Co-Occurring Bipolar and Alcohol Use Disorders</td>
<td></td>
</tr>
<tr>
<td>Stephen M. Strakowski, M.D., Melissa P. Delbello, M.D., Wendelyn Wigh, M.S.W., A. Monique Brock, B.A., David E. Fleck, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>D Anticonvulsants in Bipolar Illness with Alcohol Comorbidity</td>
<td></td>
</tr>
<tr>
<td>Mark A. Frye, M.D., Kirk D. Denicoff, M.D., Earlia-Smith Jackson, R.N., Elizabeth Vanderham, M.A., Gabriele S. Leverich, M.S.W., Robert M. Post, M.D.</td>
<td></td>
</tr>
<tr>
<td>E Anticonvulsants in Alcohol Withdrawal and Relapse</td>
<td></td>
</tr>
<tr>
<td>Donald L. Myrick, M.D.</td>
<td></td>
</tr>
<tr>
<td>Discussant: Kathleen T. Brady, M.D.</td>
<td></td>
</tr>
<tr>
<td>THIS SESSION WILL BE AUDIOTAPED.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIUM 4</th>
<th>2:00 p.m. - 5:00 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room E253 D, Level 2, McCormick Place Lakeside</td>
<td></td>
</tr>
<tr>
<td>ESTROGEN-REPLACEMENT THERAPY IN MENOPAUSE-RELATED MOOD DISORDERS</td>
<td></td>
</tr>
<tr>
<td>Chp.: Natalie L. Rasgon, M.D.</td>
<td></td>
</tr>
<tr>
<td>A Estrogen-Replacement Therapy: Cognition and Depression in Postmenopausal Women</td>
<td></td>
</tr>
<tr>
<td>Natalie L. Rasgon, M.D., Jennifer Dunkin, Ph.D., Lori L. Altshuler, M.D., Andrea Rapkin, M.D.</td>
<td></td>
</tr>
<tr>
<td>B Mood Disorders in Perimenopause: The Estrogen-Serotonin Connection</td>
<td></td>
</tr>
<tr>
<td>Hadine Joffe, M.D.</td>
<td></td>
</tr>
<tr>
<td>C Estrogen, Depression and the Perimenopause</td>
<td></td>
</tr>
<tr>
<td>Peter J. Schmidt, M.D., Catherine A. Roca, M.D., David R. Rubinow, M.D.</td>
<td></td>
</tr>
<tr>
<td>D Estrogen and Cognition in Older Women</td>
<td></td>
</tr>
<tr>
<td>Barbara B. Sherwin, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>E On the Cusp of Perimenopause: Depression in Older Premenopausal Women</td>
<td></td>
</tr>
<tr>
<td>Lee S. Cohen, M.D.</td>
<td></td>
</tr>
<tr>
<td>F Perimenopause As Context</td>
<td></td>
</tr>
<tr>
<td>David R. Rubinow, M.D.</td>
<td></td>
</tr>
<tr>
<td>Discussant: David R. Rubinow, M.D.</td>
<td></td>
</tr>
<tr>
<td>THIS SESSION WILL BE AUDIOTAPED.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIUM 5</th>
<th>2:00 p.m. - 5:00 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room S402 A, Level 4, McCormick Place South</td>
<td></td>
</tr>
<tr>
<td>PROFESSIONAL BOUNDARIES: TRAINING METHODS</td>
<td></td>
</tr>
<tr>
<td>Chp.: Gregg E. Gorton, M.D.</td>
<td></td>
</tr>
<tr>
<td>A Teaching Boundaries to Residents: A Model Course</td>
<td></td>
</tr>
<tr>
<td>Gregg E. Gorton, M.D., Steven E. Samuel, Ph.D., Gail Zibin, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>B An Adaptable Curriculum on Boundary Violations with Patients</td>
<td></td>
</tr>
<tr>
<td>Gail E. Robinson, M.D., Donna E. Stewart, M.D.</td>
<td></td>
</tr>
<tr>
<td>C After the Fall: Remedial Boundaries Training</td>
<td></td>
</tr>
<tr>
<td>Gary R. Schoener, Psy.D.</td>
<td></td>
</tr>
<tr>
<td>Discussants: Carolyn Quadrio, M.D., Werner Tschan, M.D.</td>
<td></td>
</tr>
<tr>
<td>THIS SESSION WILL BE AUDIOTAPED.</td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM 6</td>
<td>2:00 p.m. - 5:00 p.m.</td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Room S402 B, Level 4, McCormick Place South</td>
<td>Room S403 B, Level 4, McCormick Place South</td>
</tr>
<tr>
<td>NEUROBIOLOGY OF BPD</td>
<td>BIPOLAR DEPRESSION: CLINICAL, BIOLOGICAL AND TREATMENT SPECIFICITY</td>
</tr>
<tr>
<td>Chp.: Robert A. Grossman, M.D.</td>
<td>Chp.: Alan C. Swann, M.D.</td>
</tr>
<tr>
<td><strong>A</strong> Predictors of Improvement for Borderline Patients</td>
<td><strong>A</strong> Biological Specificity of Bipolar Depression</td>
</tr>
<tr>
<td>Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D.</td>
<td>Alan C. Swann, M.D., Terry Allen, Ph.D., Martin M. Katz, Ph.D.</td>
</tr>
<tr>
<td><strong>B</strong> HPA Axis Activity in BPD</td>
<td><strong>B</strong> Cerebral Function in Bipolar Depression</td>
</tr>
<tr>
<td><strong>C</strong> Biological Factors in Impulsive Aggression</td>
<td><strong>C</strong> Recent Clinical Research in Bipolar Depression</td>
</tr>
<tr>
<td>Emil F. Coccaro, M.D.</td>
<td>Joseph R. Calabrese, M.D.</td>
</tr>
<tr>
<td><strong>D</strong> Genetic Studies of Impulsive Aggression in Personality Disorders</td>
<td><strong>D</strong> Clinical Evidence on Antidepressants for Bipolar Disorder</td>
</tr>
<tr>
<td>Antonia S. New, M.D., Joel Gelemter, M.D., Vivian Mitropoulou, M.A., Larry J. Siever, M.D.</td>
<td>Patricia Suppes, M.D.</td>
</tr>
<tr>
<td><strong>E</strong> Imaging the Serotonin System in Personality Disorder Patients</td>
<td>Discussant: Charles L. Bowden, M.D.</td>
</tr>
<tr>
<td>Larry J. Siever, M.D., Antonia S. New, M.D., Monte S. Buchsbaum, M.D., Erin A. Hazlett, Ph.D., Marianne Goodman, M.D., Diedre A. Reynolds, M.D., Harold W. Koenigsberg, M.D.</td>
<td>THIS SESSION WILL BE AUDIOTAPED.</td>
</tr>
<tr>
<td><strong>F</strong> Childhood Trauma and Loss of Affect Regulation</td>
<td><strong>F</strong> Childhood Trauma and Loss of Affect Regulation</td>
</tr>
<tr>
<td>Bessel A. Van Der Kolk, M.D.</td>
<td>Bessel A. Van Der Kolk, M.D.</td>
</tr>
<tr>
<td>THIS SESSION WILL BE AUDIOTAPED.</td>
<td>THIS SESSION WILL BE AUDIOTAPED.</td>
</tr>
<tr>
<td>SYMPOSIUM 7</td>
<td>SYMPOSIUM 9</td>
</tr>
<tr>
<td>Room S403 A, Level 4, McCormick Place South</td>
<td>Room S404 A, Level 4, McCormick Place South</td>
</tr>
<tr>
<td>TREATMENT-REFRACTORY SCHIZOPHRENIA: A NEW LOOK</td>
<td>THE PRACTICAL MEDICAL MANAGEMENT OF HIV DISEASE</td>
</tr>
<tr>
<td>Chp.: Alexander L. Miller, M.D.</td>
<td>Chp.: Francine Cournos, M.D.</td>
</tr>
<tr>
<td><strong>A</strong> Implications of Definitions for Treatment</td>
<td><strong>A</strong> New Antiretroviral Treatments in HIV Disease</td>
</tr>
<tr>
<td>Nina R. Schooler, Ph.D.</td>
<td>Marshall Forstein, M.D.</td>
</tr>
<tr>
<td><strong>B</strong> Optimization of Clozapine Treatment</td>
<td><strong>B</strong> Treatment Approaches to HIV-Related Neurocognitive Disorders</td>
</tr>
<tr>
<td>Del D. Miller, M.D.</td>
<td>Mark H. Halman, M.D.</td>
</tr>
<tr>
<td><strong>C</strong> Medication Guidelines and Algorithms</td>
<td><strong>C</strong> Complications of Drug-Drug Interactions and Substance Use</td>
</tr>
<tr>
<td>Alexander L. Miller, M.D., John A. Chiles, M.D., M. Lynn Crismon, Pharm.D.</td>
<td>Karl Goodkin, M.D.</td>
</tr>
<tr>
<td><strong>D</strong> The Role of Second-Generation Antipsychotics in Treatment-Refactory Schizophrenia</td>
<td><strong>D</strong> Adherence Strategies</td>
</tr>
<tr>
<td>Robert R. Conley, M.D.</td>
<td>Milton L. Wainberg, M.D.</td>
</tr>
<tr>
<td>THIS SESSION WILL BE AUDIOTAPED.</td>
<td>THIS SESSION WILL BE AUDIOTAPED.</td>
</tr>
<tr>
<td><strong>E</strong> Managing Comorbid Manifestations of Schizophrenia</td>
<td>SYMPOSIUM 10</td>
</tr>
<tr>
<td>Peter F. Buckley, M.D.</td>
<td>Room S404 B/C, Level 4, McCormick Place South</td>
</tr>
<tr>
<td>THIS SESSION WILL BE AUDIOTAPED.</td>
<td>TRAGEDY AND REMEDY: REMEMBERING LITTLETON ONE YEAR LATER</td>
</tr>
<tr>
<td>APA Alliance and APA Committee on Juvenile Justice Issues</td>
<td>APA Alliance and APA Committee on Juvenile Justice Issues</td>
</tr>
<tr>
<td>Chp.: Helen L. Sacks, M.S.W.</td>
<td><strong>A</strong> New and Improved: Chicago's Juvenile Court Clinic</td>
</tr>
<tr>
<td><strong>A</strong> New and Improved: Chicago's Juvenile Court Clinic</td>
<td>Bernardine Dohrn, J.D.</td>
</tr>
</tbody>
</table>
B Points of Intervention with Delinquents: Timely or Too Late?
Wade C. Myers, M.D., Kimberly M. Donat, M.S.W., Paul R.S. Burton, Jane Cheney, O.T., Paula D. Sanders, C.T.R.S., Linda Monaco, Ph.D.

C The Role of Policy Makers in Delinquency Prevention
Altha J. Stewart, M.D.

D Is This Child at Risk for Violence? A School Assessment
Louis J. Kraus, M.D.

E Violence and the Culture of Fear: The Legislative Challenge
Herbert S. Sacks, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 11
2:00 p.m. - 5:00 p.m.
Continental Ballroom A, Lobby Level, Chicago Hilton

THE MANY FACES OF TRANSFERENCE IN EVERYDAY CLINICAL CARE: PART 1
American Academy of Psychoanalysis and the American Psychoanalytic Association

Chp.: Samuel Slipp, M.D.
Co-Chp.: Stephen F. Bauer, M.D.

A Woman to Woman: The Psychotherapeutic Relationship
Jennifer I. Downey, M.D.

B Man to Man: The Psychotherapeutic Relationship
Richard C. Friedman, M.D.

C Boundary Violations in the Therapeutic Relationship
Glen O. Gabbard, M.D.

D The Doctor and the Suicidal Patient
Joan Wheels, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 12
2:00 p.m. - 5:00 p.m.
Continental Ballroom B, Lobby Level, Chicago Hilton

FRONTIERS IN ALCOHOLISM TREATMENT: PHARMACOLOGY
National Institute on Alcohol Abuse and Alcoholism

Chp.: Stephanie S. O'Malley, Ph.D.

A Update on Anticonvulsants for Alcohol Withdrawal
Robert J. Malcolm, Jr., M.D., Donald L. Myrick, M.D., Raymond F. Anton, M.D., James Roberts, Ph.D.

B Acamprosate Treatment of Alcohol Dependence
Barbara J. Mason, M.D.

C Naltrexone: Effect of Therapy and Treatment Duration
Stephanie S. O'Malley, Ph.D., Patrick G. O'Connor, M.D., Conor K. Farren, M.D., Kee Namkoong, M.D., Bruce J. Rounsaville, M.D.

D Naltrexone: Effects of Treatment Duration
Joseph R. Volpicelli, M.D., John Monterosso, Ph.D., Helen M. Pettinati, Ph.D.

E Matching SSRI Treatment to Specific Groups of Alcoholics
Henry R. Krantz, M.D., Helen M. Pettinati, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 13
2:00 p.m. - 5:00 p.m.
Continental Ballroom C, Lobby Level, Chicago Hilton

PROFESSIONAL ADVOCACY: PERSONAL LEADERSHIP ODYSSEYS

Chp.: Jeremy A. Lazarus, M.D.

A Leadership in Organized Psychiatry
Rodrigo A. Muñoz, M.D.

B Professional Advocacy: Promoting Privacy and Confidentiality
Richard K. Harding, M.D.

C Advocacy in Organized Medicine
Daniel B. Borenstein, M.D.

D Advocating for the Profession: Mentorship
Miles F. Shore, M.D.

E Professional Leadership in Ethics
Jeremy A. Lazarus, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 14
2:00 p.m. - 5:00 p.m.
Boulevard Room A/B, Second Floor, Chicago Hilton

SOCIAL PSYCHIATRY: 21ST CENTURY PERSPECTIVES

Chp.: H. Steven Moffic, M.D.

A Harry Stack Sullivan and the 21st Century
Steven S. Sharfstein, M.D.

B Social Violence: Psychiatric and Sociological Aspects
Gerald J. Sarwer-Foner, M.D.

C Social Psychiatry, Family Function and the Millennium
John J. Schwab, M.D., Helen Gray, M.D., Florence Prentice, Ph.D.

Discussants: Edmond H. Pi, M.D., Beverly J. Fauman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 15
2:00 p.m. - 5:00 p.m.
Boulevard Room C, Second Floor, Chicago Hilton

DOCTOR INFLUENCE ON HASTENED DEATH IN WOMEN AND MEN WORLDWIDE

Chp.: Kalman J. Kaplan, Ph.D.
Co-Chp.: Mark E. Schneiderman, Pharm.D.

(Continued on next page)
MONDAY

A Physical Health Factors in Completed Suicide
Yeates Conwell, M.D., Paul R. Duberstein, Ph.D., Larry Seidtiz, Ph.D., Andrea Digjrgno, M.A., Christopher Cox, Ph.D., Eric D. Caine, M.D., Nicholas Forbes, M.D.

B Demoralization and Burden in Darwin’s Euthanasia Series
David W. Kissane, M.D., Annett Street, Ph.D.

C Gender, the Doctor-Patient Relationship and Hastened Death
Silvia S. Canetto, Ph.D.

D Patient Gender, Doctor Involvement and Decisions on Dying
Kalman J. Kaplan, Ph.D., Martin Harrow, Ph.D., Mark E. Schneiderman, Pharm.D.

E Gender, Help-Seeking and Euthanasia
Joseph A. Flaherty, M.D., Judy Richman, Ph.D.

Discussant: Linda Emanuel, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 16 2:00 p.m. - 5:00 p.m.
Joliet Room, Third Floor, Chicago Hilton
WORLD VIEWS AND THE DOCTOR-PATIENT RELATIONSHIP
Chp.: Allan M. Josephson, M.D.

A The Weltanschauung of Sigmund Freud: Clinical Implications
Armand M. Nicholi, Jr., M.D.

B Clinical Models and a Spiritual World View: A Rapprochement
Allan M. Josephson, M.D.

C Suffering and the Patient’s World View
John R. Peteeet, M.D.

D World Views and Hope in Psychiatry
Leigh C. Bishop, M.D.

E A Clinician Looks at Patients and Their World Views
Irving S. Wiesner, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 17 2:00 p.m. - 5:00 p.m.
Marquette Room, Third Floor, Chicago Hilton
BUPRENORPHINE TREATMENT: RESEARCH AND PRACTICE
American Academy of Addiction Psychiatry
Chp.: Marc Galanter, M.D.

A Overview of Research Options
Thomas R. Kosten, M.D.

B Buprenorphine/Naloxone Office-Based Treatment of Opiate Dependence
Paul P. Casadonte, M.D.

C National Institute on Drug Abuse’s Medication Development Perspective
Frank J. Vocci, Ph.D.

D Regulation of Clinical Practice
H. Westley Clark, M.D.

Discussant: Joseph G. Liberto, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 18 2:00 p.m. - 5:00 p.m.
PDR 2, Third Floor, Chicago Hilton
THERAPEUTIC ALLIANCE: EVALUATION, TREATMENT AND OUTCOME
Chp.: J. Christopher Perry, M.D.

A The Building of Therapeutic Alliance: An Empirical Study
Jean-Nicolas Despland, M.D., Yves DeRolen, Ph.D., M. Sigler, M.D., E. Martinez, M.P.S., S. Solis, M.P.S.

B Alliance, Adherence and Outcome in Pharmacotherapy
Arthur Dworetz, M.D.

C The Therapeutic Alliance Across Time and Treatments
J. Christopher Perry, M.D., Barbara Zheutlin, M.S., Leveen Laptisky, M.S., Eric M. Plakun, M.D.

D Psychotherapeutic Interventions and the Alliance
Michael P. Bond, M.D., Elisabeth Banon, M.D., Marcella Grenier, Ph.D.

E Patient and Therapist Contributions to the Alliance
Mary Beth Connolly, Ph.D., Paul Crits-Christoph, Ph.D., Clara De LaCruz, B.A.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 19 2:00 p.m. - 5:00 p.m.
Waldorf Room, Third Floor, Chicago Hilton
DEVELOPMENTS IN THE USE OF SECLUSION AND RESTRAINT
Chp.: Roger Peele, M.D.
Co-Chp.: Lien A. Hung, M.D.

A The Experiences of a JCAHO Surveyor
Thomas B. Stage, M.D.

B Reducing Seclusion and Restraint by a CQI Process
Lloyd I. Sederer, M.D.

C Experience in Reducing the Use of Seclusion and Restraint
Lynn C. DeLacy, M.S.

D Developments in the Use of Seclusion and Restraint: The Experience of a State System
Dale P. Svendsen, M.D.
E What's Behind Lower Seclusion and Restraint in the VA?  
William W. Van Stone, M.D.

Discussant: Thomas N. Wise, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 20 2:00 p.m. - 5:00 p.m.  
Williford Room C, Third Floor, Chicago Hilton

PSYCHIATRIC MANAGEMENT IN NEUROLOGICAL DISEASE
Chp.: Edward C. Lauterbach, M.D.

A Psychiatric Aspects of Parkinson's Disease  
Matthew A. Menza, M.D.

B Psychiatric Management in Huntington's Disease  
Neal G. Ranen, M.D.

C Psychiatric Management in Wilson's Disease  
Edward C. Lauterbach, M.D.

D Psychiatric Management of Stroke  
Robert G. Robinson, M.D.

E Psychiatric Management in Multiple Sclerosis  
Randolph B. Schifffer, M.D.

F Neuropsychiatric Aspects of AIDS  
Francisco Fernandez, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 21 2:00 p.m. - 5:00 p.m.  
Lake Erie Room, Eighth Floor, Chicago Hilton

EATING DISORDERS: A CLINICAL RESEARCH UPDATE
Chp.: Evelyn Attia, M.D.

A Inpatient Treatment of Anorexia Nervosa  
Evelyn Attia, M.D., Laurel Mayer, M.D.

B Partial Hospitalization and Weight Gain in Anorexia Nervosa  
Angela S. Guarda, M.D., Leslie J. Heinberg, Ph.D.

C Psychotherapy and Medication in the Treatment of Bulimia  
B. Timothy Walsh, M.D.

D Eating Disorders in Children and Adolescents  
Lisa A. Kotler, M.D., B. Timothy Walsh, M.D., Michael J. Devlin, M.D.

E Treatment of Obese Patients with Binge Eating Disorder  
Michael J. Devlin, M.D., Juli A. Goldfein, Ph.D., Pamela Raizman, Ph.D.

Discussant: James E. Mitchell, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 22 2:00 p.m. - 5:00 p.m.  
Lake Huron Room, Eighth Floor, Chicago Hilton

CULTURAL COMPETENCE AT SAMHSA, CMHS AND STATE LEVELS
Chp.: Francis G. Lu, M.D.

A Center for Mental Health Services and Western Interstate  
Commission for Higher Education: Cultural Competence Standards  
Andres J. Pumariega, M.D.

B Performance Measures of Cultural Competence  
Carole E. Siegel, Ph.D.

C Cultural Competence Implementation in California: A  
Statewide View  
Rachel G. Guerrero, M.S.W.

D Integrating Cultural Competence Standards at the County  
Level  
Josie Romero-Torralba, L.C.S.W.

E Analysis of Access: 15 California Counties  
Courtenay M. Harding, Ph.D., A. Marie Sanchez, B.S.W.

F California Cultural Competence Plan: Long-Term-Care  
Services  
Robbin L. Huff-Musgrove, Ph.D.

Discussant: Harriet McCombs, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 23 2:00 p.m. - 5:00 p.m.  
Lake Michigan Room, Eighth Floor, Chicago Hilton

UPDATE OF TREATMENT OF STIMULANT ABUSE
Chp.: David A. Gorelick, M.D.

A Recovery-Oriented Psychosocial Treatment  
Douglas M. Ziedonis, M.D., Ilana Pinsky, Ph.D., Jonathan  
Krejci, Ph.D., Edward Mann, A.A.S., Victoria Lipinski, M.S.W.,  
Frank Baffige, M.A., Brenda Rambo, B.A.

B Psychotherapy and Counseling Approaches to Cocaine  
Abuse Treatment  
David R. Gastfriend, M.D.

C Pharmacological Treatment of Stimulant Abuse  
David A. Gorelick, M.D.

D Psychiatric Comorbidity in Stimulant Abusers  
Richard N. Rosenthal, M.D.

E Update on Treating Methamphetamine Abuse  
Steven L. Batki, M.D.
THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 24 2:00 p.m. - 5:00 p.m.
Lake Ontario Room, Eighth Floor, Chicago Hilton

ADMINISTRATIVE RELATIONS IN PSYCHIATRIC LEADERSHIP
Chp.: Wesley E. Sowers, M.D.

A Divide and Cooperate: The Medical Director and the CEO
Clifton R. Tennonson, Jr., M.D.

B Sleep at Night: The Travels of a Managed Care Physician
Jerome V. Vaccaro, M.D.

C Public System Clinician-Administrator Relationships
Christopher G. Fichtner, M.D., Daniel J. Luchins, M.D.

D Avoiding the Pitfalls: When It Doesn't Work
Gordon H. Clark, Jr., M.D.

E I Had a Dream: Making It Work
Kathleen A. Daly, M.D.

Discussants: Jacqueline M. Feldman, M.D., A. Anthony Arce, M.D.

THIS SESSION WILL BE AUDIO TAPE.

3:00 p.m. Session

NEW RESEARCH YOUNG INVESTIGATORS' POSTER SESSION 4
3:00 p.m. - 5:00 p.m.
Hall E, Level 2, McCormick Place Lakeside

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

7:30 p.m. Session

CONVOCATION OF FELLOWS
7:30 p.m.
Room E354, Level 3, McCormick Place Lakeside

All Fellows, members and registered guests are invited.

Presiding: Allan Tasman, M.D., President

Grand Marshals: Jerome S. Begler, M.D., Harold M. Visotsky, M.D.

Marshals: Carl C. Bell, M.D., Nada L. Slotland, M.D.

INTRODUCTION OF LIFE FELLOWS
Daniel B. Borenstein, M.D., President-Elect

LECTURE 10
7:30 p.m.
Room E354, Level 3, McCormick Place Lakeside

WILLIAM C. MENINGER MEMORIAL LECTURE
Bertrand Piccard, M.D.

The Metaphor of Ballooning in Psychotherapy

Bertrand Piccard, M.D., is a scientist-adventurer, doctor, psychiatrist and aeronaut who combines science and adventure to explore the human soul. Born into a celebrated family of Swiss adventurers, Dr. Piccard has explored most...
forms of free flight from microlight aircraft and aerobatic hang-gliders to parachuting and ballooning. He has long been fascinated by human behavior and the effects of extreme atmospheres on levels of consciousness. Wishing to acquire a deeper understanding of the human “inner world,” he became a doctor, then a specialist in adult, child and adolescent psychiatry and psychotherapy. Dr. Piccard also trained himself in hypnosis techniques and opened a psychotherapy practice where he organizes hypnosis training seminars. Through his work as a doctor, Dr. Piccard was brought back to the family tradition of hot-air ballooning. In March 1999, after two previous attempts, he completed the first nonstop round-the-world voyage in a hot-air balloon, with Brian Jones of Britain, setting the record for farthest and longest flight. For Dr. Piccard, hot-air ballooning has become a metaphor for life, the symbol of a new relationship between man, technology and nature which considerably enriches the way he practices medicine. In this vision, the balloon is prisoner of the currents which propel it, just as man is the captive of his certitudes, of his problems and of his destiny. But, in the same way as a balloon can change altitude in order to find the currents which will make it change direction, man can raise himself psychologically and spiritually to become responsible for the direction of his existence once again.

THIS SESSION WILL BE AUDIOTAPED.
CALL FOR PAPERS

PRESIDENT'S THEME:
MIND MEETS BRAIN
INTEGRATING PSYCHIATRY, PSYCHOANALYSIS, NEUROSCIENCE

Daniel B. Borenstein, M.D.
President

Philip R. Muskin, M.D., Chairperson
Scientific Program Committee

THE SUBMISSION SCHEDULE

<table>
<thead>
<tr>
<th>Format</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry-Supported</td>
<td>June 5, 2000</td>
</tr>
<tr>
<td>Symposium-Part A</td>
<td></td>
</tr>
<tr>
<td>Course</td>
<td>September 5, 2000</td>
</tr>
<tr>
<td>Media</td>
<td>September 5, 2000*</td>
</tr>
<tr>
<td>Reports</td>
<td>September 5, 2000</td>
</tr>
<tr>
<td>Symposium</td>
<td>September 5, 2000</td>
</tr>
<tr>
<td>Workshops</td>
<td>Issue and Innovative: September 5, 2000</td>
</tr>
<tr>
<td></td>
<td>Component: October 2, 2000</td>
</tr>
<tr>
<td>New Research</td>
<td>January 5, 2001</td>
</tr>
</tbody>
</table>

Incomplete and/or Incorrect Forms Will Not Be Considered.

*A single copy of the media item must be included with submission material.

For complete submission forms, contact the APA toll free at 1-888-357-7924 and speak directly with an Answer Center Coordinator.

If you want to volunteer to chair a session, please send a letter to the attention of Dr. Muskin at the American Psychiatric Association. Please indicate your name, address, area of expertise and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.
TUESDAY, MAY 16, 2000

153rd ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 29-33

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 29, PART 2
7:00 a.m. - 8:30 a.m.
Room E450, Level 4, McCormick Place Lakeside
MANAGING PSYCHOSES ACROSS THE AGE SPECTRUM
Supported by AstraZeneca Pharmaceuticals
Chp.: Rajiv Tandon, M.D.
Co-Chp.: S. Charles Schulz, M.D.
A Psychosis Genotypes and Phenotypes: Diagnosis and Treatment
Henry A. Nasrallah, M.D.
B Geriatric Psychoses
Dilip V. Jeste, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART 2
7:00 a.m. - 8:30 a.m.
Grand Ballroom A, Level 1, McCormick Place Lakeside
ANTIEPILEPTIC DRUGS IN PSYCHIATRIC DISORDERS
Supported by Parke-Davis
Chp.: F. Moises Gaviria, M.D.
Co-Chp.: Andres M. Kanner, M.D.
A Use of Antiepileptics in Drug Abuse Detoxification
Sylvia J. Dennison, M.D.
B Negative Psychotropic Effects of Antiepileptic Drugs
F. Moises Gaviria, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 2
7:00 a.m. - 8:30 a.m.
Regency Ballroom, Second Floor, Hyatt Regency
EVIDENCE-BASED MANAGEMENT OF REFRACTORY DEPRESSION
Supported by Organon Inc.
Chp.: Andrew A. Nierenberg, M.D.
Co-Chp.: Madhukar H. Trivedi, M.D.
A Juvenile Depression: Diagnosis and Treatment
Jefferson B. Prince, M.D.
B Divergence of Practice from Evidence for Refractory Depression
Andrew A. Nierenberg, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 2
7:00 a.m. - 8:30 a.m.
Grand Ballroom, Second Floor, Chicago Hilton
LENGTHENING THE FUSE: TREATMENT OF AGGRESSION
Supported by Abbott Laboratories
Chp.: Susan L. McElroy, M.D.
A Impulsivity in Aggression: BPD and Autism
Eric Hollander, M.D., Sherie Novotny, M.D., Andrea Allen, Ph.D.,
Charles Cartwright, M.D., Carol Bienstock, B.A.
B Agitation and Aggression in the Elderly
Pierre N. Tariot, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 33, PART 2
7:00 a.m. - 8:30 a.m.
International Ballroom North, Second Floor, Chicago Hilton
NEW CLINICAL ADVANCES IN DEPRESSION
Supported by Bristol-Myers Squibb Company
Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.
A A Concise Review of What We Know and What We Don't Know About the Biology and Course of Chronic Depression
David L. Dunner, M.D.
B New Treatment Findings on Combining Pharmacotherapy and Psychotherapy for Chronic Depression
Martin B. Keller, M.D.
Discussant: Paula J. Clayton, M.D.

8:00 a.m. Sessions

COURSES 63-69
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 63 8:00 a.m. - 12 noon
Room N426 B, Level 4, McCormick Place North
THE DETECTION OF MALINGERED MENTAL ILLNESS
Director: Phillip J. Resnick, M.D.

COURSE 64 8:00 a.m. - 12 noon
Room S501 B/C, Level 5, McCormick Place South
DUAL DIAGNOSIS: BASIC PRINCIPLES
Director: Kenneth Minkoff, M.D.
TUESDAY

COURSE 65 8:00 a.m. - 12 noon
Room S501 D, Level 5, McCormick Place South
DOING RESEARCH ON A SHOESTRING BUDGET
Director: Mantosh J. Dewan, M.D.
Faculty: Michele T. Pato, M.D., Edward K. Silberman, M.D.

COURSE 66 8:00 a.m. - 12 noon
Room S502 B, Level 5, McCormick Place South
COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS
Director: Jesse H. Wright, M.D.
Faculty: Michael E. Thase, M.D., Monica A. Basco, Ph.D.

COURSE 67 8:00 a.m. - 12 noon
Room S503 B, Level 5, McCormick Place South
DISASTER PSYCHIATRY: ADVANCED TOPICS
APA Committee on Psychiatric Dimensions of Disasters
Co-Directors: Robert J. Ursano, M.D., Michael Blumenfield, M.D.
Faculty: Ann E. Norwood, M.D., Kemuel Philbrick, M.D., Steven M. Southwick, M.D.

COURSE 68 8:00 a.m. - 12 noon
Room S504 A, Level 5, McCormick Place South
ASSESSMENT AND THERAPY OF TRAUMATIC BEREAVEMENT
Co-Directors: Edward K. Rynearson, M.D., Jennifer Favell, Ph.D.

COURSE 69 8:00 a.m. - 12 noon
Room S504 D, Level 5, McCormick Place South
FAMILIES AND MEDICAL ILLNESS: AN INTEGRATIVE TREATMENT APPROACH
Director: John S. Rolland, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 2
9:00 a.m. - 10:30 a.m.
Williford Room C, Third Floor, Chicago Hilton
AFFECT DYSREGULATION: CLINICAL ISSUES AND PSYCHOTHERAPY
Moderator: Roslyn Seligman, M.D.
Discussant: Brenda C. Solomon, M.D.

CONTINUOUS CLINICAL CASE CONFERENCE 1:
PART 2
9:30 a.m. - 12 noon
PDR 2, Third Floor, Chicago Hilton

PATIENTS WITH MEDICALLY UNEXPLAINED PHYSICAL SYMPTOMS: PSYCHIATRY AND FAMILY MEDICINE AS PHYSICIAN PARTNERS
American Academy of Family Physicians
Moderators: Arthur J. Barsky III, M.D., Frank V. deGruy, M.D.
Presenters: Susan McDaniel, M.D., Tom G. Campbell, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 70-77
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 70 9:00 a.m. - 4:00 p.m.
Room N426 A, Level 4, McCormick Place North
RATIONAL USE OF HORMONE-REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN
Director: Marjorie L. Shuer, M.D.
Faculty: Joel T. Hargrove, M.D., Y.W. Francis Lam, Pharm.D.

COURSE 71 9:00 a.m. - 4:00 p.m.
Room N426 C, Level 4, McCormick Place North
DEMENTIA: ADVANCED DIAGNOSIS AND TREATMENT
Director: William E. Reichman, M.D.
Faculty: Jeffrey L. Cummings, M.D., David L. Sultzer, M.D., Peter M. Aupperle, M.D., Jacobo E. Mintzer, M.D., Pierre N. Tariot, M.D.

COURSE 72 9:00 a.m. - 4:00 p.m.
Room N427 A, Level 4, McCormick Place North
A PRACTICAL APPROACH TO HERBAL MEDICINE IN PSYCHIATRY
Director: Richard P. Brown, M.D.
Faculty: Joseph R. Hibbeln, M.D., Lorraine Innes, M.D.
COURSE 73  9:00 a.m. - 4:00 p.m.
Room N427 D, Level 4, McCormick Place North

THERAPEUTIC ADAPTATIONS WITH DEAF AND HARD OF HEARING PATIENTS
APA Caucus on the Deaf and Hard of Hearing

Director: Dorothea L. De Gutiis, M.D.
Faculty: Barbara G. Haskins, M.D., Sanjay Gulati, M.D., Toby Perlman, Ph.D., Karen Graham, M.S.W., Howard Rosenblum, J.D., Jill N. Aftran, M.D.

COURSE 74  9:00 a.m. - 4:00 p.m.
Room S501 A, Level 5, McCormick Place South

DEPRESSION: INDIVIDUAL/GROUP INTERPERSONAL THERAPY
American Group Psychotherapy Association

Director: K. Roy MacKenzie, M.D.

COURSE 75  9:00 a.m. - 4:00 p.m.
Room S502 A, Level 5, McCormick Place South

HYPNOSIS IN PSYCHIATRY

Director: Jose R. Maldonado, M.D.
Faculty: David Spiegel, M.D.

COURSE 76  9:00 a.m. - 4:00 p.m.
Room S503 A, Level 5, McCormick Place South

MULTIMODAL TREATMENT OF EATING DISORDERS

Co-Directors: Kathryn J. Zerbe, M.D., Mae S. Sokol, M.D.

COURSE 77  9:00 a.m. - 4:00 p.m.
Room S504 B/C, Level 5, McCormick Place South

DIAGNOSTIC CHALLENGES IN NEUROPSYCHIATRY

Co-Directors: Patricia I. Rosebush, M.D., Michael F. Mazurek, M.D.
Faculty: Sarah Garside, M.D., Anthony J. Levinson, M.D.

DISCUSSION GROUPS 8-10

9:00 a.m. - 10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

8  Daniel K. Winstead, M.D., on Restraints and Seclusion
Revisited
Room 4G, Fourth Floor, Chicago Hilton

9  Catherine C. Chang-Crone, M.D., on Consultation-Liaison Psychiatry: Highlighting Subspecialty Options Through Discussion of Transplant Psychiatry (For Residents Only)
Room 4L, Fourth Floor, Chicago Hilton

10  Arthur T. Meyerson, M.D., on Current Trends in Community Psychiatry
Room 4L, Fourth Floor, Chicago Hilton

LECTURES 11-13

LECTURE 11

9:00 a.m. - 10:30 a.m.
Room E350, Level 3, McCormick Place Lakeside

APA'S GEORGE TARJAN AWARD LECTURE
Jambur V. Ananth, M.D.
The Contributions of the International Medical Graduates to American Psychiatry

Chp.: Norma C. Panahon, M.D.
Co-Chp.: Gopalakrishna K. Upadhya, M.D.

International Medical Graduates (IMGs) constitute nearly a quarter of the American physician workforce and nearly 30% of psychiatrists. Jambur Ananth, M.D., discusses the contributions of IMGs to American psychiatry in the areas of clinical service, research, education and professional leadership. Dr. Ananth is a Professor in the Department of Psychiatry at the University of California, Los Angeles, and Director of the Psychopharmacology Unit and Clinical Director of Adult Psychiatric Services at Harbor-UCLA Medical Center in Torrance, California. A Fellow of the American Psychiatric Association and the Royal College of Psychiatrists (United Kingdom), Dr. Ananth has conducted several research projects in the areas of biological psychiatry and psychopharmacology and is the author of more than 350 publications. He graduated from Kasturba Medical College in Manipal, India, completed a postgraduate fellowship at the National Institute of Mental Health and Neuro Sciences in Bangalore, India, and completed residencies in psychiatry in Canada at hospitals in Vancouver, British Columbia and Montreal.

THIS SESSION WILL BE AUDIOTAPED.
LECTURE 12
9:00 a.m. - 10:30 a.m.
Room E353 A/B, Level 3, McCormick Place Lakeside

APA’S OSKAR PFISTER AWARD LECTURE

Professor Paul Ricoeur

The Difference Between the Normal and the Pathological As a Source or Respect: Therapeutic and Ethical Implications

Chp.: George T. Harding IV, M.D.
Co-Chp.: Reverend Clark S. Aist, Ph.D.

Professor Paul Ricoeur is a Professor Emeritus of the University of Paris and the University of Chicago, and is one of the most influential of contemporary French philosophers. In his lecture, Professor Ricoeur examines the relationship between the person with illness and his or her environment and explores the implications of the respect due to persons with handicapping conditions, either physical or mental. In illness, a person must actively adjust to a narrowed environment, and it is this "catastrophic" response that makes the patient infinitely respectable. Professor Ricoeur is well known for his studies of various theories of language and the interpretation of meaning. His writings cover a wide range of topics, including the history of philosophy, literary criticism, ethics, religion, semiotics, and psychoanalysis. His numerous books include Philosophy of the Will, History and Truth, Freud and Philosophy: An Essay on Interpretation, Conflict of Interpretations: Essays in Hermeneutics, The Living Metaphor and Time and Narrative. Recently he co-authored Thinking Biblically: Exegetical and Hermeneutic Studies and Critique and Conviction. Professor Ricoeur has received several honors for his work, including the Hegel Prize, the Karl Jaspers Prize, the Grand Prize of the French Academy and the Eugenio Balzan Prize. He studied philosophy at the Sorbonne in Paris and received his doctoral degree there in 1960.

University in New York City. He is also Attending Psychiatrist at New York Presbyterian Hospital and a training and supervising analyst and lecturer at the Columbia University Center for Psychoanalytic Training and Research. A Life Fellow of the American Psychiatric Association and a Fellow of the American Association for the Advancement of Science, Dr. Michels has received the Seymour D. Vestermark Award from APA and the Distinguished Service Award from the American College of Psychiatrists. He is a member of the Editorial Boards of the New England Journal of Medicine, Journal of the American Psychoanalytic Association and American Journal of Psychotherapy. Dr. Michels graduated from Northwestern University Medical School in Chicago, completed his residency in psychiatry at Presbyterian Hospital–New York State Psychiatric Institute in New York City and completed his psychoanalytic training at the Columbia University Center for Psychoanalytic Training and Research in New York City.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 5-7
9:00 a.m. - 10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

5 James H. Scully, Jr., M.D., on Resident Supervision
   Room 4E, Fourth Floor, Chicago Hilton

6 Malkah T. Notman, M.D., on Psychotherapy: Gender Issues
   Room 4F, Fourth Floor, Chicago Hilton

7 Sheldon I. Miller, M.D., on Dual Diagnosis
   National Institute on Alcohol Abuse and Alcoholism
   Room 4H, Fourth Floor, Chicago Hilton

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 10-11

MEDIA SESSION 10 9:00 a.m.-11:00 a.m.
Room E351, Level 3, McCormick Place Lakeside

A WIDOW’S JOURNEY TO VIETNAM: HOPE AND HEALING

Chp.: Cheryl A. Kennedy, M.D.

16 Regret to Inform
(72 minutes)

Distributor: New Yorker Films
C/O Linda Duchin
16 W. 16th Street, 11th Floor
New York, NY 10023
Fresh from its world premier at the 1999 Sundance Film Festival, this groundbreaking film portrays the devastation of the Vietnam War through the eyes of women, both American and Vietnamese, who lost their husbands. Intensely personal, yet universal in scope, *Regret to Inform* tells of love cut short and of war's lasting effects on the people left in its wake. Ten years in the making, this film is quiet, yet moving. What initially began as a letter from the director to her late husband has evolved finally into a poignant, powerful statement on the personal toll of war.

**MEDIA SESSION 11**  
9:00 a.m. - 11:00 a.m.  
Room E352, Level 3, McCormick Place Lakeside  
THE DOCTOR-PATIENT RELATIONSHIP: BOUNDARY ISSUES  
Chp.: Elmore F. Rigamer, M.D.

17 **Uncertain Borders Part 1: Boundary Issues in Psychotherapy**  
(47 minutes)

Distributor  
Cavalcade Productions, Inc.

For 17 & 18:  
P.O. Box 2480  
Nevada City, CA 95959

Doctors Glen Gabbard and Thomas Gutheil, along with Nanette Gartrell, Richard Kluft, Laurie Pearlman and Anne Pratt, describe in two parts how boundary issues may surface in a therapist's work, and outline strategies for the prevention of boundary violations. In Part I, *Boundary Issues* explores a wide range of topics, including self-disclosure by the therapist, time and place of therapy sessions, gifts and services, clothing and language, and physical contact. The particular boundary issues that arise in therapies with trauma survivors also are highlighted and the need for consultation and supervision is stressed.

18 **Uncertain Borders Part 2: Sexual Boundary Violations**  
(39 minutes)

In Part II, *Sexual Boundary Violations* examines the "slippery slope" phenomenon, in which small changes in the therapeutic frame can progress to sexual contact. Factors that contribute to sexual boundary violations are discussed, including countertransference, vicarious traumatization, isolation and lack of self-care by the clinician. The program concludes with specific suggestions for prevention.

**NEW RESEARCH ORAL/SLIDE SESSIONS 5-6**  
9:00 a.m. - 10:30 a.m.

5 **SCHIZOPHRENIA AND SEVERE MENTAL ILLNESS**  
Room E255, Level 2, McCormick Place Lakeside

6 **ANXIETY DISORDERS**  
Room E256 Level 2, McCormick Place Lakeside

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.
WORKSHOPS

COMPONENTS 18-22

COMPONENT WORKSHOP 18 9:00 a.m. - 10:30 a.m.
Williford Room B, Third Floor, Chicago Hilton
VICTIMS IN THE WORKPLACE: AWFUL TO OPTIMAL OUTCOMES
APA Committee on Psychiatry in the Workplace
Chp.: Leonard T. Sperry, M.D.
Participants: Robert C. Larsen, M.D., Jeffrey P. Kahn, M.D., Ronald Schouten, M.D., J.D.

COMPONENT WORKSHOP 19 9:00 a.m. - 10:30 a.m.
Room 4D, Fourth Floor, Chicago Hilton
MENTAL ILLNESS IN PSYCHIATRISTS: TRAINING AND BEYOND
The National Alliance for the Mentally Ill
Co-Chps.: Michael Myers, M.D., Leah J. Dickstein, M.D.
Participants: Elizabeth A. Baxter, M.D., Mark L. Dembert, M.D., Suzanne E. Vogel-Scibilia, M.D., Marian Fireman, M.D., Julie Wilcox, M.D., Frederick J. Frese III, Ph.D.

COMPONENT WORKSHOP 20 9:00 a.m. - 10:30 a.m.
Room 4K, Fourth Floor, Chicago Hilton
MISUSE AND ABUSE OF PSYCHIATRY: CLINICAL ISSUES
APA Committee on Abuse of Psychiatry and Psychiatrists
Co-Chps.: Renato D. Alarcon, M.D., Jose E. De La Gandara, M.D.
Participants: Abraham L. Halpern, M.D., Satyanarayana Chandragiri, M.D., Robert P. Cabaj, M.D.

COMPONENT WORKSHOP 21 9:00 a.m. - 10:30 a.m.
Lake Michigan Room, Eighth Floor, Chicago Hilton
ABPN EXAMINERS AND ABPN EXAMINEES
APA Committee of Early Career Psychiatrists and APA Assembly Committee of Early Career Psychiatrists
Chp.: Anand Pandya, M.D.
Participants: Paul P. Yeung, M.D., Rodrigo A. Muñoz, M.D., Joseph I. Sison, M.D., Troy L. Thompson II, M.D.

COMPONENT WORKSHOP 22 9:00 a.m. - 10:30 a.m.
Lake Ontario Room, Eighth Floor, Chicago Hilton
RACISM AND PSYCHOPATHOLOGY
APA Committee of Black Psychiatrists
Chp.: Michelle O. Clark, M.D.
Participants: Carl C. Bell, M.D., George L. Mallory, M.D., Nada L. Slotland, M.D.

ISSUES 22-37

ISSUE WORKSHOP 22 9:00 a.m. - 10:30 a.m.
Room E253 A, Level 2, McCormick Place Lakeside
CAREER STRATEGIES Y2K: STAY GENERATIVE AND STIMULATED
Chp.: Joel Yager, M.D.
Participants: Jerald Kay, M.D., Carol C. Nadelson, M.D., Carolyn B. Robinowitz, M.D., Zebulon C. Taintor, M.D.

ISSUE WORKSHOP 23 9:00 a.m. - 10:30 a.m.
Room E253 B, Level 2, McCormick Place Lakeside
PORTRAYAL OF PSYCHIATRY IN RECENT AMERICAN FILM
Chp.: Steven E. Pflanz, M.D.

ISSUE WORKSHOP 24 9:00 a.m. - 10:30 a.m.
Room E253 C, Level 2, McCormick Place Lakeside
STRATEGIES TO BETTER IMPLEMENT THE WORLD PSYCHIATRIC ASSOCIATION EDUCATIONAL PROGRAMS
The World Psychiatric Association
Chp.: Roger M. Montenegro, M.D.
Participants: Pedro Ruiz, M.D., Sam Tyano, M.D., Srinivasa Murthy, M.D., Constantin Soldatos, M.D.

ISSUE WORKSHOP 25 9:00 a.m. - 10:30 a.m.
Room E253 D, Level 2, McCormick Place Lakeside
DEVELOPING A STATEWIDE PSYCHIATRIC DISASTER PLAN
Chp.: Sheila G. Jowsey, M.D.
Participants: David R. Johnson, M.D., Alan Q. Radke, M.D., Steve M. Kubas, M.D., Suzanne T. Witterholt, M.D.

ISSUE WORKSHOP 26 9:00 a.m. - 10:30 a.m.
Room S402 B, Level 4, McCormick Place South
USING TREATMENT OUTCOMES IN RESIDENCY TRAINING
Co-Chps.: Winston Brown, M.D., James A. Clardy, M.D.
Participant: R. Greg Wooten, M.D.

ISSUE WORKSHOP 27 9:00 a.m. - 10:30 a.m.
Room S403 A, Level 4, McCormick Place South
SPLIT TREATMENT: CLINICAL, LEGAL AND ETHICAL ISSUES
Co-Chps.: Robert I. Simon, M.D., Donald J. Meyer, M.D.
Participants: Steven Behnke, Ph.D., James M. Ellison, M.D.
ISSUE WORKSHOP 28  9:00 a.m. - 10:30 a.m.
Room S403 B, Level 4, McCormick Place South
UNDERSTANDING THE DYNAMICS OF ABUSIVE RELATIONSHIPS
Chp.: Gary J. Maier, M.D.

ISSUE WORKSHOP 29  9:00 a.m. - 10:30 a.m.
Room S404 A, Level 4, McCormick Place South
PSYCHIATRIC IMPLICATIONS OF WEAPONS OF MASS DESTRUCTION
Chp.: Dickson Diamond, M.D.

ISSUE WORKSHOP 30  9:00 a.m. - 10:30 a.m.
Room S404 B/C, Level 4, McCormick Place South
TELEPSYCHIATRY SERVICES: FROM DESIGN TO GLOBAL IMPLICATIONS
Psychiatric Society of Informatics
Co-Chps.: Harry Karlinsky, M.D., Douglas A. Urness, M.D.
Participants: Norman E. Alessi, M.D., Rhonda G. Vought, M.D.

ISSUE WORKSHOP 31  9:00 a.m. - 10:30 a.m.
Room S404 D, Level 4, McCormick Place South
DOCTOR-PATIENT RELATIONSHIP IN CHEKHOV'S WRITING
Chp.: Lesley R. Dickson, M.D.

ISSUE WORKSHOP 32  9:00 a.m. - 10:30 a.m.
Boulevard Room A/B, Second Floor, Chicago Hilton
A CHAIR'S LIFE: ETHIOPIA, TAIWAN, GENEVA, ATLANTA AND LOS ANGELES
Co-Chps.: Milton H. Miller, M.D., Charles B. Nemeroff, M.D.
Participants: Fikre Workneh, M.D., Eng-Kung Yeh, M.D., Norman Sartorius, M.D.

ISSUE WORKSHOP 33  9:00 a.m. - 10:30 a.m.
Boulevard Room C, Second Floor, Chicago Hilton
ACADEMIC/CORRECTIONS MODELS OF MENTAL HEALTH CARE
Co-Chps.: Robert L. Trestman, M.D., Kenneth L. Appelbaum, M.D.
Participants: Brett S. Rayford, M.A., Montgomery Brower, M.D.

ISSUE WORKSHOP 34  9:00 a.m. - 10:30 a.m.
Williford Room A, Third Floor, Chicago Hilton
POETRY AND MEDICINE
Co-Chps.: Janis B. Petzel, M.D., Chelsea L. Chesn, M.D.
Participants: Kimberly W. Larsen, M.D., Robert Coleman, Ph.D., David R. Kopacz, M.D.

ISSUE WORKSHOP 35  9:00 a.m. - 10:30 a.m.
Room 4M, Fourth Floor, Chicago Hilton
BEETHOVEN AND HIS CREATIVE EVOLUTION
Chp.: Richard Kogan, M.D.
Participant: Arnold M. Cooper, M.D.

ISSUE WORKSHOP 36  9:00 a.m. - 10:30 a.m.
Lake Erie Room, Eighth Floor, Chicago Hilton
DIAGNOSIS AND TREATMENT OF HEPATITIS-C IN MENTAL HEALTH SETTINGS
Chp.: Peter Hauser, M.D.
Participants: Fred C. Osher, M.D., Jaswinder S. Khosla, M.D., Richard Goldberg, Ph.D.

ISSUE WORKSHOP 37  9:00 a.m. - 10:30 a.m.
Lake Huron Room, Eighth Floor, Chicago Hilton
TRAUMA SURVIVORS: HETEROGENEITY OF PSYCHIATRIC MANIFESTATIONS
Chp.: Andrei Novac, M.D.
Participants: Rita R. Newman, M.D., Rachel Yehuda, Ph.D., Jean P. Goodwin, M.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 11-12
11:00 a.m. - 12:30 p.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

11 Carol A. Bernstein, M.D., on Clinical Training in Psychiatry: A Moving Target
Room 4l, Fourth Floor, Chicago Hilton
12 D.F. Rendinell, M.D., on Patient Rights in Psychotherapy
Room 4L, Fourth Floor, Chicago Hilton

LECTURES 14-15

LECTURE 14
11:00 a.m. - 12:30 p.m.
Room E350, Level 3, McCormick Place Lakeside
APA'S KUN-PO SOO AWARD LECTURE
Eng-Kung Yeh, M.D.
Mental Health Problems in Taiwan: Issues, Dilemmas and Challenges
(Continued on next page)
The national mental health program in Taiwan has gone through several stages of service and policy development but it remains an underdeveloped area of the country's health administration. Eng-Kung Yeh, M.D., Professor Emeritus of Psychiatry at Taipei Medical College and Clinical Professor of Psychiatry at National Taiwan University, discusses the issues and challenges facing Taiwan's mental health system in socioeconomic and cultural context. Dr. Yeh was the founding director and chief of service at Taipei City Psychiatric Center from 1969 to 1989. There he instituted a program of research in clinical and biological psychiatry and a system of comprehensive hospital and community care known as the Taipei Model. He was a founding fellow and member of the Board of Directors of the Pacific Rim College of Psychiatrists and is currently a Corresponding Fellow and International Fellow of APA. His honors in Taiwan include a national award for achievement in science and technology and the 1st Rank Medal for Outstanding Services from the Prime Minister. Dr. Yeh received his medical degree from the College of Medicine, National Taiwan University, and completed residency training in Taiwan and further training in the U.S., Canada, and England. He received his medical science degree from the School of Medicine of the National Hokkaido University in Japan.

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MASTER EDUCATOR CLINICAL CONSULTATIONS 8-9

11:00 a.m. - 12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

8 Jerry M. Wiener, M.D., on the Effects and Management of Childhood Trauma in the Transference

Room 4F, Fourth Floor, Chicago Hilton

9 David W. Preven, M.D., on the Impaired Physician: Disciplinary and Therapeutic Issues

Room 4H, Fourth Floor, Chicago Hilton

THESE SESSIONS WILL BE AUDIOTAPED.

LECTURE 15

11:00 a.m. - 12:30 p.m.
Room E353 C, Level 3, McCormick Place Lakeside

APA'S PATIENT ADVOCACY AWARD LECTURE
National Institute on Alcohol Abuse and Alcoholism
The Honorable George McGovern
Terry: A Life and Death Struggle with Alcoholism and Depression

Chp.: Thomas R. Kostan, M.D.
Co-Chp.: Stephen L. Dils, M.D.

As a pilot of a B-24 bomber during World War II, George McGovern flew 35 missions and was decorated with the Distinguished Flying Cross. He then earned a Ph.D. in History and Government at Northwestern University and served as Professor of History at Dakota Wesleyan University. In 1956, he was elected to the U.S. House of Representatives, where he served until 1960 when President Kennedy appointed him first Director of the U.S. Food for Peace Program and Special Assistant to the President. He was instrumental in launching the World Food Program. Elected to the U.S. Senate in 1962, he was reelected in 1968 and 1974 and served on various committees. In 1972, Senator McGovern was the Democratic nominee for President. In 1976, President Ford appointed him as delegate to the 31st session of the General Assembly of the United Nations. In 1978, President Carter appointed him as delegate to the United Nations for the Special Session on Disarmament. Ambassador McGovern is the author of seven books, among them, Terry: My Daughter's Life and Death Struggle with Alcoholism, and numerous articles for leading journals and magazines. President Clinton appointed him to his current position as U.S. Ambassador to the Rome-based UN Food and Agricultural Agencies.

THESE SESSIONS WILL BE AUDIOTAPED.

MEDIA SESSIONS 12-13

MEDIA SESSION 12 11:00 a.m.-2:00 p.m.
Room E351, Level 3, McCormick Place Lakeside

THE TRAUMA AND TRAGEDY OF COMBAT: A STANLEY KUBRICK TRIBUTE

Chp.: Harvey R. Greenberg, M.D.

19 Full Metal Jacket
(116 minutes)

Distributor: Swank Motion Pictures, Inc.
350 Vanderbilt Motor Parkway
Hauppauge, NY 11787

This 1987 Stanley Kubrick film is a saga about the Vietnam War and the dehumanizing process that turns people into trained killers. Recruits are plunged into a bootcamp hell pitted by a leather-lunged GI. The action is savage, the story unsparing and the dialogue spiked with scathing humor throughout the journey from bootcamp to combat in Hue City during the Tet Offensive. This film honors the work of one of Cinema's great master directors.
TUESDAY

MEDIA SESSION 13  
11:00 a.m. - 2:00 p.m.  
Room E352, Level 3, McCormick Place Lakeside

THE DOCTOR-PATIENT RELATIONSHIP  
Chp.: Francis G. Lu, M.D.

20 Films in Teaching Psychiatry, Diversity, Morality and Healing  
(180 minutes)

Distributor: Francis G. Lu, M.D.  
Department of Psychiatry  
San Francisco General Hospital  
1001 Potrero Avenue  
San Francisco, CA 94110

This film has replaced literature as the dominant narrative medium of the 20th Century. Four psychiatrists will share how they use film in teaching. Dr. Levine will demonstrate the use of film clips from feature films to teach about psychopathology and portrayals of psychiatrists and patients based on her teaching at the University of Texas. Dr. Chang will discuss the use of documentary videotapes in teaching about diversity focusing on cultural identity, supports and stressors based on her work at the University of California. Dr. Stone will describe his Harvard Law School seminar, "Law, Psychology and Morality: An Exploration Through Film," focusing on who one is and what one sees, fact and interpretation, empathy identification, ethics and life as moral adventure and methods of interpreting film as a text. Finally, Dr. Lu will describe his intensive five-day film seminars at Esalen Institute focused on healing, transpersonal psychology and spirituality.

Discussants: Ruth E. Levine, M.D., Jacquelyn B. Chang, M.D., Alan A. Stone, M.D.

MEDICAL UPDATE 2  
11:00 a.m. - 12:30 p.m.  
Room S404 B/C, Level 4, McCormick Place South

SEVENTEEN WAYS TO HAVE A BABY: REPRODUCTION IN THE 21ST CENTURY  
Chp.: Gilla P. Davis, M.D.  
Presenter: Charles Strom, M.D.

THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH  
11:00 a.m. - 12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

1 Steven E. Hyman, M.D., on the National Institute of Mental Health 101  
Room 4G, Fourth Floor, Chicago Hilton

SCIENTIFIC AND CLINICAL REPORT  
SESSIONS 10-18

SCIENTIFIC AND CLINICAL REPORT SESSION 10  
11:00 a.m. - 12:30 p.m.  
Room E253 C, Level 2, McCormick Place Lakeside

ECONOMIC ISSUES IN PATIENT CARE  
Chp.: Saul M. Levin, M.D.  
Co-Chp.: Rob McCullum-Smith, M.D.

11:00 a.m.

29 Evaluating Payor Type Effects on Adolescent Care  
Thomas W. Lane, Ph.D., Michael W. Kaufmann, M.D., Elliot J. Sussman, M.D., Thomas Wasser, Ph.D., Kenneth Mead, B.S.

30 WITHDRAWN

11:45 a.m.

31 Care Coordination Reduces Inpatient Costs  
Laurence P. Karper, M.D., Michael W. Kaufmann, M.D., Elliot J. Sussman, M.D., Donna Stevens, OTR/L, Gail Stern, M.S.N., D. James Ezrow, M.S.W.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 11  
11:00 a.m. - 12:30 p.m.  
Room E255, Level 2, McCormick Place Lakeside

NOVEL ISSUES IN THE TREATMENT OF MOOD DISORDERS  
Chp.: Sidney Zisook, M.D.  
Co-Chp.: Vladimir Coric, M.D.

11:00 a.m.

32 Combined Treatment for Major Depression: Does It Save Hospital Days?  
Antonio Andreoli, M.D., Yvonne Bumand, Ph.D., Eveline Kolatte, M.D., Aurora Venturini, M.D.

11:30 a.m.

33 A Doubled-Blind, Randomized 12-Week Comparison of Nortriptyline and Paroxetine in the Treatment of Late-Life Depression  
Benoit H. Mulsant, M.D., Bruce G. Pollock, M.D., Robert Nebes, Ph.D., Mark D. Miller, M.D., Robert A. Sweet, M.D., Satl Mazumdar, Ph.D., Charles F. Reynolds III, M.D.

12 noon

34 Fish Consumption and Depressive Symptoms in the Population  
Antti Tanskanen, M.D., Joseph R. Hibbein, M.D., Jaakko Tuomilehto, M.D., Antti Utela, Ph.D., Johannes Lehtonen, M.D., Heimo Vinnamaki, M.D., Erkki Vartiainen, M.D.

THIS SESSION WILL BE AUDIOTAPED.
TUESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 12
11:00 a.m. - 12:30 p.m.
Room S402 B, Level 4, McCormick Place South

CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Chp.: Timothy D. Brewerton, M.D.
Co-Chp.: Cynthia Fowler, M.D.

11:00 a.m.
35 Novel Antipsychotic in ADHD with Conduct Disorder
   Mohammad Z. Hussain, M.D., Zubaida A. Chaudhry, M.B.

11:30 a.m.
36 Compliance with Antiseizure Medication in Adolescent
   Psychiatric Patients
   David L. Pogge, Ph.D., Millissa Singer, B.S., Susan R.
   Boragno, Ph.D., Douglas Wayland-Smith, M.A., Michele L.
   Zaccario, M.A., John M. Stokes, Ph.D., Philip D. Harvey, Ph.D.

12 noon
37 Trends in Psychotropic Medication Use Among Youth
   Elizabeth L. McGarvey, Ed.D., Randolph J. Canterbury, M.D.,
   Cheryl Koopman, Ph.D., Dennis Waite, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 13
11:00 a.m. - 12:30 p.m.
Room S403 B, Level 4, McCormick Place South

TREATMENTS AND OUTCOMES IN ANXIETY DISORDERS

Chp.: Constantine G. Lyketsos, M.D.
Co-Chp.: Ahsan A. Naseem, M.D.

11:00 a.m.
38 Function and Well-Being of Primary Care Patients with
   Anxiety Disorders
   Risa Weisberg, Ph.D., Martin B. Keller, M.D., Jennifer
   Altsworth, A.B., Regina T. Dolan, Ph.D., Larry Culpepper, M.D.

11:30 a.m.
39 Use of Alternative Therapies Among Patients with Anxiety
   Disorders
   Michael A. Van Ameringen, M.D., Catherine L. Mancini, M.D.,
   Peter Farvolden, Ph.D.

12 noon
40 Outcome in Anxiety Disorders
   Oscar C. Carion, M.D., Gustavo Bustamante, Ph.D., Hans
   Spatz, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 14
11:00 a.m. - 12:30 p.m.
Boulevard Room A/B, Second Floor, Chicago Hilton

IMPACT OF THE DOCTOR-PATIENT RELATIONSHIP ON
MEDICAL TREATMENT

Chp.: Richard Balon, M.D.
Co-Chp.: Alexandra Obiora-Oputa, M.D.

11:00 a.m.
41 Attachment Theory and Adherence to Medical Treatment
   Paul Clechanowski, M.D., Wayne J. Katon, M.D., Joan
   Russo, Ph.D., Edward A. Walker, M.D.

11:30 a.m.
42 A Pilot Study of Herbal Remedy Use by Psychiatric Patients
   Cornelle W. Lange, M.D., Joel Yager, M.D., Virgil Etsitty, M.D.,
   Robert Rhyne, M.D., Lewis Erwin, M.D., Betty Skipper, Ph.D.

12 noon
43 What Can Be Learned from the Placebo Effect?
   Roger Peele, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 15
11:00 a.m. - 12:30 p.m.
Marquette Room, Third Floor, Chicago Hilton

MANAGED CARE ISSUES

Chp.: Bruce J. Schwartz, M.D.
Co-Chp.: Yeshuschandra Dhaibar, M.D.

11:00 a.m.
44 Benefits Managers’ Views on Mental Health
   Benton H. McFarland, M.D., Norman R. Penner, M.P.H.,
   Walter K. Lierman, Ph.D.

11:30 a.m.
45 The Impact of Managed Care
   Mark Freeman, M.P.A., Mina Chang, Ph.D., Dean
   Kauffman, M.A.

12 noon
46 Risk Management in Shared Treatment
   Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 16
11:00 a.m. - 12:30 p.m.
Williford Room B, Third Floor, Chicago Hilton

SOCIETAL ISSUES IN MENTAL ILLNESS

Chp.: Gopalakrishna K. Upadhya, M.D.
Co-Chp.: Janet La Grenade, M.D.

11:00 a.m.
47 Major Depression and Mother’s Marital Transition
   Terrance J. Wade, Ph.D., John Cairney, M.A.

11:30 a.m.
48 Outpatient Commitment in New York: From Pilot Project to
   State Law
   Howard W. Telson, M.D.

12 noon
49 Six-Month Follow-Up of the Nairobi Embassy Bombing
   Pius A. Kigamwa, M.D, Dr. Margaret Makanyengo, Josephine
   Omondi, M.D, Victoria Wells, M.D, Lawson R. Wulsin, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 17  
11:00 a.m. - 12:30 p.m.  
Room 4M, Fourth Floor, Chicago Hilton  

SPECIAL ISSUES IN MOOD DISORDERS  
Chp.: Morton M. Silverman, M.D.  
Co-Chp.: Karla Blackwood, M.D.  

11:00 a.m.  
50 Quality of Life After Cognitive-Behavior Therapy  
Gerhard Lenz, M.D., Ulrike Demal, MAG  

11:30 a.m.  
51 Secular Trend of Violent Methods in Suicide Victims  
Zoltan Rihmer, M.D., Wolfgang Rutz, M.D., Hans Pihlgren, M.D.,  
Gergely H. Kiss, M.D.  

12 noon  
52 An Open Study of Olanzapine and Fluoxetine for Psychotic Depression: Interim Analyses  
John D. Matthews, M.D., Laura M. Polania, B.A., Meridith A. Rankin, Robert W. Irvin, M.D., Jerrold F. Rosenbaum, M.D., Maurizio Fava, M.D.  

THIS SESSION WILL BE AUDIOTAPED.  

SCIENTIFIC AND CLINICAL REPORT SESSION 18  
11:00 a.m. - 12:30 p.m.  
Lake Michigan Room, Eighth Floor, Chicago Hilton  

ALCOHOL AND DRUG RELATED DISORDERS  
Chp.: Patricia I. Ordorica, M.D.  
Co-Chp.: Michelle E. Montemayor, M.D.  

11:00 a.m.  
53 Impulsivity, Serotonin and Adolescent Alcohol Abuse  
National Institute on Alcohol Abuse and Alcoholism  
Paul H. Soloff, M.D., Kevin G. Lynch, Ph.D., Howard B. Moss, M.D.  

11:30 a.m.  
54 DWI Prevention: The Psychiatrist's Role  
National Institute on Alcohol Abuse and Alcoholism  
Bryce Templeton, M.D., Richard P. Amar, M.D.  

12 noon  
55 Self-Help Strategies Among Substance Abusers  
Joseph J. Westermeyer, M.D., Sarah Myott, B.S., Rembrandt Aarts, M.S.  

WORKSHOPS  
COMPONENTS 23-30  

COMPONENT WORKSHOP 23  
11:00 a.m. - 12:30 p.m.  
Room E353 A/B, Level 3, McCormick Place Lakeside  

PAUL RICOEUR IN DIALOGUE WITH AMERICAN PSYCHIATRISTS  
APA Committee on Religion and Psychiatry  
Chp.: Reverend Clark S. Atit, Ph.D.  
Participants: Leigh C. Bishop, M.D., Professor Paul Ricoeur, William J. Richardson, Ph.D., Peter Homans, Ph.D.  

COMPONENT WORKSHOP 24  
11:00 a.m. - 12:30 p.m.  
Room S404 A, Level 4, McCormick Place South  

LESBIAN, GAY, BISEXUAL AND TRANSGENDERED RESIDENTS: CHALLENGES IN TRAINING  
APA Northern California Psychiatric Society's Committee on Lesbian, Gay, Bisexual and Transgender Issues  
Chp.: Dan H. Karasic, M.D.  
Participants: Ellen Haller, M.D., Tamar D. Gershon, M.D., Elias Aboujaoude, M.D.  

COMPONENT WORKSHOP 25  
11:00 a.m. - 12:30 p.m.  
Room S404 D, Level 4, McCormick Place South  

ANALYZE THIS: PSYCHIATRY, CULTURE AND THE MEDIA  
APA/Center for Mental Health Services Minority Fellows and APA/AstraZeneca Minority Fellows  
Co-Chps.: Varanise C. Booker, M.D., Tracy L. Benford, M.D.  
Participants: Rajendra A. Morey, M.D., Ramon Solkhah, M.D., Jacquelyn D. McLemore, M.D.  

COMPONENT WORKSHOP 26  
11:00 a.m. - 12:30 p.m.  
Williford Room A, Third Floor, Chicago Hilton  

SPLIT THERAPY AND THE PSYCHIATRIC RESIDENT  
APA Committee of Residents and Fellows  
Chp.: Geoffrey M. Gabriel, M.D.  
Participants: Lori Simon, M.D., Kira D. Stein, M.D., Jessica G. Roberts, M.D., Jason M. Andrus, M.D.  

COMPONENT WORKSHOP 27  
11:00 a.m. - 12:30 p.m.  
Williford Room C, Third Floor, Chicago Hilton  

PATIENT AUTONOMY AND PATERNALISM ACROSS CULTURES  
APA Council on International Psychiatry  
Co-Chps.: Ramaswamy Viswanathan, M.D., Jeffrey L. Geller, M.D.  
Participants: Silvia W. Ollarte, M.D., Giovanni Caracci, M.D., Kristin J. O'Dell, M.D., Hicham M. Ibrahim, M.D.  

COMPONENT WORKSHOP 28  
11:00 a.m. - 12:30 p.m.  
Room 4D, Fourth Floor, Chicago Hilton  

RISK-MANAGEMENT ISSUES IN PSYCHIATRIC PRACTICE  
APA Psychiatrists' Purchasing Group, Inc. and APA-Sponsored Professional Liability Insurance  
Chp.: Alan I. Levenson, M.D.  
Participants: Ellen R. Fischbein, M.D., Martin G. Tracy, J.D., Jacqueline Melonas, J.D.  

COMPONENT WORKSHOP 29  
11:00 a.m. - 12:30 p.m.  
Room 4K, Fourth Floor, Chicago Hilton  

FACING THE CHANGING REALITIES OF PHYSICIAN STRESS  
APA Committee on Physician Health, Illness and Impairment  
Chp.: Richard F. Limoges, M.D.  
Participants: Patti Tighe, M.D., Carmen T. Webb, M.D., Linda Logsdon, M.D., Michael H. Gendel, M.D.
TUESDAY

COMPONENT WORKSHOP 30 11:00 a.m. - 12:30 p.m.
Lake Ontario Room, Eighth Floor, Chicago Hilton

LATIN AMERICA: SOCIAL AND POLITICAL TURMOIL AND PTSD
APA Committee of Hispanic Psychiatrists

Chp.: Oscar E. Perez, M.D.
Participants: Maria C. Bayon, M.D., Alejandra Ruiz Lopez, M.D., Marta B. Rondon, M.D., Renato D. Alarcon, M.D.

ISSUES 38-44

ISSUE WORKSHOP 38 11:00 a.m. - 12:30 p.m.
Room E253 A, Level 2, McCormick Place Lakeside

THE REAL SPICE GIRLS: BLACK FEMINISM THROUGH SONG

Chp.: Yvonne B. Ferguson, M.D.
Participant: Esmond H. Edwards

ISSUE WORKSHOP 39 11:00 a.m. - 12:30 p.m.
Room E253 B, Level 2, McCormick Place Lakeside

RESIDENCY TRAINING: INTERNATIONAL PERSPECTIVES

Co-Chps.: Michelle Riba, M.D., Allan Tasman, M.D.
Participants: Mauel Beneyto, M.D., Anne Lindhardt, M.D., Fritz Hohagen, Roelof J.A. ten Doesschate, M.D.

ISSUE WORKSHOP 40 11:00 a.m. - 12:30 p.m.
Room E256, Level 2, McCormick Place Lakeside

PROBLEMATIC EXCESSIVE SEXUAL BEHAVIOR

Co-Chps.: Reid Finlayson, M.D., John R. Sealy, M.D.
Participants: Patrick J. Carnes, Ph.D., Richard R. Irons, M.D., Jennifer P. Schneider, M.D., Stephen S. Brockway, M.D., James C. Montgomery, M.D.

ISSUE WORKSHOP 41 11:00 a.m. - 12:30 p.m.
Room S403 A, Level 4, McCormick Place South

MANAGEMENT OF DIFFICULT SCHIZOPHRENIA

Co-Chps.: Michael Y. Hwang, M.D., Samuel G. Siris, M.D.
Participants: Douglas M. Ziedonis, M.D., Jeffrey P. Kahn, M.D., Naveed Iqbal, M.D.

ISSUE WORKSHOP 42 11:00 a.m. - 12:30 p.m.
Joliet Room, Third Floor, Chicago Hilton

WHEN CAN INCOMPETENT PERSONS BE RESEARCH SUBJECTS?

Chp.: Herbert S. Peyser, M.D.
Participants: John M. Oldham, M.D., Barry B. Perlman, M.D., Seth P. Stein, J.D., Paul S. Appelbaum, M.D.

ISSUE WORKSHOP 43 11:00 a.m. - 12:30 p.m.
Lake Erie Room, Eighth Floor, Chicago Hilton

BALINT GROUPS: PSYCHOLOGICAL LEARNING FOR PHYSICIANS

Chp.: Roy W. Menninger, M.D.
Participant: Susan E. Farmer, M.D.

ISSUE WORKSHOP 44 11:00 a.m. - 12:30 p.m.
Lake Huron Room, Eighth Floor, Chicago Hilton

SHARED CARE: THE CANADIAN PSYCHIATRIC ASSOCIATION AND THE COLLEGE OF FAMILY PHYSICIANS OF CANADA

Co-Chps.: Nick S. Kates, M.B., Marilyn Craven, M.D.
Participants: Richard Handfield-Jones, Roger C. Bland, M.D., Ken LeClair, M.D.

12 noon Sessions

FORUMS 4-6

FORUM 4 12 noon - 1:30 p.m.
Room E253 D, Level 2, McCormick Place Lakeside

BEYOND JUST WATCHING HATE CRIMES: IN OR INTO THE 21ST CENTURY

Chp.: Leah J. Dickstein, M.D.
Participants: Carl C. Bell, M.D., Silvia W. Olarte, M.D., Robert P. Cabaj, M.D.

FORUM 5 12 noon - 1:30 p.m.
Room S402 A, Level 4, McCormick Place South

SEX, DRUGS (NOT ROCK & ROLL), NATIONAL AND INTERNATIONAL POLITICS: PUBLIC VERSUS PRIVATE MORALITY

Chp.: David M. McDowell, M.D.
Participants: Herbert D. Kleber, M.D., Nada L. Stotland, M.D., Andrew Solomon, Stephen M. Goldfinger, M.D., Kaylie Jones

FORUM 6 12 noon - 1:30 p.m.
Boulevard Room C, Second Floor, Chicago Hilton

MATERNITY LEAVE DURING PSYCHIATRY RESIDENCY TRAINING

Chp.: Michelle L. Kramer, M.D.
Presenters: Carol C. Nadelson, M.D., Lindsey George, M.D., Helen L. Egger, M.D., Carol A. Bernstein, M.D.
NEW RESEARCH POSTER SESSION 7
12 noon - 2:00 p.m.
Hall E, Level 2, McCormick Place Lakeside
ANXIETY, COGNITIVE, PERSONALITY AND PREMENSTRUAL
DYSPHORIC DISORDERS; GERIATRIC AND BIOLOGICAL
PSYCHIATRY; AND NEUROSCIENCE
For further information on New Research Sessions, please refer to
the New Research Program and Abstracts Book included in your
registration packet.

1:00 p.m. Sessions

COURSES 78-84
Course descriptions are available in the CME
Course Brochure included in your registration
packet. Admission by ticket only.

COURSE 78 1:00 p.m. - 5:00 p.m.
Room N426 B, Level 4, McCormick Place North
USE OF MELATONIN/LIGHT IN SLEEP AND MOOD DISORDERS
Director: Alfred J. Lewy, M.D.

COURSE 79 1:00 p.m. - 5:00 p.m.
Room N427 B/C, Level 4, McCormick Place North
ADVANCED ASSESSMENT AND TREATMENT OF ADD
Director: Thomas E. Brown, Ph.D.
Faculty: Margaret D. Weiss, M.D.

COURSE 80 1:00 p.m. - 5:00 p.m.
Room S501 B/C, Level 5, McCormick Place South
DUAL DIAGNOSIS: ADVANCED CLINICAL APPLICATION
Director: Kenneth Minkoff, M.D.

COURSE 81 1:00 p.m. - 5:00 p.m.
Room S502 B, Level 5, McCormick Place South
IRRESISTIBLE SLEEP: NARCOLEPSY UPDATE
Director: Lois E. Krahn, M.D.
Faculty: Jarrett W. Richardson, M.D., Mark R. Hansen, M.D.,
Steven I. Altschuler, M.D.

COURSE 82 1:00 p.m. - 5:00 p.m.
Room S503 B, Level 5, McCormick Place South
BEYOND MUNCHAUSEN: FACTITIOUS DISORDERS TODAY
Director: Marc D. Feldman, M.D.
Faculty: Charles V. Ford, M.D., Stuart J. Eisenbrand, M.D.

COURSES 83 1:00 p.m. - 5:00 p.m.
Room S504 A, Level 5, McCormick Place South
ASSESSING POSITIVE AND NEGATIVE SYMPTOMS WITH THE
POSITIVE AND NEGATIVE SYNDROME SCALE
Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D.

COURSE 84 1:00 p.m. - 5:00 p.m.
Room S504 D, Level 5, McCormick Place South
PSYCHIATRISTS AS TEACHERS OF BOUNDARIES TO
PHYSICIANS
Director: Samia Barakat, M.D.
Faculty: Mark S. Etkin, M.D., Mark A. Prober, M.D.

2:00 p.m. Sessions

LECTURES 16-17

LECTURE 16
2:00 p.m. - 3:30 p.m.
Room E350, Level 3, McCormick Place Lakeside
K. Ranga R. Krishnan, M.D.
Depression in the Medically Ill
Chp.: Mohammad Shafi, M.D.
Co-Chp.: Deborah Spitz, M.D.
Depression is a common but often underrecognized and
undertreated problem in the medically ill. K. Ranga Rama
Krishnan, M.D., discusses the relationship between de-
pression and medical illness, drawing on examples from
the interplay of depression and cardiac disease to examine
issues of illness risk, treatment and outcome. Dr. Krishnan
is Professor and Chairman of the Department of Psychiatry
and Behavioral Sciences, Head of the Division of Biological
Psychiatry, and Director of the Affective Disorders Program
at Duke University Medical Center in Durham, North
Carolina. His current research interests include enhancing
recovery in coronary heart disease, neuromaging in human
immunodeficiency virus infection, and bipolar disorder in
late life. The author of more than 250 scientific papers and
book chapters, Dr. Krishnan serves on the Editorial Board
of several journals, including the American Journal of
Psychiatry, Biological Psychiatry, and Psychiatric Research:
Neuromaging. He was awarded the Distinguished Investi-
gator Award from the National Alliance for Research on
Schizophrenia and Depression for his research on bipolar
disorder. Dr. Krishnan graduated from Madras Medical
College in Madras, India, where he also served a rotating
internship. He completed his residency and a fellowship in
neurobiology at Duke University Medical Center.
Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.
represent the extraordinary power of human spirit. It focuses on the
last year of war, when Adolf Hitler, already defeated and with his
resources running out, revealed the depth of his racial hatred by
diverting men and supplies to the task of exterminating Hungary's
Jews. Extraordinarily moving, it was the winner of the 1999
Academy Award for Best Documentary.

Discussant: Maurice Pruter, M.D.

MEDIA SESSION 15
2:00 p.m. - 4:00 p.m.
Room E352, Level 3, McCormick Place Lakeside

THE DOCTOR-PATIENT RELATIONSHIP
Chp.: Glen O. Gabbard, M.D.

22 The Therapeutic Relationship in Hollywood Cinema
(90 minutes)

When psychotherapy is portrayed in the Hollywood cinema, the
therapeutic relationship depicted often bears little relationship to
psychotherapy in the real world. The relationship between the
psychotherapist and the patient is usually based on the needs of the
genre, and the accuracy of the portrayal is subverted to the
requirements of the story line. This presentation will present film
clips that reflect the therapeutic relationship both in classic cinema
and in more contemporary American films. Some of the films that will
be discussed include: Carefree, Snake Pit, The Three Faces of Eve,
Bananas, Prince of Tides, What About Bob, Good Will Hunting, As
Good As It Gets, Deconstructing Harry and Analyze This. The
portrayals of psychotherapy reflect certain views widely held by
filmmakers and audiences as well. The clinical impact of these
portrayals on patients and therapists alike will be discussed, and
strategies of dealing with the clinical issues will be suggested.

REVIEW OF PSYCHIATRY: SECTION 3
2:00 p.m. - 5:30 p.m.
Room E451, Level 4, McCormick Place Lakeside

ETHNICITY AND PSYCHOPHARMACOLOGY
Chp.: Pedro Ruiz, M.D.

10 Psychopharmacotherapy in the Context of Culture and
Ethnicity
Keh-Ming Lin, M.D.

11 Issues in the Pharmacotherapy of African Americans
William B. Lawison, M.D.

12 A Closer Look at the Hispanic Response to Psychotropic
Medications
Ricardo P. Mendoza, M.D., Michael W. Smith, M.D., Yvonne
Wan, M.D., Russell Poland, M.D.

13 Ethnopsychopharmacology of Asians
Edmond H. Pi, M.D., Gregory E. Gray, M.D.

14 Ethnopsychopharmacology in the Public Sector
Roy V. Varner, M.D., Pedro Ruiz, M.D., David R. Small, M.B.A.
SYMPOSIUM 25 2:00 p.m. - 5:00 p.m.
Room E253 A, Level 2, McCormick Place Lakeside

DSM-V PERSONALITY DISORDERS: TOWARDS AN EMPIRICALLY-BASED DIMENSIONAL CLASSIFICATION
Chp.: Robert L. Spitzer, M.D.
Co-Chp.: Michael B. First, M.D.
A A Stepwise Psychobiological Classification
C. Robert Cloninger, M.D.
B A Two-Component Structure for Classifying Personality Disorder
John Livesley, M.D., Kerry L. Jang, Ph.D.
C Five-Factor Model of Personality Disorders
Thomas A. Widiger, Ph.D.
D Empirical Prototypes Based on Clinical Observation
Drew Westen, Ph.D., Jonathan Shedler, Ph.D.
Discussant: Andrew E. Skodol II, M.D.

SYMPOSIUM 26 2:00 p.m. - 5:00 p.m.
Room E253 B, Level 2, McCormick Place Lakeside
THE DOCTOR-PATIENT RELATIONSHIP IN THE AMERICAS
Inter-American Council of Psychiatric Organizations
Chp.: Roberto E. Chaskel, M.D.
Co-Chp.: Nestor F. Marchant, M.D.
A Practice of Psychopharmacology and the Doctor-Patient Relationship
Antonio Pacheco, M.D., Gabriela Iglesias, M.D., Ruben J. Hernandez-Serrano, M.D.
B Influence of Culture in Patient-Psychiatrist Relationship
Carlos Leon-Andrade, M.D.
C Cultural Issues in the Doctor-Patient Relationship
Miguel R. Jorge, M.D.
D Physical or Mental Chronic Illness: Characteristics of the Doctor-Patient Relationship
Rodolfo D. Fahrer, M.D., Amelia E. Musacchio de Zan, M.D.
E Language and Doctor-Patient Relations in Psychiatry
Roberto E. Chaskel, M.D., Sharon C. Harvey, M.D., Enrique Camarena, M.D., Nichole Steiner, M.S.
Discussants: Renato D. Alarcón, M.D., Carlos Berganza

SYMPOSIUM 27 2:00 p.m. - 5:00 p.m.
Room E253 C, Level 2, McCormick Place Lakeside
QUALITY INDICATORS IN PSYCHIATRY
APA Council on Quality Improvement
Chp.: John M. Oldham, M.D.
Co-Chp.: John S. McIntyre, M.D.
A Clinically-Based Quality Indicators
John M. Oldham, M.D.
B Quality Indicators and Practice Guidelines
John S. McIntyre, M.D.
C Conformance with Quality Indicators in Routine Practice
Joyce C. West, M.P.P., Deborah A. Zarin, M.D., Phillip S. Wang, M.D., Christine Rose, M.S., Steven Marcus, Ph.D.
D Quality Measurement in a Clinical Facility
Lloyd I. Sederer, M.D.
Discussant: Sara C. Charles, M.D.

SYMPOSIUM 28 2:00 p.m. - 5:00 p.m.
Room E253 D, Level 2, McCormick Place Lakeside
THE PSYCHIATRIC HOSPITAL IN THE 21ST CENTURY
Chp.: Robert K. Schreter, M.D.
Co-Chp.: Steven S. Sharfstein, M.D.
A What Works Best for Whom and at the Lowest Cost?
Efram Bleiberg, M.D.
B Partners, Psychiatry and the Mental Health System
Gary L. Gottlieb, M.D.
C Academic Challenges in the Psychiatric Hospital in the 21st Century
Sheldon I. Miller, M.D.
D The Montefiore and University Behavioral Associates’ Experience
Bruce J. Schwartz, M.D.
E The Reinvention of Sheppard Pratt
Steven S. Sharfstein, M.D.

SYMPOSIUM 29 2:00 p.m. - 5:00 p.m.
Room E255, Level 2, McCormick Place Lakeside
THE COMING OF AGE OF THE BIPOLAR SPECTRUM
Chp.: Hagop S. Akiskal, M.D.
(Continued on next page)
A Bipolarity at 2000: Progress Beyond Classic Mania
Hagop S. Akiskal, M.D.

B Agitated Depression As a Mixed State
Athanasio Koukopoulos, M.D.

C Are Impulse Control Disorders Bipolar?
Susan L. McElroy, M.D.

D Anticonvulsant Augmentation in Borderline Personality II
and Borderline Personality III
Olavo D. Pinto, M.D.

E Advances in Treatments for Bipolar Disorder
Charles L. Bowden, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 30 2:00 p.m. - 5:00 p.m.
Room E256, Level 2, McCormick Place Lakeside

EVOLUTION OF CARE: SCHIZOPHRENGIA AND SUBSTANCE ABUSE

Chp.: Richard N. Rosenthal, M.D.
Co-Chp.: Andrew L. Shaner, M.D.

A Integrating Service for Substance Abuse and Schizophrenia
David J. Hellerstein, M.D., Richard N. Rosenthal, M.D.,
Christian R. Miner, Ph.D.

B Effects of Assertive Outreach in the Dually Diagnosed Patient
Christian R. Miner, Ph.D., Richard N. Rosenthal, M.D., David J.
Hellerstein, M.D.

C Dual Recovery Therapy and Motivation
Douglas M. Zedonia, M.D., Ilana Pinsky, Ph.D., Jonathan
Krejci, Ph.D., Brenda Rambo, B.A., Phyllis Reilly, M.A., Ann
Hummel, B.A.

D Alliance and Engagement in Substance-Abusing Schizophrenia Patients
Richard N. Rosenthal, M.D., Christian R. Miner, Ph.D., Sana
Philomene, M.A., David J. Hellerstein, M.D., J. Christopher
Muran, Ph.D.

E Skills Training for Substance Abusing Patients
Andrew L. Shaner, M.D., Lisa J. Roberts, M.A., Thad
Eckman, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 31 2:00 p.m. - 5:00 p.m.
Room S402 B, Level 4, McCormick Place South

PSYCHOSOCIAL REHABILITATION ADVANCES FOR THE SEVERELY AND PERSISTENTLY MENTALLY ILL

Chp.: Troy L. Thompson II, M.D.

A Impact of Public Sector Managed Care on Psychosocial Rehabilitation
Clifton R. Tennison, Jr., M.D.

B Integrating Psychiatric Rehabilitation and Psychiatric Care
Selby C. Jacobs, M.D.

C Psychosocial Rehabilitation: Emerging Best Practices in Recovery
Dale P. Svendsen, M.D.

D Report from the American Psychiatric Association’s Psychosocial Rehabilitation Committee
Troy L. Thompson II, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 32 2:00 p.m. - 5:00 p.m.
Room S402 B, Level 4, McCormick Place South

EATING DISORDERS 2000: CAUSES, PATTERNS AND OUTCOMES

Chp.: Joel Yager, M.D.
Co-Chp.: David B. Herzog, M.D.

A Susceptibility Factors in Eating Disorders
Walter H. Kaye, M.D., Lisa Lillefeld, Ph.D., Katherine A.
Halmi, M.D., Price Foundation Study Group

B Predictions of Simple and Complex PTSD in Bulimia Nervosa
Marcia E. Rorty, Ph.D., Stephen A. Wonderlich, Ph.D., Joel
Yager, M.D., Ross D. Crosby, Ph.D., Catherine Haudek, B.A.

C Inpatients with Eating Disorders: Changing Epidemiology
Katherine A. Halmi, M.D., Claire Wiseman, Ph.D., Suzanne
Sunday, Ph.D., Fern Klapper, Ph.D.

D The Impact of Eating Disorders on Babies and Bones
David B. Herzog, M.D., Steven K. Grinspoon, M.D., Mark A.
Blais, Psy.D., Debra L. Franko, Ph.D., Pamela K. Keel, Ph.D.,
Sherrie E. Selwyn, B.A., Andrea T. Flores, M.Ed., Anne
Kubanski, M.D.

E Outcome of Gastric Bypass for Bedridden and Nonbedridden Obese Patients
James E. Mitchell, M.D., Stephen A. Wonderlich, Ph.D., Blake
Gosnell, Ph.D., Ross D. Crosby, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 33 2:00 p.m. - 5:00 p.m.
Room S403 A, Level 4, McCormick Place South

DOMESTIC VIOLENCE AND HEALTH INTERVENTIONS
U.S. Department of Justice’s Office for Victims of Crime, APA Task
Force on Violence and APA Committee on Family Violence and Sex

Chp.: Sandra J. Kaplan, M.D.
A Domestic Violence: An Overview
Sandra J. Kaplan, M.D.

B Domestic Violence: Legal Trends
Diane Geraghty, J.D.

C Meeting the Mental Health Needs of Battered Women: Critical Review of Treatment Interventions
Carole L. Warshaw, M.D.

D Mental Health Treatment of the Domestic Violence Batterer
Donald G. Dutton, Ph.D.

E Collaborative Approaches to Children Exposed to Violence: The Experience of a Police/Mental Health Partnership
Miriam Berkman, M.S.W.

Discussants: Carolyn A. Hightower, M.P.A., Marylouise Kelley
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 34
2:00 p.m. - 5:00 p.m.
Room S403 B, Level 4, McCormick Place South

NEW TRENDS IN EMERGENCY PSYCHIATRY IN NORTH AMERICA AND EUROPE
Chp.: Michel De Clercq, M.D.
Co-Chp.: Allan Tasman, M.D.

A Emergency Psychiatry in the U.S.: Facing the Managed Care Revolution
James R. Hillard, M.D.

B The Challenges of Emergency Psychiatry in Europe
Michel De Clercq, M.D.

C Canadian Versus American Psychiatric Emergency Services
Suzanne Lamarre, M.D., Andreanne Elie, M.D.

D Innovating Acute Treatment: A Swiss Pilot Project
Antonio Andreoli, M.D.

Discussants: Pier M. Furlan, M.D., Joseph J. Zealberg, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 35
2:00 p.m. - 5:00 p.m.
Room S404 A, Level 4, McCormick Place South

ANTIPSYCHOTIC MEDICATIONS AND SEXUALITY
Chp.: Ruth A. Dickson, M.D.

A Review of Pathomechanisms of Sexual Dysfunction Secondary to Antipsychotic and Antidepressant Medications
R. Taylor Segraves, M.D.

B Sexuality and the Cost of Compliance for Consumers
Francine Chisholm, B.A.

C Sexual Problems in a Women's Clinic for Schizophrenia
Mary V. Seeman, M.D.

D Development of a Scale to Assess Sexual Functioning
Ruth A. Dickson, M.D., William M. Glazer, M.D., Joan M.C. Hillson, Ph.D.

E Sexual Dysfunctions in Patients on Antipsychotics
Rikus Kneegtering, Maroo Boks, M.D., Durk Wiersma, Ph.D.,
Carl Blijd, M.D., Richard Bruggeman, M.D., Robert Bosch van Oer, Ph.D.

Discussant: William M. Glazer, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 36
2:00 p.m. - 5:00 p.m.
Room S404 B/C, Level 4, McCormick Place South

RECOVERED MEMORY: LAW, SCIENCE AND THE CLINICIAN
Chp.: Alan A. Stone, M.D.

A Memory Distortion: Data, Theory and Application
Daniel L. Schacter, Ph.D.

B Recovered Memories: A Multidisciplinary Analysis
Christopher Barden, Ph.D.

C Justice and Pseudoscience in the Memory Wars
Alan W. Scheflin, LL.M.

D Standard Practices with Recovered Memories
Paul R. McHugh, M.D.

E Recovery and Memory
David Spiegel, M.D., Catherine Classen, Ph.D., Kirsten Neill-Manning, Cheryl Koopman, Ph.D.

Discussant: Alan A. Stone, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 37
2:00 p.m. - 5:00 p.m.
Room S404 D, Level 4, McCormick Place South

THE PSYCHOTHERAPY OF PRESCRIBING
Chp.: Michelle Riba, M.D.

A Overview: Prescriptions of Medications and Doctor-Patient Relationships
Michael D. Jibson, M.D., Kenneth R. Silk, M.D., James M. Ellison, M.D., Jonathan M. Metzl, M.D.

B Factors Affecting Adherence to a Pharmacotherapeutic Treatment
James M. Ellison, M.D., Kenneth R. Silk, M.D., Jonathan M. Metzl, M.D., Michael D. Jibson, M.D.

C Understanding the Symbolic Value of Medications
Jonathan M. Metzl, M.D., Kenneth R. Silk, M.D., James M. Ellison, M.D., Michael D. Jibson, M.D.

Discussant: Allan Tasman, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIAUM 38  2:00 p.m. - 5:00 p.m.
Continental Ballroom A, Lobby Level, Chicago Hilton

THE MANY FACES OF TRANSFERENCE IN EVERYDAY CLINICAL CARE: PART 2
American Academy of Psychoanalysis and the American Psychoanalytic Association

Chp.: Miriam F. Tasini, M.D.
Co-Chp.: Stephen F. Bauer, M.D.

A  The Therapeutic Relationship: Cultural Influences on Boundaries
   Silvia W. Olarte, M.D.

B  Impact of the Changing Social Context on the Doctor-Patient Relationship
   Edward R. Shapiro, M.D.

C  The Active Engagement of Patients in Supportive Relationships
   Milton Viederman, M.D.

D  How Psychodynamic Therapists Modify Behavior
   Saul Tutman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 39  2:00 p.m. - 5:00 p.m.
Continental Ballroom B, Lobby Level, Chicago Hilton

NEUROSCIENCE OF ALCOHOLISM: TREATMENT IMPLICATIONS
National Institute on Alcohol Abuse and Alcoholism

Chp.: Raymond F. Anton, M.D.

A  Extracellular and Intracellular Signals in Alcohol Dependence
   Boris Tabakoff, Ph.D.

B  Are There Genes for Alcoholism? Neurobiology of Alcohol Reward and Dependence
   George F. Koob, Ph.D.

C  Neurobiology of Alcohol Dependence and Withdrawal
   Howard C. Becker, Ph.D.

D  Neurobehavioral Aspects of Alcohol Craving and Relapse
   Raymond F. Anton, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 40  2:00 p.m. - 5:00 p.m.
Continental Ballroom C, Lobby Level, Chicago Hilton

REHABILITATION AS A DYNAMIC PROCESS

Chp.: Zebulan C. Taintor, M.D.
Co-Chp.: Robert Canoro, M.D.

A  The World Psychiatric Association's Consensus Statement on Psychosocial Rehabilitation
   Robert Canoro, M.D., Zebulan C. Taintor, M.D.

B  Program Retention Prevents Relapse Better than Program Type
   Martin Gittelman, Ph.D.

C  Progress in Deinstitutionalization in Japan
   Naotaka Shinfuku, M.D.

D  Sector Treatment in Germany
   Michael Stark, M.D.

E  Pressures on Sectorization in France
   Jacques M. Dubuis, M.D.

Discussant: Ida Kosza, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 41  2:00 p.m. - 5:00 p.m.
Boulevard Room A/B, Second Floor, Chicago Hilton

MERGERS AND INTEGRATION OF VA MENTAL HEALTH SERVICES

Chp.: Laurent S. Lehmann, M.D.
Co-Chp.: Boris M. Astrachan, M.D.

A  Consolidation of Psychiatric Services at the VA Chicago Health Care System
   Suninder S. Nand, M.D., Laurent S. Lehmann, M.D., Boris M. Astrachan, M.D., Christine LaGana, Ph.D., Richard A. McCormick, Ph.D.

B  VA Maryland Health Care System: An Integrated Continuum of Mental Health Care
   Christine LaGana, Ph.D., Laurent S. Lehmann, M.D., Boris M. Astrachan, M.D., Suninder S. Nand, M.D., Richard A. McCormick, Ph.D.

C  VISN Mental Health Service Line
   Richard A. McCormick, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 42  2:00 p.m. - 5:00 p.m.
Boulevard Room C, Second Floor, Chicago Hilton

MINORITY VETERANS: OBSTACLES TO MENTAL HEALTH CARE

Chp.: Jose M. Canive, M.D.
Co-Chp.: Joseph J. Westermeyer, M.D.

A  A Coding Scheme for Barriers to Psychiatric Care
   Judith M. Garrard, Ph.D.

B  Veterans Administration Minority Staff Identifies Obstacles to Mental Health Services
   Jose M. Canive, M.D., Eligio Padilla, Ph.D.
C Veterans Administration Mental Health Workers and Barriers to Care
Joseph J. Westermeyer, M.D.

D Psychiatric Care Barriers: 2000 Veteran Reports
Roes D. Crosby, Ph.D., Sean Nugent, Paul D. Thuras, Ph.D.
Discussants: James W. Thompson, M.D., Javier I. Escobar, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 43
2:00 p.m. - 5:00 p.m.
Joliet Room, Third Floor, Chicago Hilton
THE TREATMENT OF PSYCHIATRICALLY ILL HIV-INFECTED PATIENTS
Chp.: Marshall Forstein, M.D.
Co-Chp.: Francine Cournos, M.D.
A Mood Disorders
Stephen J. Ferrando, M.D.
B Psychotic Disorders
Francine Cournos, M.D.
C Anxiety Disorders
J. Stephen McDaniel, M.D.
D Pain Disorders
William Breitbart, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 44
2:00 p.m. - 5:00 p.m.
Marquette Room, Third Floor, Chicago Hilton
POLITICAL VIOLENCE IN THE NEW MILLENNIUM
Chp.: Jerrold M. Post, M.D.
A Millennial Hopes and the Psychology of Mass Violence
David A. Rothstein, M.D.
B When History Is a Nightmare
Stevan M. Weine, M.D.
C Justice and Righteousness After Genocide
Kenneth B. Dekleva, M.D.
D Virtual Group Dynamics and the Propagation of Hatred
Jerrold M. Post, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 45
2:00 p.m. - 5:00 p.m.
PDR 2, Third Floor, Chicago Hilton
THE FIRST INTERVIEW
Chp.: Rodrigo A. Muñoz, M.D.
Co-Chp.: Maurice Rappaport, M.D.
A Computerized Psychological Testing: Expanding Psychiatrists' Clinical and Fiscal Potentials
Maurice Rappaport, M.D.
B Evaluation of the Ill Physician
Michael Myers, M.D.
C Computerized Psychiatric Diagnostic Interview for DSM-IV
Mark Zetin, M.D., Tasha Glenn, Ph.D.
Discussants: Michael Myers, M.D., Mark Zetin, M.D., Kathleen M. Mogul, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 46
2:00 p.m. - 5:00 p.m.
Waldorf Room, Third Floor, Chicago Hilton
MOOD AND MENOPAUSE: TREATING WOMEN IN MIDLIFE
Chp.: Marian I. Butterfield, M.D.
Co-Chp.: Leah J. Dickstein, M.D.
A Psychotherapy During the Perimenopause
Nada L. Stotland, M.D.
B Gender-Based Biology and Public Policy
Florence Haseltine, M.D.
C Mood and Menopause: Clinical Issues in Treating Midlife Women
Diana L. Dell, M.D.
D Psychotropic Medications in the Perimenopause and Menopause
Margaret F. Jensvold, M.D.
E Promoting Informed Decision-Making About Hormone-Replacement Therapy
Lori A. Bastian, M.D.
Discussant: Donna E. Stewart, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 47
2:00 p.m. - 5:00 p.m.
Williford Room C, Third Floor, Chicago Hilton
ELECTRONIC RECORDS: THE END OF CONFIDENTIALITY?
Chp.: David P. Olson, M.D.
Co-Chp.: Robert C. Hsiung, M.D.
A Computerized Psychiatric Records Today: Can They Be Protected?
David P. Olson, M.D.
B Electronic Patient Records: The Ethical Challenges
Ronald J. Draper, M.D.

(Continued on next page)
SYMPOSIUM 50 2:00 p.m. - 5:00 p.m.
Lake Michigan Room, Eighth Floor, Chicago Hilton

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE
APA Committee of Early Career Psychiatrists

Chp.: William E. Callahan, Jr., M.D.
Co-Chp.: Ann S. Maloney, M.D.

A Balancing Multiple Roles in Private Practice
William E. Callahan, Jr., M.D., Ann S. Maloney, M.D., Barry W. Wall, M.D., Keith W. Young, M.D.

B Personal Factors Leading to a Successful Private Practice
Ann S. Maloney, M.D., William E. Callahan, Jr., M.D., Barry W. Wall, M.D., Keith W. Young, M.D.

C Streamlining Overhead in Private Practice
Barry W. Wall, M.D., William E. Callahan, Jr., M.D., Ann S. Maloney, M.D., Keith W. Young, M.D.

D Marketing Your Unique Private Practice
Keith W. Young, M.D., William E. Callahan, Jr., M.D., Ann S. Maloney, M.D., Barry W. Wall, M.D.

Discussants: Barry W. Wall, M.D., Keith W. Young, M.D.
THIS SESSION WILL BE AUDIOTAPED.

TELECOMMUNICATION SESSION 2
2:00 p.m. - 5:00 p.m.
International Ballroom South, Second Floor, Chicago Hilton

VARIETIES OF ELECTRONIC MEDICAL RECORDS

Chp.: Norman E. Alessi, M.D.
2:15 p.m.

4 Continuous Monitoring of Symptoms and Medications
Elliot D. Luby, M.D.
2:45 p.m.

5 The University of Michigan's Electronic Medical Record Model
Sheila M. Marcus, M.D.
3:15 p.m.

6 Psychiatrist-Programmed Electronic Medical Records
Daniel A. Deutschman, M.D.
3:45 p.m.

7 Caper Software
Peter F. Fore, M.D., Richard Weaver, Ph.D.
3:00 p.m. Session

NEW RESEARCH POSTER SESSION 8
3:00 p.m. - 5:00 p.m.
Hall E, Level 2, McCormick Place Lakeside

SCHIZOPHRENIA, EATING AND GENDER IDENTITY DISORDERS,
HEALTH SERVICES RESEARCH, AND TREATMENT TECHNIQUES
AND OUTCOME STUDIES

For further information on New Research Sessions, please refer to
the New Research Program and Abstracts Book included in your
registration packet.

4:00 p.m. Session

MEDIA SESSION 16
4:00 p.m. - 5:00 p.m.
Room E352, Level 3, McCormick Place Lakeside

THE DOCTOR-PATIENT RELATIONSHIP
Co-Chps.: Manuel Trujillo, M.D., Waguih W. Ishak, M.D.

23 Training Issues in Short-Term Dynamic Psychotherapy
(45 minutes)

Distributor: Manuel Trujillo, M.D.
Department of Psychiatry
NYU School of Medicine
550 First Avenue, NB20N11
New York, NY 10016

Short-term dynamic psychotherapy, a time-limited therapy, is gaining
more attention as an effective and efficient treatment modality for a
variety of psychiatric disorders. Training in this particular modality
requires the trainee to have an adequate knowledge base of
psychodynamic theory and to acquire new therapeutic skills
throughout the process. The trainees have to change their stance
from the traditional active listener role to active participants who
confront defenses, evoke and tolerate intense emotions and help
develop insights. The supervisor's role is to help the trainees
develop a psychodynamic understanding of the patient's problems, to
identify the patient's responses in the therapeutic interaction
including verbal and nonverbal communication guiding the trainee in
making the most appropriate interventions. The use of videotaped
sessions for supervision has proven to be extremely helpful in
assisting the trainees in overcoming their initial difficulties.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIUM 34-39

INDUSTRY-SUPPORTED SYMPOSIUM 34 7:00 p.m. - 10:00 p.m.
Room E450, Level 4, McCormick Place Lakeside

MANIC-DEPRESSIVE ILLNESS: AN UPDATE
Supported by Solvay Pharmaceuticals, Inc.

Chp.: Frederick K. Goodwin, M.D.
Co-Chp.: Kay R. Jamison, Ph.D.

A Bipolar Disorder and Genetics: A Clinician's Perspective
J. Raymond DePaulo, Jr., M.D.

B Molecular Mechanisms Underlying Mood Stabilization on
MDI
Husseini K. Manji, M.D.

C Brain Anatomy and Function in Bipolar Disorder
Harold A. Sackeim, Ph.D.

D Suicide in Bipolar Disorders
Jan A. Fawcett, M.D.

E Pharmacological Treatment: Challenges and Controversies
Frederick K. Goodwin, M.D.

F Manic-Depressive Illness: An Update on Psychological
Issues
Kay R. Jamison, Ph.D.

Discussant: Myrna M. Weissman, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 35 7:00 p.m. - 10:00 p.m.
Grand Ballroom A, Level 1, McCormick Place South

NEUROTRANSMITTERS AND DEPRESSION: NEW
POSSIBILITIES
Supported by Glaxo Wellcome Inc.

Chp.: Richard J. Metzner, M.D.

A Neuroregulators in Depression
Jack D. Barchas, M.D.

B Molecular Adaptations to Drugs Used for Depression
Chris J. Evans, Ph.D.

C Depletion of Neurotransmitters in Humans
Pedro L. Delgado, M.D., Francisco A. Moreno, M.D.

D The Targeted Treatment of Depression
Richard J. Metzner, M.D.
TUESDAY

INDUSTRY-SUPPORTED SYMPOSIUM 36  7:00 p.m. - 10:00 p.m.
Grand Ballroom B, Level 1, McCormick Place South

PSYCHIATRY IN UNCHARTED TERRITORY: ASSESSING AND TREATING PSYCHIATRIC CONDITIONS IN MEDICAL PATIENTS
Supported by Forest Laboratories, Inc.

Chp.: Ellen Frank, Ph.D.
Co-Chp.: Wayne J. Katon, M.D.

A Broken Hearts: Ischemic Heart Disease, Depression and Gender
Donna E. Stewart, M.D., Susan E. Abbey, M.D., Zach Shnek, Jane Irvine, Paul Daly

B Effective Treatment of Minor Depression in Primary Care
Ellen Frank, Ph.D.

C Effectiveness of an SSRI and Problem-Solving Therapy for Primary Care Patients with Dysthymia
Wayne J. Katon, M.D., Ellen Frank, Ph.D., James E. Barrett, M.D., John A. Williams, M.D., Thomas E. Oxman, M.D., Mark Sullivan, M.D., John Cornell, Ph.D.

D Improving Care for Panic in Primary Care
Peter P. Roy-Byrne, M.D., Deborah S. Cowley, M.D., Joan Russo, Ph.D., Wayne J. Katon, M.D.

E Primary Care Training Improves Depression Outcomes
Kathryn M. Rost, Ph.D., Paul Nutting, M.D., Jeffrey Smith, B.S., James Werner, M.A.

INDUSTRY-SUPPORTED SYMPOSIUM 37  7:00 p.m. - 10:00 p.m.
Regency Ballroom, Second Floor, Hyatt Regency

DEFINING BIPOLAR DISORDER: A PUBLIC HEALTH CHALLENGE
Supported by Abbott Laboratories

Chp.: Robert M.A. Hirschfeld, M.D.
Co-Chp.: Paul E. Keck, Jr., M.D.

A A New Screening Tool for Bipolar Disorder: The Mood Disorder Questionnaire
Robert M.A. Hirschfeld, M.D.

B Systematic Treatment Alternatives
Gary S. Sachs, M.D.

C Rapid Stabilization of Mood and Psychiatric Symptoms in Mania
Paul E. Keck, Jr., M.D.

D Pharmacologic Treatment for Women with Bipolar Disorder
Lauren B. Marangell, M.D.

E Recognition and Management of Bipolar Disorder in Children and Adolescents
Neal D. Ryan, M.D.

Discussants: Laurie M. Flynn, Lydia Lewis

INDUSTRY-SUPPORTED SYMPOSIUM 38  7:00 p.m. - 10:00 p.m.
Grand Ballroom, Second Floor, Chicago Hilton

ADULT ADHD: RESEARCH FINDINGS AND CLINICAL PRACTICE
Supported by Shire Richwood

Chp.: Joseph Biederman, M.D.

A Age-Dependent Decline of ADHD Symptoms
Joseph Biederman, M.D.

B Neuroimaging in Patients with ADHD
Jean A. Frazier, M.D.

C Genetics of Adult ADHD
Stephen V. Faraone, Ph.D.

D Cholinergic Mechanisms and ADHD: Treatment Implications
Timothy E. Wilens, M.D.

E Efficacy and Tolerability of a Mixed Amphetamine Salts Compound in Adults with ADHD
Thomas J. Spencer, M.D., Joseph Biederman, M.D., Jeff Q. Bostic, M.D., Jefferson B. Prince, M.D., Kristine Gerard, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 39  7:00 p.m. - 10:00 p.m.
International Ballroom North, Second Floor, Chicago Hilton

COGNITION IN SCHIZOPHRENIA: MAXIMIZING RECOVERY
Supported by U.S. Pharmaceuticals, Pfizer Inc.

Chp.: Herbert Y. Meltzer, M.D.

A Cognitive Impairment and Outcome in Schizophrenia
Herbert Y. Meltzer, M.D.

B Cognition: The Link to Functional Outcomes
Michael F. Green, Ph.D.

C Cognition-Enhancing Treatments in Schizophrenia
John W. Newcomer, M.D.

D Cognitive Rehabilitation for Schizophrenia
Alan S. Bellak, Ph.D.

MEDIA SESSIONS 17-18

MEDIA SESSION 17  7:00 p.m. - 10:00 p.m.
Room E351, Level 3, McCormick Place Lakeside

THE HOLOCAUST: LIFE IS BEAUTIFUL

Chp.: Alan A. Stone, M.D.

24 Life Is Beautiful: The Holocaust As Fable
(114 minutes)
**TUESDAY**

**Distributor** Swank Motion Pictures, Inc.
**For 24 & 25:** 350 Vanderbilt Motor Parkway
Hauppauge, NY 11787

*Life Is Beautiful* earned the Best Jewish Experience Award at the Jerusalem International Film Festival and three Oscars, including best foreign film. Roberto Benigni’s film breaks a half-century taboo and takes audiences from the reality of death camps to a bittersweet fable. The fact that audiences and particularly Jews can laugh as well as cry and do not experience this movie as a sacrilege is something of a psychological milestone. Playing the world’s most overprotective father, Benigni convinces his young son that their incarceration as Jews at a German death camp during World War II is all part of an elaborate game. From his bulbous forehead to his frantic gestures, Benigni is a clown in the great classic tradition, and he uses every bit of comic business in his vast repertoire to maintain the conceit he’s concocted to protect his son. Far from trivializing the horror of the Holocaust, this film underscores an elemental truth vouches by many survivors that the human spirit can triumph over the most horrific adversity.

**Discussants:** Rachel Yehuda, Ph.D., Lawrence Hartmann, M.D.

**MEDIA SESSION 18**
7:00 p.m. - 10:00 p.m.
Room E352, Level 3, McCormick Place Lakeside

THE DOCTOR-PATIENT RELATIONSHIP: A RARE REALISTIC PORTRAYAL

Chp.: Harvey R. Greenberg, M.D.

25 Good Will Hunting
(125 minutes)

This drama, set in Boston and Cambridge, is about rebellious 20-year-old MIT janitor Will Hunting (Matt Damon), gifted with a photographic memory, who hangs out with his South Boston bar buddies, his best friend Chuckie, and his affluent British girlfriend Skylar. After MIT professor Lambeau stumps students with a challenging math formula on a hallway blackboard, Will anonymously leaves the correct solution, prompting Lambeau to track the elusive young genius. As Will’s problems with the police escalate, Lambeau offers an out, but with two conditions, visits to a therapist and weekly math sessions. Will agrees to the latter but refuses to cooperate with a succession of therapists. Lambeau then contacts his former classmate, therapist Sean McGuire (Robin Williams), an instructor at Bunker Hill Community College. Both are equally stubborn, but Will is finally forced to deal with both his past and his future.

**SYMPOSIUM 51-54**

**SYMPOSIUM 51**
7:00 p.m. - 10:00 p.m.
Continental Ballroom A, Lobby Level, Chicago Hilton

APPLYING VIRTUAL ENVIRONMENTS IN PSYCHIATRY

Chp.: Milton Huang, M.D.

A An Introduction to Virtual Environments
Milton Huang, M.D.

B Virtual Environment for Neuropsychiatric Assessment and Rehabilitation
Albert A. Rizzo, Ph.D.

C Virtual Humans: The Future Occupants of Virtual Reality
Norman E. Alessi, M.D.

D A Virtual Future for Psychiatry
Mark Wiederhold

SYMPOSIUM 52
7:00 p.m. - 10:00 p.m.
Continental Ballroom B, Lobby Level, Chicago Hilton

ARAB PERSPECTIVE ON PSYCHOTIC DISORDERS

Chp.: Mohamed A. Elrafei, M.D.

A Arab Perspective on Psychosis
Nasser F. Loza, M.B., Ahmed Eldosoky, Sherif Atalla, M.R.C., Mohamed Fakhri-Flislam, Khaled Nabil, Mona Botros, Elizabeth Coker, M.S.

B Transcultural Aspects of Expressed Emotions in Relapse of Psychotics
Ahmed M.F. Okasha, M.D.

C Prevalence of Early Postpartum Psychiatric Morbidity in Dubai: A Treatment Perspective
Mohammed Abou-Saleh, M.D., Rafia O.S. Ghabash, Ph.D.

D Structured Clinical Interview in Psychotic Disorders: Arab Perspective
Adel Sadek, M.D.

**Discussants:** David V. Sheehan, M.D., Aziz Salama

**THIS SESSION WILL BE AUDIOTAPE**

SYMPOSIUM 53
7:00 p.m. - 10:00 p.m.
Continental Ballroom C, Lobby Level, Chicago Hilton

ONE PSYCHIATRY, TWO CULTURES AND SCORES OF TREATMENT GUIDELINES: VIVE LA DIFFERENCE

Chp.: Jean-Francois Allilaire, M.D.
Co-Chp.: John A. Talbott, M.D.

A Development of Treatment Guidelines in the U.S.
John S. McIntyre, M.D.

B Interview and Clinical Assessment in France
Jean-Jacques Labouliere, M.D.

C Practice Guidelines for the Psychiatric Evaluation of Adults
Ronald A. Shellow, M.D.

(Continued on next page)
TUESDAY

D Consensus Conference and Guidelines in Paris
   Vivione Kovess, Jean-Charles Pascal, M.D.

E The 1999 Expert Consensus Guidelines for the Treatment of Schizophrenia
   Allen J. Frances, M.D.

F Treatment of Schizophrenia: The French Consensus Statement
   François C. Petitjean, M.D., Charles Gury, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 54 7:00 p.m. - 10:00 p.m.
Boulevard Room A/B, Second Floor, Chicago Hilton

PSYCHOPHARMACOLOGICAL APPROACHES TO THE ATHLETIC AND EXERCISE POPULATION
   International Society for Sport Psychiatry
   Chp.: Ronald L. Kamm, M.D.

A Pharmacologic Management of Anxiety and Mood Disorders in the Athlete
   Antonia L. Baum, M.D.

B Diagnosis and Psychiatric Treatment of Athletes
   Ira D. Glick, M.D., Jessica L. Horstall, M.S.

C Eating Disorders and ADHD in Athletes:
   Psychopharmacologic Management Issues
   Robert W. Burton, M.D.

   Expert Panel: Julie Krone, Winning jockey at the Belmont Stakes;
   other athletes to be announced
   THIS SESSION WILL BE AUDIOTAPED.
PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 40-44

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 40, PART 1
7:00 a.m. - 8:30 a.m.
Room E450, Level 4, McCormick Place Lakeside

WHY DO ANXIOUS PEOPLE BECOME DEPRESSED? THE ROLE OF STRESS SUPERSENSITIVITY
Supported by Wyeth-Ayerst Laboratories

Chp.: Philip T. Ninan, M.D.
A The Epidemiology of Comorbid Depression and Anxiety
Scott W. Woods, M.D.
B The HPA Axis and the Pathophysiology of Depression
Dominique L. Musselman, M.D.
C Antidepressants: Why Are They Anxiolytic Also?
Alan Frazer, Ph.D.
Discussant: Philip T. Ninan, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 41, PART 1
7:00 a.m. - 8:30 a.m.
Grand Ballroom A, Level 1, McCormick Place South

CLINICAL CHALLENGES AND CHOICES IN THE TREATMENT OF ADD/ADHD
Supported by Shire Richwood

Chp.: Laurence L. Greenhill, M.D.
A Biological Basis of ADD/ADHD
James Swanson, Ph.D.
B ADDIADHD Diagnostic Criteria: A Framework for Diagnosis
Mark L. Wolraich, M.D.
C Innovations in the Design and Implementation of Clinical Trials for the Treatment of ADD/ADHD
William E. Pelham, Jr., Ph.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42, PART 1
7:00 a.m. - 8:30 a.m.
Grand Ballroom B, Level 1, McCormick Place South

THE MENTAL HEALTH OF WOMEN AND CHILDREN
Supported by U.S. Pharmaceuticals, Pfizer Inc.

Chp.: Karen D. Wagner, M.D.
A Pregnancy and Breastfeeding: What Psychiatrists Need to Know
Lori L. Altshuler, M.D.
B Update on OCD in Children and Adolescents
Henrietta L. Leonard, M.D.
C Major Depression in Children and Adolescents
Karen D. Wagner, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 43, PART 1
7:00 a.m. - 8:30 a.m.
Regency Ballroom, Second Floor, Hyatt Regency

THE INTERFACE OF NEUROPSYCHIATRIC DISORDERS IN THE ELDERLY
Supported by Eli Lilly and Company

Chp.: Jacobo E. Mintzer, M.D.
Co-Chp.: Ian G. McKeth, M.D.
A Diagnosis and Treatment of Psychosis and Other Behavioral Disturbances in Dementia I: A Focus on Conventional Neuroleptics
Brian A. Lawlor, M.D.
B Diagnosis and Treatment of Psychosis and Other Behavioral Disturbances in Dementia II: A Focus on Atypical Neuroleptics
Jacobo E. Mintzer, M.D.
C Diagnosis and Treatment of Psychosis in Dementia with Lewy Bodies
Ian G. McKeth, M.D.
Discussant: Barry D. Lebowitz, Ph.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 44, PART 1
7:00 a.m. - 8:30 a.m.
Grand Ballroom, Second Floor, Chicago Hilton

BREAKING THE CYCLE: NOVEL TREATMENTS IN BIPOLAR DISORDER
Supported by Janssen Pharmaceutica and Research Foundation

Chp.: Joseph R. Calabrese, M.D.
A Making Polypharmacy Work: Homer's Treatment Plan
Gary S. Sachs, M.D.
B Treating Depression in Bipolar Disorder
Dwight L. Evans, M.D.
C How Useful Are Third-Generation Anticonvulsants?
Patricia Suppes, M.D.
### 8:00 a.m. Sessions

#### COURSE 85
- Course: Factitious Disorder and Munchausen’s Syndrome: Diagnosis and Treatment
- Time: 8:00 a.m. - 12 noon
- Location: Room N426 A, Level 4, McCormick Place North
- Director: Jose R. Maldonado, M.D.

#### COURSE 86
- Course: Insanity Defense Evaluations
- Time: 8:00 a.m. - 12 noon
- Location: Room S501 A, Level 5, McCormick Place South
- Director: Phillip J. Resnick, M.D.

#### COURSE 87
- Course: Video Review of Neuropsychiatric Conditions
- Time: 8:00 a.m. - 12 noon
- Location: Room S501 B/C, Level 5, McCormick Place South
- Co-Directors: Thomas E. Hansen, M.D., Edward C. Lauterbach, M.D.
- Faculty: Dietrich P. Blumer, M.D., Andrew J. Francis, Jr., M.D.

#### COURSE 88
- Course: Evidence-Based Management of SAD: Focus on Light Therapy
- Time: 8:00 a.m. - 12 noon
- Location: Room S502 A, Level 5, McCormick Place South
- Co-Directors: Raymond W. Lam, M.D., Anthony J. Levitt, M.D.

### 9:00 a.m. Sessions

#### CLINICAL CASE CONFERENCE 3
- Time: 9:00 a.m. - 10:30 a.m.
- Location: Williford Room C, Third Floor, Chicago Hilton
- Title: An Elderly Patient with Medically Unexplained Physical Symptoms
- Presenter: William E. Reichman, M.D.
- Discussants: Sandra S. Swantek, M.D., Lawrence W. Lazarus, M.D.

---

**COURSES 89-95**

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

#### COURSE 89
- Time: 9:00 a.m. - 4:00 p.m.
- Location: Room N426 B, Level 4, McCormick Place North
- Title: Dialectical Behavior Therapy
- Director: Suzanne T. Witterholt, M.D.
- Faculty: Cynthia Sanderson, Ph.D.

#### COURSE 90
- Time: 9:00 a.m. - 4:00 p.m.
- Location: Room N427 D, Level 4, McCormick Place North
- Title: Outcomes: Use of Rating Scales
- Director: Luis F. Ramirez, M.D.
- Faculty: Martha Sajatovic, M.D., C. Raymond Bingham, Ph.D., Sudeep Kundu, Ph.D.

#### COURSE 91
- Time: 9:00 a.m. - 4:00 p.m.
- Location: Room S501 D, Level 5, McCormick Place South
- Title: Transpersonal Psychiatry: Clinical Applications
- Co-Directors: John F. Hiatt, M.D., William W. Foote, M.D.

#### COURSE 92
- Time: 9:00 a.m. - 4:00 p.m.
- Location: Room S503 A, Level 5, McCormick Place South
- Title: Interpersonal Psychotherapy
- Director: Scott P. Stuart, M.D.
- Faculty: Michael W. O'Hara, Ph.D., Michael Robertson, M.D.

#### COURSE 93
- Time: 9:00 a.m. - 4:00 p.m.
- Location: Room S503 B, Level 5, McCormick Place South
- Title: Personality and Political Behavior
- Director: Jerrold M. Post, M.D.

#### COURSE 94
- Time: 9:00 a.m. - 4:00 p.m.
- Location: Room S504 A, Level 5, McCormick Place South
- Title: The Assessment and Treatment of Child Molesters
- Director: John M.W. Bradford, M.B.
- Faculty: Gene G. Abel, M.D., Graham G. Glancy, M.B.

#### COURSE 95
- Time: 9:00 a.m. - 4:00 p.m.
- Location: Room S504 D, Level 5, McCormick Place South
- Title: Foundations of Clinical EEG Biofeedback/Neurotherapy
- Director: Thomas M. Brod, M.D.
- Faculty: Joel F. Lubar, Ph.D., J. Peter Rosenfeld, Ph.D., Daniel A. Hoffman, M.D., M. Barry Sterman, Ph.D., Siegfried Othmer, Ph.D.
DEBATE 3 – CANCELLED

DISCUSSION GROUPS 13-15

9:00 a.m. - 10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

13 Marcia Slomowitz, M.D., on the Role of Inpatient Psychiatry in the Changing Health Care System
Room 4G, Fourth Floor, Chicago Hilton

14 Carolyn B. Robinowitz, M.D., on Administrative Psychiatry: Challenges and Opportunities (For Residents Only)
Room 4I, Fourth Floor, Chicago Hilton

15 Joel Yager, M.D., on Managing Eating Disorders
Room 4L, Fourth Floor, Chicago Hilton

LECTURES 18-19

LECTURE 18
9:00 a.m. - 10:30 a.m.
Room E350, Level 3, McCormick Place Lakeside
Kenneth Kosik, M.D.

Mutant Alleles of Brain Genes with Mid- to Late-Life Phenotypes

Chp.: Richard J. Frances, M.D.
Co-Chp.: Ann G. Hess, M.D.

Many late-onset neurodegenerative diseases, such as Alzheimer’s Disease and Parkinson’s Disease, have a rare genetic form in which age of onset is accelerated relative to the more common sporadic form of the disease. Kenneth S. Kosik, M.D., discusses recent research involving a large kindred in Anioquia, Colombia, with a clearly genetic form of Alzheimer’s Disease. Dr. Kosik is Professor of Neurology and Neuroscience at Harvard Medical School in Boston. He is also Senior Neurologist at Brigham and Women’s Hospital in Boston, where he was one of the founders of the Memory Disorders Clinic. He is a Faculty Fellow with the Mind/Brain/Behavior Initiative at Harvard University and a faculty member in the Biological and Biomedical Sciences Program at Harvard Medical School. Dr. Kosik is the author of more than 150 research publications and is the coauthor with Earl Grossman of the popular book When Someone You Love Has Alzheimer’s. He has received the Derek Denny-Brown Neurological Scholar Award from the American Neurological Association and the Zenith Award and Temple Award from the Alzheimer’s Association. Dr. Kosik received his medical degree from the Medical College of Pennsylvania in 1985 and completed his residency in neurology at Tufts New England Medical Center in Boston.

LECTURE 19
9:00 a.m. - 10:30 a.m.
Room E353 A/B, Level 3, McCormick Place Lakeside
Jack M. Gorman, M.D.

The Gene-Environment Interaction: Schizophrenia As an Illustrative Case

Chp.: David M. McDowell, M.D.

As understanding of the pathophysiology of schizophrenia has advanced, a key role for the interaction of genetic predisposition and prenatal environmental events has become increasingly evident. Jack M. Gorman, M.D., highlights recent epidemiological findings about events during fetal life that may elevate the risk for later schizophrenia and discusses integration of these findings with knowledge about human brain development to create a plausible model of schizophrenia risk. Dr. Gorman is Lieber Professor and Vice Chair for Research in the Department of Psychiatry at the Columbia University College of Physicians and Surgeons in New York City. He is also Director of the Mental Health Clinical Research Center at the New York State Psychiatric Institute and Scientific Director of the Phobia, Anxiety and Stress Disorders Clinic at Long Island Jewish Medical Center, Hillside Division. He serves as the Deputy Editor of the American Journal of Psychiatry. He is the author of more than 200 scientific articles, as well as two books on mental health treatment for the general audience. Dr. Gorman received his medical degree from the Columbia University College of Physicians and Surgeons, completed his residency in psychiatry at the New York State Psychiatric Institute and Columbia–Presbyterian Medical Center, and completed a fellowship in psychiatric research and psychopharmacology at Columbia University.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.
This documentary is a rare uninhibited look at sexual addiction/compulsion. Cross-sections of sex addicts/compulsives tell their stories honestly and openly. They take us from their first childhood sexual experiences through their worst act of compulsion to how they are recovering today. Interwoven with these testimonies, three sex addiction/compulsive specialists, including a board-certified psychiatrist, discuss the history and treatment of this disorder.

**Discussant:** John R. Sealy, M.D.

**MEDIA SESSION 20**  
9:00 a.m. - 11:00 a.m.  
Room E352, Level 3, McCormick Place Lakeside

**INNOVATIVE USES OF MEDIA: PROFESSIONAL AND PUBLIC EDUCATION**

Chp.: Mitchell J.M. Cohen, M.D.

28 **Doctor in Health and Illness**  
(11 minutes)

**Distributor:** Patrick Gilligan  
Jefferson Medical College  
125 S. 9th Street, #1005  
Philadelphia, PA 19107

This videotape is a montage of highlights from eight sessions of the first-year behavioral science course Doctor in Health and Illness (DHI). DHI classes outline as follows: 1) musical tour of development; 2) adolescence: case-based dilemmas; 3) a physician's personal perspective on sexuality; 4) human sexuality discussion panel; 5) disease and illness experience of a transplant patient and family; 6) issues of middle life and the doctor-patient relationship; 7) comprehensive case formulation; and 8) medical student transformation. Sessions shown provoke engagement and participation. Faculty are challenged to create class experiences not easily captured in note-service transcriptions.

**Discussant:** Mitchell J.M. Cohen, M.D.

29 **Linking Health Promotion with Entertainment Television**  
(60 minutes)

**Distributor:** Alan Langlieb, M.D.  
Johns Hopkins Hospital  
Department of Psychiatry  
600 N. Wolfe Street/Meyer 131  
Baltimore, MD 21287-7131

The media is the public's leading source of information about medical research, diagnosis and treatment, and thus serves as a common reference point in the doctor-patient relationship. For the last four years, the most-watched television drama has been NBC's *ER*. In an effort to harness the power and reach of *ER*, a syndicated feature called *Following ER* has been developed. *Following ER* is broadcast each week by local TV stations during the late news after *ER*. The goal of these segments is to educate and motivate viewers to take action on a series of important health topics dramatized on *ER*.

**Discussant:** Alan Langlieb, M.D.
NEW RESEARCH ORAL/SLIDE SESSIONS 9-10
9:00 a.m. - 10:30 a.m.

9 MOOD DISORDERS I
Room E255, Level 2, McCormick Place Lakeside

10 MOOD DISORDERS II
Room E256 Level 2, McCormick Place Lakeside

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

REVIEW OF PSYCHIATRY: SECTION 4
9:00 a.m.-12:30 p.m.
Room E451, Level 4, McCormick Place Lakeside

PAIN: WHAT PSYCHIATRISTS NEED TO KNOW
Chp.: Mary Jane Massie, M.D.

15 Pain: Definition and Assessment
Russell K. Portenoy, M.D.

16 Pharmacological and Non-Pharmacological Treatments in Pain Management
Russell K. Portenoy, M.D.

17 Psychogenic Models of Chronic Pain: A Selective Review and Critique
Randy S. Roth, Ph.D.

18 Pain Rounds: The Experts Comment
Mary Jane Massie, M.D.

TELECOMMUNICATION SESSION 3
9:00 a.m. - 12 noon
International Ballroom South, Second Floor, Chicago Hilton

AN INTERNET-BASED SYSTEM FOR IMPROVING PSYCHOPHARMACOLOGY PRACTICE
Chp.: Ronnie S. Stangler, M.D.

9:15 a.m.
8 Overview of the System
Robert D. Patterson, M.D.

9:30 a.m.
9 Anxiety in Patients with Chemical Abuse/Dependence
David N. Osser, M.D.

9:50 a.m.
10 Acute Depression in Bipolar Disorder
Anne E. Dantzler, M.D.

10:10 a.m.
11 Feasibility Study on the Use of Two Algorithms at Taunton State Hospital
David N. Osser, M.D.

10:30 a.m.
12 The Use of Algorithms at the Mendota Mental Health Institute
David V. Mays, M.D.

10:50 a.m.
13 The Cytochrome P450 Drug Interaction Program
Jessica R. Oesterheld, M.D.

11:10 a.m.
14 The P450 Program in the Hospital Setting
Dean Najarian, R.Ph.

WORKSHOPS
COMPONENTS 31-36

COMPONENT WORKSHOP 31 9:00 a.m.-10:30 a.m.
Room 4K, Fourth Floor, Chicago Hilton

SEXUAL HARASSMENT: A MILLENNIUM UPDATE
APA New Jersey Psychiatric Association
Chp.: Rita R. Newman, M.D.

Participants:
Annette J. Hollander, M.D., Arlene G. Sherer, M.D.,
Louise F. Fitzgerald, Ph.D., Penny N. Kahan, Esq., Naomi J. Weinshenker, M.D.

COMPONENT WORKSHOP 32 9:00 a.m. -10:30 a.m.
Room 4M, Fourth Floor, Chicago Hilton

RESIDENCY TRAINING IN PUBLIC SERVICE LEADERSHIP
APA Committee on Graduate Education
Co-Chps.: James W. Lomax II, M.D., Deborah Hales, M.D.
Participants: Carol A. Bernstein, M.D., Jacquelyn D.
McLemore, M.D., Jacqueline C. McGregor, M.D., Kimberly A.
Busi, M.D.

COMPONENT WORKSHOP 33 9:00 a.m. -10:30 a.m.
Lake Erie Room, Eighth Floor, Chicago Hilton

INTERNATIONAL MEDICAL GRADUATES: CAREER CHOICES
APA Committee of International Medical Graduates
Chp.: Jambur V. Ananth, M.D.

Participants:
Rodrigo A. Munoz, M.D., Mantosh J. Dewan, M.D.,
Syed M. Husain, M.D., Hagop S. Akiskal, M.D.

COMPONENT WORKSHOP 34 9:00 a.m.-10:30 a.m.
Lake Huron Room, Eighth Floor, Chicago Hilton

HOW MEDICAL RECORD PRIVACY PROPOSALS WILL CHANGE MEDICINE
APA Joint Commission on Government Relations
Chp.: Richard K. Harding, M.D.
Participants: Robert Gellman, J.D., Paul S. Appelbaum, M.D.
WEDNESDAY

COMPONENT WORKSHOP 35
9:00 a.m. - 10:30 a.m.
Lake Michigan Room, Eighth Floor, Chicago Hilton

MANDATORY OUTPATIENT TREATMENT: IS IT WORTHWHILE?
APA Council on Psychiatry and Law
Chp.: Renee L. Binder, M.D.
Participants: Howard W. Telson, M.D., Marvin S. Swartz, M.D.,
Joan B. Gerbasi, M.D., J.D.

COMPONENT WORKSHOP 36
9:00 a.m. - 10:30 a.m.
Lake Ontario Room, Eighth Floor, Chicago Hilton

CERTIFICATION IN PSYCHIATRIC ADMINISTRATION
APA Council on Medical Education and Career Development
Co-Chps.: William H. Reid, M.D., Carmel A. Foley, M.D.
Participants: Gary E. Miller, M.D., W. Walter Menninger, M.D.,
Philip E. Veenhuis, M.D.

ISSUE WORKSHOP 45
9:00 a.m. - 10:30 a.m.
Room E253 A, Level 2, McCormick Place Lakeside

SPIRITUAL/RELIGIOUS ASSESSMENT IN CLINICAL WORK
Co-Chps.: Francis G. Lu, M.D., Christina M. Puchalski, M.D.
Participant: David B. Larson, M.D.

ISSUE WORKSHOP 46
9:00 a.m. - 10:30 a.m.
Room E253 B, Level 2, McCormick Place Lakeside

BODY IMAGE IN ADOLESCENCE: CONTEXT AND CURRICULAS
Chp.: Patricia R. Recupero, M.D.
Participants: Katharine A. Phillips, M.D., Alison M. Heru, M.D.,

ISSUE WORKSHOP 47
9:00 a.m. - 10:30 a.m.
Room E253 C, Level 2, McCormick Place Lakeside

SEVERE PTSD AND THE DOCTOR-PATIENT RELATIONSHIP
Chp.: Gordon D. Strauss, M.D.
Participant: Michelle A. Fiorella, D.O.

ISSUE WORKSHOP 48
9:00 a.m. - 10:30 a.m.
Room E253 D, Level 2, McCormick Place Lakeside

GROUP PSYCHOTHERAPY OF ADOLESCENT DRUG ABUSERS
Chp.: David W. Brock, M.D.
Participants: Paul Kymissis, M.D., Mary A. Pressman, M.D.

ISSUE WORKSHOP 49
9:00 a.m. - 10:30 a.m.
Room S402 A, Level 4, McCormick Place South

A VERTICALLY INTEGRATED CONSULTATION-LIAISON
TEACHING MODEL
Academy of Psychosomatic Medicine
Co-Chps.: Stephen M. Saraway, M.D., Maurice D. Steinberg, M.D.
Participants: Joseph S. Weiner, M.D., Diana M. Hughes, M.D.,
David Straker

ISSUE WORKSHOP 50
9:00 a.m. - 10:30 a.m.
Room S402 B, Level 4, McCormick Place South

THE MANDATED PATIENT, PART 2: CONTROVERSIES AND
EFFICACY
Co-Chps.: Susan Stabinsky, M.D., Harvey Stabinsky, M.D.
Participants: Michael M. Scimeca, M.D., David W. Freven, M.D.,
Sheldon Travin, M.D.

ISSUE WORKSHOP 51
9:00 a.m. - 10:30 a.m.
Room S403 A, Level 4, McCormick Place South

CLINICAL AND FORENSIC ISSUES IN SEXUAL HARASSMENT
Chp.: Malkah T. Notman, M.D.
Participants: Carl P. Malmquist, M.D., Elissa P. Benedek, M.D.,
Linda M. Jorgenson, J.D.

ISSUE WORKSHOP 52
9:00 a.m. - 10:30 a.m.
Room S403 B, Level 4, McCormick Place South

CARE MANAGEMENT FOR CHRONIC ADDICTIVE DISORDERS
National Institute on Alcohol Abuse and Alcoholism
Chp.: Mark L. Willenbring, M.D.

ISSUE WORKSHOP 53
9:00 a.m. - 10:30 a.m.
Room S404 A, Level 4, McCormick Place South

VOYAGES OF THE STARSHIP EMPATHY: TO BOLDLY GO...
Co-Chps.: Christine A. Barney, M.D., Sandra L. Waugh, V.M.D.
Participant: Katherine I. Benziger, Ph.D.

ISSUE WORKSHOP 54
9:00 a.m. - 10:30 a.m.
Room S404 B/C, Level 4, McCormick Place South

VIDEO CASE STUDIES OF COUPLES IN TREATMENT
Chp.: Ian E. Alger, M.D.

ISSUE WORKSHOP 55
9:00 a.m. - 10:30 a.m.
Room S404 D, Level 4, McCormick Place South

MANAGED CARE IMPACT IN PUBLIC SECTOR PSYCHIATRY
Co-Chps.: Pedro Ruiz, M.D., Robert W. Guynn, M.D.
Participants: David R. Small, M.B.A., Roy V. Varner, M.D.,
Patricia M. Averill, Ph.D.
WEDNESDAY

ISSUE WORKSHOP 56
9:00 a.m. - 10:30 a.m.
Boulevard Room A/B, Second Floor, Chicago Hilton

THE DOCTOR AS PATIENT
Co-Chps.: R. Andrew Schultz-Ross, M.D., Aleen Grabow, M.D.

ISSUE WORKSHOP 57
9:00 a.m. - 10:30 a.m.
Boulevard Room C, Second Floor, Chicago Hilton

CHILDREN OF PSYCHIATRISTS: WORKSHOP III
Co-Chps.: Leah J. Dickstein, M.D., Michelle Riba, M.D.
Participants: Marina Gilman, Daniel Weintraub, M.D., David Spiegel, M.D., Roy R. Grinker, Jr., M.D., Barni Katz Stryer, M.D., Kenneth H. Talian, M.D.

ISSUE WORKSHOP 58
9:00 a.m. - 10:30 a.m.
Joliet Room, Third Floor, Chicago Hilton

CLINICAL CHALLENGES IN CORRECTIONAL PSYCHIATRY
Chp.: Lee H. Rome, M.D.
Participants: James E. Dillon, M.D., Jeffrey L. Metzner, M.D.

ISSUE WORKSHOP 59
9:00 a.m. - 10:30 a.m.
PDR 2, Third Floor, Chicago Hilton

PSYCHODYNAMICS IN TREATMENT-REFRACTORY DEPRESSION
Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 60
9:00 a.m. - 10:30 a.m.
Williford Room A, Third Floor, Chicago Hilton

AN INTERPERSONAL NEUROBIOLOGY OF PSYCHOTHERAPY
Chp.: Daniel J. Siegel, M.D.

ISSUE WORKSHOP 61
9:00 a.m. - 10:30 a.m.
Williford Room B, Third Floor, Chicago Hilton

GIVING CARE TO THE CAREGIVER
Chp.: William F. Haning III, M.D.
Participant: Chad Y. Koyanagi, M.D.

ISSUE WORKSHOP 62
9:00 a.m. - 10:30 a.m.
Room 4D, Fourth Floor, Chicago Hilton

HOW INTUITION CAN BE USED TO ENHANCE PATIENT CARE
Chp.: Judith C. Orloff, M.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 16-17
11:00 a.m. - 12:30 p.m.
These sessions are limited to 25 participants on a first-come, first-served basis.
16 Jerald Kay, M.D., on Combining Psychotherapy and Psychopharmacology
Room 4l, Fourth Floor, Chicago Hilton
17 Leah J. Dickstein, M.D., on Gender Issues in Psychiatric Disorder
Room 4L, Fourth Floor, Chicago Hilton

MASTER EDUCATOR CLINICAL CONSULTATION
11:00 a.m. - 12:30 p.m.
These sessions are limited to 25 participants on a first-come, first-served basis.
13 David Spiegel, M.D., on Psychotherapy for Trauma and Medical Illness
Room 4E, Fourth Floor, Chicago Hilton

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 21-22

MEDIA SESSION 21
11:00 a.m. - 2:00 p.m.
Room E351, Level 3, McCormick Place Lakeside
ANNUAL JAZZ FEATURE: CUBAN PERSPECTIVES
Chp.: Edward K. Rynearson, M.D.
30 Buena Vista Social Club
(101 minutes)
Distributor: Artisan Films
2700 Colorado Avenue, 2nd Floor
Santa Monica, CA 90404

In 1996 Ry Cooder gathered together some of the greatest names in the history of Cuban music to collaborate on the best selling and Grammy winning album Buena Vista Social Club. This groundbreaking documentary, inspired by the album, includes appearances by legendary performers Ry and Joaquin Cooder, Ibrahim Ferrer, Ruben Gonzalez, Eliades Ochoa, Omara Portuondo, Compay Segundo and many other renowned Cuban Musicians. Excited by these colorful characters and their extraordinary music, director Wim Wenders traveled to Havana, Cuba, to chronicle the cooperation and camaraderie between Ry Cooder and his veteran friends.
Discussants: Jose M. Canive, M.D., Ricardo Galbis, M.D.
WEDNESDAY

MEDIA SESSION 22  11:00 a.m. - 2:00 p.m.
Room E352, Level 3, McCormick Place Lakeside

LESBIAN AND GAY IDENTITY: INTEGRATING RELIGION AND AGING

Chp.: Ellen Haller, M.D.

31 Treyf  (55 minutes)
Distributor: Women Make Movies, Inc. Distribution Department
462 Broadway, Suite 500E
New York, NY 10013

Treyf is an unorthodox documentary by and about two Jewish lesbians who met and fell in love at a Passover seder. A humorous and compelling film, Treyf situates the filmmakers' own histories within the larger realm of Jewish history. The film takes us on a personal journey from kibbuts summers to their first taste of "treyf," from the Lower East Side of New York to Jerusalem and the West Bank. With its surprising and striking visual images, this beautiful film manages to keep a lighthearted touch while it explores the pleasures and paradoxes of a progressive, secular Jewish identity. Attempting to redefine "treyf" in a positive light, Madansky and Lebvow discover that their untraditional worldview has deep roots in Jewish history.

32 Beauty Before Age: Growing Older in Gay Culture  (22 minutes)
Distributor: New Day Films
22-D Hollywood Avenue
Ho Ho Kus, NJ 07423

This groundbreaking film explores the power of youth and beauty in the gay community. A diverse group of men, ages 19 to 77, navigate their fears of becoming old, undesirable and alone. The film critically examines the pressure to look young and attractive, the lack of positive older role models and the ways in which AIDS intensifies the fear and process of aging. Beauty Before Age offers a male perspective on a historically female issue, and illuminates the larger societal obsession with physical appearance.

33 Golden Threads  (56 minutes)
Distributor: Women Make Movies, Inc. Distribution Department
462 Broadway, Suite 500E
New York, NY 10013

Profiling the life of 93-year-old lesbian activist, Christine Burton, founder of a global networking service for mid-life and elder lesbians, Golden Threads, a film by Lucy Winer and Karen Eaton, exuberantly overturns our most deeply rooted stereotypes and fears of aging. By adding the wry and introspective narrative of the director undergoing a mid-life crisis, the film generates a groundbreaking, intergenerational dialogue about sexuality, life choices and aging. At a time when the media commonly sentimentalizes, dismisses or altogether ignores the old, Golden Threads offers an urgently needed antidote.

MEDICAL UPDATE 3  11:00 a.m. - 12:30 p.m.
Room S404 B/C, Level 4, McCormick Place South

LIVER DISEASE BY ALCOHOL AND HEPATITIS C: EARLY DETECTION AND INSIGHTS IN PATHOGENESIS LEAD TO IMPROVED TREATMENT
National Institute on Alcohol Abuse and Alcoholism

Chp.: David M. McDowell, M.D.
Presenter: Charles Lieber, M.D.
THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH

11:00 a.m. - 12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

2 Jeffrey L. Cummings, M.D., on Clinical Trials in Alzheimer's Disease
Room 4G, Fourth Floor, Chicago Hilton

SCIENTIFIC AND CLINICAL REPORT SESSIONS 19-27

SCIENTIFIC AND CLINICAL REPORT SESSION 19  11:00 a.m. - 12:30 p.m.
Room E253 C, Level 2, McCormick Place Lakeside

EATING DISORDERS

Chp.: Evelyn Attia, M.D.
Co-Chp.: Samuel J. Langer, M.D.
11:00 a.m.

56 Leptin Dynamics in Bulimia Nervosa
Palmiero Monteleone, M.D., Alfonso Tortorella, M.D., Michele Fabrazzo, M.D., Antonello Di Lieto, M.D., Mario Maj, M.D.
11:30 a.m.

57 A Comparison of Inpatient and Day Treatment for Anorexia Nervosa
Allan S. Kaplan, M.D., Marion P. Olmsted, Ph.D., Jacqueline Carter, D.Phil., D. Blake Woodside, M.D.
12 noon

58 Self-Loathing As a Risk Factor for Eating Disorders
Alayne Yates, M.D., Jeanne Edman, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 20
11:00 a.m. - 12:30 p.m.
Room E255, Level 2, McCormick Place Lakeside

DIAGNOSIS AND TREATMENT OF BIPOLAR ILLNESS: PART 1

Chp.: Conrad M. Swartz, M.D.
Co-Chp.: Michael R. Harris, M.D.

11:00 a.m.
59 Unipolar Mania: A Separate Diagnostic Entity?
Vishal K. Adma, M.D., Ekkehard Othmer, M.D., Cherilyn Desouza, M.D., Elizabeth C. Penick, Ph.D., Elizabeth J. Nickel, M.A., Sanjay M. Vaswani, M.D., William F. Gabrielli, Jr., M.D.

11:30 a.m.
60 Rapid Cycling: Testing Four Definitions
Mario Maj, M.D.

12 noon
61 Compliance in Bipolar Illness
Michael Z. Sobel, M.D., Eric D. Peselow, M.D., Ronald R. Fieve, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 21
11:00 a.m. - 12:30 p.m.
Room S402 B, Level 4, McCormick Place South

ADHD AND SAVANT SYNDROME

Chp.: David S. Rue, M.D.
Co-Chp.: Jacqueline C. McGregor, M.D.

11:00 a.m.
62 Long-Term Treatment of ADHD with OROS Methylphenidate
Timothy E. Wilens, M.D.

11:30 a.m.
63 ADHD and Depressive Subtypes Among Adults with Major Depression
Jonathan E. Alpert, M.D., Karen E. Kelly, B.A., Amy Farabaugh, M.A., Shamsah B. Sonawalla, M.D., Andrew A. Nierenberg, M.D., David Mischoulon, M.D., Maurizio Fava, M.D.

12 noon
64 Savant Syndrome: Genius Among Us, Genius Within Us?
Darold A. Treffert, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 22
11:00 a.m. - 12:30 p.m.
Room S403 B, Level 4, McCormick Place South

DIAGNOSTIC ISSUES AND PERSONALITY DISORDERS

Chp.: Eva M. Szigethy, M.D.
Co-Chp.: Fusheng Zhang, M.D.

11:00 a.m.
65 A 25-Year Follow-Up of BPD: Preliminary Findings
Joel F. Paris, M.D., Hallie Zweig-Frank, Ph.D.

11:30 a.m.
66 DSM-IV Personality Disorder Criteria: Diagnostic Efficiency

12 noon
67 Stability of Personality Disorder Diagnoses in Remitted Depressed Outpatients
Amy Farabaugh, M.A., Gabrielle I. Siegel, B.A., Joel Pava, Ph.D., Jonathan E. Alpert, M.D., Andrew A. Nierenberg, M.D., Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 23
11:00 a.m. - 12:30 p.m.
Boulevard Room A/B, Second Floor, Chicago Hilton

NICOTINE DEPENDENCE

Chp.: Michael M. Scimeca, M.D.
Co-Chp.: Art C. Wataszek, M.D.

11:00 a.m.
68 Short-Term Nicotine Patch Use: Is It Effective?
Edward D. Simmer, M.D., Patrick H. Bowers, M.D., Richard Ellis, M.D.

11:30 a.m.
69 Correlates of Cigarette Smoking in Schizophrenia
Dale A. D’Mello, M.D., Rafael Villicana

12 noon
70 Detoxification from Nicotine Dependence
Carlo Bayrakdarian, M.D., Judy Weingram, M.D., Daniel Wagner, M.D., Linton Dorfman, R.N., Aurora Ana Dogaru, M.D., Tatsu Kakuma, Ph.D., Barnett S. Meyers, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 24
11:00 a.m. - 12:30 p.m.
Marquette Room, Third Floor, Chicago Hilton

NEW ISSUES IN SUBSTANCE ABUSE

Chp.: Evaristo O. Akerele, M.D.
Co-Chp.: David G. Ostrow, M.D.

11:00 a.m.
71 Childhood Physical Abuse: Effects on Addiction
Karen J. Wahmanholm, M.D., Joseph J. Westermeyer, M.D., Paul D. Thuras, Ph.D.

11:30 a.m.
72 Biomarkers to Evaluate Treatment for Alcoholism
National Institute on Alcohol Abuse and Alcoholism
John P. Allen, Ph.D., Raye Z. Litten, Ph.D.

(Continued on next page)
12 noon
73 High-Versus Low-Structure Individual Counseling for Substance Abuse: A Controlled Comparison
Edward Gottheil, M.D., Charles Thornton, Ph.D., Stephen P. Weinstein, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 25
11:00 a.m. - 12:30 p.m.
Willford Room B, Third Floor, Chicago Hilton

ACQUIRED IMMUNE DEFICIENCY SYNDROME AND HUMAN IMMUNODEFICIENCY VIRUS: RELATED DISORDERS
Chp.: Joel J. Wallack, M.D.
Co-Chp.: Patricia R. Knaudt, M.D.

11:00 a.m.
74 Group Therapy, Depression and CD4 in an HIV-Positive Person
Cheryl Koopman, Ph.D., Xin-Hua Chen, B.A., Dennis Israelski, M.D., Cheryl Core-Felton, Ph.D., Jose R. Maldonado, M.D., Alan F. Schatzberg, M.D., David Spiegel, M.D.

11:30 a.m.
75 Psychiatric Service Utilization by HIV-Positive Patients
John M. Budin, M.D., Sarah Bostlough, Ph.D., Mark Winiarski, Ph.D., Emily Beckett

12 noon
76 Psychiatric Disorders in Injecting Drug Users Infected with HIV
Andre Malbergier, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 26
11:00 a.m. - 12:30 p.m.
Room 4M, Fourth Floor, Chicago Hilton

ISSUES IN SLEEP AND OUTCOME RESEARCH
Chp.: Jambur V. Ananth, M.D.
Co-Chp.: Mary Kay Smith, M.D.

11:00 a.m.
77 Open Infrastructure for Outcome Research
Andrew P. Ho, M.D., Robert Paul Liberman, M.D., Keh-Ming Lin, M.D.

11:30 a.m.
78 Drug Treatment of Chronic Insomnia: Case Studies
Milton Kramer, M.D.

12 noon
79 The Contextualizing Image: The Center of the Dream
Ernest L. Hartmann, M.D., Michael Zborowski, Ph.D., Robert Kunzendorf, Ph.D., Robert Stickgold, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS
COMPONENTS 37-42
COMPONENT WORKSHOP 37 11:00 a.m. - 12:30 p.m.
Room E256, Level 2, McCormick Place Lakeside

CAREER CHOICES IN PSYCHIATRY
APA Assembly Committee of Area Member-in-Training Representatives
Chp.: Kimberly L. Valentine, M.D.
Participants: Patrice A. Harris, M.D., Anna Holmgren, M.D., Robert M. Weinrieb, M.D., Gregory J. Brown, M.D.

COMPONENT WORKSHOP 38 11:00 a.m. - 12:30 p.m.
Room S404 A, Level 4, McCormick Place South

TEACHING PSYCHIATRY IN AN AMBULATORY SETTING
APA Committee on Medical Student Education
Co-Chps.: Michael J. Vergare, M.D., Carl B. Greiner, M.D.
Participants: Steven P. Wengel, M.D., H. Jonathan Polan, M.D., Linda F. Pessar, M.D.

COMPONENT WORKSHOP 39 11:00 a.m. - 12:30 p.m.
Room S404 D, Level 4, McCormick Place South

USING COMPUTERS TO GUIDE CLINICAL PRACTICE
APA Steering Committee on Practice Guidelines
Chp.: Joel Yager, M.D.
Participants: Kenneth Z. Altshuler, M.D., John S. McIntyre, M.D., Ian A. Cook, M.D., Amarendra Das, M.D., Madhukar H. Trivedi, M.D.
<table>
<thead>
<tr>
<th>Component Workshop 40</th>
<th>11:00 a.m. - 12:30 p.m.</th>
<th>Williford Room A, Third Floor, Chicago Hilton</th>
</tr>
</thead>
<tbody>
<tr>
<td>Innovations in Veterans Affairs' Mental Illness Research Education and Clinical Centers</td>
<td>APA Consortium on Organized Service Systems</td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Laurent S. Lehmann, M.D., Frederick G. Guggenheim, M.D.</td>
<td>Participants: Larry J. Siever, M.D., Greer Sullivan, M.D., Jerome A. Yesavage, M.D., Thomas B. Horvath, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Component Workshop 41</th>
<th>11:00 a.m. - 12:30 p.m.</th>
<th>Room 4D, Fourth Floor, Chicago Hilton</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Media and Disasters and Other Traumatic Events</td>
<td>APA Joint Commission on Public Affairs and APA Committee on Psychiatric Dimensions of Disasters</td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Michael Blumenfield, M.D., Robert J. Ursano, M.D.</td>
<td>Participants: Barry Kaufman, Helen Chickering</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Component Workshop 42</th>
<th>11:00 a.m. - 12:30 p.m.</th>
<th>Lake Ontario Room, Eighth Floor, Chicago Hilton</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is It a Crime to Be Homeless? Ideas for Change</td>
<td>APA Committee on Poverty, Homelessness and Psychiatric Disorders</td>
<td></td>
</tr>
<tr>
<td>Chp.: Hunter L. McQuistion, M.D.</td>
<td>Participants: Paulette M. Gillig, M.D., Gene Pettit, Kenneth Steele</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 63</th>
<th>11:00 a.m. - 12:30 p.m.</th>
<th>Room E253 A, Level 2, McCormick Place Lakeside</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partnering with Parents:Treating Preschoolers</td>
<td>Chp.: Peter D. Garmane, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Joanne Dunnigan, M.S.W., Grace Hickey, Psy.D., Phillip Repasky, M.A., Diane Beebe, R.N.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 64</th>
<th>11:00 a.m. - 12:30 p.m.</th>
<th>Room E253 B, Level 2, McCormick Place Lakeside</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strategies for Residency Training in Managed Care</td>
<td>Chp.: Emily Harris, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Mark E. Servis, M.D., John Luo, M.D., Terence Witham, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 65</th>
<th>11:00 a.m. - 12:30 p.m.</th>
<th>Room S402 A, Level 4, McCormick Place South</th>
</tr>
</thead>
<tbody>
<tr>
<td>Addiction Psychiatrists, HMOS and Patient Relationships</td>
<td>Chp.: Richard J. Frances, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Shelley B. Blume, M.D., Robert B. Millman, M.D., Sheldon I. Miller, M.D., Frances R. Levin, M.D., Solorsh Lionel, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 66</th>
<th>11:00 a.m. - 12:30 p.m.</th>
<th>Room S403 A, Level 4, McCormick Place South</th>
</tr>
</thead>
<tbody>
<tr>
<td>Integrating Mind and Body in the Undergraduate Curriculum</td>
<td>Co-Chps.: Barbara A. Schindler, M.D., Dilip Ramchandani, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participant: Bryce Templeton, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 67</th>
<th>11:00 a.m. - 12:30 p.m.</th>
<th>Joliet Room, Third Floor, Chicago Hilton</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leadership in Organizational Transitions</td>
<td>Chp.: Stewart Gabel, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 68</th>
<th>11:00 a.m. - 12:30 p.m.</th>
<th>PDR 2, Third Floor, Chicago Hilton</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMGs in Psychiatry: Challenges and Opportunities</td>
<td>Co-Chps.: Anu Matorin, M.D., Nalini V. Juthani, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Richard Balon, M.D., Vinay Kapoor, M.D., Pedro Ruiz, M.D., Tarek A. Okasha, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 69</th>
<th>11:00 a.m. - 12:30 p.m.</th>
<th>Room 4K, Fourth Floor, Chicago Hilton</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proving It's All Worth It</td>
<td>Chp.: Leila B. Laitman, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Linda Sacco, C.S.W., Rebecca Morales, C.S.W.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 70</th>
<th>11:00 a.m. - 12:30 p.m.</th>
<th>Lake Erie Room, Eighth Floor, Chicago Hilton</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collaboration in Academia: Tales from the Trenches</td>
<td>Chp.: Deborah Spitz, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: David A. Goldberg, M.D., Debra L. Klamen, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 71</th>
<th>11:00 a.m. - 12:30 p.m.</th>
<th>Lake Huron Room, Eighth Floor, Chicago Hilton</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychosocial Adjustment of Elderly Asian Americans</td>
<td>Chp.: Jagannathan Srinivasaraghavan, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Albert C. Gaw, M.D., Suk Choo Chang, M.D., Norma C. Panahon, M.D., S. Arshad Husain, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
WEDNESDAY

12 noon Sessions

FORUMS 7-8

FORUM 7
Room E253 D, Level 2, McCormick Place Lakeside
ALCOHOL AND INTERPERSONAL VIOLENCE: PUBLIC HEALTH AND CRIMINAL JUSTICE ISSUES
National Institute on Alcohol Abuse and Alcoholism
Chp.: Linda Teplin, Ph.D.
Participants: Raul Caetano, M.D., Jacquelyn C. Campbell, Ph.D., Susan E. Martin, Ph.D.

FORUM 8
Boulevard Room C, Second Floor, Chicago Hilton
THE PHARMACEUTICAL INDUSTRY AND THE APA: CONTROVERSIES AND APPROACHES
APA Committee on Commercial Support
Chp.: Stephen M. Goldfinger, M.D.
Participants: Jacqueline M. Feldman, M.D., Charles R. Goldman, M.D., Carol C. Nadelson, M.D., Michelle Riba, M.D., Pedro Ruiz, M.D., James H. Scully, Jr., M.D., James W. Thompson, M.D., Daniel K. Winstead, M.D., Ian E. Alger, M.D.

NEW RESEARCH POSTER SESSION 11
12 noon - 2:00 p.m.
Hall E, Level 2, McCormick Place Lakeside
MOOD, DISSOCIATIVE, SLEEP, SOMATOFORM AND OTHER DISORDERS; VIOLENCE, TRAUMA AND VICTIMIZATION; SUICIDE; AND OTHER SOMATIC THERAPIES
For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

1:00 p.m. Sessions

COURSES 96-99
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 96
Room N426 A, Level 4, McCormick Place North
MEDICARE COMPLIANCE FOR PSYCHIATRISTS
Director: Michael D. Murphy, M.D.
Faculty: Donald L. Kerste, M.D., Ralph C. Menezes, M.D., Anne M. DeFelippo, J.D.

COURSE 97
Room N427 A, Level 4, McCormick Place North
ANTICONVULSANTS IN BIPOLAR DISORDER
Co-Directors: Joseph R. Calabrese, M.D., Mark A. Frye, M.D.
Faculty: Terence A. Ketter, M.D.

COURSE 98
Room S502 A, Level 5, McCormick Place South
MALPRACTICE: HOW TO LEGALLY AND EMOTIONALLY SURVIVE LITIGATION
Co-Directors: Kenneth C. Olson, M.D., Larry Riley, J.D.

COURSE 99
Room S502 B, Level 5, McCormick Place South
CURRENT CODING AND DOCUMENTATION REQUIREMENTS
APA Committee on Codes and Reimbursements
Director: Chester W. Schmidt, Jr., M.D.

2:00 p.m. Sessions

LECTURES 20-22

LECTURE 20
2:00 p.m. - 3:30 p.m.
Room E350, Level 3, McCormick Place Lakeside
APA'S SOLOMON CARTER FULLER AWARD LECTURE
Kweisi Mfume
Chp.: Patrice A. Harris, M.D.
Co-Chp.: Michelle O. Clark, M.D.

Kweisi Mfume became President and Chief Executive Officer of the National Association for the Advancement of Colored People (NAACP) in 1996. Providing a clear blueprint for NAACP in the 21st century, Mr. Mfume has instituted a five-point action agenda that encompasses civil rights, political empowerment, educational excellence, economic development and youth outreach. Before he became President of NAACP, Mr. Mfume served for ten years in the U.S. Congress as Representative of Maryland's 7th Congressional District. In Congress, he served on the Banking and Financial Services Committee, the General Oversight and Investigations Subcommittee and the House Ethics Committee. He chaired both the Congressional Black Caucus and the Joint Economic Committee of the House and Senate and co-sponsored the Americans With Disabilities Act. During his last term, he...
was appointed by the House Democratic Caucus as Vice-Chairman for Communications. Mr. Mfume’s background in broadcasting includes 13 years in radio, and for the last six years, he has hosted the award-winning television show The Bottom Line. He has written a best-selling autobiography entitled No Free Ride: From the Mean Streets to the Mainstream. Mr. Mfume holds a master’s degree in liberal arts, with a concentration in international studies, from Johns Hopkins University in Baltimore.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 21
2:00 p.m. - 3:30 p.m.
Room E353 A/B, Level 3, McCormick Place Lakeside

APA’S SIMON BOLIVAR AWARD LECTURE
Rodrigo A. Muñoz, M.D.

The Shaky Foundations of Managed Care
Chp.: Oscar E. Perez, M.D.
Co-Chp.: Ana E. Campo-Bowen, M.D.

The era of managed care that began in the 1970s produced new rules that eventually controlled most of medicine in subsequent decades. Rodrigo A. Muñoz, M.D., critiques the ideas of Paul M. Ellwood, M.D., and Alain C. Entrovon, Ph.D., whose writings helped form the foundations of managed care. He also discusses the American Psychiatric Association’s proposed responses to the uncertain future of managed care. Dr. Muñoz is Clinical Professor of Psychiatry at the University of California, San Diego, and Medical Director of the Day Treatment Program at Mercy Hospital and Medical Center in San Diego. He has held several offices within APA, including President (in 1996-1999), Vice-President, Trustee-at-Large, Chairperson of the Committee on Foreign Medical Graduates and Chair of the Nominating Committee. A Fellow of APA, the American College of Psychiatry and the Pacific Rim College of Psychiatrists. Dr. Muñoz has received the Distinguished Service Award from the American Academy of Clinical Psychiatrists, the Presidential Commendation and George Tarjan Award from APA, and the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill. Dr. Muñoz received his medical degree from the University of Cauca in Popayán, Colombia, and completed residencies in psychiatry at the Mental Hospital in Medellín, Columbia, Fairfield Hills Hospital in Newton, Connecticut, and Washington University in St. Louis, Missouri.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 22
2:00 p.m. - 3:30 p.m.
Room E353 C, Level 3, McCormick Place Lakeside

Herman M. van Praag, M.D.

Anxiety/Aggression-Driven Depression: The Importance of Functionalization and Verticalization of Psychiatric Diagnosing
Chp.: Juan J. Lopez-Ibor, Jr., M.D.
Co-Chp.: Evanisto O. Akerele, M.D.

Using the example of a proposed subtype of depression characterized by dysregulation of anxiety and aggression, Herman M. Van Praag, M.D., describes a novel approach to the diagnosis of mental disorders and discusses ways it can facilitate research into the relationship between abnormal neurobiological and psychological functions. A pioneer in the field of biological psychiatry and psychopharmacology, Dr. Van Praag is currently Scientific Advisor to the Department of Psychiatry and Neuropsychology of the Academic Hospital in Maastricht, the Netherlands, and the Brain and Behavior Research Institute at Maastricht University. His research in the 1950s on the brain serotonergic system helped lay the foundation for the development of the selective serotonin reuptake inhibitors. Dr. Van Praag has devoted himself to critical analysis of the diagnostic process and diagnostic principles in psychiatry and has made important contributions to this revaluation process. He is the author or coauthor of more than 550 scientific papers and six books. A Fellow of the American Psychiatric Association, Dr. Van Praag was knighted by Queen Beatrix of the Netherlands in 1990. He received his medical degree from the State University in Leiden and his doctoral degree in neurobiology from the University of Utrecht in the Netherlands.

International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

MEDIA SESSIONS 23-24

MEDIA SESSION 23
2:00 p.m. - 5:00 p.m.
Room E351, Level 3, McCormick Place Lakeside

A CINEMA MASTERPIECE FROM INDIA: THE WORLD OF APU
Chp.: Gopalakrishna K. Upadhya, M.D.

34 The World of Apu (101 minutes)
Distributor: New Yorker Films
C/o Linda Duchin
16 West 61st Street, 11th Floor
New York, NY 10023

(Continued on next page)
Set in India in the 1930s, this film is the conclusion of the wondrous trilogy (the first two installments are Pather Panchali and Aparajito) from the great Satyajit Ray, perhaps Indian cinema's greatest director. Based on a novel by Bibhuti Bannerjee, this film follows the life of the young boy and his family as they deal with the tricky problem of arranged marriage. The trilogy's protagonist, Apu, is now grown up and has finished his schooling. His attempts to get a job are constantly thwarted by a single-minded bureaucracy, and his life becomes even more complicated when, in a visit to his cousin's wedding, he is talked into marrying the girl himself when the groom has a seizure during the ceremony. The film then follows the two newlyweds and explores the love that grows between them, the tragedy that befalls Apu and the completion of the cycle as he attempts to become reunited with his own son after several years of estrangement. Although the story appears simple, its delineation of character makes the film seem timeless, placeless and a fair telling of the pains of love and subsequent troubles. This film is on a par with its predecessors in terms of knowing insight, poetic imagery and ability, but surpasses them in sheer craftsmanship.

MEDIA SESSION 24
Room E352, Level 3, McCormick Place Lakeside

HOMOSEXUALITY AND THE JEWISH RELIGION
Chp.: Abba E. Borowich, M.D.

35 Trembling Before G-D
(120 minutes)
Distributor: Simcha Leib Productions
25 Bleecker Street
New York, NY 10012

Trembling Before G-D is a feature-length documentary about Hasidim and other orthodox Jews who “come out” as gays and lesbians and the ways in which they negotiate their sexuality and identity in religious communities. It also portrays those who feel they must abandon their intertwined worlds of family and faith. Shot in Israel, Brooklyn, London, Los Angeles, San Francisco and Miami, it is an international project of global implications. Never before has any film or book documented in depth these stories and struggles.

Discussants: Abba E. Borowich, M.D., Simcha L. DuBowski, Rabbi Barry Freundel

REVIEW OF PSYCHIATRY: SECTION 5
2:00 p.m. - 5:30 p.m.
Room E451, Level 4, McCormick Place Lakeside

LEARNING DISABILITIES
Chp.: Laurence L. Greenhill, M.D.

20 Learning Disabilities and the Rise of Psychiatric Disorders in Children and Adolescents
Betty B. Osman, Ph.D.

21 What Cognitive and Neurobiological Studies Have Taught Us About Dyslexia
Sally E. Shaywitz, M.D.

22 Criteria for the Diagnosis of Learning Disabilities: Psychiatric Implications
James Swanson, Ph.D.

23 Language, Reading and Motor Control Problems in ADHD: A Potential Behavior Phenotype
Rosemary Tannock, Ph.D.

SYMPOSIUM 55-78

SYMPOSIUM 55
2:00 p.m. - 5:00 p.m.
Room E253 A, Level 2, McCormick Place Lakeside

TOWARD INTEGRATION IN INTERNATIONAL CLASSIFICATION
The World Psychiatric Association
Chp.: Juan E. Mezzich, M.D.
Co-Chp.: Allan Tasman, M.D.

A World Health Organization's Perspectives on International Classification
Bedirhan Ustun, M.D., Shekhar Saxena, M.D.

B APA/DSM Perspectives on International Classification
Michael B. First, M.D.

C Chinese Perspectives on International Classification
Yuan-Fang Chen, M.D.

D World Psychiatric Association and International Cooperation on Psychiatric Classification
Juan E. Mezzich, M.D., Ahmed M.F. Okasha, M.D., Sing Lee, M.D., Petr Smolik, M.D.

E Latin American Views on International Classification
Carlos Berganza, Angel A. Otero, M.D., Miguel R. Jorge, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 56
2:00 p.m. - 5:00 p.m.
Room E253 B, Level 2, McCormick Place Lakeside

MANAGEMENT OF SCHIZOPHRENIA WITH COMORBID CONDITIONS
Chp.: Michael Y. Hwang, M.D.
Co-Chp.: Lewis A. Opler, M.D.

A Management of Schizophrenia with Depression
Samuel G. Siris, M.D.
WEDNESDAY

B Management of Obsessive-Compulsive Schizophrenia
Michael Y. Hwang, M.D., Miklos F. Losonczy, M.D., Merton Lee, B.S., James Crichton, M.A.

C Cognitive-Functional Rehabilitation in Older Patients
Dilip V. Jeste, M.D., Eric Granholm, Ph.D., John McQuaid, Ph.D., Barton W. Palmer, Ph.D., Robert K. Heaton, Ph.D., Thomas L. Patterson, Ph.D.

D Schizophrenia and Comorbid Substance Abuse
Douglas M. Ziedonis, M.D., David A. Smelson, Psy.D., Jonathan Krejcic, Ph.D., Jill Williams, M.D., Julie Grofis, R.N., Ilana Pinsky, Ph.D., Phyllis Reilly, M.A.

E Schizophrenia and Persistent Aggressive Behavior
Leslie L. Citrome, M.D., Jan Volavka, M.D.

Discussants: Lewis A. Opler, M.D., Javier I. Escobar, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 57
2:00 p.m. - 5:00 p.m.
Room E253 C, Level 2, McCormick Place Lakeside

NEW RESEARCH ON DELUSIONS
Chp.: Paul S. Appelbaum, M.D.

A The Continuum Between Obsessions and Delusions in OCD and BDD
Jane L. Eisen, M.D., Katharine A. Phillips, M.D., Steven A. Rasmussen, M.D.

B Are Delusions on a Continuum?
Emmanuelle Peters, Ph.D., Samantha Day, R.S.C., Philip A. Garety, Ph.D.

C Delusions: More Fluid than Fixed
Paul S. Appelbaum, M.D.

D Dimensions of Delusions: A 15-Year Follow-Up
Martin Harrow, Ph.D., Ellen S. Herberne, Ph.D., Anne V. Shankin, B.A., Thomas H. Jobe, M.D., Franoine Rattenbury, Ph.D., Kalman J. Kaplan, Ph.D.

E Social Cognition and Paranoid Delusions
Richard P. Bentall, Ph.D.

Discussant: Gary J. Tucker, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 58
2:00 p.m. - 5:00 p.m.
Room E255, Level 2, McCormick Place Lakeside

PRODROMAL INTERVENTION TO FIRST-Episode Psychosis
Chp.: Thomas H. McGlashan, M.D.

A Early Detection and Intervention: Rationale
Thomas H. McGlashan, M.D., Jan O. Johannessen, M.D.

B Description and Assessment of Prodromal States
Tandy J. Miller, Ph.D., Scott W. Woods, M.D., Larry Davidson, Ph.D., Ralph E. Hoffman, M.D., Thomas H. McGlashan, M.D.

C Help-Seeking in Families of Individuals Prodromal to Psychosis
Larry Davidson, Ph.D., Cheryl Corcoran, M.D., Connie Nikou, Psy.D., Tandy J. Miller, Ph.D., Scott W. Woods, M.D., Ralph E. Hoffman, M.D., Thomas H. McGlashan, M.D.

D Neuropsychological Markers of Susceptibility
Keith A. Hawkins, Psy.D., Ralph E. Hoffman, M.D., A. Jocelyn Ritchie, Ph.D.

E Novel Early Interventions for Prodromal States
Scott W. Woods, M.D., Bruce E. Wexler, M.D., Tandy J. Miller, Ph.D., Keith A. Hawkins, Psy.D., Walid Abi-Saab, M.D., Larry Davidson, Ph.D., Thomas H. McGlashan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 59
2:00 p.m. - 5:00 p.m.
Room E256, Level 2, McCormick Place Lakeside

PSYCHIATRIC ASPECTS OF OBESITY: UPDATE 2000
Chp.: Lisa A. Kotler, M.D.

A Review of Child and Adolescent Obesity
Lisa A. Kotler, M.D.

B Novel Antipsychotic Medications and Weight Gain
Michael J. Devlin, M.D., Merrill Simpson, Ph.D., B. Timothy Walsh, M.D.

C Treatment for Obese Patients with Binge Eating Disorder
Denise E. Wilfley, Ph.D.

D Eating Behavior in Obese Binge and Nonbinge Eaters
B. Timothy Walsh, M.D., Janet L. Guss, B.A., Harry R. Kissileff, Ph.D., Michael J. Devlin, M.D.

E Psychiatric Aspects of Obesity Surgery
L.K. George Hsu, M.D.

Discussant: Scott J. Goldsmith, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 60
2:00 p.m. - 5:00 p.m.
Room S402 A, Level 4, McCormick Place South

INTERACTIONS BETWEEN PERSONALITY AND MOOD DISORDERS
Chp.: Andres Heerlein, M.D.
Co-Chp.: Christoph Mundt, M.D.

A Personality Traits Affecting Mood Disorder Outcome
Michael H. Stone, M.D.

(Continued on next page)

77
B Hyperthymic and Cyclothymic Depressions
Hagop S. Akiskal, M.D.

C Personality and Treatment Response in Major Depression
Andres Heerlein, M.D., Paul Richter, Ph.D., Guillermo Gabler, M.D., Cristian Chaparro, M.D.

D Perfectionism, Normal Orientation and Rigidity in Depressive Patients: Consequences for Course and Therapy Response
Christoph Mundt, M.D., Matthias Backenstrass, Ph.D., Klaus Kronmueller, M.D., Peter Fiedler, Ph.D.

E Depression and Personality Disorders Over Time
Daniel N. Klein, Ph.D., Joseph E. Schwartz, Ph.D.

Symposium 61
2:00 p.m. - 5:00 p.m.
Room S402 B, Level 4, McCormick Place South

Advances in Etiology, Diagnosis, Treatment and Outcome in Major Depression
Chp.: Eric D. Peselow, M.D.
Co-Chp.: Waguih W. Ishak, M.D.

A Acute Pharmacological Treatment of Depression
Maurizio Fava, M.D.

B Biological Basis for Major Depressive Illness
Norman Sussman, M.D.

C Psychotherapies for Depression
John C. Markowitz, M.D.

D Antidepressant Prophylaxis in a Naturalistic Clinical Setting
Wieslawa Tomaszewska, M.D., Eric D. Peselow, M.D., Ronald R. Fieve, M.D.

E Recent Advances in Screening for Depressive Disorders
Waguih W. Ishak, M.D., Eric D. Peselow, M.D., Benjamin J. Sadock, M.D., Michael Z. Sobel, M.D.

Discussant: Donald F. Klein, M.D.

Symposium 62
2:00 p.m. - 5:00 p.m.
Room S403 A, Level 4, McCormick Place South

Enhancing the Physician-Patient Relationship
Chp.: Roger Peele, M.D.
Co-Chp.: Donna M. Norris, M.D.

A Education and the Physician-Patient Relationship
Carolyn B. Robinswwitz, M.D.

B From the Perspective of the Psychiatric Clinician
John S. McIntyre, M.D.

C Medical Ethic's Enhancement of the Physician-Patient Relationship
Roger Peele, M.D.

D Doctor and Patient in the Public Eye
Nada L. Stotland, M.D.

E Government Relations and the Physician-Patient Relationship
Jeremy A. Lazarus, M.D.

Discussants: Frederick K. Goodwin, M.D., Harold I. Eist, M.D.

Symposium 63
2:00 p.m. - 5:00 p.m.
Room S403 B, Level 4, McCormick Place South

NMS and Catatonia: One Syndrome or Two?
Chp.: Max Fink, M.D.
Co-Chp.: Stephan C. Mann, M.D.

A NMS As Malignant Catatonia
Teresa A. Rumans, M.D.

B Malignant Catatonia
Stephan C. Mann, M.D., Stanley N. Caroff, M.D., E. Cabrina Campbell, M.D., Henry R. Bleier, M.D., Gregory L. Fracchione, M.D., Paul E. Keck, Jr., M.D.

C Identification and Treatment of NMS
Patricia I. Rosebush, M.D., Michael F. Mazurek, M.D.

D Identifying Catatonia in Cases of NMS
Georgios Petrides, M.D.

E NMS As a Type of Catatonia: Treatment Implications
Max Fink, M.D.

F Catatonia and NMS: One Entity or Two?
Denise A.C. White, M.D.

Discussants: Denise A.C. White, M.D., Chester A. Pearlman, Jr., M.D.

Symposium 64
2:00 p.m. - 5:00 p.m.
Room S404 A, Level 4, McCormick Place South

Stress and Coping in Personality Disorders
Chp.: Andrew E. Skodol II, M.D.
Co-Chp.: Mary C. Zanarini, Ed.D.

A Life Events in Four Types of Personality Disorder
B Defensive Functioning of Borderline Patients
Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D.

C Change in Defensive Functioning and Life Stress
J. Christopher Perry, M.D., Stephen Beck, M.Psy., Barbara Zheutlin, M.S., Leveen Lapitsky, M.S., Eric M. Plakun, M.D.

D Adolescent PD and Maladaptive Transition to Adulthood
Patricia Cohen, Ph.D., Stephanie Kasen, Ph.D., Hunian Chen, M.D., Jeffrey G. Johnson, Ph.D., Andrew E. Skodol II, M.D., John M. Oldham, M.D.

Discussant: John M. Oldham, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 65 2:00 p.m. - 5:00 p.m.
Room S404 B/C, Level 4, McCormick Place South

THE DOCTOR AND PATIENTS' HUMAN RIGHTS
Chp.: Edward F. Foulks, M.D.

A Dual Loyalty and the Protection of Human Rights
Leonard Rubenstein, J.D.

B Patients' Human Rights: International Perspective
Eric Rosenthal, J.D.

C World Association for Psychosocial Rehabilitation Advocacy Work for Human Rights
Humberto L. Martinez, M.D.

D The National Alliance for the Mentally Ill's Perspective and Patients' Human Rights
Laurie M. Flynn

Discussant: Kenneth G. Busch, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 66 2:00 p.m. - 5:00 p.m.
Continental Ballroom A, Lobby Level, Chicago Hilton

CLINICAL TOPICS IN POSTPARTUM MOOD DISORDERS
Chp.: Kimberly A. Yonkers, M.D.
Co-Chp.: C. Neill Epperson, M.D.

A Detecting Postpartum Depression in a Community Clinic
Kimberly A. Yonkers, M.D.

B Paroxetine in the Treatment of Postpartum Depression
A. Chris Heath, M.D., Kimberly A. Yonkers, M.D., A. John Rush, M.D.

C Assessing the Safety of SSRIs During Breast Feeding
C. Neill Epperson, M.D., Erica Welas, M.D., Deborah Ward-O'Brien, M.S.N., Katheryn Czarkowski, M.A., Peter Jatlow, M.D., George M. Anderson, Ph.D.

D Course and Treatment of Bipolar Illness During Pregnancy and the Postpartum Period
Adele C. Viguera, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 69 2:00 p.m. - 5:00 p.m.
Boulevard Room A/B, Second Floor, Chicago Hilton

OCD UPDATE: EUROPEAN AND AMERICAN COLLABORATIONS

Chp.: Donatella Marazziti, M.D.
Co-Chp.: Eric Hollander, M.D.

A The Obsessive-Compulsive Spectrum Disorders
Eric Hollander, M.D., Concetta M. DeCaria, Ph.D., Suzanne Yoon, M.D., Charles Cartwright, M.D., Sherie Novotny, M.D., Carol Bienstock, B.A., Jared Finkell, B.A.

B Epidemiology and Treatment of OCD and Schizophrenia
Joseph Zohar, M.D., Yehuda Sasson, M.D., Vital Iaz, M.D., Miriam Chopra, M.A.

C The Role of Second Messengers in OCD
Donatella Marazziti, M.D., Silvio Presta, M.D., Irene Masala, Ph.D., Eric Hollander, M.D., Alessandra Rossi, Ph.D., Giovanni B. Cassano, M.D.

D Long-Term Treatment of OCD
Luigi Ravizza, M.D., Gaetano Maini, M.D., Umberto Albert, M.D., Filippo Bogetto, M.D.

E Advances in the Treatment of Resistant OCD
Stefano Pallanti, Ph.D., Leonardo Quercioli, M.D., Lorrin M. Koran, M.D., Floyd R. Sallee, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 70 2:00 p.m. - 5:00 p.m.
Boulevard Room C, Second Floor, Chicago Hilton

MODEL RESIDENCY PROGRAMS ON RELIGION AND SPIRITUALITY

Chp.: Francis G. Lu, M.D.
Co-Chp.: Christina M. Puchalski, M.D.

A The Religion and Spirituality in Psychiatry Curriculum at Southern Illinois University School of Medicine
Gary E. Myers, Ph.D., Karen E. Broquet, M.D.

B The Georgetown Curriculum on Religion, Spirituality and Psychiatry
Thomas Zaubler, M.D., Alleen P. Oandasan, M.D.

C The Cleveland Clinic Curriculum on Spirituality, Culture and Psychiatry
David S. Rue, M.D.

D The Curriculum on Religion, Spirituality and Psychiatry at East Tennessee State University
Brent R. Coyle, M.D.

E University of Pennsylvania Child and Adolescent Psychiatry Curriculum on Religion
Mary L. Dell, M.D.

F Spirituality and Education: A Primer for Child and Adolescent Psychiatric Consultants and the Wright State University Curriculum
David M. Rube, M.D.

G Teaching Psychiatric Residents About the Role of Spirituality in Practice
Nancy K. Morrison, M.D.

Discussant: David B. Larson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 71 2:00 p.m. - 5:00 p.m.
Joliet Room, Third Floor, Chicago Hilton

CLINICAL FEATURES OF OCD: FAMILY STUDY PERSPECTIVE

Chp.: Gerald Nestadt, M.D.
Co-Chp.: Mark A. Riddle, M.D.

A Familial Nature of OCD
Gerald Nestadt, M.D., Jack F. Samuels, Ph.D., Oscar J. Bienvenu III, M.D., Mark A. Riddle, M.D., Marco A. Grados, M.D., Rudolf Hoehn-Saric, M.D., Kung-Yee Liang, Ph.D.

B OCD, Anxiety and Affective Disorders
Mark A. Riddle, M.D., Gerald Nestadt, M.D., Jack F. Samuels, Ph.D., Oscar J. Bienvenu III, M.D., Marco A. Grados, M.D., Rudolf Hoehn-Saric, M.D., Bernadette Cullen, M.D.

C A Family Study of Obsessive-Compulsive Spectrum Disorders
Oscar J. Bienvenu III, M.D., Gerald Nestadt, M.D., Jack F. Samuels, Ph.D., Mark A. Riddle, M.D., Marco A. Grados, M.D., Bernadette Cullen, M.D., Rudolf Hoehn-Saric, M.D.

D OCD and Tics
Marco A. Grados, M.D., Gerald Nestadt, M.D., Jack F. Samuels, Ph.D., Oscar J. Bienvenu III, M.D., Mark A. Riddle, M.D., Rudolf Hoehn-Saric, M.D., Kung-Yee Liang, Ph.D.

E Personality and Personality Disorders in OCD
Jack F. Samuels, Ph.D., Gerald Nestadt, M.D., Oscar J. Bienvenu III, M.D., Mark A. Riddle, M.D., Bernadette Cullen, M.D., Rudolf Hoehn-Saric, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 72 2:00 p.m. - 5:00 p.m.
Marquette Room, Third Floor, Chicago Hilton

LONG-TERM CONSEQUENCES OF CHILDHOOD SEXUAL ABUSE

Chp.: Catherine Classen, Ph.D.

A Dysfunctional Sexual Behavior and Sexual Abuse
John N. Briere, Ph.D., Diana Elliott, Ph.D.
B Sexual Revictimization in Survivors of Child Sex Abuse
Catherine Classen, Ph.D., Cheryl Koopman, Ph.D., Kirsten Nevill-Manning, Nigel Field, Ph.D., Lisa Butler, Ph.D., David Spiegel, M.D.

C Substance-Abusing Women and Sexual Abuse
Rita K. Teusch, Ph.D.

D Sex Abuse and Medical Utilization: Clinical Implications
Bruce A. Arnow, Ph.D., Stacey Hart, Ph.D.

E Treating Somatization Related to Child Abuse
Elizabeth S. Bowman, M.D.

Discussant: David Spiegel, M.D.

SYMPOSIUM 73
2:00 p.m. - 5:00 p.m.
PDR 2, Third Floor, Chicago Hilton

NEUROANATOMY AND NEUROENDOCRINOLOGY OF PTSD
Chp.: Rachel Yehuda, Ph.D.
Co-Chp.: J. Douglas Bremner, M.D.

A Analyzing Biologic Changes Over the Course of Chronic PTSD
Rachel Yehuda, Ph.D., Heidi S. Resnick, Ph.D., Julia A. Goller, M.D., A. McFarlane, Robert A. Grossman, M.D.

B Hippocampus and HPA in Abuse-Related PTSD
J. Douglas Bremner, M.D., Meena Narayan, M.D., Thomas H. McGlashan, M.D., George R. Heninger, M.D., Ann M. Rasmussen, M.D., Steven M. Southwick, M.D., Dennis S. Charney, M.D.

C Neurobiology of PTSD in Aging Trauma Survivors
Julia A. Goller, M.D., Rachel Yehuda, Ph.D., Mony deLeon, Ph.D., Susan DeSantis, Ph.D., Antonio J. Convit, M.D.

D Hippocampus in Twins Discordant Recombat and PTSD
Mark W. Gilbertson, Ph.D., Martha E. Shenton, Ph.D., Natasha B. Lasko, Ph.D., Scott P. Orr, Ph.D., Roger K. Pitman, M.D.

E Hydrocortisone PET Imaging in PTSD
Robert A. Grossman, M.D., Rachel Yehuda, Ph.D., Nelly Sta-Maria, M.A., Richard Lee, M.D., Mony deLeon, Ph.D., Monte S. Buchsbaum, M.D.

Discussant: Elizabeth A. Young, M.D.

SYMPOSIUM 74
2:00 p.m. - 5:00 p.m.
Waldorf Room, Third Floor, Chicago Hilton

VULNERABILITY TO PERSONALITY DISORDERS
Chp.: James H. Reich, M.D.

A Biological Factors in Vulnerability to Personality Disorders
Kenneth R. Silk, M.D.

B The Genetic Architecture of Personality Disorder Traits
John Livesley, M.D., Kerry L. Jang, Ph.D.

C Borderline Pathology: A Childhood Precursor of Personality Disorders
Joel F. Paris, M.D., Jaswant Guzder, M.D., Phyllis Zeikowitz, Ph.D., Ron Feldman, M.D.

D Family History and Vulnerability to Personality Disorder
James H. Reich, M.D.

E Behavioral Schema and Personality Dysfunction
Marsha M. Linehan, Ph.D.

Discussant: Giovanni de Girolamo, M.D.

SYMPOSIUM 75
2:00 p.m. - 5:00 p.m.
Williford Room C, Third Floor, Chicago Hilton

TRAUMA AND THE DEVELOPMENT OF DISORDERED EATING
Chp.: Timothy D. Brewerton, M.D.

A Behavior Therapy in Post-Traumatic Feeding Disorders
Diane Benoit, M.D.

B Disordered Eating in Children with Alleged Maltreatment
Timothy D. Brewerton, M.D., Elizabeth Ralston, Ph.D., Michelle Dean, M.A., Lisa D. Hand, M.D.

C Sexual Abuse and Eating Disturbances in Children
Stephen A. Wonderland, Ph.D., Ross D. Crosby, Ph.D., Jennifer Roberts, M.S., James E. Mitchell, M.D., Beth Hassel, M.S., Kevin Thompson, Ph.D., Gail DeMuth, R.N.

D Atypical Depression Associated with Early Parental Strain
Robert D. Levitan, M.D., Tess Sheldon, M.S.C., Sagar V. Parikh, M.D., Elizabeth H.B. Lin, M.D., Paula N. Goering, Ph.D.

E Trauma and Neurobiological Status in Bulimia Nervosa
Howard Steiger, Ph.D., Naomi Kermer, B.A., Ninh Ying Koon Ng, Ph.D., Mimi Israel, M.D., Pascale Lehoux, M.A., Simon Young, Ph.D.

Discussant: Michael Strober, Ph.D.

SYMPOSIUM 76
2:00 p.m. - 5:00 p.m.
Lake Erie Room, Eighth Floor, Chicago Hilton

ADOLESCENTS AND THE MEDIA IN THE NEW MILLENNIUM
Chp.: Norman E. Alessi, M.D.
Co-Chp.: Donna M. Woods, M.D.

A Adolescents and the Media: An Introduction
Victor Strasburger, M.D.

B Vietnam and Littleton: Violent Video Games and Murder Simulators
David Grossman

(Continued on next page)
C Teen Violence and the Internet  
Norman E. Alessi, M.D.

D Adolescent Sexuality, the Media and the Internet  
Donna M. Woods, M.D.

SYMPOSIUM 77  
2:00 p.m. - 5:00 p.m.  
Lake Huron Room, Eighth Floor, Chicago Hilton

NIHAA/NIDA/NIMH GRANTS AND CAREER DEVELOPMENT  
Chp.: Ernestine Vanderveen, Ph.D.

A Welcome and Introductory Comments  
Ernestine Vanderveen, Ph.D.

B Career Development Opportunities at NIH  
Walter L. Goldschmidt, Ph.D.

C National Research Service Award Training Programs  
Lucinda Miner, Ph.D.

D The Peer Review Process at NIH  
Mark Green, Ph.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 78  
2:00 p.m. - 5:00 p.m.  
Lake Michigan Room, Eighth Floor, Chicago Hilton

MEASURING CHANGE IN BORDERLINE PATIENTS  
Chp.: Frank E. Yeomans, M.D.

A Evaluating Suicidal and Self-Mutilating Behavior in BPD  
Barbara Stanley, Ph.D.

B Changes in Attachment, Symptoms and Personality in  
Transference Forced Psychotherapy  
Diana Diamond, Ph.D., Ken Levy, Ph.D., John F. Clarkin, M.D.,  
Pamela A. Foelsch, Ph.D., Hilary Levine

C Therapy Process Predicts Intrapsychic Structural Change  
Pamela A. Foelsch, Ph.D., Lina Normandin, Ph.D., John F.  
Clarkin, M.D., Frank E. Yeomans, M.D.

D Family Factors and BPD  
Perry D. Hoffman, Ph.D.

Discussants: Otto F. Kernberg, M.D., John F. Clarkin, M.D.

THIS SESSION WILL BE AUDIOTAPE.

TELECOMMUNICATION SESSION 4  
2:00 p.m. - 5:00 p.m.  
International Ballroom South, Second Floor, Chicago Hilton

OFFICE OF THE FUTURE  
Co-Chps.: Ronnie S. Stangler, M.D., Bertram Warren, M.D.

2:00 p.m.  
15 Overview of the Office of the Future  
Ronnie S. Stangler, M.D.

2:15 p.m.  
16 How Technology is Going to Transform the Dividing Line  
Between Research and Clinical Practice  
Joshua E. Freedman, M.D.

2:45 p.m.  
17 Personal Digital Assistants in Psychiatric Practice  
John Luo, M.D.

3:15 p.m.  
18 Privacy Issues and Technology  
Cheryl A. Chessick, M.D., Richard K. Harding, M.D.

3:45 p.m.  
19 Computer-Assisted Diagnostic Interviews  
Paul R. Miller, M.D.

4:15 p.m.  
20 The Creation of an Audiovisual Archive  
Thomas A.M. Kramer, M.D.

Discussant: Rodrigo A. Muñoz, M.D.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 12  
3:00 p.m. - 5:00 p.m.  
Hall E, Level 2, McCormick Place Lakeside

CHILD AND ADOLESCENT DISORDERS; ADDICTION  
PSYCHIATRY; BRAIN IMAGING; CONSULTATION-LIAISON AND  
EMERGENCY PSYCHIATRY; CROSS-CULTURAL, DIAGNOSTIC  
AND OTHER PSYCHIATRIC ISSUES AND DISORDERS

For further information on New Research Sessions, please refer to  
the New Research Program and Abstracts Book included in your  
registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 45-49  
INDUSTRY-SUPPORTED SYMPOSIUM 45 7:00 p.m. - 10:00 p.m.  
Room E450, Level 4, McCormick Place Lakeside

SEVEN HABITS OF HIGHLY EFFECTIVE  
PSYCHOPHARMACOLOGISTS  
Supported by Wyeth-Ayerst Laboratories

Chp.: Stephen M. Stahl, M.D.
WEDNESDAY

A Tips on How to Begin with the End in Mind, Synergize and Sharpen the Saw
Stephen M. Stahl, M.D.

B Clinical Pearls on How to Become Proactive, Understand and Then Be Understood
David V. Sheehan, M.D.

C Practical Psychopharmacologists: Put First Things First and Think Win-Win
John M. Zajecka, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 46 7:00 p.m. - 10:00 p.m.
Grand Ballroom A, Level 1, McCormick Place South

BEHAVIORAL DISTURBANCES IN DEMENTIA: CAUSES, TREATMENTS AND IMPACT
Supported by Eisai Inc., Pfizer Inc.

Chp.: Pierre N. Tariot, M.D.

A Neuroimaging in Dementia Evaluation and Research
Gary W. Small, M.D.

B Tools, Tips and Atypicals
Pierre N. Tariot, M.D.

C Psychosocial Impact of Alzheimer's Disease on the Family
Beth Smith-Boivin, M.S.

D Etiology of Behavioral Disturbances in Dementia
Murray A. Raskind, M.D.

E Can We Help Behavior Without Hurting Cognition?
Larry E. Tune, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 47 7:00 p.m. - 10:00 p.m.
Grand Ballroom B, Level 1, McCormick Place South

SCHIZOPHRENIA: ACROSS THE LIFE CYCLE
Supported by Janssen Pharmaceutica and Research Foundation

Chp.: Daniel R. Weinberger, M.D.

A Developmental Antecedents of Schizophrenia: Signposts to Causes and Prevention
Peter B. Jones, Ph.D.

B Treating the Early Stages of Schizophrenia
Jeffrey A. Lieberman, M.D.

C Schizophrenia of Childhood-Onset: Something Old and Something New
Judith H. Rapoport, M.D.

D The Evolution of Cognitive Impairment in Schizophrenia
Terry E. Goldberg, Ph.D.

E Late-Life Schizophrenia: Course and Treatment
Dilip V. Jeste, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 48 7:00 p.m. - 10:00 p.m.
Regency Ballroom, Second Floor, Hyatt Regency

ADVENTURES IN ADHD: FROM RESEARCH TO CLINICAL PRACTICE
Supported by Alza Corporation

Chp.: Timothy E. Wilens, M.D.
Co-Chp.: Joseph Biederman, M.D.

A Global Functioning in Boys with Persistent ADHD
Eric Mick, Sc.D.

B ADHD in Girls: Results from a Family Genetic Study
Joseph Biederman, M.D.

C Genetics of ADHD
Stephen V. Faraone, Ph.D.

D Psychopharmacology of Pediatric ADHD
Timothy E. Wilens, M.D.

E Pharmacotherapy of Adult ADHD
Thomas J. Spencer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 49 7:00 p.m. - 10:00 p.m.
Grand Ballroom, Second Floor, Chicago Hilton

THE ETHICS OF PSYCHIATRIC RESEARCH
Supported by Ortho-McNeil Pharmaceutical

Chp.: Paul S. Appelbaum, M.D.
Co-Chp.: B. Timothy Walsh, M.D.

A Psychiatric Research Ethics: Concepts and Data
Laura W. Roberts, M.D.

B The Use of Placebos in Studies of Depression
B. Timothy Walsh, M.D.

C The Challenge Study Controversy
William T. Carpenter, Jr., M.D., Matthew Avila, Robert R. Conley, M.D.

D Competence and Consent in Research
Paul S. Appelbaum, M.D.

E The Ethics of Psychiatric Research
Suzanne E. Vogel-Schilling, M.D.

Discussant: Steven E. Hyman, M.D.
WEDNESDAY

MEDIA SESSION 25  7:00 p.m. - 10:00 p.m.
Room E351, Level 3, McCormick Place Lakeside
CULTURAL IDENTITY ON THE TEX MEX BORDER: IMPACT ON RELATIONSHIPS PAST AND PRESENT
Chp.: Ira D. Glick, M.D.
36 Lone Star (138 minutes)
Distributor: Columbia Pictures
Sony Entertainment
10202 W. Washington Boulevard
Culver City, CA 90232

The development of a secure individual identity as part of personality development is a requisite for normal adult function. Lone Star is a movie about three sheriffs in a Texas bordertown with a past and present full of racial, ethnic, cultural, economic and gender tensions between the dominant whites, prevalent Mexicans and well-armed blacks. We follow three depressed families whose intertwined pasts are slowly revealed in the solving of a 40-year-old murder. The current sheriff believes his father (a past sheriff) might have been the killer. How this question plays out is the essence of this taut and elegant classic. This movie is clinically useful for psychiatrists who treat individuals or families and want to understand the development of character and family systems.

Discussant: Ira D. Glick, M.D.

MEDIA SESSION 26  7:00 p.m. - 10:00 p.m.
Room E352, Level 3, McCormick Place Lakeside
THE BODY IN CONTEMPORARY ART AND DANCE
Chp.: Rima Styra, M.D.
37 Alone Together (11 minutes)
Distributor: I-20 Gallery
529 West 20th Street
New York, NY 10011

The body has been a popular subject in 1990s art. Examining the presentation of the body in art can provide insights into our understanding of the body. Artists such as Kiki Smith, Mona Hatoum and Jeanne Dunning push our limits of defining the body and its boundaries. Through the lens of psychosomatic medicine, we will explore the work of contemporary artist, Spencer Tunick, who photographs individuals and large groups, sometimes hundreds, naked in public spaces. People who pose describe the experience as transformative, changing the way they view their bodies. Slides of his photographs will be shown along with this video, Alone Together, that documents the process of a group shoot in Times Square. The discussion will focus on the concept of the naked body from four perspectives: developmental, psychodynamic, sociocultural and legal.

Discussant: William F. Pirl, M.D.

38 Can't Stop Now (58 minutes)
Distributor: Filmmakers Library
Attn: Linda Gottesman
124 East 40th Street
New York, NY 10016

This film features six dancers, who at the height of their powers were among the world's most praised artists. Thanks to the vision of Jiri Kylian of Netherlands Dance Theatre III, these superb dancers have been able to continue their careers beyond the age of forty. Their remarkable performances break all stereotypes of the older dancer. These articulate men and women feel that wisdom and experience gives a depth to their performance that is out of the reach of the younger dancer. Their appreciative audiences worldwide have been touched by their spirituality and expressiveness. Among the performers featured are Karen Kain, National Dance Theater of Canada; Gary Cryst, protégé of Nureyev; Jeanne Solan, former dancer with the Harkness Ballet and collaborator of George Balanchine and Jerome Robbins. Here is a film not just for dance aficionados, but for all those who need confirmation that aging need not diminish their capabilities, but may even enhance them.
B Dine' (Navajo) Spirituality and Healing
Johnson Dennison, M.A.

C Dine' Psychiatric Practice: Religion and Spirituality
Mary H. Roessel, M.D.

D Spirituality and Culture: Its Impact in Psychiatric Practice
Edward J. Neidhardt, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 81 7:00 p.m. - 10:00 p.m.
Continental Ballroom C, Lobby Level, Chicago Hilton

SOCIAL PHOBIA: A NEGLECTED DISORDER COMES OF AGE
Chp.: Franklin R. Schneier, M.D.
Co-Chp.: Michael R. Liebowitz, M.D.

A Social Anxiety Disorder: From Neglect to the Spotlight
Michael R. Liebowitz, M.D.

B Is Social Phobia a Discrete Disorder?
Franklin R. Schneier, M.D.

C Social Anxiety Disorder: An FDA Perspective
Thomas P. Laughrren, M.D.

D Social Phobia: The Advocacy Perspective
Jerilyn Ross, M.A.

E Medicating Shyness: Enhancement or Treatment?
Peter D. Kramer, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 82 7:00 p.m. - 10:00 p.m.
Boulevard Room A/B, Second Floor, Chicago Hilton

MUSIC THERAPY: INTEGRATIVE MEDICINE FOR THE NEW MILLENNIUM
Chp.: John S. McIntyre, M.D.
Co-Chp.: Bryan C. Hunter, Ph.D.

A The Mozart Effect: Education, Medicine or Mythology?
Bryan C. Hunter, Ph.D.

B Music Therapy in the Treatment of Alzheimer's-Type Dementia
Alicia A. Clair, Ph.D.

C Music Therapy in Neurologic Rehabilitation: A Scientific Model of Rhythmicity in Brain Function
Michael H. Thaut, Ph.D.

D Music Therapy in Oncology: Psychosocial Care and Pain Management
Deforia L. Lane, Ph.D.

E The Use of Vocal Improvisation in Analytically Oriented Music Therapy
Diane S. Austin, M.A.
Discussant: Richard Kogan, M.D.
THIS SESSION WILL BE AUDIOTAPED.
INSTITUTE OBJECTIVES: At the conclusion of the 2000 Institute on Psychiatric Services, participants will better understand about clinical aspects of psychiatry in the current health care system, and clinical applications in private practice and other settings.

Did you know that...

★ The 1999 Institute received the highest attendee-rated evaluations?
★ APA members receive a 40% discount on their cost for registration?
★ All scientific sessions will be held in the Philadelphia Marriott Hotel?
★ Industry-Supported Breakfast, Lunch and Dinner Symposia are presented each day?
★ You can earn up to 48 hours of category 1 credit for attending the Institute?
★ There are prize drawings, beverages and receptions held daily in the exhibit hall?

For further information, please write to:

Office to Coordinate Annual Meetings
American Psychiatric Association
1400 K Street, N.W.
Washington, DC 20005
Telephone: 1 (888) 357-7924 (Toll Free)
Fax: (202) 682-6345

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 48 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
THURSDAY, MAY 18, 2000

153rd ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 40-44

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 40, PART 2
7:00 a.m. - 8:30 a.m.
Room E450, Level 4, McCormick Place Lakeside
WHY DO ANXIOUS PEOPLE BECOME DEPRESSED? THE ROLE OF STRESS SUPERSENSITIVITY
Supported by Wyeth-Ayerst Laboratories
Chp.: Philip T. Ninan, M.D.
A Neural Circuits Underlying Anxiety and Depressive Disorders
Ned H. Kalin, M.D.
B Experimental Models of Anxiety and Depression
Trevor Robbins, Ph.D.
C Management of Complex Anxiety and Depression
Philip T. Ninan, M.D.
Discussant: Philip T. Ninan, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 41, PART 2
7:00 a.m. - 8:30 a.m.
Grand Ballroom A, Level 1, McCormick Place South
CLINICAL CHALLENGES AND CHOICES IN THE TREATMENT OF ADD/ADHD
Supported by Shire Richwood
Chp.: Laurence L. Greenhill, M.D.
A Emerging Technologies for the Treatment of ADD/ADHD
James Swanson, Ph.D.
B Evidence-Based Stimulant Treatments for ADHD
Laurence L. Greenhill, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42, PART 2
7:00 a.m. - 8:30 a.m.
Grand Ballroom B, Level 1, McCormick Place South
THE MENTAL HEALTH OF WOMEN AND CHILDREN
Supported by U.S. Pharmaceuticals, Pfizer Inc.
Chp.: Karen D. Wagner, M.D.
A Considerations Regarding the Course of Social Anxiety Disorder
Stanley P. Kutchler, M.D.
B Family Violence in the U.S.
Bruce D. Perry, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 43, PART 2
7:00 a.m. - 8:30 a.m.
Regency Ballroom, Second Floor, Hyatt Regency
THE INTERFACE OF NEUROPSYCHIATRIC DISORDERS IN THE ELDERLY
Supported by Eli Lilly and Company
Chp.: Jacobo E. Mintzer, M.D.
Co-Chp.: Ian G. McKeith, M.D.
A Assessment of Cognition in Schizophrenia: What We Learn from Alzheimer's Disease and Other Dementias
Richard C. Mols, Ph.D.
B Treatment of Cognitive Deficits in Schizophrenia with Antipsychotic Drugs
Scot E. Purdon, Ph.D.
C Translating Academia's Impact on the Future of Clinical Practice
Barry D. Lebowitz, Ph.D.
Discussant: Barry D. Lebowitz, Ph.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 44, PART 2
7:00 a.m. - 8:30 a.m.
Grand Ballroom, Second Floor, Chicago Hilton
BREAKING THE CYCLE: NOVEL TREATMENTS IN BIPOLAR DISORDER
Supported by Janssen Pharmaceutica and Research Foundation
Chp.: Joseph R. Calabrese, M.D.
A Update on the Use of Topiramate in Bipolar Disorder
Joseph R. Calabrese, M.D.
B The Use of Atypical Antipsychotic Agents in Bipolar Disorder
S. Nassir Ghaemi, M.D.

8:00 a.m. Sessions

COURSES 100-103
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

(Continued on next page)
COURSE 100 8:00 a.m. • 12 noon
Room S501 D, Level 5, McCormick Place South

BEHAVIORAL NEUROANATOMY: AN INTRODUCTION

Director: Nashaat N. Boutros, M.D.
Faculty: David L. Clark, Ph.D., Edward C. Lauterbach, M.D.

COURSE 101 8:00 a.m. - 12 noon
Room S502 A, Level 5, McCormick Place South

ADOLESCENT VIOLENCE: TREATMENT APPROACHES

Director: Maria C. Sauzier, M.D.

COURSE 102 8:00 a.m. • 12 noon
Room S503 A, Level 5, McCormick Place South

NEUROLEPTIC-INDUCED MOVEMENT DISORDERS:
ASSESSMENT AND TREATMENT

Director: Leonardo Cortese, M.D.
Faculty: Richard Williams, M.D., Michael Caligiuri, Ph.D.

COURSE 103 8:00 a.m. • 12 noon
Room S504 A, Level 5, McCormick Place South

BALINT GROUP: UNDERSTANDING THE DOCTOR AND PATIENT

Director: Geoffrey M. Margo, M.D.
Faculty: Katherine Margo, M.D., Laurel C. Milberg, Ph.D., C. Paul Scott, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 4
9:00 a.m. - 10:30 a.m.
Williford Room C, Third Floor, Chicago Hilton

WOMEN AND ADDICTION: ENHANCING MOTIVATION FOR CHANGE

Moderator: Tedra L. Anderson-Brown, M.D.
Presenter: Tanya R. Cheevers, M.D.
Discussants: Mary C. Cole, M.S.W., David M. McDowell, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 104-105
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 104 9:00 a.m. - 4:00 p.m.
Room S501 B/C, Level 5, McCormick Place South

PSYCHOTHERAPY OF BORDERLINE PERSONALITY

Co-Directors: Otto F. Kernberg, M.D., Frank E. Yeomans, M.D.
Faculty: John F. Clarkin, M.D.

COURSE 105 9:00 a.m. • 4:00 p.m.
Room S504 D, Level 5, McCormick Place South

AFFECT, EMPATHY AND THE HEALING RELATIONSHIP: THE TOMKINS SYSTEM

Co-Directors: Susan L. Deppe, M.D., Jonathan L. Grindlinger, M.D.
Faculty: Donald L. Nathanson, M.D.

DISCUSSION GROUPS 18-19
9:00 a.m. • 10:30 a.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

18 Richard J. Goldberg, M.D., on Financial Management Challenges for Psychiatry 2000
Room 4G, Fourth Floor, Chicago Hilton

19 Keh-Ming Lin, M.D., on Individual and Ethnic Variations in Psychotropic Responses
Room 4I, Fourth Floor, Chicago Hilton

LECTURES 23-24

LECTURE 23
9:00 a.m. - 10:30 a.m.
Room E350, Level 3, McCormick Place Lakeside

APA'S BENJAMIN RUSH AWARD LECTURE

Ronald L. Numbers, Ph.D.
Millennial Madness: Religion and Insanity in American History
Chp.: Richard J. Thurrell, M.D.
Co-Chp.: Robert W. Baker, M.D.
During the mid-19th century, American asylum superintendents so frequently made the diagnosis of "religious insanity" for members of millennial groups and others who were obsessed with Biblical prophecies that it ranked among the leading causes of institutionalization. Ronald L. Numbers, Ph.D., examines the history of thinking about religion and mental illness in American medicine, down to the present day, when critics continue to question the mental health of ardent fanatics - from Jehovah's Witnesses to Branch Davidians. Dr. Numbers is the Hilldale and William Coleman Professor of the History of Science and Medicine and chair of the Department of the History of Medicine at the University of Wisconsin-Madison. He has written or edited more than two dozen books, including *The Creationists: Darwinism Comes to America* and *Disseminating Darwinism: The Role of Race, Religion, and Gender*. He is currently writing a history of science in America, editing a series of monographs on the history of medicine, science and religion for the Johns Hopkins University Press and coediting the eight-volume *Cambridge History of Science*. A Fellow of the American Academy of Arts and Sciences, Dr. Numbers is currently President of the History of Science Society.

**LECTURE 24**

9:00 a.m. - 10:30 a.m.

Room E353 C, Level 3, McCormick Place Lakeside

Francine Cournos, M.D.

City of One: A Memoir of Childhood Loss and Its Aftermath

Chp.: Philip R. Muskin, M.D.

Francine Cournos, M.D., is Professor of Clinical Psychiatry at Columbia University and Director of the Washington Heights Community Service at the New York State Psychiatric Institute in New York City. She is the author of *City of One: A Memoir*, published in 1999, which describes her experiences of being orphaned at age 11 and growing up in foster care. In this lecture, Dr. Cournos integrates her personal story of loss with the literature on childhood bereavement, including perspectives from psychoanalysis and empirically-based studies of bereaved children. She examines the implications of childhood parental loss for childhood and adult mental illnesses and the capacity for intimacy in adult life. Dr. Cournos is the author of more than 60 published papers and book chapters. Her preferred topics include involuntary treatment, capacity to consent to treatment, AIDS among persons with severe mental illness, as well as many others. In the last few years, she has become involved in planning for the care of orphans left by the AIDS epidemic. It was this experience that spurred her to write about her own experiences of early loss. Dr. Cournos graduated from New York University School of Medicine and completed her residency in psychiatry at the New York State Psychiatric Institute. Distinguished Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.
A suicide in the family is completely devastating for many reasons. Not only has a loved one died, but the pain of knowing they suffered in life is almost unbearable. Even in the face of such trauma people do survive. You will meet family members in this video and find out how each of them copes differently. This program can help survivors of suicide see that they can make it through their grief. It is also excellent training for those who are learning to help suicide survivors.

MEDIAS SESSION 28
9:00 a.m. - 11:00 a.m.
Room E352, Level 3, McCormick Place Lakeside

AMERICAN INDIAN MASCOTS IN SPORTS: MENTAL HEALTH IMPLICATIONS
Chp.: Francis G. Lu, M.D.

The Atlanta Braves, Kansas City Chiefs, Washington Redskins and Cleveland Indians all bear American Indian nicknames. American Indian nicknames and mascots have been used in sports for years. So what's wrong? Find out in this moving, award-winning documentary. *In Whose Honor* takes a critical look at the long-running practice of "honoring" American Indians by using them as mascots and nicknames in sports. It follows the remarkable story of Charlene Teters (Spokane) and her transformation from a graduate student at the University of Illinois into a national movement leader. *In Whose Honor* examines the issues of race, stereotypes, minority representation and the powerful effects of mass-media imagery and also shows the extent to which one community will go to defend and justify its mascot.

Discussants: Jay Rosenstein, Carol Spindel

NEW RESEARCH ORAL/SLIDE SESSIONS 13-14
9:00 a.m. - 10:30 a.m.

13 SUBSTANCE ABUSE
Room E255, Level 2, McCormick Place Lakeside

14 PSYCHOPHARMACOLOGY
Room E256, Level 2, McCormick Place Lakeside

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.
THURSDAY

COMPONENT WORKSHOP 48 9:00 a.m. - 10:30 a.m.
Room 4D, Fourth Floor, Chicago Hilton

PSYCHIATRIC SCOPE OF PRACTICE AND ITS IMPLICATIONS
APA Committee on Workforce Issues

Chp.: Nyapati R. Rao, M.D.
Participants: Larry R. Faulkner, M.D., Gloria Pitts, D.O., James H. Scully, Jr., M.D., Mary Kay Smith, M.D., Eva M. Szegedy, M.D., Allan Tasman, M.D.

COMPONENT WORKSHOP 49 9:00 a.m. - 10:30 a.m.
Room 4M, Fourth Floor, Chicago Hilton

THE HEALING WAYS OF THE ANISHINAABE OJIBWE PEOPLE
APA Committee of American Indian, Alaska Native and Native Hawaiian Psychiatrists

Co-Chps.: Robert C. Palmer, M.D., Blackwolf Jones, M.S.

COMPONENT WORKSHOP 50 9:00 a.m. - 10:30 a.m.
Lake Huron Room, Eighth Floor, Chicago Hilton

DOCTORS AND INMATES: PSYCHIATRIC CHALLENGE AND OPPORTUNITY
APA Consortium on Special Delivery Settings

Co-Chps.: Charles A. Meyer, Jr., M.D., Cassandra F. Newkirk, M.D.
Participants: Henry C. Weinstein, M.D., Edward A. Harrison

COMPONENT WORKSHOP 51 9:00 a.m. - 10:30 a.m.
Lake Ontario Room, Eighth Floor, Chicago Hilton

INNOVATIVE THERAPEUTICS IN CONSULTATION-LIAISON PSYCHIATRY
APA Committee on Consultation-Liaison Psychiatry and Primary Care Education

Co-Chps.: Francisco Fernandez, M.D., James L. Griffith, M.D.
Participant: Edwin H. Cassem, M.D.

ISSUES 72-83

ISSUE WORKSHOP 72 9:00 a.m. - 10:30 a.m.
Room E253 A, Level 2, McCormick Place Lakeside

FORESTS, TREES AND THERAPY: PSYCHIATRY'S PASTORAL ROLE

Chp.: Rabbi Terry Bard, Ph.D.

ISSUE WORKSHOP 73 9:00 a.m. - 10:30 a.m.
Room E253 B, Level 2, McCormick Place Lakeside

HIDDEN ABUSE: EXPLOITATION OF THE IMPAIRED ELDERLY

Chp.: Michael J. Tueth, M.D.

ISSUE WORKSHOP 74 9:00 a.m. - 10:30 a.m.
Room E253 C, Level 2, McCormick Place Lakeside

PREVENTING INCARCERATION OF MENTALLY ILL ADULTS

Chp.: J. Steven Lambert, M.D.
Participant: Robert L. Weisman, D.O.

ISSUE WORKSHOP 75 9:00 a.m. - 10:30 a.m.
Room E253 D, Level 2, McCormick Place Lakeside

PRINCIPLES OF EFFECTIVE STATE LEGISLATIVE LIAISON

Co-Chps.: Stephen M. Soltys, M.D., Geoffrey J. Mason, M.P.A.
Participants: Mark Binkley, J.D., David Rusin, M.D.

ISSUE WORKSHOP 76 9:00 a.m. - 10:30 a.m.
Room S402 A, Level 4, McCormick Place South

TERMINATION ISSUES IN A PSYCHOPHARMACOLOGY CLINIC

Chp.: Toby D. Goldsmith, M.D.
Participants: Marcia J. Kaplan, M.D., Hima B. Donepudi, M.D.

ISSUE WORKSHOP 77 CANCELLED

ISSUE WORKSHOP 78 9:00 a.m. - 10:30 a.m.
Room S403 A, Level 4, McCormick Place South

HOW TO MAKE AN EFFECTIVE PSYCHIATRIC PRESENTATION

Chp.: Phillip J. Resnick, M.D.

ISSUE WORKSHOP 79 9:00 a.m. - 10:30 a.m.
Room S404 A, Level 4, McCormick Place South

CHILD-preadolescent SUBSTANCE USE DISORDERS
National Institute on Alcohol Abuse and Alcoholism

Co-Chps.: Catherine A. Nageotte, M.D., Kevin M. Murphy, L.C.S.W.

ISSUE WORKSHOP 80 9:00 a.m. - 10:30 a.m.
Boulevard Room A/B, Second Floor, Chicago Hilton

GUERILLA INTERVIEWING: A GUIDE TO ASSESSMENT

Chp.: Gary A. Chaimowitz, M.D.
Participant: Jodi S. Lofchy, M.D.
THURSDAY

ISSUE WORKSHOP 81
9:00 a.m. - 10:30 a.m.
Boulevard Room C, Second Floor, Chicago Hilton
PTSD AND MEMORY: THE DEBATE GOES INTERNATIONAL
Chp.: Landy F. Sparr, M.D.
Participants: J. Douglas Brenner, M.D., Charles A. Morgan III, M.D.,
Luka Misevic, J.D., James K. Boehnelein, M.D.

ISSUE WORKSHOP 82
9:00 a.m. - 10:30 a.m.
Joliet Room, Third Floor, Chicago Hilton
CULTURAL ISSUES IN THE DOCTOR-PATIENT RELATIONSHIP
Co-Chps.: Jon M. Streltzer, M.D., Richard J. Castillo, Ph.D.
Participants: Robert T. Carter, Ph.D., Hoyle Leigh, M.D., J. David
Kinzie, M.D.

ISSUE WORKSHOP 83
9:00 a.m. - 10:30 a.m.
Lake Michigan Room, Eighth Floor, Chicago Hilton
APPLYING NARRATIVE THERAPY IN PSYCHIATRIC PRACTICE
Co-Chps.: Shoshana R. Sokoloff, M.D., SuEllen I. Hamkins, M.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 20-21
11:00 a.m. - 12:30 p.m.
These sessions are limited to 25 participants on a first-come,
first-served basis.
20 Elizabeth B. Weller, M.D., on Mood Disorders in Children and
Adolescents
Room 41, Fourth Floor, Chicago Hilton
21 Richard T. Suchinsky, M.D., on Emerging Issues in the
Treatment of Addictive Disorders
National Institute on Alcohol Abuse and Alcoholism
Room 4L, Fourth Floor, Chicago Hilton

LECTURES 25-26

LECTURE 25
11:00 a.m. - 12:30 a.m.
Room E359, Level 3, McCormick Place Lakeside
APA/NIMH VESTERMARK PSYCHIATRY EDUCATOR
AWARD LECTURE
Leah J. Dickstein, M.D.

Off the Wall: A Quarter Century of Opportunities for
Creativity in Psychiatric Education

Chp.: Troy L. Thompson II, M.D.
Co-Chp.: Saul M. Levine, M.D.
Leah J. Dickstein, M.D., discusses her experience in
developing a variety of formal and informal opportunities for
psychiatric education, including programs related to
students and residents' personal mental health, lectures
on mental health and gender issues for the academic
medical center community, use of videos, and exhibits of
art by students and physicians. Dr. Dickstein is Professor,
Associate Chair for Academic Affairs, and Director of the
Division of Attitudinal and Behavioral Medicine and Arts in
Medicine Program in the Department of Psychiatry and
Behavioral Sciences at the University of Louisville (KY)
School of Medicine. She is also Associate Dean for
Faculty and Student Advocacy at the School of Medicine.
A former Vice-President of the American Psychiatric
Association, Dr. Dickstein has received the Alexandra
Symonds Award from the APA and the Association of
Women Psychiatrists in recognition of her leadership in
promoting women's health and the advancement of
women. She is the author of more than 60 peer-reviewed
scientific papers and book chapters and the editor of six
books, including Career Planning for Psychiatrists. She
received her medical degree from the University of
Louisville School of Medicine and completed residencies in
psychiatry at Norton Psychiatric Clinic and Louisville
General Hospital in Louisville and at Maudsley Hospital in

LECTURE 26
11:00 a.m. - 12:30 p.m.
Room E353 C, Level 3, McCormick Place Lakeside
Francis S. Collins, M.D.
The Human Genome Project, Medicine and Society
Chp.: Carol A. Tamminga, M.D.
Co-Chp.: Jeffrey A. Berman, M.D.
The Human Genome Project is expected to produce a
working draft of the sequence of human DNA, covering 90
percent of the human genome, by the middle of the year
2000. Francis S. Collins, M.D., Director of the National
Human Genome Research Institute at the National
Institutes of Health, discusses the potential impact of this
work for identifying the genetic contributions to common
psychiatric illnesses and the clinical uses of the findings in
diagnosis and development of new treatments. Dr. Collins
is currently on leave from his position as Professor of
Internal Medicine and Human Genetics at the University of
Michigan in Ann Arbor, where he developed innovative
methods of crossing large stretches of DNA to identify
disease genes. His research team has been instrumental in
identifying the genes for cystic fibrosis, neurofibromatosis
and Huntington's Disease. Dr. Collins' accomplishments

THIS SESSION WILL BE AUDIOTAPE.
When does life become a fate worse than death? In this age of medical "miracles," an increasing number of doctors, patients and their families are being forced to deal with this troubling, complex and universal question. The Vanishing Line, a contemplative, personal film by physician/filmmaker Maren Monsen, explores the timeless implications of this modern medical dilemma. It chronicles one physician's exploration of trying to meet the needs of the dying and their families and looks at the choices involved in treating terminal illness with the right balance of technology, compassion and care.

Death: A Love Story is a unique and timely documentary that looks into the extraordinary gift that death can be when we are able to put our fears and confusions about death aside and simply sit and listen to our loved ones as they pass.

Genetic Dilemmas in Primary Care is an educational videotape for primary care clinicians (physicians, nurses, others) on the clinically relevant science and counseling skills needed to provide accurate and sensitive clinical genetic services. This video raises issues relevant to psychiatric practice. Specific goals are to: 1) provide basic scientific information about genetic medicine; 2) increase awareness of how patients understand and use probabilistic information; 3) motivate clinicians to make attitudinal and behavioral adjustments required by the psychosocial complexity of genetic medicine; 4) provide specific clinical techniques for patient decision-support; and 5) serve as a catalyst for the development of ethical, legal and clinical standards in genetic services.

Defying cultural dismissal and government censorship, a Vietnamese-American woman investigates ancestral medicines practiced by her great-uncle, an indigenous healer in Vietnam. Her inquiry into the healing of tumors, leprosy and gangrene reveals the value of this approach.
THURSDAY

SCIENTIFIC AND CLINICAL REPORT SESSIONS 28-36

SCIENTIFIC AND CLINICAL REPORT SESSION 28
11:00 a.m. - 12:30 p.m.
Room E253 C, Level 2, McCormick Place Lakeside

DIFFICULT ISSUES IN FORENSIC PSYCHIATRY

Chp.: Ruben J. Hernandez-Serrano, M.D.
Co-Chp.: Todd Moore, M.D.

11:00 a.m.
83 Detection of Malingering with the Rey Auditory Verbal Learning Test (RAVLT)
David A. Alcorn, M.D., Graeme J. Senior, Ph.D.

11:30 a.m.
84 Culture, English Proficiency and Trial Outcome
S. Peter Kim, M.D.

12 noon
85 Residential Treatment Unit: A Two-Year Study
Cristinel M. Coconcea, M.D., Frances Ray, M.H.A., Cherie Craig, M.S.N., Robert Chula, Jr., R.N.C.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 29
11:00 a.m. - 12:30 p.m.
Room E255, Level 2, McCormick Place Lakeside

DIAGNOSIS AND TREATMENT OF BIPOLAR ILLNESS: PART 2

Chp.: Geetha Jayaram, M.D.
Co-Chp.: Sarabjit Singh, M.D.

11:00 a.m.
86 Bipolar Depressive Mixed State: Delineation of a Neglected Condition
Giulio Perugi, M.D., Donato Madaro, M.D., Franco Frare, M.D., Barbara Vitale, M.D., Cristina Toni, M.D., Giuseppe Ruffolo, M.D., Hagop S. Akiskal, M.D.

11:30 a.m.
87 From Cell to Patient: Are There Common Effects on Membrane Currents by Anticonvulsants Efficacious in Treating Bipolar Rapid Cycling?
Heinz C. Grunze, M.D., Sandra Schlesiesser, M.A., Benedikt Aman, M.D., Claus Normann, M.D., Joerg Walden, M.D.

12 noon
88 Anticonvulsant Prophylaxis in a Naturalistic Clinical Setting
Eric D. Peselow, M.D., Ronald R. Fieve, M.D., Vanessa Fieve, J.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 30
11:00 a.m. - 12:30 p.m.
Room S402 B, Level 4, McCormick Place South

TREATMENT ISSUES AND MOOD DISORDERS

Chp.: Renato D. Alarcon, M.D.
Co-Chp.: Fuad J. Antun, M.D.

11:00 a.m.
89 Double-Blind Study of High-Dose Fluoxetine Versus Lithium or Desipramine Augmentation of Fluoxetine in Partial and Nonresponders to Fluoxetine
Maurizio Fava, M.D., Jonathan E. Alpert, M.D., Andrew A. Nierenberg, M.D., John J. Worthington III, M.D., Jerrold F. Rosenbaum, M.D.

11:30 a.m.
90 Cholesterol Levels in Major Depressive Disorder and Response to Fluoxetine Treatment
Shamsah B. Sonawalla, M.D., Margarita L. Delgado, B.A., Johanna A. Gordon, B.A., Albert Young, M.D., Josh A. Israel, M.D., Maurizio Fava, M.D.

12 noon
91 SSRIs and Time of Onset of Antidepressant Action
Andrew A. Nierenberg, M.D., Maurizio Fava, M.D., Jerrold F. Rosenbaum, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 31
11:00 a.m. - 12:30 p.m.
Room S403 B, Level 4, McCormick Place South

DIAGNOSTIC AND OUTCOME ISSUES IN DEPRESSION

Chp.: William T. McKinney, Jr., M.D.
Co-Chp.: Claire C. Holderness, M.D.

11:00 a.m.
92 Melancholia and Axis II Comorbidity
Joyce R. Tedlow, M.D., Megan M. Smith, B.A., Laura M. Polania, B.A., Jonathan E. Alpert, M.D., Andrew A. Nierenberg, M.D., Maurizio Fava, M.D.

11:30 a.m.
93 Clinical and Demographic Differences of Neurotic Versus Non-Neurotic Depressives
Timothy J. Petersen, Ph.D., Johanna A. Gordon, B.A., Kathryn A. Boltonari, B.A., Jonathan E. Alpert, M.D., Maurizio Fava, M.D., Andrew A. Nierenberg, M.D.

12 noon
94 Global Assessment Function and Length of Stay As Predictors of Outcome in Depression
John W. Goethe, M.D., Stephen B. Woolley, M.P.H.

THIS SESSION WILL BE AUDIOTAPED.

94
THURSDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 32
11:00 a.m. - 12:30 p.m.
Boulevard Room A/B, Second Floor, Chicago Hilton

ANXIETY: SYMPTOM OR DISORDER?
Chp.: Gabriela Cora-Locatelli, M.D.
Co-Chp.: Victor Sierra, M.D.

11:00 a.m.
95 Augmentation with Noradrenergic Agents for Treatment-Resistant Depression in Patients with OCD
Catherine L. Mancini, M.D., Michael A. Van Ameringen, M.D., Peter Farvorlad, Ph.D.

11:30 a.m.
96 Dreams in PTSD: A Review
Milton Kramer, M.D.

12 noon
97 Gender Differences: Drug Abuse and Related Anxiety
Istvan Kecskes, M.D., Zoltan Rimmer, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 33
11:00 a.m. - 12:30 p.m.
Marquette Room, Third Floor, Chicago Hilton

HORMONES AND PSYCHIATRY
Chp.: Mark J. Russ, M.D.
Co-Chp.: Diana Chapa, M.D.

11:00 a.m.
98 Treatment of Major Depression in Perimenopausal Women: Results from a Randomized, Double-Blind, Placebo-Controlled Trial of 17B-Oestradiol
Claudio N. Scares, M.D., Osvaldo P. Almeida, M.D., C.E. Fernandes, M.D., N.R. Melo, M.D., Lee S. Cohen, M.D.

11:30 a.m.
99 Cortisol and Acute Stress in Women with PTSD
Cheryl Koopman, Ph.D., Catherine Clesen, Ph.D., Sandra E. Sephton, Ph.D., Cheryl Gore-Felton, Ph.D., Lisa Butler, Ph.D., David Spiegel, M.D.

12 noon
100 Neuroactive Steroids in Chronic Fatigue Syndrome
Beverley E. Pearson-Murphy, Ph.D., A. Missagh Ghadrian, M.D., Cyndie Allison, M.S.C.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 34
11:00 a.m. - 12:30 p.m.
Williford Room B, Third Floor, Chicago Hilton

COMORBIDITY IN MOOD DISORDERS
Chp.: William Bech, M.D.
Co-Chp.: Julie Holman, M.D.

11:00 a.m.
101 Psychiatric Comorbidity in Patients Presenting for In-Vitro Fertilization
Rajesh M. Parikh, M.D., Shamsah B. Sonawalla, M.D., Firuza R. Parikh, M.D.

11:30 a.m.
102 Psychotherapy of Psychosis
Jon E. Gudeman, M.D.

12 noon
103 Familial Aggregation of Eating and Mood Disorders
James I. Hudson, M.D., Nan M. Laird, Ph.D., Rebecca A. Betensky, Ph.D., Paul E. Keck, Jr., M.D., Harrison G. Pope, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 35
11:00 a.m. - 12:30 p.m.
Room 4M, Fourth Floor, Chicago Hilton

TREATMENT ISSUES IN SCHIZOPHRENIA
Chp.: Richard Balon, M.D.
Co-Chp.: Khushro B. Unwalla, M.D.

11:00 a.m.
104 Recovery from Schizophrenia
Joseph Ventura, Ph.D., Alex J. Kopelowicz, M.D., Mark R. Vanelli, M.D., Philip Burstein, Ph.D.

11:30 a.m.
105 Antipsychotic Adherence Among Outpatients
Mark R. Vanelli, M.D., Philip Burstein, Ph.D.

12 noon
106 Adjunctive Valproate in Schizophrenia
Leslie L. Citrome, M.D., Jerome Levine, M.D., Baerbel Allingham, M.S.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 36
11:00 a.m. - 12:30 p.m.
Lake Michigan Room, Eighth Floor, Chicago Hilton

COURSE OF ILLNESS IN SCHIZOPHRENIA
Chp.: Marvin I. Herz, M.D.
Co-Chp.: Gabrielle F. Beaubrun, M.D.

11:00 a.m.
107 Neurocognition and Recovery in Schizophrenia
Thomas E. Smith, M.D., James W. Hull, Ph.D., Jonathan Huppert, Ph.D.

11:30 a.m.
108 Antisocial Comorbidity and Homelessness
Carol L.M. Caton, Ph.D., Deborah S. Hasin, Ph.D., Patrick E. Shrout, Ph.D., Alan D. Felix, M.D., Lewis A. Opler, M.D.

12 noon
109 Anhedonia in Schizophrenia: Longitudinal Analyses
Ellen S. Herbener, Ph.D., Martin Harrow, Ph.D.

THIS SESSION WILL BE AUDIOTAPE.
THURSDAY

WORKSHOPS

COMPONENTS 52-53

COMPONENT WORKSHOP 52 11:00 a.m. - 12:30 p.m.
Williford Room A, Third Floor, Chicago Hilton

FEARING AND WELCOMING THE NEW MILLENNIUM
APA Committee on History and Library
Chp.: Richard J. Thurrell, M.D.
Participants: Marc Galanter, M.D., George T. Harding IV, M.D.,
James G. Donat, Ph.D., Ronald L. Numbers, Ph.D.

COMPONENT WORKSHOP 53 11:00 a.m. - 12:30 p.m.
Lake Ontario Room, Eighth Floor, Chicago Hilton

TEACHER/LEARNER: BOUNDARIES IN MEDICAL EDUCATION
APA Rhode Island Psychiatric Society
Co-Chps.: Patricia R. Recupero, M.D., Alison M. Heru, M.D.
Participant: Marilyn Price, M.D.

ISSUES 84-92

ISSUE WORKSHOP 84 11:00 a.m. - 12:30 p.m.
Room E253 A, Level 2, McCormick Place Lakeside

DOCTOR-PATIENT RELATIONSHIP AND MALPRACTICE SUITS
Co-Chps.: Sara C. Charles, M.D., Miguel A. Leibovich, M.D.

ISSUE WORKSHOP 85 11:00 a.m. - 12:30 p.m.
Room E253 B, Level 2, McCormick Place Lakeside

AVOIDING LEGAL RISKS IN PSYCHOPHARMACOLOGY
Chp.: David W. Preven, M.D.
Participants: Amy B. Rowan, M.D., Martin G. Tracy, J.D., Vernon M.
Neppe, M.D.

ISSUE WORKSHOP 86 11:00 a.m. - 12:30 p.m.
Room E255, Level 2, McCormick Place Lakeside

THE PHYSICIAN-PATIENT RELATIONSHIP: NOT JUST MEDICATION
Chp.: Eugene J. Fierman, M.D.
Participants: Gregory G. Harris, M.D., Ann L. Potter, M.D.

ISSUE WORKSHOP 87 11:00 a.m. - 12:30 p.m.
Room S402 A, Level 4, McCormick Place South

INTENSIVE OUTPATIENT PROGRAMS
Chp.: Anand Pandya, M.D.
Participant: Mary Speiman Sciutto, M.D.

ISSUE WORKSHOP 88 11:00 a.m. - 12:30 p.m.
Room S404 A, Level 4, McCormick Place South

STALKING AND CYBERSTALKING: A RISK ASSESSMENT
Co-Chps.: John M. Deirmenjian, M.D., Philip J. Resnick, M.D.

ISSUE WORKSHOP 89 11:00 a.m. - 12:30 p.m.
Room S404 D, Level 4, McCormick Place South

AIM FOR THE RIGHT TARGET: FOCUS ON MOTIVATION
Chp.: Mary C. Cole, M.S.W.
Participant: Theresa A. Yuschok, M.D.

ISSUE WORKSHOP 90 11:00 a.m. - 12:30 p.m.
Joliet Room, Third Floor, Chicago Hilton

SPIRITUAL ISSUES IN END-OF-LIFE CARE
Co-Chps.: Christina M. Puchalski, M.D., William Breitbart, M.D.

ISSUE WORKSHOP 91 11:00 a.m. - 12:30 p.m.
Lake Erie Room, Eighth Floor, Chicago Hilton

COGNITIVE THERAPY FOR PERSONALITY DISORDERS
Chp.: Judith S. Beck, Ph.D.

ISSUE WORKSHOP 92 11:00 a.m. - 12:30 p.m.
Lake Huron Room, Eighth Floor, Chicago Hilton

NEUROANATOMY AND NEUROPHYSICS OF THE UNCONSCIOUS
Co-Chps.: Vincenzo R. Sanguineti, M.D., Stuart R. Hameroff, M.D.

12 noon Sessions

FORUMS 9-10

FORUM 9 12 noon - 1:30 p.m.
Room E253 D, Level 2, McCormick Place Lakeside

PSYCHOTHERAPY BY PSYCHIATRISTS IN A MANAGED CARE ENVIRONMENT: MUST IT BE AN OXYMORON?
APA Commission on Psychotherapy by Psychiatrists
Chp.: Norman A. Clemens, M.D.
Participants: James L. Griffith, M.D., K. Roy MacKenzie, M.D.,
John C. Markowitz, M.D.

FORUM 10 12 noon - 1:30 p.m.
Boulevard Room C, Second Floor, Chicago Hilton

SUBSTANCE ABUSE: AN INTERNATIONAL PERSPECTIVE
Chp.: Rodrigo A. Muñoz, M.D.
Participants: Pedro Ruiz, M.D., Ismael Rolden, M.D., Ivan D.
Montoya, M.D., Patricia Needle, Ph.D.
THURSDAY

NEW RESEARCH POSTER SESSION 15
12 noon - 2:00 p.m.
Hall E, Level 2, McCormick Place Lakeside

PSYCHOPHARMACOLOGY AND OTHER PSYCHIATRIC ISSUES

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

2:00 p.m. Sessions

SYMPOSIA 83-106

SYMPOSIUM 83 2:00 p.m. - 5:00 p.m.
Room E253 A, Level 2, McCormick Place Lakeside

THE CHALLENGES OF TREATING POSTPARTUM DEPRESSION
Chp.: Susanne I. Steinberg, M.D.
Co-Chp.: Mary Blehar, Ph.D.

A Sexual Abuse in Pregnant and Postpartum Women
Shaila Misri, M.D., Ariel Cantin, R.N.

B Work Discrimination by Gender and Postpartum Depression
Susanne I. Steinberg, M.D., Francois Bellavance, Ph.D., Karen Aboud, B.A., Fraida Weiskop, R.N.

C The Effects of Childbearing on Sleep, Mood and Cognitive Function
Michael W. O'Hara, Ph.D.

D Seasonal and Sleep Changes in Postpartum Depression
Jan Berle, M.D., Fred Holstten, M.D., Trond F. Aarre, M.D.

E Decision Making for Treatment of Depression in Pregnancy
Katherine L. Wisner, M.D., Alan J. Gelenberg, M.D., Henrietta L. Leonard, M.D., Deborah A. Zarin, M.D., Ellen Frank, Ph.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 84 2:00 p.m. - 5:00 p.m.
Room E253 B, Level 2, McCormick Place Lakeside

NMS 1960-2000: FORTY YEARS OF PROGRESS
Neuroleptic Malignant Syndrome Information Service
Chp.: Stanley N. Caroff, M.D.
Co-Chp.: Andrew J. Francis, Jr., M.D.

A Analysis of the North American NMS Information Service Database
Stanley N. Caroff, M.D., Stephan C. Mann, M.D., Paul E. Keck, Jr., M.D., Group NMSI Study

B Novel Antipsychotics and NMS: The United Kingdom's NMS Database
Dora D. Kohen, M.D.

C Catatonia and NMS: What is the Connection?
Andrew J. Francis, Jr., M.D.

D Hypothermia Syndromes in Psychiatry: One or Many?
Ronald J. Guriera, M.D.

E Central Dopamine Hypoactivity and the Pathogenesis of NMS
Stephan C. Mann, M.D., Stanley N. Caroff, M.D., Gregory L. Frichione, M.D., Paul E. Keck, Jr., M.D., E. Cabrina Campbell, M.D.

Discussants: Paul E. Keck, Jr., M.D., John M. Davis, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 85 2:00 p.m. - 5:00 p.m.
Room E253 C, Level 2, McCormick Place Lakeside

THERAPEUTIC RELATIONSHIP AND PSYCHOTHERAPY EFFICACY
Chp.: Arnold Winston, M.D.

A A Comparative Analysis of Therapy Outcome and Failure
Arnold Winston, M.D., J. Christopher Muran, Ph.D., Jeremy Safran, Ph.D., Lisa Wallner-Samstag, Ph.D., Elizabeth Bernbach, M.A.

B A Comparative Analysis of the Therapeutic Alliance
J. Christopher Muran, Ph.D., Eyal Rozmarin, Ph.D., Bernard Gorman, Ph.D., Jeremy Safran, Ph.D., Lisa Wallner-Samstag, Ph.D., Arnold Winston, M.D.

C Interpersonal and Attachment Perspectives on the Alliance and Outcome
Lisa Wallner-Samstag, Ph.D., J. Christopher Muran, Ph.D., Paul L. Wachtel, Ph.D., Arietta Slade, Ph.D., Jeremy Safran, Ph.D., Arnold Winston, M.D.

D Therapeutic Climate in Group Treatments for Dually Diagnosed Patients
Richard N. Rosenthal, M.D., Christian R. Miner, Ph.D., David J. Hellerstein, M.D., J. Christopher Muran, Ph.D.

Discussant: K. Roy MacKenzie, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 86 2:00 p.m. - 5:00 p.m.
Room E253 D, Level 2, McCormick Place Lakeside

COMORBID DISEASE AND MORTALITY IN SCHIZOPHRENIA
Chp.: Peter F. Buckley, M.D.
Co-Chp.: John L. Waddington, D.Sc.

A Physical Comorbidity in Schizophrenia
Pov Munk-Jorgensen, Ph.D., Henrik Ewald, Ph.D., Ole Mors, Ph.D., Prebenbo Mortensen, Ph.D.

(Continued on next page)

97
THURSDAY

B HIV and Schizophrenia
Francine Courno, M.D.

C Diabetes and Schizophrenia
Lisa B. Dixon, M.D., Anthony F. Lehman, M.D., Alicia Lucksted, Ph.D.,
Janine C. Delahanty, M.A., Leticia T. Postrado, Ph.D., Richard
goldberg, Ph.D.

D Weight Gain and Antipsychotics
Peter F. Buckley, M.D.

E Mortality and Polypharmacy in Schizophrenia
Kinsella, M.S.C.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 87  2:00 p.m. - 5:00 p.m.
Room E255, Level 2, McCormick Place Lakeside

THE BODY SELF AND ITS DISORDERS

Chp.: Gary M. Rodin, M.D.

A The Body Self: An Overview
Gary M. Rodin, M.D.

B Culture and the Body Self
Melanie A. Katzman, Ph.D.

C BDD: New Data on an Old Disorder
Katharine A. Phillips, M.D.

D Muscle Dysmorphia in Male Weightlifters
Roberto Olivardia, M.A., Harrison G. Pope, M.D., James I.
Hudson, M.D.

E Body Self-Esteem in Cancer
Mark R. Katz, M.D., Jonathan Irish, M.D., Gerald Devins, Ph.D.,
Gary M. Rodin, M.D., Patrick Gullane, M.D.

F Motivations for and Psychological Effects of Changing the
Body
Marcia K. Goin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 88  2:00 p.m. - 5:00 p.m.
Room E256, Level 2, McCormick Place Lakeside

HEALTH SERVICES USE IN SCHIZOPHRENIA: NEW DATA

Chp.: Dilip V. Jeste, M.D.
Co-Chp.: Susan M. Essock, Ph.D.

A Older Veterans with Schizophrenia: Three-Year Treatment
Outcomes
Frederic C. Blow, Ph.D., Scott Roberts, Ph.D., Kristen Barry, Ph.D.,
Laurel A. Copeland, M.P.H.

B Age-Related Comparison of Health Resource Utilization in
Women Admitted to an Acute-Care State Psychiatric Facility
Martha Sajatovic, M.D., Karl Donewirth, Dilara Sultana, M.D.,
Peter F. Buckley, M.D.

C ACT Versus Standard Case Management Clients Use
Different Services
Susan M. Essock, Ph.D.

D Are Atypical Antipsychotics Cost Effective?
Jonathan P. Lacro, Pharm.D., Thomas L. Patterson, Ph.D.,
James B. Lohr, M.D., Steve Stolley, Pharm.D., Robert V.
Ashley, B.A., Dilip V. Jeste, M.D.

E Inappropriate Nursing Home Use by Elderly with
Schizophrenia
Stephen J. Bartels, M.D., Keith Miles, M.P.A., Kristin A. Levine, Ph.D.

Discussant: Michael F. Hogan, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 89  2:00 p.m. - 5:00 p.m.
Room S402 A, Level 4, McCormick Place South

CLINICAL APPLICATIONS OF PSYCHIATRIC GENETICS

Chp.: Ming T. Tsuang, M.D.
Co-Chp.: Stephen V. Faraone, Ph.D.

A Clinical Applications of Genetic Knowledge: An Overview
Stephen V. Faraone, Ph.D.

B Applications to Clinical Issues in Schizophrenia
Ming T. Tsuang, M.D.

C Applications to Anxiety Disorders
Joseph Biederman, M.D.

D Psychiatric Genetic Counseling
Debby Wen Tsuang, M.D.

Discussants: Joseph Biederman, M.D., Debby Wen Tsuang, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 90  2:00 p.m. - 5:00 p.m.
Room S402 B, Level 4, McCormick Place South

DOCTOR-PATIENT RELATIONSHIP: PAST, PRESENT AND
FUTURE

Chp.: Irwin N. Hassenfeld, M.D.

A Doctor-Patient Relations in Nazi Germany and the Fate of
Patients
Irwin N. Hassenfeld, M.D.

B Tarasoff and the Psychiatrist-Patient Relationship
Paul S. Appelbaum, M.D.
C The Placebo Effect in the Contemporary Doctor-Patient Relationship
Walter A. Brown, M.D.

D Men Doctors/Women Patients: Problem or Potential?
Nada L. Stotland, M.D.
Discussant: Leah J. Dickstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 91 2:00 p.m. - 5:00 p.m.
Room S403 A, Level 4, McCormick Place South
MANAGED CARE AND THE PATIENT-DOCTOR RELATIONSHIP
Chp.: Donna M. Morris, M.D.

A Consumer Technology and Organized Systems of Care
Mary Jane England, M.D.

B The Changing Nature of the Doctor-Patient Relationship
Alan A. Stone, M.D.

C Developing a Communitarian Ethic
James Sabin, M.D.

D The African-American Experience in Managed Care
Donna M. Morris, M.D., Billy E. Jones, M.D.

E The Patient-Doctor Relationship: What Happened?
Leon Eisenberg, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 92 2:00 p.m. - 5:00 p.m.
Room S403 B, Level 4, McCormick Place South
NEW DEVELOPMENTS IN INTERPERSONAL PSYCHOTHERAPY
Chp.: John C. Markowitz, M.D.

A Overview of Interpersonal Psychotherapy
John C. Markowitz, M.D.

B Treating Dysthymia in Primary Care: Sertraline Versus Interpersonal Psychotherapy
Meir Steiner, M.D., Gina Browne, Ph.D., Jacqueline Roberts, M.S.C., Amiram Gafni, Ph.D., Carolyn Byrne, M.H.S.C., Barbara Bell, M.D., Edward Dunn, Ph.D.

C Maintenance Interpersonal Psychotherapy in Late-Life Depression
Charles F. Reynolds III, M.D.

D Interpersonal Psychotherapy for Perinatal Depression
Scott P. Stuart, M.D., Michael W. O'Hara, Ph.D.

E Interpersonal Psychotherapy for Social Phobia
Joshua D. Lipsitz, Ph.D.
Discussant: Myrna M. Weissman, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 93 2:00 p.m. - 5:00 p.m.
Room S404 A, Level 4, McCormick Place South
UPDATE ON THE ETIOLOGY, TREATMENT, DIAGNOSIS AND COMORBIDITY OF PANIC DISORDER
Chp.: Eric D. Peselow, M.D.
Co-Chp.: Mary T. Guardino, B.A.

A Panic Disorder Across the Life Span
R. Bruce Lydiard, M.D.

B Recent Advances in the Biology of Panic Disorder
Donald F. Klein, M.D.

C Panic Disorder in a Clinical Setting: Issues of Comorbidity
Eric D. Peselow, M.D., Mary T. Guardino, B.A., Wieslawa Tomaszewska, M.D., R. Sandlin Lowe III, M.D.

D Cognitive-Behavioral Therapy for Panic Disorder
Mark Sisti, Ph.D.

E Panic Disorder: A First-Person Account
Mary T. Guardino, B.A.
Discussants: Michael R. Liebowitz, M.D., Norman Sussman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 94 2:00 p.m. - 5:00 p.m.
Room S404 B/C, Level 4, McCormick Place South
THE DIFFICULT-TO-TREAT PSYCHIATRIC PATIENT
Chp.: Mantosh J. Dewan, M.D.

A The Difficult-to-Treat Bipolar Patient
Frederick K. Goodwin, M.D.

B Treatment-Resistant Schizophrenia
Ronald W. Pies, M.D.

C The Difficult-to-Treat PTSD Patient
Randall D. Marshall, M.D., Lee A. Fitzgibbons, Ph.D., Edna B. Foa, Ph.D.

D The Difficult-to-Treat Eating Disorder Patient
Katherine A. Halmi, M.D., Wendy A. Harris, M.D., Claire Wiseman, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 95 2:00 p.m. - 5:00 p.m.
Continental Ballroom A, Lobby Level, Chicago Hilton
TREATMENT OF SUBSTANCE USE DISORDERS IN ROUTINE CLINICAL PRACTICE
Chp.: Ivan D. Montoya, M.D.
Co-Chp.: Dace Svikis, Ph.D.

(Continued on next page)
THURSDAY

A Addiction and Co-Occurring Psychiatric Disorders
Douglas M. Ziedonis, M.D., Jill Williams, M.D., David A. Smelson, Psy.D., Maureen Kaune, M.D., John A. Williams, M.D., Brenda Rambo, B.A., Ilana Pinsky, Ph.D.

B Use of ASAM Criteria for SUD Patient Placement
David R. Gastfriend, M.D.

C Substance Use Disorders in Routine Psychiatric Practice
Ivan D. Montoya, M.D., Dace Svikis, Ph.D., Diane Herbeck, M.A., Terri L. Tanielian, M.A., Steven Marcus, Ph.D., Harold Alan Pincus, M.D.

D Treatment for Pregnant and Postpartum Drug-Dependent Women
Dace Svikis, Ph.D.

E Matching Patients to Substance Use Treatments
Thomas McLelland, Ph.D.

F Child Welfare Referral to Substance Abuse Treatment
Kathleen M. Carroll, Ph.D., Bryce Libby, Joseph P. Sheehan

Discussant: Thomas R. Kosten, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 96  2:00 p.m. - 5:00 p.m.
Continental Ballroom B, Lobby Level, Chicago Hilton

FRONTIERS IN CLINICAL ALCOHOLISM TREATMENT/BEHAVIORAL THERAPIES
National Institute on Alcohol Abuse and Alcoholism

Chp.: Richard K. Fuller, M.D.

A Enhancing Motivation for Change in Alcoholism Treatment
Carlo C. DiClemente, Ph.D.

B Cognitive-Behavioral Therapy: Status and New Directions
Gerard J. Conners, Ph.D.

C Couples Therapy for Alcoholism and Drug Abuse
Timothy J. O'Farrell, Ph.D., William Fals-Stewart, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 97  2:00 p.m. - 5:00 p.m.
Continental Ballroom C, Lobby Level, Chicago Hilton

DEPERSONALIZATION DISORDER: AN OVERVIEW

Chp.: Daphne Simeon, M.D.

A Feeling Unreal: Introduction to Depersonalization Disorder
Daphne Simeon, M.D., Orna Guralnik, Psy.D., Eric Holland, M.D., James Schneider, Ph.D.

B Autonomic Response in Depersonalization Disorder
Mauricio Sierra, M.D., Carl Senior, B.S.C., Jeffrey Dalton, Mary L. Phillips, M.D., Alyson Bond, M.D., Anthony S. David, M.D.
SYMPOSIUM 100  2:00 p.m. - 5:00 p.m.
Joliet Room, Third Floor, Chicago Hilton

IMPACT OF OLDER AGE ON HIV

Chp.: Karl Goodkin, M.D.

A  Age, Cognitive Motor Impairment and Disorder, and Functional Status in HIV
Karl Goodkin, M.D., Frances L. Wilkie, Ph.D., Mary Tyll, Ph.D., Wen Li Zheng, M.B.A., Imad Khamis, Ph.D., Joshua Cohen, B.S.

B  The Effects of Age on Cognition in HIV Infection
Frances L. Wilkie, Ph.D., Karl Goodkin, M.D., Hose Van Zullen, Ph.D., Mary Tyll, Ph.D., Diedrik Hoag, Ph.D.

C  Psychological Symptoms Among Older Men Living with HIV and AIDS
Timothy G. Heckman, Ph.D., Arlene Kochman, M.S.W., Kathleen Sikkema, Ph.D., Seth Kalichman, Ph.D., James Masten, M.S.W.

D  Older Caregivers of HIV-Affected Kin: Impact on Affect and Care
Sally J. Mason, Ph.D.

Discussant: Carl Eisdorfer, M.D.

THIS SESSION WILL BE AUDIOTAPE'D.

SYMPOSIUM 101  2:00 p.m. - 5:00 p.m.
Marquette Room, Third Floor, Chicago Hilton

COMPLEMENTARY MEDICINES AND THE PSYCHIATRIST

Chp.: Susan R. Downs, M.D.

A  Homeopathy for the Difficult-to-Treat Psychiatric Patient
Edward B. Gogek, M.D.

B  What the Psychiatrist Needs to Know About Herbs
Hyla R. Cass, M.D.

C  Acupuncture and Psychiatry
John M. Ackerman, M.D.

THIS SESSION WILL BE AUDIOTAPE'D.

SYMPOSIUM 102  2:00 p.m. - 5:00 p.m.
Waldorf Room, Third Floor, Chicago Hilton

VIOLENT PATIENTS: ASSESSMENT, MANAGEMENT AND TREATMENT

Chp.: W. Walter Menninger, M.D.

A  Violence and Mental Illness: An Overview
W. Walter Menninger, M.D.

B  Assessment and Management of the Violent Patient
Carl C. Bell, M.D.

C  Psychopharmacological Treatments for Violence
Stuart C. Yudofsky, M.D.

D  New Developments in the Duty to Protect
James C. Beck, M.D.

E  Juvenile Violence: Causes and Effects
Charles L. Scott, M.D.

F  Violence in the Workplace
Ronald Schouten, M.D., J.D.

THIS SESSION WILL BE AUDIOTAPE'D.

SYMPOSIUM 103  2:00 p.m. - 5:00 p.m.
Williford Room C, Third Floor, Chicago Hilton

DEFINING PHENOTYPES IN THE GENETIC STUDY OF OCD

Chp.: Michele T. Pato, M.D.

A  Symptom Subtypes and Family History in OCD
Margaret A. Richter, M.D., Laura J. Summerfeldt, Ph.D., Richard P. Swinson, M.D., James L. Kennedy, M.D.

B  Beyond Types: Examining the Evidence for a Dimensional Model of OCD
Laura J. Summerfeldt, Ph.D., Margaret A. Richter, M.D., Martin M. Antony, Ph.D., Richard P. Swinson, M.D.

C  OCD Phenotypes: The Role of the Sensory Phenomena
Euripedes C. Miguel, M.D., Maria C.R. Rosario-Campos, M.D., Roseli G. Shavitt, M.D., Ana G. Hounie, M.D., Marcos T. Mercadante, M.D.

D  Issues in the Genetics OCD
Michele T. Pato, M.D., Kim M. Schindler, B.S., Carlos N. Pato, M.D.

Discussant: Carlos N. Pato, M.D.

THIS SESSION WILL BE AUDIOTAPE'D.

SYMPOSIUM 104  2:00 p.m. - 5:00 p.m.
Lake Erie Room, Eighth Floor, Chicago Hilton

OUTCOMES OF DEPRESSION IN EUROPE: THE ODIN PROJECT

Chp.: Christopher F. Dowrick, M.D.
Co-Chp.: Patricia R. Casey, M.D.

A  The ODIN Project: Study, Design and Instruments
Jose Luis Vazquez-Barquero, M.D., Jose Luis Ayuso-Mateos, Lourdes Lasa

B  The ODIN Project: Epidemiology and Prevalence
Ville Lehtinen, M.D.

C  Social Support, Life Events and Prevalence of Depression
Steffen Dalgard, D.M.

(Continued on next page)
THURSDAY

D  Impact of Personality on Depression: Risk and Outcome
   Patricia R. Casey, M.D.

E  Trial of Psychological Interventions in the Community
   Christopher F. Dowrick, M.D.

Discussant: Gregory E. Simon, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 105 2:00 p.m. - 5:00 p.m.
Lake Huron Room, Eighth Floor, Chicago Hilton

MOLECULES TO MIND: PSYCHIATRY AT THE MILLENNIUM
Chp.: Julio Licinio, M.D.
Co-Chp.: Eva Redei, Ph.D.

A  DNA Information Will Individualize Patient Care
   James L. Kennedy, M.D., Vincenzo S. Basile, B.S.C., Mario
   Masellis, B.S.C., Vural Ozdemir, Ph.D., Herbert Y. Meltzer, M.D.,
   Jeffrey A. Lieberman, M.D., Fabio Maciardi, M.D.

B  Genetic Susceptibility to Psychoses
   Wade H. Berrettini, M.D.

C  Weight Dysregulation: Symptom and Side Effect
   Julio Licinio, M.D., Andre B. Negao, M.D., Paolo Prolo, M.D.,
   Ma-Li Wong, M.D.

D  Stress, Immunity and Behavior
   Esther M. Sternberg, M.D.

E  Long-Term Medical Consequences of Depression
   Philip W. Gold, M.D.

Discussants: Elliott S. Gershon, M.D., Eva Redei, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 106 2:00 p.m. - 5:00 p.m.
Lake Michigan Room, Eighth Floor, Chicago Hilton

PHARMACOTHERAPY OF IMPULSIVE PERSONALITY
   DISORDERS
Chp.: John M. Oldham, M.D.
Co-Chp.: Andrew E. Skodol II, M.D.

A  The Use of Mood Stabilizers in the Treatment of Impulsivity
   Charles L. Bowden, M.D.

B  Medication Management of Impulsive Substance Abuse
   Herbert D. Kleber, M.D.

C  Pharmacotherapy of Patients with Impulsive Personality
   Disorders
   Paul S. Links, M.D.

D  Longitudinal Patterns of Medication Utilization in BPD
   John M. Oldham, M.D., Andrew E. Skodol II, M.D., Donna S.
   Bender, Ph.D., Regina T. Dolan, Ph.D., John G. Gunderson, M.D.

E  Cognitive Therapy Techniques to Enhance Medication
   Compliance
   Judith S. Beck, Ph.D.

Discussant: Renato D. Alarcon, M.D.
THIS SESSION WILL BE AUDIOTAPED.
2000 ANNUAL MEETING
TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

DISORDERS
1. AIDS and HIV-Related Disorders
2. Alcohol and Drug-Related Disorders
3. Anxiety Disorders
4. Cognitive Disorders (Dementia, Amnestic, etc.)
5. Eating Disorders
6. Mental Retardation (Child/Adolescent/Adult)
7. Mood Disorders
8. Personality Disorders
9. Premenstrual Dysphoric Disorder
10. Schizophrenia and Other Psychotic Disorders
11. Sexual and Gender Identity Disorders
12. Sleep Disorders
13. Somatoform Disorders
14. Other Disorders Not Listed Above

PRACTICE AREAS/SETTINGS
15. Psychiatric Administration and Services: Public, Private and University

SUBSPECIALTY AREAS OR SPECIAL INTERESTS
16. Addiction Psychiatry
17. Biological Psychiatry and Neuroscience
18. Child and Adolescent Psychiatry and Disorders
19. Consultation-Liaison and Emergency Psychiatry
20. Cross-Cultural and Minority Psychiatry
21. Diagnostic Issues
22. Ethics and Human Rights
23. Forensic Psychiatry
24. Genetics
25. Geriatric Psychiatry
26. Neuropsychiatry
27. Psychiatric Education
28. Psychiatric Rehabilitation
29. Psychoanalysis
30. Research Issues
31. Social and Community Psychiatry
32. Suicide
33. Violence, Trauma and Victimization

TREATMENTS
34. Behavior and Cognitive Therapies
35. Combined Pharmacotherapy and Psychotherapy
36. Couple and Family Therapies
37. Group Therapy
38. Individual Psychotherapies
39. Psychopharmacology
40. Other Somatic Therapies
41. Treatment Techniques and Outcome Studies

OTHER ISSUES
42. Computers
43. Creativity and the Arts
44. Electronic Medical Records
45. Gender Issues
46. Health Services Research
47. Historical Questions
48. Information Technology
49. Internet
50. Lesbian/Gay/Bisexual/Transgender Issues
51. Managed Care and Health Care Funding
52. National Institute on Alcohol Abuse and Alcoholism: Alcohol Research: Achievements and Promise
53. Political Questions
54. Presidential Theme: The Doctor-Patient Relationship
55. Professional and Personal Issues
56. Religion, Spirituality and Psychiatry
57. Resident and Medical Student Concerns
58. Stigma/Advocacy
59. Telepsychiatry
60. Virtual Reality

GUIDE TO USING THE TOPIC INDEX

Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas/Settings, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this Program Book to obtain further details about the session.
<table>
<thead>
<tr>
<th>TOPIC INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DISORDERS</strong></td>
</tr>
<tr>
<td><strong>TOPIC 1: AIDS AND HIV-RELATED DISORDERS</strong></td>
</tr>
<tr>
<td><strong>MEDIA PROGRAM</strong></td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>WORKSHOP - COMPONENT</strong></td>
</tr>
<tr>
<td><strong>TOPIC 2: ALCOHOL AND DRUG-RELATED DISORDERS</strong></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>FORUM</strong></td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>TOPIC 3: ANXIETY DISORDERS</strong></td>
</tr>
<tr>
<td><strong>COURSE</strong></td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIA</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>TOPIC 4: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)</strong></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIA</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>RESEARCH CONSULTATION</strong></td>
</tr>
<tr>
<td><strong>TOPIC 5: EATING DISORDERS</strong></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>TOPIC 6: MENTAL RETARDATION (CHILD/ADOLESCENT/ADULT)</strong></td>
</tr>
<tr>
<td><strong>COURSE</strong></td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
</tr>
<tr>
<td><strong>TOPIC 7: MOOD DISORDERS</strong></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIA</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
## LECTURES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>Depression in the Medically Ill</td>
</tr>
<tr>
<td>17</td>
<td>Depression and the Indigent: Your Tired, Your Poor, Your Huddled Masses: The Depression Epidemic Among the Indigent and How to Treat It</td>
</tr>
<tr>
<td>22</td>
<td>Anxiety/Aggression-Driven Depression: The Importance of Functionalization and Verticalization of Psychiatric Diagnosing</td>
</tr>
</tbody>
</table>

## MASTER EDUCATION CLINICAL CONSULTATIONS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>Depression and Bipolar Disorder</td>
</tr>
<tr>
<td>23</td>
<td>Psychopharmacology of Patients with Mood Disorders</td>
</tr>
</tbody>
</table>

## SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>48</td>
<td>Major Depression and Mother's Marital Transition</td>
</tr>
<tr>
<td>49</td>
<td>An Open Study of Olanzapine and Fluoxetine for Psychotic Depression: Interim Analyses</td>
</tr>
<tr>
<td>71</td>
<td>Unipolar Mania: A Separate Diagnostic Entity?</td>
</tr>
<tr>
<td>71</td>
<td>Rapid Cycling: Testing Four Definitions</td>
</tr>
<tr>
<td>71</td>
<td>Compliance in Bipolar Illness</td>
</tr>
<tr>
<td>71</td>
<td>AD and Depressive Subtypes Among Adults with Major Depression</td>
</tr>
<tr>
<td>94</td>
<td>Bipolar Depressive Mixed State: Delineation of a Neglected Condition</td>
</tr>
<tr>
<td>94</td>
<td>From Cell to Patient: Are There Common Effects on Membrane Currents by Anticonvulsants Efficacious in Treating Bipolar Rapid Cycling?</td>
</tr>
<tr>
<td>94</td>
<td>Anticonvulsant Prophylaxis in a Naturalistic Clinical Setting</td>
</tr>
<tr>
<td>94</td>
<td>Double-Blind, Study of High-Dose Fluoxetine Versus Lithium or Desipramine Augmentation of Fluoxetine in Partial and Nonresponders to Fluoxetine</td>
</tr>
<tr>
<td>94</td>
<td>Cholesterol Levels in Major Depressive Disorder and Response to Fluoxetine Treatment</td>
</tr>
<tr>
<td>94</td>
<td>SSRI's and Time of Onset of Antidepressant Action</td>
</tr>
<tr>
<td>94</td>
<td>Melancholia and Axis II Comorbidity</td>
</tr>
<tr>
<td>94</td>
<td>Clinical and Demographic Differences of Neurotic Versus Non-Neurotic Depressives</td>
</tr>
<tr>
<td>95</td>
<td>Psychiatric Comorbidity in Patients Presenting for In-Vitro Fertilization</td>
</tr>
</tbody>
</table>

## SYMPOSIAS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td>Estrogen-Replacement Therapy in Menopause-Related Mood Disorders</td>
</tr>
<tr>
<td>32</td>
<td>Bipolar Depression: Clinical, Biological and Treatment Specificity</td>
</tr>
<tr>
<td>53</td>
<td>The Coming of Age of the Bipolar Spectrum</td>
</tr>
<tr>
<td>57</td>
<td>Mood and Menopause: Treating Women in Middle Life</td>
</tr>
<tr>
<td>77</td>
<td>Interactions Between Personality and Mood Disorders</td>
</tr>
<tr>
<td>78</td>
<td>Advances in Etiology, Diagnosis, Treatment and Outcome in Major Depression</td>
</tr>
<tr>
<td>79</td>
<td>Clinical Topics in Postpartum Mood Disorders</td>
</tr>
<tr>
<td>97</td>
<td>The Challenges of Treating Postpartum Depression</td>
</tr>
<tr>
<td>101</td>
<td>Outcomes of Depression in Europe: The CCN Project</td>
</tr>
</tbody>
</table>

## TOPIC 8: PERSONALITY DISORDERS

### COURSES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Disorders of the Self: Differential Diagnosis and Treatment</td>
</tr>
<tr>
<td>6</td>
<td>The Practical Management of Personality Disorder</td>
</tr>
<tr>
<td>64</td>
<td>Personality and Political Behavior</td>
</tr>
<tr>
<td>88</td>
<td>Psychotherapy of Borderline Personality</td>
</tr>
</tbody>
</table>

### REVIEW OF PSYCHIATRY

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>43</td>
<td>Psychotherapy of the Personality Disorders</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>Role of the Mother in Psychoanalytic Theories of BPD</td>
</tr>
<tr>
<td>71</td>
<td>DSM-IV Personality Disorder Criteria: Diagnostic Efficiency</td>
</tr>
<tr>
<td>71</td>
<td>Stability of Personality Disorder Diagnoses in Remitted Depressed Outpatients</td>
</tr>
<tr>
<td>95</td>
<td>Antisocial Comorbidity and Homelessness</td>
</tr>
</tbody>
</table>

### SYMPOSIAS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>32</td>
<td>Neurobiology of BPD</td>
</tr>
<tr>
<td>53</td>
<td>DSM-V Personality Disorders: Towards an Empirically-Based Dimensional Classification</td>
</tr>
<tr>
<td>78</td>
<td>Stress and Coping in Personality Disorders</td>
</tr>
<tr>
<td>81</td>
<td>Vulnerability to Personality Disorders</td>
</tr>
<tr>
<td>82</td>
<td>Measuring Change in Borderline Patients</td>
</tr>
</tbody>
</table>

## WORKSHOP-ISSUE

### INDUSTRY-SUPPORTED SYMPOSIUM

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Reproductive Psychosis: An Update on Women's Health</td>
</tr>
</tbody>
</table>

## TOPIC 10: SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS

### ADVANCES IN RESEARCH

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>Pathophysiology and Treatment of the Early Stages of Schizophrenia</td>
</tr>
<tr>
<td>22</td>
<td>Schizophrenia: Directions in Pathophysiology Research</td>
</tr>
</tbody>
</table>

### COURSES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>Drug Treatment of Schizophrenia</td>
</tr>
<tr>
<td>51</td>
<td>Assessing Positive and Negative Symptoms with the Positive and Negative Syndrome Scale</td>
</tr>
</tbody>
</table>

### INDUSTRY-SUPPORTED SYMPOSIUM

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>The Many Faces of Psychosis</td>
</tr>
<tr>
<td>3</td>
<td>Schizophrenia: From Social Isolation to Social Reintegration</td>
</tr>
<tr>
<td>9</td>
<td>Managing Patients with Acute Psychosis: An Interactive Program</td>
</tr>
<tr>
<td>13</td>
<td>From Patients to People: Redefining Wellness in Psychosis</td>
</tr>
<tr>
<td>15</td>
<td>Managing Psychoses Across the Age Spectrum (Part 1)</td>
</tr>
<tr>
<td>39</td>
<td>Managing Psychoses Across the Age Spectrum (Part 2)</td>
</tr>
<tr>
<td>60</td>
<td>Cognition in Schizophrenia: Maximizing Recovery</td>
</tr>
<tr>
<td>83</td>
<td>Schizophrenia: Across the Life Cycle</td>
</tr>
</tbody>
</table>

## LECTURES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>Schizophrenia and the Third Age: Old Controversies, New Insights</td>
</tr>
<tr>
<td>22</td>
<td>Psychology in the Post-Genome Era: A Potential Meyerian Renaissance in Schizophrenia</td>
</tr>
<tr>
<td>65</td>
<td>The Gene-Environment Interaction: Schizophrenia As an Illustrative Case</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>95</td>
<td>Recovery from Schizophrenia</td>
</tr>
<tr>
<td>95</td>
<td>Antipsychotic Adherence Among Outpatients</td>
</tr>
<tr>
<td>95</td>
<td>Neurocognition and Recovery In Schizophrenia</td>
</tr>
<tr>
<td>95</td>
<td>Anhedonia in Schizophrenia: Longitudinal Analyses</td>
</tr>
</tbody>
</table>

### SYMPOSIAS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>32</td>
<td>Treatment-Refractory Schizophrenia: A New Look</td>
</tr>
<tr>
<td>55</td>
<td>Antipsychotic Medications and Sexuality</td>
</tr>
<tr>
<td>61</td>
<td>Arab Perspective on Psychotic Disorders</td>
</tr>
<tr>
<td>76</td>
<td>Management of Schizophrenia with Comorbid Conditions</td>
</tr>
<tr>
<td>77</td>
<td>New Research on Delusions</td>
</tr>
<tr>
<td>77</td>
<td>Prophylactic Intervention to First-Episode Psychosis</td>
</tr>
<tr>
<td>97</td>
<td>Comorbid Disease and Mortality in Schizophrenia</td>
</tr>
</tbody>
</table>

### WORKSHOP-ISSUE

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>Management of Difficult Schizophrenia</td>
</tr>
</tbody>
</table>

## TOPIC 11: SEXUAL AND GENDER IDENTITY DISORDERS

### COURSE

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>64</td>
<td>The Assessment and Treatment of Child Molesters</td>
</tr>
</tbody>
</table>

### INDUSTRY-SUPPORTED SYMPOSIUM

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Sexual Dysfunction: Epidemiology, Etiology, Diagnosis and Management</td>
</tr>
</tbody>
</table>
# TOPIC INDEX

## MEDIA PROGRAM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 Addicted to Sex</td>
<td>56</td>
</tr>
<tr>
<td>12 Is Homophobia a Mental Disorder?</td>
<td>21</td>
</tr>
<tr>
<td>40 Problematic Excessive Sexual Behavior</td>
<td>50</td>
</tr>
</tbody>
</table>

## TOPIC 12: SLEEP DISORDERS

### COURSES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 Clinical Topics in Sleep Medicine</td>
<td>1</td>
</tr>
<tr>
<td>35 Overview and Update of Sleep Disorders Medicine</td>
<td>8</td>
</tr>
<tr>
<td>81 Irresistible Sleep: Narcolepsy Update</td>
<td>51</td>
</tr>
</tbody>
</table>

### INDUSTRY-SUPPORTED SYMPOSIA

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 Advances in the Treatment of Insomnia</td>
<td>7</td>
</tr>
<tr>
<td>17 Controversies at the Interface of Sleep and Psychiatry</td>
<td>9</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>78 Drug Treatment of Chronic Insomnia: Case Studies</td>
<td>72</td>
</tr>
<tr>
<td>79 The Contextualizing Image: The Center of the Dream</td>
<td>72</td>
</tr>
</tbody>
</table>

### WORKSHOP - ISSUE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 A Nonalgorithmic Approach to Insomnia Treatment</td>
<td>21</td>
</tr>
</tbody>
</table>

## TOPIC 13: SOMATOFORM DISORDERS

### COURSE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>58 The Evaluation and Management of Pain</td>
<td>28</td>
</tr>
</tbody>
</table>

## TOPIC 14: OTHER DISORDERS NOT LISTED ABOVE

### COURSE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>17 ADD in Adults</td>
<td>5</td>
</tr>
</tbody>
</table>

## PRACTICE AREAS

## TOPIC 15: PSYCHIATRIC ADMINISTRATION AND SERVICES: PUBLIC, PRIVATE AND UNIVERSITY

### COURSES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Leadership: Survival Skills for the 21st Century</td>
<td>1</td>
</tr>
<tr>
<td>22 Personnel Management for Clinicians-Managers</td>
<td>5</td>
</tr>
<tr>
<td>59 How to Take the Pain Out of &quot;Doc-to-Doc&quot; Reviews</td>
<td>28</td>
</tr>
<tr>
<td>96 Medicare Compliance for Psychiatrists</td>
<td>74</td>
</tr>
<tr>
<td>99 Current Coding and Documentation Requirements</td>
<td>74</td>
</tr>
</tbody>
</table>

### DISCUSSION GROUP

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Career Development in Administrative Psychiatry</td>
<td>17</td>
</tr>
</tbody>
</table>

### SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 Administrative Relations in Psychiatric Leadership</td>
<td>36</td>
</tr>
<tr>
<td>28 The Psychiatric Hospital in the 21st Century</td>
<td>53</td>
</tr>
<tr>
<td>41 Mergers and Integration of VA Mental Health Services</td>
<td>56</td>
</tr>
<tr>
<td>50 How to Launch a Successful Private Practice</td>
<td>56</td>
</tr>
</tbody>
</table>

### WORKSHOPS - COMPONENTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 How to Launch a Successful Private Practice: Part 1</td>
<td>20</td>
</tr>
<tr>
<td>6 Solving Management Problems in Vivo</td>
<td>20</td>
</tr>
<tr>
<td>13 Documentation Requirements and Coding Update</td>
<td>26</td>
</tr>
<tr>
<td>14 How to Launch a Successful Private Practice: Part 2</td>
<td>28</td>
</tr>
<tr>
<td>36 Certification in Psychiatric Administration</td>
<td>68</td>
</tr>
<tr>
<td>52 Fearing and Welcoming the New Millennium</td>
<td>96</td>
</tr>
</tbody>
</table>

## TOPIC 16: ADDICTION PSYCHIATRY

### COURSE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>60 Dealing with Resistance in Addiction Patients</td>
<td>28</td>
</tr>
</tbody>
</table>

### DISCUSSION GROUP

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 Network Therapy: Office Treatment for the Substance Abuser</td>
<td>22</td>
</tr>
</tbody>
</table>

### MASTER EDUCATION CLINICAL CONSULTATION

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 The Impaired Physician: Disciplinary and Therapeutic Issues</td>
<td>46</td>
</tr>
</tbody>
</table>

### MEDIA PROGRAM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>26 Repetition Compulsion</td>
<td>66</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>71 Correlates of Cigarette Smoking in Schizophrenia</td>
<td>71</td>
</tr>
<tr>
<td>71 Detoxification from Nicotine Dependence</td>
<td>71</td>
</tr>
<tr>
<td>72 High-Venous Low-Structure Individual Counselling for Substance Abuse: A Controlled Comparison</td>
<td>72</td>
</tr>
</tbody>
</table>

### SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 Evolution of Care: Schizophrenia and Substance Abuse</td>
<td>54</td>
</tr>
</tbody>
</table>

### WORKSHOP - COMPONENT

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 Residency Training: Addictions Treatment Advances</td>
<td>20</td>
</tr>
</tbody>
</table>

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>65 Addiction Psychiatrists, HMOs and Patient Relationships</td>
<td>73</td>
</tr>
<tr>
<td>89 Aim for the Right Target: Focus on Motivation</td>
<td>96</td>
</tr>
</tbody>
</table>

## TOPIC 17: BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE

### COURSES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>23 Mind at the Millennium: Consciousness and Modern Science</td>
<td>6</td>
</tr>
<tr>
<td>100 Behavioral Neuroanatomy: An Introduction</td>
<td>68</td>
</tr>
</tbody>
</table>

### INDUSTRY-SUPPORTED SYMPOSIA

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Dopamine: Beyond Schizophrenia, Tools for Treatment</td>
<td>3</td>
</tr>
<tr>
<td>22 Neurobiology of Disease: From the Lab to the Clinic</td>
<td>11</td>
</tr>
</tbody>
</table>

### LECTURE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 Novel Neurotransmitters, Drugs and Psychiatry</td>
<td>28</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORT

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 Neuroactive Steroids in Chronic Fatigue Syndrome</td>
<td>95</td>
</tr>
</tbody>
</table>

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>60 An Intercellular Neurobiology of Psychotherapy</td>
<td>69</td>
</tr>
<tr>
<td>92 Neuroanatomy and Neurophysics of the Unconscious</td>
<td>96</td>
</tr>
</tbody>
</table>

## TOPIC 18: CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS

### CLINICAL CASE CONFERENCE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 A Child with Medically Unexplained Physical Symptoms</td>
<td>16</td>
</tr>
</tbody>
</table>

### COURSES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 Advanced Child and Adolescent Psychopharmacology</td>
<td>6</td>
</tr>
<tr>
<td>40 ADD in Children and Adolescents</td>
<td>16</td>
</tr>
<tr>
<td>79 Advanced Assessment and Treatment of ADD</td>
<td>51</td>
</tr>
</tbody>
</table>
## DISCUSSION GROUP

### 20 Mood Disorders in Children and Adolescents

Page # 92

### INDUSTRY-SUPPORTED SYMPOSIUM

#### 19 Bipolar Children and Adolescents: Controversies in Diagnosis and Treatment

Page # 10

#### 41 Clinical Challenges and Choices in the Treatment of ADD/ADHD (Part 1)

Page # 63

#### 41 Clinical Challenges and Choices in the Treatment of ADD/ADHD (Part 2)

Page # 63

#### 42 The Mental Health of Women and Children (Part 1)

Page # 87

#### 42 The Mental Health of Women and Children (Part 2)

Page # 87

#### 46 Advances in ADHD: From Research to Clinical Practice

Page # 83

### LECTURES

#### 5 The Natural History of Babies

Page # 22

#### 24 City of One: A Memoir of Childhood Loss and Its Aftermath

Page # 89

### MASTER EDUCATION CLINICAL CONSULTATIONS

#### 2 ADHD in Children and Adolescents

Page # 19

#### 8 The Effects and Management of Childhood Trauma in the Transference

Page # 46

### MEDIA PROGRAMS

#### 8 Soldier Child

Page # 23

#### 10 The Other Side of Blue: The Truth About Teenage Depression

Page # 29

#### 11 Black Tar Heroin: The Dark End of the Street

Page # 29

### RESEARCH CONSULTATION

#### 3 Childhood Psychoses

Page # 93

### REVIEW OF PSYCHIATRY

#### 5 Learning Disabilities

Page # 76

### SCIENTIFIC AND CLINICAL REPORTS

#### 5 Two-Year Stability of Personality Disorder Dimensions in Adolescents

Page # 24

#### 29 Evaluating Payor Type Effects on Adolescent Care

Page # 47

#### 36 Compliance with Antidepressant Medication in Adolescent Psychiatric Patients

Page # 48

#### 37 Trends in Psychotropic Medication Use Among Youth

Page # 48

#### 62 Long-Term Treatment of ADHD with OROS Methylphenidate

Page # 71

### SYMPOSIUM

#### 76 Adolescents and the Media in the New Millennium

Page # 81

### WORKSHOPS - ISSUES

#### 46 Body Image in Adolescence: Context and Curricula

Page # 68

#### 63 Partnering with Parents: Treating Preschoolers

Page # 73

### TOPIC 19: CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY

### CONTINUOUS CLINICAL CASE CONFERENCES

#### 1 Patients with Medically Unexplained Physical Symptoms: Psychiatry and Family Medicine As Physician Partners, Part 1

Page # 17

#### 2 Patients with Medically Unexplained Physical Symptoms: Psychiatry and Family Medicine As Physician Partners, Part 2

Page # 40

### COURSES

#### 25 Psychiatry and Primary Care: Sharing Care

Page # 6

#### 82 Beyond Munchhausen: Factitious Disorders Today

Page # 51

#### 85 Factitious Disorder and Munchausen's Syndrome: Diagnosis and Treatment

Page # 64

### DISCUSSION GROUP

#### 9 Consultation-Liaison Psychiatry: Highlighting Subspecialty Options Through Discussion of Transplant Psychiatry

Page # 41

### INDUSTRY-SUPPORTED SYMPOSIUM

#### 30 Psychiatry in Uncharted Territory: Assessing and Treating Psychiatric Conditions in Medical Patients

Page # 60

### MEDICAL UPDATE

#### 4 Human Engineering of the Jarvik 2000 Heart for Psychosocial Acceptability

Page # 93

### SCIENTIFIC AND CLINICAL REPORTS

#### 23 Outcome of Liver Transplants for Patients on Methadone

Page # 25

#### 26 Is Depression a Risk for Coronary Artery Disease Onset? A Meta-Analysis

Page # 25

### SYMPOSIUM

#### 34 New Trends in Emergency Psychiatry in North America and Europe

Page # 55

### WORKSHOP - COMPONENT

#### 51 Innovative Therapeutics in Consultation-Liaison Psychiatry

Page # 91

### WORKSHOPS - ISSUES

#### 44 Shared Care: The Canadian Psychiatric Association and the College of Family Physicians of Canada Initiative

Page # 50

#### 49 A Vertically Integrated Consultation-Liaison Teaching Model

Page # 68

### TOPIC 20: CROSS-CULTURAL AND MINORITY PSYCHIATRY

### COURSES

#### 36 DSM-IV Cultural Formulations: Diagnosis and Therapy

Page # 8

#### 46 Treatment Issues for Women in Minority Groups

Page # 16

### DISCUSSION GROUP

#### 19 Individual and Ethnic Variations in Psychotropic Responses

Page # 88

### LECTURES

#### 11 The Contributions of the International Medical Graduates to American Psychiatry

Page # 41

#### 14 Mental Health Problems in Taiwan: Issues, Dilemmas and Challenges

Page # 46

### MEDIA PROGRAMS

#### 2 Three Seasons

Page # 13

#### 3 Black and Blue: Depression in the African-American Community

Page # 19

#### 4 The D Files

Page # 19

#### 5 Familias Unidos Saben

Page # 19

#### 6 Rabbit in the Moon

Page # 19

#### 15 Dancing Through Death: Monkey, Magic and Madness in Cambodia

Page # 30

#### 21 The Last Days

Page # 52

#### 36 Lone Star

Page # 84

### SCIENTIFIC AND CLINICAL REPORT

#### 15 Screening of Major Depression Among Chinese Patients in a Primary Care Setting

Page # 25

### SYMPOSIUM

#### 22 Cultural Competence at SAMHSA, CMHS and State Levels

Page # 35

#### 53 One Psychiatry, Two Cultures and Scores of Treatment Guidelines: Vive La Difference

Page # 51

#### 66 Psychiatry and Culturally Diverse Populations

Page # 79

#### 98 Urban Mental Health: International Perspective

Page # 100

### WORKSHOPS - COMPONENTS

#### 22 Racism and Psychopathology

Page # 44

#### 25 Analyze This: Psychiatry, Culture and the Media

Page # 49

#### 30 Latin America: Social and Political Turmoil and PTSD

Page # 50

#### 33 International Medical Graduates: Career Choices

Page # 67

### WORKSHOP - ISSUE

#### 71 Psychosocial Adjustment of Elderly Asian Americans

Page # 73

### TOPIC 21: DIAGNOSTIC ISSUES

### COURSES

#### 5 Advanced Interviewing Techniques

Page # 1

#### 34 Learn CHIPS: A New Children's Diagnostic Interview

Page # 8

#### 50 The Delicate Art of the Initial Interview: Traps, Roadblocks, Strategies and Solutions

Page # 17

### SCIENTIFIC AND CLINICAL REPORTS

#### 12 Characteristics of Pre-Impaired Male Physicians

Page # 24

#### 83 Detection of Malingering with the Rey Auditory Verbal Learning Test (RAVLT)

Page # 94
## TOPIC INDEX

### SYMPOSIA
- **Page #**
  - 45 The First Interview: 57
  - 55 Toward Integration in International Classification: 76

### WORKSHOP - COMPONENT
- **Page #**
  - 11 New Tools for Assessment and Diagnosis of Toddlers: 20

### WORKSHOP - ISSUE
- **Page #**
  - 80 Guerilla Interviewing: A Guide to Assessment: 91

### TOPIC 22: ETHICS AND HUMAN RIGHTS

#### COURSE
- **Page #**
  - 20 Medical Ethics: 5

#### DEBATE
- **Page #**
  - 1 Resolved: Recovery Memories Can Be Ethically and Appropriately Integrated into the Treatment of Trauma Patients: 17

#### FORUMS
- **Page #**
  - 5 Sex, Drugs (Not Rock & Roll), National and International Politics: Public Versus Private Morality: 50
  - 8 The Pharmaceutical Industry and the APA: Controversies and Approaches: 74

#### LECTURE
- **Page #**
  - 12 The Difference Between the Normal and the Pathological As a Source of Respect: Therapeutic and Ethical Implications for the Practice of Psychiatry: 42

#### SCIENTIFIC AND CLINICAL REPORT
- **Page #**
  - 11 Assessing the Impact of Research on Patients: 24

### SYMPOSIUM
- **Page #**
  - 1 International Aspects of Ethics: 30

### TOPIC 23: FORENSIC PSYCHIATRY

#### COURSES
- **Page #**
  - 1 The Psychiatrist As Expert Witness: 1
  - 63 The Detection of Malingered Mental Illness: 39
  - 86 Insanity Defense Evaluations: 64

#### LECTURE
- **Page #**
  - 1 Frontiers of Decision Making Competence: 10

#### SCIENTIFIC AND CLINICAL REPORTS
- **Page #**
  - 6 Asking the Right Questions to Find Teenage Killers: 24
  - 84 Culture, English Proficiency and Trial Outcome: 94
  - 85 Residential Treatment Unit: A Two-Year Study: 94

### SYMPOSIUM
- **Page #**
  - 10 Tragedy and Remedy: Remembering Littleton One Year Later: 32
  - 36 Recovered Memory: Law, Science and the Clinician: 55

### WORKSHOPS - COMPONENTS
- **Page #**
  - 31 Sexual Harassment: A Millennium Update: 67
  - 35 Mandatory Outpatient Treatment: Is It Worthwhile?: 68
  - 50 Doctors and the Inmate: Psychiatric Challenge and Opportunity: 91

### WORKSHOPS - ISSUES
- **Page #**
  - 1 Criminal Responsibility and Alcohol Intoxication: 21
  - 8 Child Custody Evaluations: Dilemmas and Solutions: 21
  - 13 How to Detect Deception: 26
  - 50 The Mandated Patient, Part 2: Controversies and Efficacy: 68
  - 51 Clinical and Forensic Issues in Sexual Harassment: 68

### TOPIC 24: GENETICS

#### LECTURES
- **Page #**
  - 18 Mutant Alleles of Brain Genes with Mid- to Late-Life Phenotypes: 65
  - 26 The Human Genome Project, Medicine and Society: 92

#### MEDIA PROGRAM
- **Page #**
  - 42 Genetic Dilemmas in Primary Care: 93

### SYMPOSIUM
- **Page #**
  - 89 Clinical Applications of Psychiatric Genetics: 98
  - 103 Defining Phenotypes in the Genetic Study of OCD: 101

### WORKSHOP - ISSUE
- **Page #**
  - 2 Voluntary Disclosure of Genetic Facts: 21

### TOPIC 25: GERIATRIC PSYCHIATRY

#### CLINICAL CASE CONFERENCE
- **Page #**
  - 3 An Elderly Patient with Medically Unexplained Physical Symptoms: 64

#### INDUSTRY-SUPPORTED SYMPOSIUM
- **Page #**
  - 5 Norepinephrine and Depression in the Elderly (Part 1): 3
  - 43 The Interface of Neuropsychiatric Disorders in the Elderly (Part 1): 63
  - 43 The Interface of Neuropsychiatric Disorders in the Elderly (Part 2): 87
  - 46 Behavioral Disturbances in Dementia: Causes, Treatments and Impact: 83

#### MASTER EDUCATION CLINICAL CONSULTATIONS
- **Page #**
  - 11 Assessing and Treating Patients with Alzheimer's Disease: 66
  - 12 Geriatric Psychiatry: 66
  - 15 Assessment and Treatment of Mood and Sleep Disorders in Old Age: 69

#### SCIENTIFIC AND CLINICAL REPORT
- **Page #**
  - 27 Depression in Elderly Patients with Congestive Heart Failure: Six-Month Follow-Up: 25

### TOPIC 26: NEUROPSYCHIATRY

#### COURSES
- **Page #**
  - 2 An Introduction to Clinical Neurodynamics: 1
  - 13 Psychiatric Disorders Related to Epilepsy: 5
  - 26 Clinical Neuropsychiatry: An Update (In Spanish): 6
  - 44 ECT in Neurological Disorders: 16
  - 48 Advances in Neuropsychiatry: 17
  - 52 Traumatic Brain Injury: Neuropsychiatric Assessment: 17
  - 77 Diagnostic Challenges in Neuropsychiatry: 41
  - 57 Video Review of Neuropsychiatric Conditions: 64

#### SYMPOSIUM
- **Page #**
  - 20 Psychiatric Management in Neurological Disease: 35
  - 63 NMS and Catatonia: One Syndrome or Two?: 78

### TOPIC 27: PSYCHIATRIC EDUCATION

#### DISCUSSION GROUP
- **Page #**
  - 11 Clinical Training in Psychiatry: A Moving Target: 45
<table>
<thead>
<tr>
<th>TOPIC INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td>LECTURE</td>
</tr>
<tr>
<td>25 Off the Wall: A Quarter Century of Opportunities for Creativity in Psychiatric Education</td>
</tr>
</tbody>
</table>

| MEDIA PROGRAM |
| 28 Doctor in Health and Illness | 66 |

| SYMPOSIA |
| 78 Model Residency Programs on Religion and Spirituality | 80 |
| 99 Psychodynamic Education: Should We? Can We? Do We? | 100 |

| WORKSHOPS - COMPONENTS |
| 21 ABPN Examiners and ABPN Examinees | 44 |
| 32 Residency Training in Public Service Leadership | 57 |
| 38 Teaching Psychiatry in an Ambulatory Setting | 72 |
| 53 Teacher/Learner: Boundaries in Medical Education | 96 |

| WORKSHOPS - ISSUES |
| 3 The American Board of Psychiatry and Neurology Update: A Guide Particularly for Residents to Understand the Requirements to Sit for the ABPN Examination | 21 |
| 14 Teaching Behavioral Sciences to Family Doctors | 26 |
| 15 A Primer on the New RRC Essentials for Psychiatry | 26 |
| 21 Medical Student Education: Challenge or Dilemma? | 27 |
| 24 Strategies to Better Implement the World Psychiatric Association Educational Programs | 44 |
| 39 Residency Training: International Perspectives | 50 |
| 43 Balint Groups: Psychological Learning for Physicians | 50 |
| 64 Strategies for Residency Training in Managed Care | 73 |
| 66 Integrating Mind and Body in the Undergraduate Curriculum | 73 |
| 78 How to Make an Effective Psychiatric Presentation | 91 |

| TOPIC 28: PSYCHIATRIC REHABILITATION |
| DISCUSSION GROUP |
| 2 Social Security Disability Evaluation: Let's Discuss the Issues | 17 |

| SYMPOSIUM |
| 40 Rehabilitation As a Dynamic Process | 56 |

| WORKSHOP - ISSUE |
| 18 Implementing the Recovery Paradigm and Best Practices for Persons with Serious Mental Illness | 26 |

| TOPIC 29: PSYCHOANALYSIS |
| MEDIA PROGRAM |
| 1 The Piano | 13 |

| SYMPOSIA |
| 11 The Many Faces of Transference in Everyday Clinical Care: Part 1 | 33 |
| 38 The Many Faces of Transference in Everyday Clinical Care: Part 2 | 56 |

| TOPIC 30: RESEARCH ISSUES |
| COURSE |
| 65 Doing Research on a Shoestring Budget | 40 |

| NEW RESEARCH SESSIONS |
| 1 Young investigators Poster Session | 20 |
| 2 Young investigators Oral/Slide Session | 28 |
| 3 Young investigators Oral/Slide Session | 28 |
| 4 Young investigators Poster Session | 36 |
| 5 Oral/Slide Session | 43 |
| 6 Oral/Slide Session | 43 |
| 7 Poster Session | 51 |

| INDUSTRY-SUPPORTED SYMPOSIUM |
| 38 Adult ADHD: Research Findings and Clinical Practice | 60 |
| 49 The Ethics of Psychiatric Research | 83 |

| RESEARCH CONSULTATION |
| 1 The National Institute of Mental Health | 101 |

| SCIENTIFIC AND CLINICAL REPORTS |
| 34 Fish Consumption and Depressive Symptoms in the Population | 47 |
| 43 What Can Be Learned from the Placebo Effect? | 46 |

| SYMPOSIUM |
| 77 NIAAA/NINDA/NIMH Grants and Career Development | 82 |
| 105 Molecules to Mind: Psychiatry at the Millennium | 102 |

| WORKSHOP - COMPONENT |
| 40 Innovations in Veterans Affairs' Mental Illness Research Education and Clinical Centers | 73 |

| WORKSHOP - ISSUE |
| 42 When Can Incompetent Persons Be Research Subjects? | 50 |

| TOPIC 31: SOCIAL AND COMMUNITY PSYCHIATRY |
| COURSE |
| 43 Individual and Community Interventions in Disaster | 16 |
| 67 Disaster Psychiatry: Advanced Topics | 40 |

| MEDIA PROGRAMS |
| 12 Hope and Remembrance: Ritual and Recovery | 29 |
| 16 Regret to Inform | 42 |
| 29 Linking Health Promotion with Entertainment Television | 66 |

| SCIENTIFIC AND CLINICAL REPORT |
| 48 Outpatient Commitment in New York: From Pilot Project to State Law | 48 |

| SYMPOSIUM |
| 14 Social Psychiatry: 21st Century Perspectives | 33 |

| WORKSHOP - COMPONENT |
| 42 Is It a Crime to Be Homeless? Ideas for Change | 73 |

| TOPIC 32: SUICIDE |
| DISCUSSION GROUP |
| 6 Physician-Assisted Suicide and Psychiatry | 22 |

| SCIENTIFIC AND CLINICAL REPORT |
| 51 Secular Trend of Violent Methods in Suicide Victims | 49 |

| SYMPOSIUM |
| 15 Doctor Influence on Hastened Death in Women and Men Worldwide | 33 |

| TOPIC 33: VIOLENCE, TRAUMA AND VICTIMIZATION |
| COURSES |
| 7 Management and Treatment of the Violent Patient | 1 |
| 18 Sexual Harassment: Psychological and Legal Aspects | 5 |
| 39 Risk Assessment for Violence | 15 |
| 68 Assessment and Therapy of Traumatic Bereavement | 40 |
| 101 Adolescent Violence: Treatment Approaches | 88 |

| 109 |
## TOPIC INDEX

### FORUMS
1. Psychiatric Perspectives on Violence 27
2. School Violence and Its Aftermath 27
3. Beyond Just Watching Hate Crimes: In or into the 21st Century 50

### INDUSTRY-SUPPORTED SYMPOSIA
1. Family Violence: Victimization and Perpetration 9
2. Violence and Its Prevention: The Role of Psychiatry 12
3. Lengthening the Fuse: Treatment of Aggression (Part 1) 15
4. Lengthening the Fuse: Treatment of Aggression (Part 2) 39

### MASTER EDUCATION CLINICAL CONSULTATIONS
1. Sexual Trauma in Women: PTSD and Comorbid Disorders 66
2. Psychotherapy for Trauma and Medical Illness 69

### MEDIA PROGRAMS
1. Full Metal Jacket 46
2. Life Is Beautiful: The Holocaust As Fable 61

### MEDICAL UPDATE
1. Infanticide in America: Madness or Malice? 24

### SCIENTIFIC AND CLINICAL REPORTS
7. Gender Differences: Youth Violence Exposure/Risk 24
14. Gender Differences in Violence 25
16. Spirituality and Resilience to Torture 25
20. Seasonal Variation of Violence and Latitude 25
22. Mental Health Impact of Hurricane Mitch 25
49. Six-Month Follow-Up of the Nairobi Embassy Bombing 48
71. Childhood Physical Abuse: Effects on Addiction 71
99. Cortisol and Acute Stress in Women with PTSD 95

### SYMPOSIA
33. Domestic Violence and Medical Interventions 54
72. Long-Term Consequences of Childhood Sexual Abuse 80
102. Violent Patients: Assessment, Management and Treatment 101

### WORKSHOPS - COMPONENTS
5. Bullying and Harassment: Paths to School Violence 20
18. Victims in the Workplace: Awful to Optimal Outcomes 44
41. The Media and Disasters and Other Traumatic Events 73

### WORKSHOPS - ISSUES
28. Understanding the Dynamics of Abusive Relationships 45
29. Psychiatric Implications of Weapons of Mass Destruction 45
37. Trauma Survivors: Heterogeneity of Psychiatric Manifestations 45
73. Hidden Abuse: Exploitation of the Impaired Elderly 91
81. PTSD and Memory: The Debate Goes International 92

### TOPIC 36: COUPLE AND FAMILY THERAPIES

### COURSE
10. Sexual Trauma in Women: PTSD and Comorbid Disorders 66
13. Psychotherapy for Trauma and Medical Illness 69

### MEDIA PROGRAMS
19. Full Metal Jacket 46
24. Life Is Beautiful: The Holocaust As Fable 61

### MEDICAL UPDATE
1. Infanticide in America: Madness or Malice? 24

### SCIENTIFIC AND CLINICAL REPORTS
7. Gender Differences: Youth Violence Exposure/Risk 24
14. Gender Differences in Violence 25
16. Spirituality and Resilience to Torture 25
20. Seasonal Variation of Violence and Latitude 25
22. Mental Health Impact of Hurricane Mitch 25
49. Six-Month Follow-Up of the Nairobi Embassy Bombing 48
71. Childhood Physical Abuse: Effects on Addiction 71
99. Cortisol and Acute Stress in Women with PTSD 95

### SYMPOSIA
33. Domestic Violence and Medical Interventions 54
72. Long-Term Consequences of Childhood Sexual Abuse 80
102. Violent Patients: Assessment, Management and Treatment 101

### WORKSHOPS - COMPONENTS
5. Bullying and Harassment: Paths to School Violence 20
18. Victims in the Workplace: Awful to Optimal Outcomes 44
41. The Media and Disasters and Other Traumatic Events 73

### WORKSHOPS - ISSUES
28. Understanding the Dynamics of Abusive Relationships 45
29. Psychiatric Implications of Weapons of Mass Destruction 45
37. Trauma Survivors: Heterogeneity of Psychiatric Manifestations 45
73. Hidden Abuse: Exploitation of the Impaired Elderly 91
81. PTSD and Memory: The Debate Goes International 92

### TOPIC 38: INDIVIDUAL PSYCHOTHERAPIES

### DISCUSSION GROUP
12. Patient Rights in Psychotherapy 45

### TOPIC 37: GROUP THERAPY

### COURSE
8. Introduction to Psychodynamic Group Psychotherapy 1
19. Outpatient Group Therapy for the Severely Mentally Ill 5

### WORKSHOP - ISSUE
48. Group Psychotherapy of Adolescent Drug Abusers 68

### TOPIC 38: INDIVIDUAL PSYCHOTHERAPIES

### CLINICAL CASE CONFERENCE
2. Affect Dysregulation: Clinical Issues and Psychotherapy 40

### COURSES
9. Psychodynamic Treatment of Panic Disorder 1
15. Interpersonal Psychotherapy 5
29. The Advanced Practice of Psychotherapy 8
31. Dream Translation: One Empirically-Based Approach 8
37. Brief Psychodynamic Psychotherapy: The Core Conflictual Relationship Theme Method 9
41. Alternative Approaches to Understanding Humans 16
53. Basic Hypnosis: Principles and Applications 17
54. Relational Theory and Key Clinical Applications 27
75. Hypnosis in Psychiatry 41
92. Interpersonal Psychotherapy 64

### DISCUSSION GROUP
12. Patient Rights in Psychotherapy 45

### TOPIC 36: COUPLE AND FAMILY THERAPIES

### COURSE
10. Sexual Trauma in Women: PTSD and Comorbid Disorders 66
13. Psychotherapy for Trauma and Medical Illness 69

### MEDIA PROGRAMS
19. Full Metal Jacket 46
24. Life Is Beautiful: The Holocaust As Fable 61

### MEDICAL UPDATE
1. Infanticide in America: Madness or Malice? 24

### SCIENTIFIC AND CLINICAL REPORTS
7. Gender Differences: Youth Violence Exposure/Risk 24
14. Gender Differences in Violence 25
16. Spirituality and Resilience to Torture 25
20. Seasonal Variation of Violence and Latitude 25
22. Mental Health Impact of Hurricane Mitch 25
49. Six-Month Follow-Up of the Nairobi Embassy Bombing 48
71. Childhood Physical Abuse: Effects on Addiction 71
99. Cortisol and Acute Stress in Women with PTSD 95

### SYMPOSIA
33. Domestic Violence and Medical Interventions 54
72. Long-Term Consequences of Childhood Sexual Abuse 80
102. Violent Patients: Assessment, Management and Treatment 101

### WORKSHOPS - COMPONENTS
5. Bullying and Harassment: Paths to School Violence 20
18. Victims in the Workplace: Awful to Optimal Outcomes 44
41. The Media and Disasters and Other Traumatic Events 73

### WORKSHOPS - ISSUES
28. Understanding the Dynamics of Abusive Relationships 45
29. Psychiatric Implications of Weapons of Mass Destruction 45
37. Trauma Survivors: Heterogeneity of Psychiatric Manifestations 45
73. Hidden Abuse: Exploitation of the Impaired Elderly 91
81. PTSD and Memory: The Debate Goes International 92

### TOPIC 34: BEHAVIOR AND COGNITIVE THERAPIES

### COURSES
49. Introduction to Behavior Therapy 17
57. Cognitive Therapy: The Basics 27
66. Cognitive Therapy for Severe Mental Disorders 40
89. Dialectical Behavior Therapy 64

### SCIENTIFIC AND CLINICAL REPORT
50. Quality of Life After Cognitive-Behavior Therapy 49

### TOPIC 35: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY

### COURSE
55. Achieving Effective Dual Diagnosis Treatment 27

### TREATMENTS

### TOPIC 35: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY

### COURSE
55. Achieving Effective Dual Diagnosis Treatment 27

### TREATMENTS
### SYMPOSIA
- 85 Therapeutic Relationship and Psychotherapy Efficacy
- 92 New Developments in Interpersonal Psychotherapy

### WORKSHOP - COMPONENT
- 46 Documenting Psychotherapy: Principles and Dilemmas

### TOPIC 39: PSYCHOPHARMACOLOGY

#### COURSES
- 12 Medical and Psychiatric Implications of Cytochrome P450
- 70 Rational Use of Hormone-Replacement Therapy in Postmenopausal Women
- 72 A Practical Approach to Herbal Medicine in Psychiatry
- 78 Use of Melatonin/Light in Sleep and Mood Disorders
- 102 Neuroleptic-Induced Movement Disorders: Assessment and Treatment

#### INDUSTRY-SUPPORTED SYMPOSIA
- 13 Novel Treatments for Depression
- 14 Individualizing Management of Depressive Disorders
- 25 Recurrent Depression: Challenges and Solutions
- 30 Antiepileptic Drugs in Psychiatric Disorders (Part 1)
- 30 Antiepileptic Drugs in Psychiatric Disorders (Part 2)
- 45 Seven Habits of Highly Effective Psychopharmacologists

#### REVIEW OF PSYCHIATRY
- 1 Ethnicity and Psychopharmacology
- 7 Ethnicity and Psychopharmacology
- 12 Ethnicity and Psychopharmacology
- 15 Ethnicity and Psychopharmacology
- 39 Ethnicity and Psychopharmacology

#### SCIENTIFIC AND CLINICAL REPORTS
- 2 SSRI-Associated Sexual Dysfunction: New Data from Prospective Trials
- 3 Sexual Dysfunction During SSRI Continuation Treatment
- 4 A Pilot Study of the Effectiveness of Nefazodone in Depressed Outpatients With or Without a History of SSRI Treatment Failure
- 17 Buspirone in Patients with Schizophrenia
- 18 Magnesium and Vitamin C Infusion in Fibromyalgia
- 33 A Doubled-Blind, Randomized 12-Week Comparison of Nortriptyline and Paroxetine in the Treatment of Late-Life Depression
- 35 Novel Antipsychotic in ADHD with Conduct Disorder
- 42 A Pilot Study of Herbal Remedy Use by Psychiatric Patients
- 68 Short-Term Nicotine Patch Use: Is It Effective?
- 106 Adjunctive Valproate in Schizophrenia

#### SYMPOSIA
- 54 Psychopharmacological Approaches to the Athletic and Exercise Population
- 84 NMS 1980-2000: Forty Years of Progress

#### TOPIC 40: OTHER SOMATIC THERAPIES

#### COURSES
- 32 ECT Practice Update
- 95 Foundations of Clinical EEG Biofeedback/Neurotherapy

#### REVIEW OF PSYCHIATRY
- 1 Complementary and Alternative Medicine and Psychiatry

#### SYMPOSIUM
- 101 Complementary Medicines and the Psychiatrist

#### TOPIC 41: TREATMENT TECHNIQUES AND OUTCOME STUDIES

#### ADVANCES IN RESEARCH
- The Adverse Impact of Depression on Cardiovascular Disease: Pathophysiology and Treatment Considerations

#### COURSE
- 90 Outcomes: Use of Rating Scales

### DISCUSSION GROUP
- 8 Restraints and Seclusion Revisited

### MEDIA PROGRAMS
- 19 Psychoeducational in Oral Cancer
- 31 Care Coordination Reduces Inpatient Costs
- 77 Open Infrastructure for Outcome Research
- 98 Treatment of Major Depression in Perimenopausal Women: Results from a Randomized, Double-Blind, Placebo-Controlled Trial of 17β-Estradiol

#### SYMPOSIA
- 19 Developments in the Use of Seclusion and Restraint
- 82 Music Therapy: Integrative Medicine for the New Millennium
- 94 The Difficult-to-Treat Psychiatric Patient

#### WORKSHOPS - ISSUES
- 10 Complementary and Alternative Medicine
- 12 Movement, Rhythm and Affective States
- 19 Developments in the Use of Seclusion and Restraint
- 31 Psychosocial Rehabilitation Advances for the Severely and Persistently Mentally Ill
- 36 Diagnosis and Treatment of Hepatitis-C in Mental Health Settings
- 43 Proving It's All Worth It

#### OTHER ISSUES

### TOPIC 42: COMPUTERS

#### LECTURE
- 8 Intimate Machines: From Digital Pets to Digital Personae

#### TELECOMMUNICATION PRESENTATIONS
- 16 How Technology is Going to Transform the Dividing Line Between Research and Clinical Practice
- 17 Personal Digital Assistants in Psychiatric Practice
- 18 Privacy Issues and Technology

#### WORKSHOP - COMPONENT
- 39 Using Computers to Guide Clinical Practice

### TOPIC 43: CREATIVITY AND THE ARTS

#### LECTURE
- 7 Celeste Ascending

#### MEDIA PROGRAMS
- 30 Buena Vista Social Club
- 34 The World of Apu
- 37 Alone Together
- 38 Can't Stop Now

#### WORKSHOPS - ISSUES
- 11 Poems on Psychiatry
- 23 Portrayal of Psychiatry in Recent American Film
- 34 Poetry and Medicine
- 35 Beethoven and His Creative Evolution
- 38 The Real Spice Girls: Black Feminism Through Song

### TOPIC 44: ELECTRONIC MEDICAL RECORDS

#### COURSE
- 47 Building Electronic Medical Records (Basic)

#### SYMPOSIA
- 47 Electronic Records: The End of Confidentiality?
<table>
<thead>
<tr>
<th>Topic Index</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOPIC INDEX</strong></td>
</tr>
<tr>
<td><strong>TELECOMMUNICATION PRESENTATIONS</strong></td>
</tr>
<tr>
<td>5 The University of Michigan's Electronic Medical Record Model</td>
</tr>
<tr>
<td>6 Psychiatrist-Programmed Electronic Medical Records</td>
</tr>
<tr>
<td>7 CAPER Software</td>
</tr>
<tr>
<td>20 The Creation of an Audiovisual Archive</td>
</tr>
<tr>
<td><strong>TOPIC 45: GENDER ISSUES</strong></td>
</tr>
<tr>
<td><strong>CLINICAL CASE CONFERENCE</strong></td>
</tr>
<tr>
<td>4 Women and Addiction: Enhancing Motivation for Change</td>
</tr>
<tr>
<td><strong>COURSE</strong></td>
</tr>
<tr>
<td>30 Psychiatric Disorders in Pregnancy and Postpartum</td>
</tr>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
</tr>
<tr>
<td>17 Gender Issues in Psychiatric Disorder</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIUM</strong></td>
</tr>
<tr>
<td>8 Advances in Women's Mental Health: A Decade of Progress</td>
</tr>
<tr>
<td><strong>LECTURE</strong></td>
</tr>
<tr>
<td>4 Six Easy Lessons in the Care of Women Patients: Using What You Already Know to Improve Your Practice</td>
</tr>
<tr>
<td><strong>MASTER EDUCATION CLINICAL CONSULTATION</strong></td>
</tr>
<tr>
<td>6 Psychotherapy: Gender issues</td>
</tr>
<tr>
<td><strong>MEDICAL UPDATE</strong></td>
</tr>
<tr>
<td>2 Seventeen Ways to Have a Baby: Reproduction in the 21st Century</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
</tr>
<tr>
<td>97 Gender Differences: Drug Abuse and Related Anxiety</td>
</tr>
<tr>
<td><strong>WORKSHOP - ISSUE</strong></td>
</tr>
<tr>
<td>7 The Interface of Estrogen and Neurotransmitters</td>
</tr>
<tr>
<td><strong>TOPIC 46: HEALTH SERVICES RESEARCH</strong></td>
</tr>
<tr>
<td><strong>DISCUSSION GROUPS</strong></td>
</tr>
<tr>
<td>4 Health Promotion, Resiliency and Prevention</td>
</tr>
<tr>
<td>13 The Role of Inpatient Psychiatry in the Changing Health Care System</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
</tr>
<tr>
<td>24 Outcomes Assessment in a Schizophrenia Service</td>
</tr>
<tr>
<td>25 Understanding Mental and General Medical Disability</td>
</tr>
<tr>
<td>28 Depression, Hostility, Gender and Myocardial Infarction</td>
</tr>
<tr>
<td>94 Global Assessment Function and Length of Stay As Predictors of Outcome in Depression</td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
</tr>
<tr>
<td>42 Minority Veterans: Obstacles to Mental Health Care</td>
</tr>
<tr>
<td>88 Health Services Use in Schizophrenia: New Data</td>
</tr>
<tr>
<td><strong>WORKSHOP - COMPONENT</strong></td>
</tr>
<tr>
<td>48 Psychiatric Scope of Practice and Its Implications</td>
</tr>
<tr>
<td><strong>WORKSHOP - ISSUE</strong></td>
</tr>
<tr>
<td>26 Using Treatment Outcomes in Residency Training</td>
</tr>
<tr>
<td><strong>TOPIC 47: HISTORICAL QUESTIONS</strong></td>
</tr>
<tr>
<td><strong>LECTURE</strong></td>
</tr>
<tr>
<td>23 Millennial Madness: Religion and Insanity in American History</td>
</tr>
<tr>
<td><strong>TOPIC 48: INFORMATION TECHNOLOGY</strong></td>
</tr>
<tr>
<td><strong>TELECOMMUNICATION PRESENTATIONS</strong></td>
</tr>
<tr>
<td>4 Continuous Monitoring of Symptoms and Medications</td>
</tr>
<tr>
<td>9 Anxiety in Patients with Chemical Abuse/Dependence</td>
</tr>
<tr>
<td>15 Overview of the Office of the Future</td>
</tr>
<tr>
<td><strong>WORKSHOP - COMPONENT</strong></td>
</tr>
<tr>
<td>15 Office of the Future</td>
</tr>
<tr>
<td><strong>TOPIC 49: INTERNET</strong></td>
</tr>
<tr>
<td><strong>TELECOMMUNICATION PRESENTATIONS</strong></td>
</tr>
<tr>
<td>1 Pornography on the Web: What's the Big Deal?</td>
</tr>
<tr>
<td>2 Hate Groups, Adolescents and the Internet</td>
</tr>
<tr>
<td>3 Domestic Violence: A CME Web Course</td>
</tr>
<tr>
<td>8 Overview of the System</td>
</tr>
<tr>
<td>10 Acute Depression in Bipolar Disorder</td>
</tr>
<tr>
<td>11 Feasibility Study on the Use of Two Algorithms at Taunton State Hospital</td>
</tr>
<tr>
<td>12 The Use of Algorithms at the Mendota Mental Health Institute</td>
</tr>
<tr>
<td>13 The Cytochrome P450 Drug Interaction Program</td>
</tr>
<tr>
<td>14 The P450 Program in the Hospital Setting</td>
</tr>
<tr>
<td><strong>WORKSHOP - ISSUE</strong></td>
</tr>
<tr>
<td>17 The World Wide Web: Safety Net or Trap?</td>
</tr>
<tr>
<td><strong>TOPIC 50: LESBIAN/GAY/BISEXUAL/TRANSGENDER ISSUES</strong></td>
</tr>
<tr>
<td><strong>MEDIA PROGRAMS</strong></td>
</tr>
<tr>
<td>31 Trety</td>
</tr>
<tr>
<td>32 Beauty Before Age: Growing Older in Gay Culture</td>
</tr>
<tr>
<td>33 Golden Threads</td>
</tr>
<tr>
<td><strong>WORKSHOP - COMPONENT</strong></td>
</tr>
<tr>
<td>24 Lesbian, Gay, Bisexual and Transgendered Residents: Challenges in Training</td>
</tr>
<tr>
<td>43 Antihomosexual Bias in Clinical Settings</td>
</tr>
<tr>
<td><strong>TOPIC 51: MANAGED CARE AND HEALTH CARE FUNDING</strong></td>
</tr>
<tr>
<td><strong>LECTURE</strong></td>
</tr>
<tr>
<td>21 The Shaky Foundations of Managed Care</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
</tr>
<tr>
<td>44 Benefits Managers' Views on Mental Health</td>
</tr>
<tr>
<td>45 The Impact of Managed Care</td>
</tr>
<tr>
<td>46 Risk Management in Shared Treatment</td>
</tr>
<tr>
<td><strong>WORKSHOPS - ISSUES</strong></td>
</tr>
<tr>
<td>55 Managed Care Impact in Public Sector Psychiatry</td>
</tr>
<tr>
<td>87 Intensive Outpatient Programs</td>
</tr>
<tr>
<td>41 In Whose Honor? American Indian Mascots in Sports</td>
</tr>
<tr>
<td><strong>TOPIC 52: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM: ALCOHOL RESEARCH: ACHIEVEMENTS AND PROMISE</strong></td>
</tr>
<tr>
<td><strong>ADVANCES IN RESEARCH</strong></td>
</tr>
<tr>
<td>21 New Developments in the Genetics of Alcoholism</td>
</tr>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
</tr>
<tr>
<td>21 Emerging Issues in the Treatment of Addictive Disorders</td>
</tr>
<tr>
<td><strong>FORUMS</strong></td>
</tr>
<tr>
<td>2 Ethnic Issues in Alcohol Research</td>
</tr>
<tr>
<td>7 Alcohol and Interpersonal Violence: Public Health and Criminal Justice Issues</td>
</tr>
<tr>
<td><strong>LECTURES</strong></td>
</tr>
<tr>
<td>3 Alcohol Research: Achievements and Promise</td>
</tr>
<tr>
<td>15 Terry: A Life and Death Struggle with Alcoholism and Depression</td>
</tr>
<tr>
<td><strong>MASTER EDUCATION CLINICAL CONSULTATION</strong></td>
</tr>
<tr>
<td>7 Dual Diagnosis</td>
</tr>
<tr>
<td><strong>MEDIA PROGRAM</strong></td>
</tr>
<tr>
<td>7 Affliction</td>
</tr>
</tbody>
</table>
### TOPIC INDEX

#### MEDICAL UPDATE
- Liver Disease by Alcohol and Hepatitis C: Early Detection and Insights in Pathogenesis Lead to Improved Treatment 70

#### RESEARCH ADVANCES IN MEDICINES
- Evolving Pharmacotherapies for Alcohol Dependence and Relapse Prevention 43
- Animal Models of Alcohol Dependence 43
- Recent Findings Using MRS 43

#### SCIENTIFIC AND CLINICAL REPORTS
- Impulsivity, Serotonin and Adolescent Alcohol Abuse 49
- DWI Prevention: The Psychiatrist’s Role 49
- Are There Genes for Alcoholism? 79
- Frontiers in Clinical Alcohoim Treatment/Behavioral Therapies 100

#### WORKSHOP - COMPONENT
- Alcohol and Drug Use in Late Life: Diagnosis and Treatment 26

#### WORKSHOPS - ISSUES
- Care Management for Chronic Addictive Disorders 68
- Child-Adolescent Substance Use Disorders 91

#### TOPIC 53: POLITICAL QUESTIONS
- Quality Indicators in Psychiatry 53
- Political Violence in the New Millennium 57

#### WORKSHOP - COMPONENT
- How Medical Record Privacy Proposals Will Change Medicine 67

#### WORKSHOP - ISSUE
- Principles of Effective State Legislative Liaison 91

#### TOPIC 54: PRESIDENTIAL THEME: "THE DOCTOR-PATIENT RELATIONSHIP"
- Money in the Doctor/Patient Relationship 1
- Mutuality in the Doctor/Patient Relationship 16
- Therapeutic Adaptations with Deaf and Hard of Hearing Patients 41
- Psychiatrists As Teachers of Boundaries to Physicians 51
- Affect, Empathy and the Healing Relationship: The Tomkins System 86

#### MEDIA PROGRAMS
- Uncertain Borders Part 1: Boundary Issues in Psychotherapy 43
- Uncertain Borders Part 2: Sexual Boundary Violations 43
- Films In Teaching Psychiatry, Diversity, Morality and Healing 47
- The Therapeutic Relationship in Hollywood Cinema 52
- Good Will Hunting 61

#### PRESIDENTIAL SYMPOSIUM
- Perspectives on the Doctor-Patient Relationship 30

#### SCIENTIFIC AND CLINICAL REPORTS
- Doctor-Patient Post-Termination Issues 24
- Patients’ View of the Doctor-Patient Relationship 24
- Attachment Theory and Adherence to Medical Treatment 48

#### SYMPOSIAS
- Professional Boundaries: Training Methods 31
- World Views and the Doctor-Patient Relationship 34
- Therapeutic Alliance: Evaluation, Treatment and Outcome 34

#### WORKSHOP - COMPONENT
- Patient Autonomy and Paternalism Across Cultures 49

#### WORKSHOPS - ISSUES
- Subjectivity: Crucial Key to the Therapeutic Alliance 21
- Blaming the Patient: Blind Spot for Doctor and Patient 21
- Swords into Ploughshares: The Importance of Dialog 26
- Doctor-Patient Relationship in Chekhov’s Writing 45
- Severe PTSD and the Doctor-Patient Relationship 68
- Voyages of the Starship Empathy: To Boldly Go... 68
- Termination issues in a Psychopharmacology Clinic 91
- Cultural Issues in the Doctor-Patient Relationship 92
- Applying Narrative Therapy in Psychiatric Practice 92
- Doctor-Patient Relationship and Malpractice Suits 96
- The Physician-Patient Relationship: Not Just Medication 96

#### TOPIC 55: PROFESSIONAL AND PERSONAL ISSUES
- Treating Medical Students and Physicians 16
- Malpractice: How to Legally and Emotionally Survive Litigation 74

#### DISCUSSION GROUPS
- Malpractice Issues 22
- Financial Management Challenges for Psychiatry 2000 88

#### FORUM
- Maternity Leave During Psychiatry Residency Training 50

#### MEDIA PROGRAMS
- The Vanishing Line 93
- Death: A Love Story 93

#### SYMPOSIUM
- Professional Advocacy: Personal Leadership Odysseys 33

#### WORKSHOPS - COMPONENTS
- Rediscovering Authority in American Life 20
- Career Lessons for Asian-American Early Career Psychiatrists 20
- Generations of Mentoring: From Receiving to Giving 26
- Misuse and Abuse of Psychiatry: Clinical Issues 44
- Risk-Management Issues in Psychiatric Practice 49
- Facing the Changing Realities of Physician Stress 49
- Private Practice: Change and Opportunity 90

#### WORKSHOPS - ISSUES
- Career Strategies Y2K: Stay Generative and Stimulated 44
- The Doctor As Patient 69
- Children of Psychiatrists: Workshop III 69
- Giving Care to the Caregiver 69
- IMGs in Psychiatry: Challenges and Opportunities 73

#### TOPIC 56: RELIGION, SPIRITUALITY AND PSYCHIATRY
- Transpersonal Psychiatry: Theory and Practice 1
- Transpersonal Psychiatry: Clinical Applications 64

#### MEDIA PROGRAM
- Trembling Before G-D 76

#### SYMPOSIAS
- Religion As a Wedge Between Doctor and Patient 31
- Clinical Challenges to the Psychiatrist of Faith 58
- Spirituality, Culture and Psychiatry: Navajo and Western Perspectives 84
## TOPIC INDEX

### WORKSHOPS - COMPONENTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>23 Paul Ricoeur in Dialogue with American Psychiatrists</td>
<td>49</td>
</tr>
<tr>
<td>44 Spirituality and Religion in Substance Abuse Treatment</td>
<td>90</td>
</tr>
<tr>
<td>49 The Healing Ways of the Anishinaabe Ojibwe People</td>
<td>91</td>
</tr>
</tbody>
</table>

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 Oskar Pfister's Impact on Psychiatry After 2000</td>
<td>27</td>
</tr>
<tr>
<td>45 Spiritual/Religious Assessment in Clinical Work</td>
<td>68</td>
</tr>
<tr>
<td>62 How Intuition Can Be Used to Enhance Patient Care</td>
<td>69</td>
</tr>
<tr>
<td>72 Forests, Trees and Therapy: Psychiatry's Pastoral Role</td>
<td>91</td>
</tr>
<tr>
<td>90 Spiritual Issues in End-of-Life Care</td>
<td>96</td>
</tr>
</tbody>
</table>

### TOPIC 57: RESIDENT AND MEDICAL STUDENT CONCERNS

### DISCUSSION GROUPS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Psychotherapy and Psychopharmacology: Combined Versus Divided</td>
<td>17</td>
</tr>
<tr>
<td>Treatment (For Residents Only)</td>
<td></td>
</tr>
<tr>
<td>10 Current Trends in Community Psychiatry (For Residents Only)</td>
<td>41</td>
</tr>
<tr>
<td>14 Administrative Psychiatry: Challenges and Opportunities</td>
<td>65</td>
</tr>
<tr>
<td>(For Residents Only)</td>
<td></td>
</tr>
</tbody>
</table>

### MASTER EDUCATION CLINICAL CONSULTATION

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 Resident Supervision</td>
<td>42</td>
</tr>
</tbody>
</table>

### RESIDENT'S SESSION

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meet the Experts: Sunny Side-Up</td>
<td>16</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORT

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 Termination of Psychotherapy: Residents' Perspective</td>
<td>24</td>
</tr>
</tbody>
</table>

### WORKSHOPS - COMPONENT

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 The Doctor As Patient: Both Sides of Transference</td>
<td>20</td>
</tr>
<tr>
<td>19 Mental Illness in Psychiatrists: Training and Beyond</td>
<td>44</td>
</tr>
<tr>
<td>26 Split Therapy and the Psychiatric Resident</td>
<td>49</td>
</tr>
<tr>
<td>37 Career Choices in Psychiatry</td>
<td>72</td>
</tr>
</tbody>
</table>

### MEDIA PROGRAMS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>39 Stigma...In Our Work, In Our Lives</td>
<td>89</td>
</tr>
<tr>
<td>40 No Easy Way</td>
<td>90</td>
</tr>
</tbody>
</table>

### TOPIC 58: STIGMA/ADVOCACY

### WORKSHOP - COMPONENT

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 Hot Issues in Telepsychiatry</td>
<td>20</td>
</tr>
</tbody>
</table>

### WORKSHOP - ISSUE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 Telepsychiatry Services: From Design to Global Implications</td>
<td>45</td>
</tr>
</tbody>
</table>

### TOPIC 59: TELEPSYCHIATRY

### SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>51 Applying Virtual Environments in Psychiatry</td>
<td>61</td>
</tr>
</tbody>
</table>

### TELECOMMUNICATION PRESENTATION

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>19 Computer-Assisted Diagnostic Interviews</td>
<td>82</td>
</tr>
<tr>
<td>Participant Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Broquet, Karen E</td>
<td>80</td>
</tr>
<tr>
<td>Brook, David W</td>
<td>68</td>
</tr>
<tr>
<td>Brodatz, Karen E</td>
<td>80</td>
</tr>
<tr>
<td>Brower, Montgomery</td>
<td>45</td>
</tr>
<tr>
<td>Brown, Gregory J</td>
<td>72</td>
</tr>
<tr>
<td>Brown, Richard P</td>
<td>30, 40</td>
</tr>
<tr>
<td>Brown, Thomas E</td>
<td>5, 16, 15</td>
</tr>
<tr>
<td>Brown, Walter A</td>
<td>99</td>
</tr>
<tr>
<td>Brown, Winston</td>
<td>44</td>
</tr>
<tr>
<td>Browne, Gina</td>
<td>99</td>
</tr>
<tr>
<td>Browning, Don S</td>
<td>31</td>
</tr>
<tr>
<td>Bruggerman, Richard</td>
<td>55</td>
</tr>
<tr>
<td>Buchhalter, Monte S</td>
<td>32, 81</td>
</tr>
<tr>
<td>Buckley, Peter F</td>
<td>12, 26, 32, 97, 98</td>
</tr>
<tr>
<td>Budin, John M</td>
<td>72</td>
</tr>
<tr>
<td>Bullmore, Edward T</td>
<td>100</td>
</tr>
<tr>
<td>Bursky, J. Clark</td>
<td>24, 79</td>
</tr>
<tr>
<td>Bux, Kimberly A</td>
<td>67</td>
</tr>
<tr>
<td>Bustamante, Gustavo</td>
<td>48</td>
</tr>
<tr>
<td>Butler, Lisa</td>
<td>81, 85</td>
</tr>
<tr>
<td>Butlerfield, Karlen I</td>
<td>26, 57, 96</td>
</tr>
<tr>
<td>Butzel, Jessica S</td>
<td>16</td>
</tr>
<tr>
<td>Byssse, Daniel J</td>
<td>7</td>
</tr>
<tr>
<td>Byrne, Carolyn</td>
<td>99</td>
</tr>
<tr>
<td>Cabaj, Robert P</td>
<td>44, 50</td>
</tr>
<tr>
<td>Cabreja, Claudio O</td>
<td>25</td>
</tr>
<tr>
<td>Caetano, Raul</td>
<td>74</td>
</tr>
<tr>
<td>Cain, Eric D</td>
<td>34</td>
</tr>
<tr>
<td>Cal, Kimberly A</td>
<td>67</td>
</tr>
<tr>
<td>Calabrese, Joseph R</td>
<td>32, 63, 74, 87</td>
</tr>
<tr>
<td>Caniguri, Michael</td>
<td>68</td>
</tr>
<tr>
<td>Cailfani, Jr. William E</td>
<td>20, 26, 58</td>
</tr>
<tr>
<td>Camanante, Enrique</td>
<td>53</td>
</tr>
<tr>
<td>Campbell, E. Cabrina</td>
<td>78, 97</td>
</tr>
<tr>
<td>Campbell, Jacqueline C</td>
<td>74</td>
</tr>
<tr>
<td>Campbell, Tom G</td>
<td>17, 40</td>
</tr>
<tr>
<td>Campano-Brown, Ana E</td>
<td>75</td>
</tr>
<tr>
<td>Canco, Robert</td>
<td>55</td>
</tr>
<tr>
<td>Canettio, Silvia S</td>
<td>34</td>
</tr>
<tr>
<td>Canive, Jose M</td>
<td>56, 69, 79</td>
</tr>
<tr>
<td>Canterbury, Randolph J</td>
<td>48</td>
</tr>
<tr>
<td>Cantin, Arvid</td>
<td>56</td>
</tr>
<tr>
<td>Canicci, Giovann</td>
<td>49, 100</td>
</tr>
<tr>
<td>Carmen, Patrick J</td>
<td>50</td>
</tr>
<tr>
<td>Carr, Stanley N</td>
<td>78, 97</td>
</tr>
<tr>
<td>Carpenter, Jr., William T</td>
<td>40</td>
</tr>
<tr>
<td>Carrion, Oscar R</td>
<td>48</td>
</tr>
<tr>
<td>Carroll, Kathleen M</td>
<td>100</td>
</tr>
<tr>
<td>Carter, Diane</td>
<td>8</td>
</tr>
<tr>
<td>Carter, Jacqueline</td>
<td>8</td>
</tr>
<tr>
<td>Carter, Robert T</td>
<td>92</td>
</tr>
<tr>
<td>Cartwright, Charles</td>
<td>12, 39, 80</td>
</tr>
<tr>
<td>Casandine, Paul P</td>
<td>34</td>
</tr>
<tr>
<td>Casancy, Daniel E</td>
<td>13</td>
</tr>
<tr>
<td>Casey, David A</td>
<td>18, 24</td>
</tr>
<tr>
<td>Casey, Patricia R</td>
<td>99</td>
</tr>
<tr>
<td>Cass, Hyle R</td>
<td>101</td>
</tr>
<tr>
<td>Cassano, Giovanni B</td>
<td>80</td>
</tr>
<tr>
<td>Castaino, Edwin H</td>
<td>61</td>
</tr>
<tr>
<td>Castellanos, F. Xavier</td>
<td>3</td>
</tr>
<tr>
<td>Castillo, Richard J</td>
<td>92</td>
</tr>
<tr>
<td>Caton, Carol L M</td>
<td>95</td>
</tr>
<tr>
<td>Chaikowitiz, Gary A</td>
<td>91</td>
</tr>
<tr>
<td>Cham, Raymond</td>
<td>25</td>
</tr>
<tr>
<td>Changar, Sayanaranayana</td>
<td>44</td>
</tr>
<tr>
<td>Chang, Jacqueline B</td>
<td>20, 47</td>
</tr>
<tr>
<td>Chang, Mina</td>
<td>48</td>
</tr>
<tr>
<td>Chang, Suix Chao</td>
<td>73</td>
</tr>
<tr>
<td>Chang-Croce, Catherine C</td>
<td>30, 41</td>
</tr>
<tr>
<td>Chang, Dianita</td>
<td>95</td>
</tr>
<tr>
<td>Chapko, Chidan</td>
<td>78</td>
</tr>
<tr>
<td>Charles, Sara C</td>
<td>20, 53, 96</td>
</tr>
<tr>
<td>Chaney, Dennis S</td>
<td>7, 11, 41, 81</td>
</tr>
<tr>
<td>Chasek, Roberto E</td>
<td>53, 100</td>
</tr>
<tr>
<td>Chaunthy, Zubaida A</td>
<td>25, 46</td>
</tr>
<tr>
<td>Cheever, Tammy R</td>
<td>68</td>
</tr>
<tr>
<td>Chen, Huanan</td>
<td>79</td>
</tr>
<tr>
<td>Chen, Xin-Hua</td>
<td>72</td>
</tr>
<tr>
<td>Chen, Yunn-Fang</td>
<td>76</td>
</tr>
<tr>
<td>Cheney, Jane</td>
<td>33</td>
</tr>
<tr>
<td>Chen, Keith</td>
<td>43</td>
</tr>
<tr>
<td>Chengappa, K.N. Roy</td>
<td>9, 12</td>
</tr>
<tr>
<td>Chiesan, Chelsea L</td>
<td>45</td>
</tr>
<tr>
<td>Chiesseck, Cheryl A</td>
<td>26, 62</td>
</tr>
<tr>
<td>Chiesseck, Richard D</td>
<td>16</td>
</tr>
<tr>
<td>Childersing, Helen</td>
<td>73</td>
</tr>
<tr>
<td>Childs, Alan</td>
<td>21</td>
</tr>
<tr>
<td>Chiles, John A</td>
<td>32</td>
</tr>
<tr>
<td>Chisham, Allen B</td>
<td>7</td>
</tr>
<tr>
<td>Childholm, Franence</td>
<td>55</td>
</tr>
<tr>
<td>Chopra, Miriam</td>
<td>80</td>
</tr>
<tr>
<td>Chou, James C.Y.</td>
<td>8, 46</td>
</tr>
<tr>
<td>Christensen, Daniel D</td>
<td>7</td>
</tr>
<tr>
<td>Chula Jr., Robert</td>
<td>94</td>
</tr>
<tr>
<td>Ciechanowski, Paul</td>
<td>48</td>
</tr>
<tr>
<td>Citrome, Leslie L</td>
<td>77, 96</td>
</tr>
<tr>
<td>Clair, Alicia A</td>
<td>85</td>
</tr>
<tr>
<td>Clardy, James A</td>
<td>44</td>
</tr>
<tr>
<td>Clark, David L</td>
<td>88</td>
</tr>
<tr>
<td>Clark, H. Westley</td>
<td>34</td>
</tr>
<tr>
<td>Clark, Michael G</td>
<td>44, 74</td>
</tr>
<tr>
<td>Clark, Jr., Gordon H</td>
<td>36</td>
</tr>
<tr>
<td>Clarkson, John F</td>
<td>82, 88</td>
</tr>
<tr>
<td>Classen, Catherine</td>
<td>55, 80, 81, 95</td>
</tr>
<tr>
<td>Clavel, Gail</td>
<td>7</td>
</tr>
<tr>
<td>Clayton, Anita L H</td>
<td>2, 7</td>
</tr>
<tr>
<td>Clayton, Paula J</td>
<td>15, 39</td>
</tr>
<tr>
<td>Clemens, Norman A</td>
<td>90, 96</td>
</tr>
<tr>
<td>Coninger, C. Robert</td>
<td>53</td>
</tr>
<tr>
<td>Cocco, Emilio F</td>
<td>12, 15, 32</td>
</tr>
<tr>
<td>Coconos, Crescide M</td>
<td>84</td>
</tr>
<tr>
<td>Coffey, Barbara J</td>
<td>6</td>
</tr>
<tr>
<td>Coffey, C. Edward</td>
<td>17</td>
</tr>
<tr>
<td>Cohen, Joshua</td>
<td>55</td>
</tr>
<tr>
<td>Cohen, Lee S</td>
<td>6, 31, 95</td>
</tr>
<tr>
<td>Cohen, Mitchell J.M.</td>
<td>66</td>
</tr>
<tr>
<td>Cohen, Patricia</td>
<td>79</td>
</tr>
<tr>
<td>Colker, Elizabeth</td>
<td>81</td>
</tr>
<tr>
<td>Cole, Mary C</td>
<td>88, 96</td>
</tr>
<tr>
<td>Cole, Michael</td>
<td>5</td>
</tr>
<tr>
<td>Coleman, Robert</td>
<td>45</td>
</tr>
<tr>
<td>Collins, Francis S</td>
<td>92</td>
</tr>
<tr>
<td>Corley, Robert R</td>
<td>9, 32, 83</td>
</tr>
<tr>
<td>Conn, Linda</td>
<td>29</td>
</tr>
<tr>
<td>Connors, Gerard J</td>
<td>100</td>
</tr>
<tr>
<td>Connolly, Mary Beth</td>
<td>34</td>
</tr>
<tr>
<td>Connor, Kathryn M</td>
<td>12</td>
</tr>
<tr>
<td>Conran, Helen J</td>
<td>21</td>
</tr>
<tr>
<td>Conroy, Henry G</td>
<td>17</td>
</tr>
<tr>
<td>Convit, Antonio J</td>
<td>81</td>
</tr>
<tr>
<td>Conwell, Yeates</td>
<td>34</td>
</tr>
<tr>
<td>Cook, Ian A</td>
<td>72</td>
</tr>
<tr>
<td>Cooper, Arnold M</td>
<td>45</td>
</tr>
<tr>
<td>Copeland, Laurel A</td>
<td>88</td>
</tr>
<tr>
<td>Cord-Locevich, Gabriela</td>
<td>95</td>
</tr>
<tr>
<td>Corcoran, Cheryl</td>
<td>77</td>
</tr>
<tr>
<td>Coric, Vladimir</td>
<td>47</td>
</tr>
<tr>
<td>Corlatt, Barbara</td>
<td>10</td>
</tr>
<tr>
<td>Correll, John</td>
<td>60</td>
</tr>
<tr>
<td>Cortes, Maria R</td>
<td>8</td>
</tr>
<tr>
<td>Cortese, Leonardo</td>
<td>88</td>
</tr>
<tr>
<td>Coutos, Francine</td>
<td>20, 32, 75, 95, 98</td>
</tr>
<tr>
<td>Coursin, David R</td>
<td>21</td>
</tr>
<tr>
<td>Coursin, Douglas B</td>
<td>21</td>
</tr>
<tr>
<td>Cowan, Ronald L</td>
<td>21</td>
</tr>
<tr>
<td>Cowley, Deborah S</td>
<td>60</td>
</tr>
<tr>
<td>Cox, Christopher</td>
<td>34</td>
</tr>
<tr>
<td>Cox, Dale N</td>
<td>1</td>
</tr>
<tr>
<td>Coyne, Brennan R</td>
<td>55</td>
</tr>
<tr>
<td>Cristiann, Joseph T</td>
<td>28</td>
</tr>
<tr>
<td>Cozza, Kelly L</td>
<td>5</td>
</tr>
<tr>
<td>Credel, Charles R</td>
<td>10</td>
</tr>
<tr>
<td>Craven, Marilyn</td>
<td>60</td>
</tr>
<tr>
<td>Crichton, James</td>
<td>77</td>
</tr>
<tr>
<td>Crill, Lyndon J</td>
<td>32</td>
</tr>
<tr>
<td>Crosby, Ross D</td>
<td>54, 54, 57, 81</td>
</tr>
<tr>
<td>Crosest, Judith H W</td>
<td>20</td>
</tr>
<tr>
<td>Croxey, Brian L</td>
<td>10</td>
</tr>
<tr>
<td>Cullen, Bernadette</td>
<td>80</td>
</tr>
<tr>
<td>Culemper, Larry</td>
<td>48</td>
</tr>
<tr>
<td>Cummings, Jeffrey L</td>
<td>17, 40, 66, 70</td>
</tr>
<tr>
<td>Custerfield, Karen Y</td>
<td>77</td>
</tr>
<tr>
<td>Coban, Paid</td>
<td>25</td>
</tr>
<tr>
<td>D'Agostino, Anthony M</td>
<td>1</td>
</tr>
<tr>
<td>Daljaard, Steffen</td>
<td>101</td>
</tr>
<tr>
<td>Dalton, Jeffrey</td>
<td>60</td>
</tr>
<tr>
<td>Dally, Kathleen A</td>
<td>36</td>
</tr>
<tr>
<td>Daily, Paul</td>
<td>80</td>
</tr>
<tr>
<td>Dantzer, Anne E</td>
<td>87</td>
</tr>
<tr>
<td>Das, Amarendra</td>
<td>72</td>
</tr>
<tr>
<td>David, Anthony S</td>
<td>100</td>
</tr>
<tr>
<td>Davis, Melinda L</td>
<td>37</td>
</tr>
<tr>
<td>Davis, Jonathan S</td>
<td>6, 66</td>
</tr>
<tr>
<td>Davis, Gillia P</td>
<td>47</td>
</tr>
<tr>
<td>Davis, Glenn C</td>
<td>21</td>
</tr>
<tr>
<td>Davis, John M...</td>
<td>75</td>
</tr>
<tr>
<td>Davis, Kenneth L</td>
<td>3</td>
</tr>
<tr>
<td>Dawkins, Karan</td>
<td>73</td>
</tr>
<tr>
<td>Dean, Michel</td>
<td>81</td>
</tr>
<tr>
<td>DeCaro, Concetta</td>
<td>12, 80</td>
</tr>
<tr>
<td>DeCesare, Michel</td>
<td>57</td>
</tr>
<tr>
<td>DeFelpo, Anne M</td>
<td>74</td>
</tr>
<tr>
<td>De Girolamo, Giovanni</td>
<td>81</td>
</tr>
<tr>
<td>De Guts, Dorothea L</td>
<td>41</td>
</tr>
<tr>
<td>DeGray, Frank V</td>
<td>64</td>
</tr>
<tr>
<td>Deimmanen, John M</td>
<td>96</td>
</tr>
<tr>
<td>Dekleva, Kenneth B</td>
<td>57</td>
</tr>
<tr>
<td>DelaCruz, Clara</td>
<td>34</td>
</tr>
<tr>
<td>DelaCruz, Lynn C</td>
<td>34</td>
</tr>
<tr>
<td>De La Guardia, Jose E</td>
<td>44</td>
</tr>
<tr>
<td>Dehanyante, Janine C</td>
<td>98</td>
</tr>
<tr>
<td>DelBello, Melissa P</td>
<td>31</td>
</tr>
<tr>
<td>deLeon, Mary J</td>
<td>81</td>
</tr>
<tr>
<td>DelLeon, Ovidio A</td>
<td>15</td>
</tr>
<tr>
<td>DelOto, Margaretta L</td>
<td>94</td>
</tr>
<tr>
<td>DeSax, Patricia R</td>
<td>17</td>
</tr>
<tr>
<td>Dell, Mary L</td>
<td>80</td>
</tr>
<tr>
<td>DeTans, Mark L</td>
<td>23</td>
</tr>
<tr>
<td>DeWitt, Mark L</td>
<td>23</td>
</tr>
<tr>
<td>Demus, Gina</td>
<td>21</td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Larsen, Robert C</td>
<td>44</td>
</tr>
<tr>
<td>Larson, David B</td>
<td>31, 58, 80</td>
</tr>
<tr>
<td>Lasus, Lourdes</td>
<td>101</td>
</tr>
<tr>
<td>Lasko, Nathalie B.</td>
<td>81</td>
</tr>
<tr>
<td>Laughery, Thomas P.</td>
<td>85</td>
</tr>
<tr>
<td>Lauerbach, Edward C.</td>
<td>35, 64, 88</td>
</tr>
<tr>
<td>Lawlor, Brian A</td>
<td>63</td>
</tr>
<tr>
<td>Lawson, David H.</td>
<td>11</td>
</tr>
<tr>
<td>Lawson, William B.</td>
<td>10, 27, 52</td>
</tr>
<tr>
<td>Lazarus, Jeremy A.</td>
<td>33, 78</td>
</tr>
<tr>
<td>Lazarus, Lawrence W.</td>
<td>64</td>
</tr>
<tr>
<td>Le, Pham-Thuy</td>
<td>13</td>
</tr>
<tr>
<td>Le Blanc, Jacqueline M.</td>
<td>20</td>
</tr>
<tr>
<td>Lebowitz, Barry D.</td>
<td>63, 87</td>
</tr>
<tr>
<td>Le Blanc, Jacquelyn M.</td>
<td>20</td>
</tr>
<tr>
<td>Le Blanc, Michelle</td>
<td>93</td>
</tr>
<tr>
<td>LeBlanc, Ken</td>
<td>50</td>
</tr>
<tr>
<td>Lee, Merton</td>
<td>77</td>
</tr>
<tr>
<td>Lee, Richard</td>
<td>32, 81</td>
</tr>
<tr>
<td>Lee, Sing</td>
<td>76</td>
</tr>
<tr>
<td>Lehman, Anthony F.</td>
<td>98</td>
</tr>
<tr>
<td>Lefkowitz, Barry D.</td>
<td>63, 87</td>
</tr>
<tr>
<td>LeBuhn, Michelle</td>
<td>93</td>
</tr>
<tr>
<td>Lead, Kevin</td>
<td>50</td>
</tr>
<tr>
<td>Le, Francis G.</td>
<td>80, 90, 93</td>
</tr>
<tr>
<td>Langer, David B</td>
<td>31, 68, 80</td>
</tr>
<tr>
<td>Larochelle, Thomas P.</td>
<td>65</td>
</tr>
<tr>
<td>Laitinen, Ville</td>
<td>101</td>
</tr>
<tr>
<td>Lachter, Johannes</td>
<td>47</td>
</tr>
<tr>
<td>LeBlanc, Miguel A.</td>
<td>96</td>
</tr>
<tr>
<td>Leigh, Hoyle</td>
<td>82</td>
</tr>
<tr>
<td>Lenz, Todd</td>
<td>10</td>
</tr>
<tr>
<td>Lenhart, Sharyn A.</td>
<td>5</td>
</tr>
<tr>
<td>Lenz, Gerhard</td>
<td>49</td>
</tr>
<tr>
<td>Leon-Andrade, Carlos</td>
<td>53</td>
</tr>
<tr>
<td>Leonard, Hennetta L.</td>
<td>63, 97</td>
</tr>
<tr>
<td>Leppanen, Francois</td>
<td>2</td>
</tr>
<tr>
<td>Levav, Itzhak</td>
<td>25</td>
</tr>
<tr>
<td>Levensky, Philip G.</td>
<td>17</td>
</tr>
<tr>
<td>Leverson, Alan I.</td>
<td>49</td>
</tr>
<tr>
<td>Leverich, Gabriele S.</td>
<td>31</td>
</tr>
<tr>
<td>Lewis, Francis R.</td>
<td>58, 73</td>
</tr>
<tr>
<td>Levin, Saul M.</td>
<td>47, 92</td>
</tr>
<tr>
<td>Levine, Hary</td>
<td>82</td>
</tr>
<tr>
<td>Levine, Jerome</td>
<td>35</td>
</tr>
<tr>
<td>Levine, Krista A.</td>
<td>98</td>
</tr>
<tr>
<td>Levine, Ruth E.</td>
<td>47</td>
</tr>
<tr>
<td>Levine, Sharon S.</td>
<td>26</td>
</tr>
<tr>
<td>Levinson, Anthony J.</td>
<td>41</td>
</tr>
<tr>
<td>Levitan, Robert D.</td>
<td>81</td>
</tr>
<tr>
<td>Levitan, Anthony J.</td>
<td>64</td>
</tr>
<tr>
<td>Levy, Ken</td>
<td>82</td>
</tr>
<tr>
<td>Lewis, Lydia</td>
<td>60</td>
</tr>
<tr>
<td>Lewis, Timothy</td>
<td>100</td>
</tr>
<tr>
<td>Lewis, William B.</td>
<td>101</td>
</tr>
<tr>
<td>Lewis, William B.</td>
<td>101</td>
</tr>
<tr>
<td>Li, Ting-Kai</td>
<td>27</td>
</tr>
<tr>
<td>Liao, Kung-Tye</td>
<td>80</td>
</tr>
<tr>
<td>Libby, James</td>
<td>98</td>
</tr>
<tr>
<td>Liberman, Robert Paul</td>
<td>72, 95</td>
</tr>
<tr>
<td>Libert, Joseph G.</td>
<td>34</td>
</tr>
<tr>
<td>Licin, Julio</td>
<td>102</td>
</tr>
<tr>
<td>Lieber, Charles</td>
<td>70</td>
</tr>
<tr>
<td>Lieberman, Jeffrey A.</td>
<td>3, 22, 83, 102</td>
</tr>
<tr>
<td>Liebke, Michael R.</td>
<td>85, 99</td>
</tr>
<tr>
<td>Lieberman, Walter K.</td>
<td>48</td>
</tr>
<tr>
<td>Lifshitz, Lisa</td>
<td>54</td>
</tr>
<tr>
<td>Lim, Russell F.</td>
<td>8, 79</td>
</tr>
<tr>
<td>Limoges, Richard F.</td>
<td>49</td>
</tr>
<tr>
<td>Lin, Elizabeth H.B.</td>
<td>81</td>
</tr>
<tr>
<td>Lin, Elizabeth H.B.</td>
<td>81</td>
</tr>
<tr>
<td>Lin, Kho-Young</td>
<td>52, 72, 79, 88</td>
</tr>
<tr>
<td>Linaker, Olev M.</td>
<td>25</td>
</tr>
<tr>
<td>Lindemayer, Jean-Pierre</td>
<td>9</td>
</tr>
<tr>
<td>Lindhardt, Anne</td>
<td>50</td>
</tr>
<tr>
<td>Linehan, Marsha M.</td>
<td>81</td>
</tr>
<tr>
<td>Linke, Paul S.</td>
<td>102</td>
</tr>
<tr>
<td>Lion, John R.</td>
<td>27</td>
</tr>
<tr>
<td>Lionel, Solanush</td>
<td>73</td>
</tr>
<tr>
<td>Lipinski, Victoria</td>
<td>35</td>
</tr>
<tr>
<td>Lipsitz, Deborah</td>
<td>34</td>
</tr>
<tr>
<td>Lipsitz, Joshua D.</td>
<td>99</td>
</tr>
<tr>
<td>Little, Raye Z.</td>
<td>71</td>
</tr>
<tr>
<td>Little, John T.</td>
<td>32</td>
</tr>
<tr>
<td>Livesley, John</td>
<td>6, 53, 81</td>
</tr>
<tr>
<td>Lofch, Joel S.</td>
<td>91</td>
</tr>
<tr>
<td>Logsdon, Linda</td>
<td>49</td>
</tr>
<tr>
<td>Loh, James B.</td>
<td>88</td>
</tr>
<tr>
<td>Lohn, Joseph D.</td>
<td>30</td>
</tr>
<tr>
<td>Lomax II, James W.</td>
<td>67, 100</td>
</tr>
<tr>
<td>Lopez-Ibor, Jr., Juan</td>
<td>30, 75</td>
</tr>
<tr>
<td>Lonsy, Mikos F.</td>
<td>77</td>
</tr>
<tr>
<td>Louis, Robert J.</td>
<td>63</td>
</tr>
<tr>
<td>Lu, Francis G.</td>
<td>80, 90, 93</td>
</tr>
<tr>
<td>Lub, Joel F.</td>
<td>64</td>
</tr>
<tr>
<td>Lub, Lloyd D.</td>
<td>58</td>
</tr>
<tr>
<td>Lucas, Christopher</td>
<td>20</td>
</tr>
<tr>
<td>Lynch, Daniel J.</td>
<td>36</td>
</tr>
<tr>
<td>Lynch, Jennifer</td>
<td>64</td>
</tr>
<tr>
<td>Lue, Francis G.</td>
<td>80, 90, 93</td>
</tr>
<tr>
<td>Maccrindale, Fabio</td>
<td>102</td>
</tr>
<tr>
<td>Mackenzie, K. Roy</td>
<td>41, 96, 97</td>
</tr>
<tr>
<td>Mackinnon, Roger A.</td>
<td>24</td>
</tr>
<tr>
<td>Madaen, Donato</td>
<td>94</td>
</tr>
<tr>
<td>Maffei, Cesare</td>
<td>21</td>
</tr>
<tr>
<td>Maier, Gary J.</td>
<td>1, 45</td>
</tr>
<tr>
<td>Maine, Leslie A.</td>
<td>80</td>
</tr>
<tr>
<td>Magrath, Dr. Margaret</td>
<td>48</td>
</tr>
<tr>
<td>Melberg, Andre</td>
<td>72</td>
</tr>
<tr>
<td>Malcolm, Jr., Robert</td>
<td>33</td>
</tr>
<tr>
<td>Malpleso, Jose R.</td>
<td>5, 17, 41, 64, 72</td>
</tr>
<tr>
<td>Mallory, George L.</td>
<td>44</td>
</tr>
<tr>
<td>Malmoqurt, Carl P.</td>
<td>24, 68</td>
</tr>
<tr>
<td>Maloney, Ann S.</td>
<td>20, 26, 56</td>
</tr>
<tr>
<td>Mandel, Catherine L.</td>
<td>46, 85</td>
</tr>
<tr>
<td>Mangan, Russell R.</td>
<td>35</td>
</tr>
<tr>
<td>Marn, Edward</td>
<td>35</td>
</tr>
<tr>
<td>Marn, Stephen C.</td>
<td>78, 97</td>
</tr>
<tr>
<td>Marangall, Laurens B.</td>
<td>12, 60</td>
</tr>
<tr>
<td>Marazzit, Donatella</td>
<td>80</td>
</tr>
<tr>
<td>Marchant, Nestor F.</td>
<td>53</td>
</tr>
<tr>
<td>Marcus, Shelly</td>
<td>58, 84</td>
</tr>
<tr>
<td>Marcus, Steven</td>
<td>25, 53, 100</td>
</tr>
<tr>
<td>Marder, Stephen R.</td>
<td>12, 27</td>
</tr>
<tr>
<td>Margo, Geoffrey F.</td>
<td>88</td>
</tr>
<tr>
<td>Margo, Katherine</td>
<td>88</td>
</tr>
<tr>
<td>Markowitz, John C.</td>
<td>5, 24, 78, 96, 99</td>
</tr>
<tr>
<td>Marsella, Anthony J.</td>
<td>100</td>
</tr>
<tr>
<td>Marshall, Randall D.</td>
<td>24, 99</td>
</tr>
<tr>
<td>Martin, Peter R.</td>
<td>20</td>
</tr>
<tr>
<td>Martin, Susan E.</td>
<td>74</td>
</tr>
<tr>
<td>Martinez, E.</td>
<td>34</td>
</tr>
<tr>
<td>Martinez, Humberto L.</td>
<td>79</td>
</tr>
<tr>
<td>Masah, Irene</td>
<td>80</td>
</tr>
<tr>
<td>Masand, Praklash S.</td>
<td>2, 11</td>
</tr>
<tr>
<td>Masella, Maria</td>
<td>102</td>
</tr>
<tr>
<td>Mason, Barbara J.</td>
<td>33</td>
</tr>
<tr>
<td>Mason, Geoffrey J.</td>
<td>91</td>
</tr>
<tr>
<td>Mason, Sally J.</td>
<td>10</td>
</tr>
<tr>
<td>Massie, Mary Jane</td>
<td>67</td>
</tr>
<tr>
<td>Masten, James</td>
<td>101</td>
</tr>
<tr>
<td>Masterson, James F.</td>
<td>6, 24</td>
</tr>
<tr>
<td>Mathe, Anelina</td>
<td>73</td>
</tr>
<tr>
<td>Matthews, John D.</td>
<td>49</td>
</tr>
<tr>
<td>Merisaskalainen, Maia R.</td>
<td>72</td>
</tr>
<tr>
<td>Meyer, Lauren</td>
<td>35</td>
</tr>
<tr>
<td>Mayor, Karenine F.</td>
<td>25</td>
</tr>
<tr>
<td>Meyers, David V.</td>
<td>67</td>
</tr>
<tr>
<td>Mazumder, Satyendranath</td>
<td>47</td>
</tr>
<tr>
<td>Mazurkiewicz, Michael F.</td>
<td>41, 78</td>
</tr>
<tr>
<td>McCaff, W. Vaughan</td>
<td>7, 8</td>
</tr>
<tr>
<td>McCarty, Cheryl F.</td>
<td>18, 26</td>
</tr>
<tr>
<td>McCarron, Harriet</td>
<td>35</td>
</tr>
<tr>
<td>McChord, Richard A.</td>
<td>25</td>
</tr>
<tr>
<td>McCullum-Smith, Cheryl B.</td>
<td>47</td>
</tr>
<tr>
<td>McCullum-Smith, Rob</td>
<td>47</td>
</tr>
<tr>
<td>McDaniel, Stephen</td>
<td>57</td>
</tr>
<tr>
<td>McDaniel, Susan</td>
<td>17, 40</td>
</tr>
<tr>
<td>McDevitt, Robert J.</td>
<td>8</td>
</tr>
<tr>
<td>McDonough, Christopher</td>
<td>7</td>
</tr>
<tr>
<td>McDowell, David M.</td>
<td>50, 58, 65, 70, 88</td>
</tr>
<tr>
<td>McElroy, Susan L.</td>
<td>15, 31, 39, 54</td>
</tr>
<tr>
<td>McFarland, Benten H.</td>
<td>48</td>
</tr>
<tr>
<td>McFarlane, A.</td>
<td>81</td>
</tr>
<tr>
<td>McSweeney, Elizabeth L.</td>
<td>48</td>
</tr>
<tr>
<td>McSlaughan, Thomas H.</td>
<td>24, 71, 77, 81</td>
</tr>
<tr>
<td>McSion, The Honorable George</td>
<td>46</td>
</tr>
<tr>
<td>Name</td>
<td>Number</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Peyser, Herbert S</td>
<td>50</td>
</tr>
<tr>
<td>Petty, Richard G</td>
<td>3, 21</td>
</tr>
<tr>
<td>Peiro, Janis B.</td>
<td>45</td>
</tr>
<tr>
<td>Peyser, Herbert S</td>
<td>50</td>
</tr>
<tr>
<td>Pfister, Bettina</td>
<td>12</td>
</tr>
<tr>
<td>Pfaff, Steven E</td>
<td>12</td>
</tr>
<tr>
<td>Pflueger, Steven J</td>
<td>63</td>
</tr>
<tr>
<td>Phillips, Katherine A</td>
<td>88, 77, 90, 98</td>
</tr>
<tr>
<td>Phillips, Mary L</td>
<td>100</td>
</tr>
<tr>
<td>Pihlgren, Hans</td>
<td>49</td>
</tr>
<tr>
<td>Pickens, Ronald W</td>
<td>99</td>
</tr>
<tr>
<td>Picard, Bertrand</td>
<td>36</td>
</tr>
<tr>
<td>Pike, Ronald W</td>
<td>99</td>
</tr>
<tr>
<td>Pihlgren, Hans</td>
<td>49</td>
</tr>
<tr>
<td>Pikler, Roger K</td>
<td>81</td>
</tr>
<tr>
<td>Pitts, Gloria</td>
<td>91</td>
</tr>
<tr>
<td>von Ramm, Eric M.</td>
<td>34, 69, 79</td>
</tr>
<tr>
<td>Piotrowski, Paul M</td>
<td>11</td>
</tr>
<tr>
<td>Pogge, David L</td>
<td>48</td>
</tr>
<tr>
<td>Pope, Brian</td>
<td>73</td>
</tr>
<tr>
<td>Polanski, Hans</td>
<td>72</td>
</tr>
<tr>
<td>Policastro, Luciana A</td>
<td>50</td>
</tr>
<tr>
<td>Popper, Bruce G</td>
<td>3, 47</td>
</tr>
<tr>
<td>Popp, William C</td>
<td>6</td>
</tr>
<tr>
<td>Porfors, Bernt C</td>
<td>79</td>
</tr>
<tr>
<td>Porst, Jerold M</td>
<td>57, 64</td>
</tr>
<tr>
<td>Post, Robert M</td>
<td>31, 32</td>
</tr>
<tr>
<td>Postero, Lucia T</td>
<td>98</td>
</tr>
<tr>
<td>Porter, Aro M.</td>
<td>96</td>
</tr>
<tr>
<td>Powell, David A.</td>
<td>27</td>
</tr>
<tr>
<td>Prathikanti, Sudha</td>
<td>93</td>
</tr>
<tr>
<td>Pretza, Silvia</td>
<td>80</td>
</tr>
<tr>
<td>Pretzer, Maurice</td>
<td>52</td>
</tr>
<tr>
<td>Preyer, Mark D.</td>
<td>68</td>
</tr>
<tr>
<td>Preyer, William T</td>
<td>1</td>
</tr>
<tr>
<td>Price, Marilyn</td>
<td>96</td>
</tr>
<tr>
<td>Prin, Annelle</td>
<td>19, 19</td>
</tr>
<tr>
<td>Prin, Denise B.</td>
<td>39, 60</td>
</tr>
<tr>
<td>Proctor, Mark A.</td>
<td>51</td>
</tr>
<tr>
<td>Proctor, Paul</td>
<td>102</td>
</tr>
<tr>
<td>Puchalski, Christina M</td>
<td>68, 62, 96</td>
</tr>
<tr>
<td>Pumariega, Andres J</td>
<td>35, 79</td>
</tr>
<tr>
<td>Purnuk, Scott E.</td>
<td>87</td>
</tr>
<tr>
<td>Pynoos, Robert S.</td>
<td>27</td>
</tr>
<tr>
<td>Q</td>
<td></td>
</tr>
<tr>
<td>Quadrio, Carolynn</td>
<td>31</td>
</tr>
<tr>
<td>Queveda, Ignacio</td>
<td>6</td>
</tr>
<tr>
<td>Quercioli, Leonardo</td>
<td>80</td>
</tr>
<tr>
<td>Quinn-Dempsey, Judge Julia</td>
<td>24</td>
</tr>
<tr>
<td>R</td>
<td></td>
</tr>
<tr>
<td>Radke, Alan Q.</td>
<td>44</td>
</tr>
<tr>
<td>Rahm, Pamela</td>
<td>35</td>
</tr>
<tr>
<td>Ralston, Elizabeth</td>
<td>81</td>
</tr>
<tr>
<td>Rambo, Brenda</td>
<td>35, 54, 100</td>
</tr>
<tr>
<td>Ramírez, Dilip F.</td>
<td>73</td>
</tr>
<tr>
<td>Ramírez, Luis F.</td>
<td>64</td>
</tr>
<tr>
<td>Ramírez, Paul M</td>
<td>51</td>
</tr>
<tr>
<td>Ranen, Neal G.</td>
<td>35</td>
</tr>
<tr>
<td>Rankin, Meridith A.</td>
<td>49</td>
</tr>
<tr>
<td>Rao, Nyapati R.</td>
<td>91</td>
</tr>
<tr>
<td>Rapin, Andrea</td>
<td>31</td>
</tr>
<tr>
<td>Rapoport, Judith H.</td>
<td>83, 93</td>
</tr>
<tr>
<td>Rappaport, Maurice</td>
<td>75</td>
</tr>
<tr>
<td>Rasgon, Natalie L.</td>
<td>31</td>
</tr>
<tr>
<td>Raskind, Murray A.</td>
<td>6, 63</td>
</tr>
<tr>
<td>Rasmussen, Keith</td>
<td>16</td>
</tr>
<tr>
<td>Rasmussen, Steven A</td>
<td>77</td>
</tr>
<tr>
<td>Ratliff, Brenda</td>
<td>5</td>
</tr>
<tr>
<td>Ratenbury, Francine</td>
<td>77</td>
</tr>
<tr>
<td>Ratzi, Luigi</td>
<td>80</td>
</tr>
<tr>
<td>Ray, Frances</td>
<td>94</td>
</tr>
<tr>
<td>Rayford, Brett S.</td>
<td>45</td>
</tr>
<tr>
<td>Recuperio, Patricia R</td>
<td>68, 96</td>
</tr>
<tr>
<td>Redei, Eva</td>
<td>102</td>
</tr>
<tr>
<td>Reed, James</td>
<td>25</td>
</tr>
<tr>
<td>Reich, James H.</td>
<td>71, 84</td>
</tr>
<tr>
<td>Reich, Theodore A.</td>
<td>10, 79</td>
</tr>
<tr>
<td>Reichman, William E</td>
<td>40, 64</td>
</tr>
<tr>
<td>Reid, William H.</td>
<td>68</td>
</tr>
<tr>
<td>Reddy, Phyllis</td>
<td>54, 77</td>
</tr>
<tr>
<td>Reddington, D.F.</td>
<td>45</td>
</tr>
<tr>
<td>Repasy, Philipp</td>
<td>73</td>
</tr>
<tr>
<td>Reznick, Heidi S.</td>
<td>81</td>
</tr>
<tr>
<td>Reznick, Philip J.</td>
<td>1, 16, 39, 64, 91, 96</td>
</tr>
<tr>
<td>Reynolds, Madge A.</td>
<td>32</td>
</tr>
<tr>
<td>Reynolds, Madge C.</td>
<td>47, 89, 99</td>
</tr>
<tr>
<td>Rhine, Robert</td>
<td>46</td>
</tr>
<tr>
<td>Ribet, Michelle</td>
<td>8, 11, 30, 50, 55, 69, 74</td>
</tr>
<tr>
<td>Richardson, Gary</td>
<td>7</td>
</tr>
<tr>
<td>Richardson, James W</td>
<td>51</td>
</tr>
<tr>
<td>Richardson, William J</td>
<td>49</td>
</tr>
<tr>
<td>Richman, Judy</td>
<td>34</td>
</tr>
<tr>
<td>Richter, Margaret A</td>
<td>101</td>
</tr>
<tr>
<td>Richter, Paul</td>
<td>78</td>
</tr>
<tr>
<td>Riddle, Mark A.</td>
<td>80</td>
</tr>
<tr>
<td>Read, Ronald O.</td>
<td>100</td>
</tr>
<tr>
<td>Rigamer, Eime F.</td>
<td>43</td>
</tr>
<tr>
<td>Rinhart, Zoltan</td>
<td>49</td>
</tr>
<tr>
<td>Riley, Larry</td>
<td>45</td>
</tr>
<tr>
<td>Rimmel, Zoltan</td>
<td>95</td>
</tr>
<tr>
<td>Ritzi, Joselyn</td>
<td>77</td>
</tr>
<tr>
<td>Rivas, Juan C.</td>
<td>6</td>
</tr>
<tr>
<td>Rito, Jonathan</td>
<td>20</td>
</tr>
<tr>
<td>Rizzuto, Albert A.</td>
<td>61</td>
</tr>
<tr>
<td>Roberts, Trevor</td>
<td>87</td>
</tr>
<tr>
<td>Roberts, Jacqueline</td>
<td>99</td>
</tr>
<tr>
<td>Roberts, James</td>
<td>33</td>
</tr>
<tr>
<td>Roberts, Jennifer</td>
<td>81</td>
</tr>
<tr>
<td>Roberts, Jessica G.</td>
<td>49</td>
</tr>
<tr>
<td>Roberts, Laura W.</td>
<td>83</td>
</tr>
<tr>
<td>Roberts, Lisa J.</td>
<td>54</td>
</tr>
<tr>
<td>Roberts, Mary W.</td>
<td>84</td>
</tr>
<tr>
<td>Roberts, Scott</td>
<td>98</td>
</tr>
<tr>
<td>Robertson, Michael</td>
<td>64</td>
</tr>
<tr>
<td>Robinovitz, Carolynn</td>
<td>44, 65, 78</td>
</tr>
<tr>
<td>Robinson, Gill E.</td>
<td>5, 31</td>
</tr>
<tr>
<td>Robinson, Robert G.</td>
<td>2, 35</td>
</tr>
<tr>
<td>Rock, Catherine A.</td>
<td>2, 31</td>
</tr>
<tr>
<td>Rodenhausen, Paul</td>
<td>28</td>
</tr>
<tr>
<td>Rodin, Gary M.</td>
<td>88</td>
</tr>
<tr>
<td>Rody, Elizabeth J.</td>
<td>28</td>
</tr>
<tr>
<td>Rose, Mary H.</td>
<td>84, 85</td>
</tr>
<tr>
<td>Rosen, Israel</td>
<td>96</td>
</tr>
<tr>
<td>Roll, Linda</td>
<td>27</td>
</tr>
<tr>
<td>Roland, John S.</td>
<td>40</td>
</tr>
<tr>
<td>Rome, Lee H.</td>
<td>69</td>
</tr>
<tr>
<td>Romero-Torrata, Josie</td>
<td>64</td>
</tr>
<tr>
<td>Rondon, Marta B.</td>
<td>50</td>
</tr>
<tr>
<td>Rondinigstam, Elsa F</td>
<td>21</td>
</tr>
<tr>
<td>Rooney, Marilyn T.</td>
<td>8</td>
</tr>
<tr>
<td>Roos, Steven P.</td>
<td>9, 24</td>
</tr>
<tr>
<td>Rotty, Mark A.</td>
<td>54</td>
</tr>
<tr>
<td>Rosario-Campos, Maria C.R.</td>
<td>101</td>
</tr>
<tr>
<td>Rose, Christine</td>
<td>53</td>
</tr>
<tr>
<td>Rosebush, Patricia I</td>
<td>41, 78</td>
</tr>
<tr>
<td>Rosen, Raymond</td>
<td>7</td>
</tr>
<tr>
<td>Rosenbaum, Jerold F.</td>
<td>7, 15, 24, 49, 94</td>
</tr>
<tr>
<td>Rosenblum, Howard</td>
<td>41</td>
</tr>
<tr>
<td>Rosenfeld, J. Peter</td>
<td>64</td>
</tr>
<tr>
<td>Rosenheck, Robert A</td>
<td>25</td>
</tr>
<tr>
<td>Rosenblum, David A.</td>
<td>57</td>
</tr>
<tr>
<td>Rothstein, David A.</td>
<td>57</td>
</tr>
<tr>
<td>Rothstein, Kenneth</td>
<td>25</td>
</tr>
<tr>
<td>Rowan, Amy B.</td>
<td>96</td>
</tr>
<tr>
<td>Roy-Syme, Ruth M.</td>
<td>81</td>
</tr>
<tr>
<td>Rozmari, Eyal</td>
<td>57</td>
</tr>
<tr>
<td>Rube, David M.</td>
<td>80</td>
</tr>
<tr>
<td>Rubenauer, Leonard G.</td>
<td>25</td>
</tr>
<tr>
<td>Rubin, Howard C.</td>
<td>21</td>
</tr>
<tr>
<td>Rubinow, David R.</td>
<td>2, 6, 31</td>
</tr>
<tr>
<td>Rudies, John R.</td>
<td>28</td>
</tr>
<tr>
<td>Rue, Dan S.</td>
<td>71, 60</td>
</tr>
<tr>
<td>Ruffolo, Giuseppe</td>
<td>94</td>
</tr>
<tr>
<td>Ruiz, Pedro</td>
<td>11, 21, 22, 24, 26, 42, 44, 52, 60, 73, 74, 79, 96</td>
</tr>
<tr>
<td>Ruiz Lopez, Alejandra</td>
<td>50</td>
</tr>
<tr>
<td>Rummans, Teresa A.</td>
<td>78</td>
</tr>
<tr>
<td>Rush, A. John</td>
<td>12, 79</td>
</tr>
<tr>
<td>Rusin, David</td>
<td>51</td>
</tr>
<tr>
<td>Russ, Mark J.</td>
<td>95</td>
</tr>
<tr>
<td>Russo, Joan</td>
<td>48, 50</td>
</tr>
<tr>
<td>Rutz, Wolfgang</td>
<td>69</td>
</tr>
<tr>
<td>Ryan, Anne T.</td>
<td>68</td>
</tr>
<tr>
<td>Ryan, Delzio M.</td>
<td>8</td>
</tr>
<tr>
<td>Ryan, Neil D.</td>
<td>17</td>
</tr>
<tr>
<td>Ryan, Ruth M.</td>
<td>17</td>
</tr>
<tr>
<td>Rylich, Abe M.</td>
<td>48</td>
</tr>
<tr>
<td>Ryman, Edward K.</td>
<td>40, 69</td>
</tr>
<tr>
<td>S</td>
<td></td>
</tr>
<tr>
<td>Sabin, James</td>
<td>99</td>
</tr>
<tr>
<td>Sacco, Linda</td>
<td>73</td>
</tr>
<tr>
<td>Sachs, Gary S.</td>
<td>60, 63</td>
</tr>
<tr>
<td>Sacks, Nadia</td>
<td>32</td>
</tr>
<tr>
<td>Saclen, Harold A.</td>
<td>59</td>
</tr>
<tr>
<td>Sackeim, Harold A.</td>
<td>32</td>
</tr>
<tr>
<td>Safar, Jeremy</td>
<td>97</td>
</tr>
<tr>
<td>Sajinstic, Martha</td>
<td>64, 96</td>
</tr>
<tr>
<td>Salama, Aziz</td>
<td>61</td>
</tr>
<tr>
<td>Saltz, Floyd R.</td>
<td>80</td>
</tr>
<tr>
<td>Saltzman, Carl.</td>
<td>2</td>
</tr>
<tr>
<td>Samuel, Steven E.</td>
<td>31</td>
</tr>
<tr>
<td>Samuel, Jack F.</td>
<td>80</td>
</tr>
<tr>
<td>Sanchez, Andrew</td>
<td>35</td>
</tr>
<tr>
<td>Santen, Paula D.</td>
<td>33</td>
</tr>
<tr>
<td>Sanderson, Cynthia</td>
<td>54</td>
</tr>
<tr>
<td>Sanguineti, Vincenzo</td>
<td>6, 21, 96</td>
</tr>
<tr>
<td>Sanjurjo, Teresita</td>
<td>20, 52</td>
</tr>
<tr>
<td>Name</td>
<td>Page</td>
</tr>
<tr>
<td>-----------------------</td>
<td>------</td>
</tr>
<tr>
<td>Sartorius, Norman</td>
<td>45</td>
</tr>
<tr>
<td>Sarver-Foner, Gerald J.</td>
<td>33</td>
</tr>
<tr>
<td>Gasian, Yehuda</td>
<td>80</td>
</tr>
<tr>
<td>Safi, Sally L</td>
<td>17</td>
</tr>
<tr>
<td>Sait, Neal R</td>
<td>28</td>
</tr>
<tr>
<td>Sauer, Marie C</td>
<td>88</td>
</tr>
<tr>
<td>Saraceni, Shikhaan</td>
<td>76</td>
</tr>
<tr>
<td>Schacter, Daniel L</td>
<td>55</td>
</tr>
<tr>
<td>Schatzberg, Alan F</td>
<td>3, 7, 23, 72</td>
</tr>
<tr>
<td>Schellin, Alan W</td>
<td>17, 56</td>
</tr>
<tr>
<td>Scheiber, Stephen C</td>
<td>21</td>
</tr>
<tr>
<td>Scheier, Donald J</td>
<td>26</td>
</tr>
<tr>
<td>Schofer, Randolph B</td>
<td>35</td>
</tr>
<tr>
<td>Schindler, Barbara A</td>
<td>73</td>
</tr>
<tr>
<td>Schindler, Kim M</td>
<td>101</td>
</tr>
<tr>
<td>Schlosser, Sandra</td>
<td>94</td>
</tr>
<tr>
<td>Schild, James</td>
<td>32, 100</td>
</tr>
<tr>
<td>Schmidt, Mark E</td>
<td>24</td>
</tr>
<tr>
<td>Schmidt, Peter J</td>
<td>2, 6, 31</td>
</tr>
<tr>
<td>Schmidt, Jr., Chester W</td>
<td>26, 74</td>
</tr>
<tr>
<td>Schedler, Donald J</td>
<td>26</td>
</tr>
<tr>
<td>Schepik, Stephen C</td>
<td>21</td>
</tr>
<tr>
<td>Schlosser, Sandra</td>
<td>94</td>
</tr>
<tr>
<td>Schmidl, James</td>
<td>32, 100</td>
</tr>
<tr>
<td>Schmit, E</td>
<td>24</td>
</tr>
<tr>
<td>Schmitt, Karen K</td>
<td>90</td>
</tr>
<tr>
<td>Schmitz, R. Andrew</td>
<td>69</td>
</tr>
<tr>
<td>Schulz, S. Charles</td>
<td>15, 39</td>
</tr>
<tr>
<td>Schuyler, Dean</td>
<td>27</td>
</tr>
<tr>
<td>Schwebel, John J</td>
<td>33</td>
</tr>
<tr>
<td>Schwartz, Bruce J</td>
<td>48, 53</td>
</tr>
<tr>
<td>Schwartz, Joseph E</td>
<td>78</td>
</tr>
<tr>
<td>Schneidman, Michael M</td>
<td>68, 71</td>
</tr>
<tr>
<td>Scholten, Mary Spelman</td>
<td>96</td>
</tr>
<tr>
<td>Schott, Alwyn</td>
<td>6, 21</td>
</tr>
<tr>
<td>Scott, C. Paul</td>
<td>68</td>
</tr>
<tr>
<td>Scott, Charles L</td>
<td>101</td>
</tr>
<tr>
<td>Scott, Jan</td>
<td>12</td>
</tr>
<tr>
<td>Scott, Bruce W</td>
<td>1</td>
</tr>
<tr>
<td>Scofly, J., Thomas H.</td>
<td>21, 42, 74, 91</td>
</tr>
<tr>
<td>Sebel, John R</td>
<td>90</td>
</tr>
<tr>
<td>Sederer, Lloyd I</td>
<td>34, 53</td>
</tr>
<tr>
<td>Seeman, Mary V</td>
<td>55</td>
</tr>
<tr>
<td>Segal, Richard</td>
<td>95</td>
</tr>
<tr>
<td>Segars, R. Taylor</td>
<td>55</td>
</tr>
<tr>
<td>Seidt, Larry</td>
<td>34</td>
</tr>
<tr>
<td>Sellman, Roslyn</td>
<td>40</td>
</tr>
<tr>
<td>Shelton, Shereen E</td>
<td>54</td>
</tr>
<tr>
<td>Senior, Carl</td>
<td>100</td>
</tr>
<tr>
<td>Senior, Graeme J</td>
<td>94</td>
</tr>
<tr>
<td>Sephton, Sandra E</td>
<td>54</td>
</tr>
<tr>
<td>Senvis, Mark E</td>
<td>58, 73</td>
</tr>
<tr>
<td>Shadaran, Richard A</td>
<td>90</td>
</tr>
<tr>
<td>Shafl, Mohammad</td>
<td>27, 51</td>
</tr>
<tr>
<td>Shamer, Andrew L</td>
<td>54</td>
</tr>
<tr>
<td>Shanklin, Anne V</td>
<td>77</td>
</tr>
<tr>
<td>Shapiro, Edward R</td>
<td>56, 69</td>
</tr>
<tr>
<td>Shapiro, Gabrielle L</td>
<td>15</td>
</tr>
<tr>
<td>Shapiro, Peter A</td>
<td>25, 93</td>
</tr>
<tr>
<td>Sharfstein, Steven S</td>
<td>33, 53</td>
</tr>
<tr>
<td>Sharma, Raj P</td>
<td>27</td>
</tr>
<tr>
<td>Shavitt, Rosal G</td>
<td>101</td>
</tr>
<tr>
<td>Shaw, Alan R</td>
<td>16</td>
</tr>
<tr>
<td>Shaywitz, Sally E</td>
<td>76</td>
</tr>
<tr>
<td>Shek, M. Tracey</td>
<td>71, 78</td>
</tr>
<tr>
<td>Shek, Shawn C</td>
<td>1, 17</td>
</tr>
<tr>
<td>Shear, M. Katherine</td>
<td>72</td>
</tr>
<tr>
<td>Sheler, Jonathan</td>
<td>53</td>
</tr>
<tr>
<td>Sheehan, David V</td>
<td>61, 83</td>
</tr>
<tr>
<td>Sheehan, Joseph P</td>
<td>100</td>
</tr>
<tr>
<td>Sheldon, Tess</td>
<td>81</td>
</tr>
<tr>
<td>Shelton, Ronald A</td>
<td>26, 61</td>
</tr>
<tr>
<td>Shenkin, Solveyn</td>
<td>61</td>
</tr>
<tr>
<td>Sherer, Arlene G</td>
<td>67</td>
</tr>
<tr>
<td>Sherwin, Barbara B</td>
<td>31</td>
</tr>
<tr>
<td>Shin, David M</td>
<td>17, 41, 55, 69, 72, 81, 95</td>
</tr>
<tr>
<td>Shires, Carol</td>
<td>40</td>
</tr>
<tr>
<td>Shirk, Margaret G</td>
<td>24</td>
</tr>
<tr>
<td>Shirls, Deborah</td>
<td>26, 51, 73, 89</td>
</tr>
<tr>
<td>Shlesinger, J.</td>
<td>73</td>
</tr>
<tr>
<td>Shermas, Nelly</td>
<td>81</td>
</tr>
<tr>
<td>Shoib, Harvey</td>
<td>68</td>
</tr>
<tr>
<td>Shimbly, Susan</td>
<td>68</td>
</tr>
<tr>
<td>Stegall, Thomas B</td>
<td>34</td>
</tr>
<tr>
<td>Stein, Stephen M</td>
<td>82, 83</td>
</tr>
<tr>
<td>Starnes, Nelly</td>
<td>32</td>
</tr>
<tr>
<td>Stanger, Ronnie S</td>
<td>26, 67, 83</td>
</tr>
<tr>
<td>Stanley, Barbara</td>
<td>52</td>
</tr>
<tr>
<td>Stark, Michael</td>
<td>56</td>
</tr>
<tr>
<td>Starky, Robert S</td>
<td>20</td>
</tr>
<tr>
<td>Stasko, Robert S</td>
<td>21</td>
</tr>
<tr>
<td>Steiger, Howard</td>
<td>81</td>
</tr>
<tr>
<td>Stein, Dan</td>
<td>12</td>
</tr>
<tr>
<td>Stein, E. D.</td>
<td>49</td>
</tr>
<tr>
<td>Stein, Minna</td>
<td>7, 12</td>
</tr>
<tr>
<td>Stein, Seth P</td>
<td>50</td>
</tr>
<tr>
<td>Steinberg, Maurice D.</td>
<td>66</td>
</tr>
<tr>
<td>Steinberg, Susanne I.</td>
<td>97</td>
</tr>
<tr>
<td>Shaffer, H.</td>
<td>10</td>
</tr>
<tr>
<td>Steiner, M.</td>
<td>2, 99</td>
</tr>
<tr>
<td>Stein, Nicholas</td>
<td>53</td>
</tr>
<tr>
<td>Stearns, M. R.</td>
<td>64</td>
</tr>
<tr>
<td>Stem, D.</td>
<td>47</td>
</tr>
<tr>
<td>Stemberg, Esther M</td>
<td>102</td>
</tr>
<tr>
<td>Steen, Glen</td>
<td>101</td>
</tr>
<tr>
<td>Stevens, Donna</td>
<td>47</td>
</tr>
<tr>
<td>Stewart, Alisa J</td>
<td>33</td>
</tr>
<tr>
<td>Stewart, Donna S</td>
<td>16, 26, 31, 57, 60</td>
</tr>
<tr>
<td>Stiglioli, Sarah</td>
<td>72</td>
</tr>
<tr>
<td>Stigler, M.</td>
<td>34</td>
</tr>
<tr>
<td>Stiles, John M</td>
<td>48</td>
</tr>
<tr>
<td>Stoltey, Steve</td>
<td>6</td>
</tr>
<tr>
<td>Stone, Alan A</td>
<td>30, 47, 55, 60, 99</td>
</tr>
<tr>
<td>Stone, Michael H</td>
<td>43, 77</td>
</tr>
<tr>
<td>Stone, Walter N</td>
<td>5</td>
</tr>
<tr>
<td>Stone, Mary E.</td>
<td>21</td>
</tr>
<tr>
<td>Stottard, Nada L</td>
<td>18, 31, 36, 44, 50, 57, 78, 99</td>
</tr>
<tr>
<td>Stout, Robert L</td>
<td>2, 6</td>
</tr>
<tr>
<td>Stowe, Zachary N</td>
<td>3, 99</td>
</tr>
<tr>
<td>Stroder, James R</td>
<td>2</td>
</tr>
<tr>
<td>Strain, James L</td>
<td>27</td>
</tr>
<tr>
<td>Straker, David</td>
<td>52</td>
</tr>
<tr>
<td>Strakowski, Stephen M.</td>
<td>31</td>
</tr>
<tr>
<td>Strasburg, Victor</td>
<td>81</td>
</tr>
<tr>
<td>Strauss, Gordon D</td>
<td>68</td>
</tr>
<tr>
<td>Street, Annett</td>
<td>34</td>
</tr>
<tr>
<td>Strekal, Jon M</td>
<td>32</td>
</tr>
<tr>
<td>Strecker, Dorothy</td>
<td>10</td>
</tr>
<tr>
<td>Strom, Charles</td>
<td>47</td>
</tr>
<tr>
<td>Strong, Bradley W</td>
<td>20</td>
</tr>
<tr>
<td>Strange, Barri Katz</td>
<td>59</td>
</tr>
<tr>
<td>Stuart, K.</td>
<td>25</td>
</tr>
<tr>
<td>Stuart, Scott P</td>
<td>64, 99</td>
</tr>
<tr>
<td>Name</td>
<td>Pages</td>
</tr>
<tr>
<td>-----------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Winston, Arnold</td>
<td>97</td>
</tr>
<tr>
<td>Wisnig, Donna A</td>
<td>12</td>
</tr>
<tr>
<td>Wise, Roy A</td>
<td>3</td>
</tr>
<tr>
<td>Wise, Thomas N</td>
<td>30, 76</td>
</tr>
<tr>
<td>Wiseman, Claire</td>
<td>54, 69</td>
</tr>
<tr>
<td>Wisner, Katherine L</td>
<td>10, 97</td>
</tr>
<tr>
<td>Wilham, Terence</td>
<td>73</td>
</tr>
<tr>
<td>Witterhoff, Suzanne T</td>
<td>44, 64</td>
</tr>
<tr>
<td>Wolf, Charles J</td>
<td>26</td>
</tr>
<tr>
<td>Wolf, Marion E</td>
<td>21</td>
</tr>
<tr>
<td>Wolniak, Mark L</td>
<td>63</td>
</tr>
<tr>
<td>Wonderlich, Stephen A</td>
<td>54, 81</td>
</tr>
<tr>
<td>Wong, Mei-Li</td>
<td>102</td>
</tr>
<tr>
<td>Woods, Donna M</td>
<td>43, 81, 82</td>
</tr>
<tr>
<td>Woods, Scott W</td>
<td>63, 77</td>
</tr>
<tr>
<td>Woodside, D. Blake</td>
<td>70</td>
</tr>
<tr>
<td>Woolley, Stephen B</td>
<td>94</td>
</tr>
<tr>
<td>Wooten, R. Greg</td>
<td>44</td>
</tr>
<tr>
<td>Wortnehr, Fritz</td>
<td>45</td>
</tr>
<tr>
<td>Worley, Linda L.M.</td>
<td>25</td>
</tr>
<tr>
<td>Worthington III, John</td>
<td>94</td>
</tr>
<tr>
<td>Wozniak, Steven T</td>
<td>90</td>
</tr>
<tr>
<td>Wright, Harry H</td>
<td>20</td>
</tr>
<tr>
<td>Wright, Jesse H</td>
<td>40</td>
</tr>
<tr>
<td>Wulzis, Lawson R</td>
<td>25, 48</td>
</tr>
<tr>
<td>Yager, Joel</td>
<td>5, 44, 48, 54, 65, 72</td>
</tr>
<tr>
<td>Yates, Alinea</td>
<td>70</td>
</tr>
<tr>
<td>Yeh, Eng-Kung</td>
<td>45</td>
</tr>
<tr>
<td>Yehuda, Rachel</td>
<td>32, 45, 81, 81</td>
</tr>
<tr>
<td>Yoonama, Frank E</td>
<td>82, 88</td>
</tr>
<tr>
<td>Yosewage, Jerome A</td>
<td>73</td>
</tr>
<tr>
<td>Yeung, Albert</td>
<td>25, 94</td>
</tr>
<tr>
<td>Yeung, Paul P</td>
<td>44</td>
</tr>
<tr>
<td>Ying, Kin Ng. Nenke</td>
<td>81</td>
</tr>
<tr>
<td>Yonnari, Kimberly A</td>
<td>79</td>
</tr>
<tr>
<td>Yoon, Susanne</td>
<td>12, 80</td>
</tr>
<tr>
<td>Young, Elizabeth A</td>
<td>81</td>
</tr>
<tr>
<td>Young, Keith W</td>
<td>20, 26, 58</td>
</tr>
<tr>
<td>Young, Larry</td>
<td>15</td>
</tr>
<tr>
<td>Young, Simon</td>
<td>81</td>
</tr>
<tr>
<td>Yousuf, Hansa A</td>
<td>98</td>
</tr>
<tr>
<td>Yudofsky, Stuart C</td>
<td>15, 39, 101</td>
</tr>
<tr>
<td>Yusuf, Theresa A</td>
<td>96</td>
</tr>
<tr>
<td>Zaccarino, Michele L</td>
<td>48</td>
</tr>
<tr>
<td>Zagar, Robert J</td>
<td>24</td>
</tr>
<tr>
<td>Zajacka, John M</td>
<td>15, 83</td>
</tr>
<tr>
<td>Zanarini, Mary C</td>
<td>32, 71, 78, 79</td>
</tr>
<tr>
<td>Zarrin, Deborah A</td>
<td>53, 90, 97</td>
</tr>
<tr>
<td>Zaubler, Thomas</td>
<td>80</td>
</tr>
<tr>
<td>Zaylor, Charles L</td>
<td>20</td>
</tr>
<tr>
<td>Zborowski, Michael</td>
<td>72</td>
</tr>
<tr>
<td>Zelkowicz, Phyllis</td>
<td>81</td>
</tr>
<tr>
<td>Zerbe, Kathryn J</td>
<td>41</td>
</tr>
<tr>
<td>Zehn, Mark</td>
<td>57</td>
</tr>
<tr>
<td>Zheng, Fusheng</td>
<td>71</td>
</tr>
<tr>
<td>Zheng, Wen Li</td>
<td>101</td>
</tr>
<tr>
<td>Zhulian, Barbara</td>
<td>34, 79</td>
</tr>
<tr>
<td>Zibin, Gall</td>
<td>31</td>
</tr>
<tr>
<td>Ziedonis, Douglas M</td>
<td>35, 50, 54, 77, 100</td>
</tr>
<tr>
<td>Zisook, Sidney</td>
<td>47</td>
</tr>
<tr>
<td>Zohar, Joseph</td>
<td>12, 80</td>
</tr>
<tr>
<td>Zweig-Frank, Hallie</td>
<td>71</td>
</tr>
</tbody>
</table>
Grow professionally and increase your knowledge of psychiatric practices through the APPG Bookstore. Our extensive selection of topics and titles allows you to pick-up the titles you've always wanted or find a title to complete series collections and annual reviews. We look forward to seeing you!

American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders (Compendium 2000)
American Psychiatric Association
2000 • 768 pages • ISBN 0-89042-315-6 • paperback
$49.95 • Order #2315
2000 • 768 pages • ISBN 0-89042-312-1 • hardcover
$64.95 • Order #2312

Edited by C. Edward Coffey, M.D., and Jeffrey L. Cummings, M.D.
2000 • 1088 pages • ISBN 0-88048-841-1 • hardcover
$150.00 • Order #8841

Handbook of Psychiatric Measures
American Psychiatric Association
hardcover & CD-ROM • $79.95 • Order #2415

Psychodynamic Psychiatry in Clinical Practice, Third Edition
By Glen O. Gabbard, M.D.
2000 • 816 pages • ISBN 1-58562-002-5
hardcover • $79.95 • Order #62002

Review of Psychiatry, Volume 19
Edited by John M. Oldham, M.D. and Michelle B. Riba, M.D.

Learning Disabilities
Implications for Psychiatric Treatment
Edited by Laurence L. Greenhill, M.D.
2000 • 196 pages • ISBN 0-88048-383-0 • paperback
$38.50 • Order #3833

Psychotherapy for Personality Disorders
Edited by John G. Gunderson, M.D., and Glen O. Gabbard, M.D.
2000 • 224 pages • ISBN 0-88048-273-7 • paperback
$28.50 • Order #273

Pain
What Psychiatrists Need to Know
Edited by Mary Jane Massie, M.D.
2000 • 244 pages • ISBN 0-88048-173-0 • paperback
$28.50 • Order #173

Complementary and Alternative Medicine and Psychiatry
Edited by Philip R. Muskin, M.D.
2000 • 320 pages • ISBN 0-88048-174-9 • paperback
$28.50 • Order #174

Ethnicity and Psychopharmacology
Edited by Pedro Ruiz, M.D.
2000 • 192 pages • ISBN 0-88048-274-5 • paperback
$28.50 • Order #274

Bookstore Hours:
Saturday, May 13 11:00 a.m. - 5:00 p.m.
Sunday, May 14 11:00 a.m. - 5:00 p.m.
Monday, May 15 10:00 a.m. - 6:00 p.m.
Tuesday, May 16 10:00 a.m. - 6:00 p.m.
Wednesday, May 17 10:00 a.m. - 3:00 p.m.
INDUSTRY-SUPPORTED SYMPOSIUM 1
Saturday, May 13, 7:00 p.m. - 10:00 p.m.
Room E450, Level 4, McCormick Place Lakeside

MIND AND BODY IN THE DEPRESSED PATIENT:
CLINICAL IMPLICATIONS OF THE INTER-RELATIONSHIP BETWEEN
PSYCHIATRIC, CEREBROVASCULAR, AND CARDIOVASCULAR DISEASE

Saturday, May 13, 2000 7:00 p.m. - 10:00 p.m.
Room E450, Level 4, McCormick Place Lakeside
Chicago, Illinois
Reception 6:00 p.m. - 7:00 p.m.
Carl Salzman, MD
Chairman
Prevalent Dysfunction in Geriatric Patients
George S. Alexopoulos, MD
Cornell University Medical College
Neuropsychiatric Consequences of Stroke
Robert G. Robinson, MD
University of Iowa School of Medicine
Cardiovascular Disease and Depression: Cause, Effect, or Conundrum?
Franziska Leipertz, MD
Memorial Heart Institute
Antidepressant Pharmacotherapy in the Elderly and Old-MDD
Carl Salzman, MD
Massachusetts Mental Health Center
Psychopharmacology in the Context of Comorbid Vascular Illness: Applying Knowledge of Drug
Metabolism to Optimize Drug Therapy
David J. Greenblatt, MD
Tufts University School of Medicine
Depression is highly prevalent among patients with vascular disease or vascular risk factors, such as coronary artery disease, history of myocardial infarction, stroke, or transient ischemic attacks. This symposium will review the findings that suggest an endocrine relationship between depression and vascular disease, and discuss the clinical implications for the treatment of depression in patients at risk for or with existing cerebrovascular or cardiovascular illness.

This program is sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and as the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

This program is supported by an unrestricted educational grant from Pfizer Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 2
Saturday, May 13, 7:00 p.m. - 10:00 p.m.
Room E451, Level 4, McCormick Place Lakeside

6:30 - 7:00 PM DINNER • 7:00 - 10:00 PM SYMPOSIUM

Chair: H. George Nurnberg, MD • University of New Mexico
Anita H. Clayton, MD • University of Virginia
Epidemiology, Classification, and Assessment of Sexual Dysfunction
Andrew A. Nierenberg, MD • Massachusetts General Hospital
Prevalence and Assessment of Antidepressant-Induced Sexual Dysfunction
H. George Nurnberg, MD • University of New Mexico
Management of Antidepressant-Induced Sexual Dysfunction
Julia K. Wainman, MD • University of Oklahoma
Hormonal Aspects of Sexual Dysfunction in Women: Improvises?
With Hormone Replacement Therapy
Matthew A. Metzger, MD • Robert Wood Johnson Medical School
Sexual Dysfunction in Men: Diagnosis and Treatment in Patients With Depression and Other Psychiatric Disorders
Alan J. Gelenberg, MD • University of Arizona
Discussion/Questions and Answers

Sponsored by the American Psychiatric Association
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and as the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

Supported by an unrestricted educational grant from Pfizer Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 3
Saturday, May 13, 7:00 p.m. - 10:00 p.m.
Grand Ballroom A, Level 1, McCormick Place South

Reproductive Psychiatry: An Update on Women's Health

Sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

SYMPOSIUM CHAIRPERSON
Shaila Misri, MD, FRCP C
Clinical Professor of Psychiatry and Obstetrics-Gynecology
University of British Columbia

PREMENSTRUAL DYSPHORIC DISORDER: NEW RESEARCH
Meir Steinier, MD, PhD, FRCP C
Professor of Psychiatry and Behavioral Neurosciences
McMaster University

MOOD DISORDERS IN PREGNANCY AND LACTATION: TREATMENT ISSUES
Zachary N. Show, MD
Associate Professor of Psychiatry and Obstetrics and Gynecology
Emory University School of Medicine

THE USE OF SSRI S IN PREGNANT AND LACTATING WOMEN
Shaila Misri, MD, FRCP C

MOOD, HORMONES, AND MENOPAUSE
Catherine Roca, MD
National Institute of Mental Health

COMMENTS FROM DISCUSSANT
Carol Nadelen, MD
Clinical Professor of Psychiatry
Harvard Medical School

PANEL DISCUSSION
Moderated by Shaila Misri, MD, FRCP C and Meir Steinier, MD, PhD, FRCP C
Symposium Co-Chairs

* A DESSERT RECEPTION WILL FOLLOW THE PROGRAM.

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM BEECHAM PHARMACEUTICALS.

INDUSTRY-SUPPORTED SYMPOSIUM 4
Saturday, May 13, 7:00 p.m. - 10:00 p.m.
Grand Ballroom B, Level 1, McCormick Place South

The Many Faces of Psychosis

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

The genetic epidemiology of psychosis
Thomas S. Kendler, MD

Psychosis associated with major depression
Craig T. Tischler, MD

Psychosis associated with bipolar and schizophrenia disorders
S. Vemuri, MD

Psychosis associated with schizoaffective disorders
Sarah T. Tischler, MS

Psychosis associated with dementia
George T. Kelly, MD
INDUSTRY-SUPPORTED SYMPOSIUM 5
Saturday, May 13, 7:00 p.m. - 10:00 p.m.
Regency Ballroom, Second Floor, Hyatt Regency

**INDUSTRY-SUPPORTED SYMPOSIUM 6**
Saturday, May 13, 7:00 p.m. - 10:00 p.m.
Grand Ballroom, Second Floor, Chicago Hilton
**INDUSTRY-SUPPORTED SYMPOSIUM 7**
Saturday, May 13, 7:00 p.m. - 10:00 p.m.
International Ballroom North, Second Floor, Chicago Hilton

**An educational program presented during the Year 2000 American Psychiatric Association Annual Meeting**

**Schizophrenia:**
From Social Isolation to Social Reintegration

- Impact of Early Identification & Treatment on First Episode Schizophrenia
  Jeffrey Lieberman, M.D., Chairperson
  University of North Carolina School of Medicine
  Chapel Hill, North Carolina

- Cognitive Defects & Everyday Functioning
  Richard E. Davis, M.D.
  Duke University Medical Center
  Durham, North Carolina

- Atypical Antipsychotic Agents: Expanding the Goals of Therapy to Improve Outcomes
  Richard G. Petty, M.D., Cochairperson
  University of Pennsylvania
  Philadelphia, Pennsylvania

- Improving Outcomes: Reintegration in Disadvantaged Populations
  Ralph Aquila, M.D.
  St. Luke's Roosevelt Hospital
  New York, New York

- Quality of Life & Economic Outcomes of Treatment
  Martin J. Knapp, Ph.D.
  Institute of Psychiatry
  London, England

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in category I credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**Educational Objectives**

- In the conclusion of this symposium, the participant should be able to:
  - Identify the importance of early identification and treatment in the successful treatment of schizophrenia.
  - Implement a comprehensive strategy for the treatment of schizophrenia that strives to engage patient and family in social reintegration.
  - Understand the relationship of psychiatric, mood, and cognitive and how treatment by medications as well as behavioral and psychosocial approaches improves patient response in these cases.

**INDUSTRY-SUPPORTED SYMPOSIUM 8**
Sunday, May 14, 9:00 a.m. - 12 noon
Room E450, Level 4, McCormick Place Lakeside

**An educational program presented during the Year 2000 American Psychiatric Association Annual Meeting**

**Advances in Women's Mental Health:**
A Decade of Progress

- Effects of Gonadal Steroids on Brain & Behavior
  David R. Rubenow, M.D.
  National Institute of Mental Health
  Bethesda, Maryland

- SSRIs in the Treatment of PMDD: A Critical Review
  Adele C. Viguera, M.D., Chairperson
  Massachusetts General Hospital
  Boston, Massachusetts

- Course & Treatment of Mood Disorders During Pregnancy & the Postpartum Period
  Lee S. Cohen, M.D., Cochairperson
  Massachusetts General Hospital
  Boston, Massachusetts

- Psychopharmacology During Pregnancy & Lactation: Determining Infant Exposure
  Zachary N. Brown, M.D.
  Emory University
  Atlanta, Georgia

- Mood Disorders in Perimenopause: The Estrogen Connection
  Haldine Jaffe, M.D.
  Massachusetts General Hospital
  Boston, Massachusetts

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in category I credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**Educational Objectives**

- At the conclusion of this symposium, the participant will have learned about:
  - The differential effect of gonadal steroids on CNS neurotransmission.
  - The critical clinical issues regarding course and treatment of illness during pregnancy, the peripartum, and perimenopause.
From Neurobiology to Novel Treatments: Applications in Alzheimer’s Disease

PROGRAM
Multidisciplinary Management of the Patient with Alzheimer’s Disease: A Case History
MURRAY A. HASKIN, MD
Ecology of Alzheimer’s Disease: Evolving Theories
PAUL R. SOLOMAN, MD
Emerging Therapeutic Options in Alzheimer’s Disease
GARY N. SMAIL, MD
The Role of the Psychologist in Optimizing Outcomes in Alzheimer’s Disease
Facilitating Cooperation Across Specialties
SILVIA PERKINS, MD

EDUCATIONAL OBJECTIVES
Recommended methods of screening and diagnosis of Alzheimer’s disease to primary care colleagues
Understand the latest theories being explored
Understand the role of information, disease-modifying agents, and NMDA receptor modulation
Apply recent advances in emerging therapeutic options to improve patient outcomes by allowing pharmacological and environmental interventions to manage the behavioral aspects

INDUSTRY-SUPPORTED SYMPOSIUM 9
Sunday, May 14, 9:00 a.m. - 12 noon
Grand Ballroom A, Level 1, McCormick Place South

Images of Anxiety

SUNDAY, MAY 14, 2000
9:00 AM TO 12:00 PM
McCormick Place South
Grand Ballroom A, Level 1

SYMPOSIUM CHAIRPERSON
Jack M. Gorman, MD
Professor of Psychiatry
Columbia University

ADVANCES IN NEUROIMAGING
Jack M. Gorman, MD

IMAGES OF FEAR IN PANIC
Justine M. Kent, MD
Research Fellow
Columbia University

POSTTRAUMATIC STRESS DISORDER: A MIND’S-EYE VIEW
Murray B. Stein, MD, FRCPC
Professor of Psychiatry
University of California San Diego

IMAGES OF SOCIAL ANXIETY DISORDER: A 5-YEAR VIDEO CASE STUDY
Daniel D. Christensen, MD
Clinical Professor of Psychiatry and Neurology
University of Utah

SOCIAL ANXIETY DISORDER: THE SHY BRAIN
Franklin R. Schneier, MD
Associate Professor of Clinical Psychiatry
Columbia University

* A BREAKFAST BUFFET WILL BE SERVED BEFORE THE PROGRAM.

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM SMITHKLINE BEECHAM PHARMACEUTICALS.
INDUSTRY-SUPPORTED SYMPOSIUM 11
Sunday, May 14, 9:00 a.m. - 12 noon
Grand Ballroom B, Level 1, McCormick Place South

Treatment Practice and Promise for SCHIZOPHRENIA in the New Millennium

8:00 AM - 9:00 AM, Breakfast
9:00 AM - 12:00 PM, Symposium

Towards the primary prevention of schizophrenia
Ming T. Tsuang, MD, PhD

Childhood-onset schizophrenia
Christopher J. McDougall, MD

Therapeutic implications of the glutamate model of schizophrenia
Donald C. Goff, MD

Optimal use of atypical antipsychotics
Samuel J. Keith, MD

Long-term outcome: staying the course
Nina R. Schoeler, PhD

Sponsored by the American Psychiatric Association
JANSSEN

INDUSTRY-SUPPORTED SYMPOSIUM 12
Sunday, May 14, 9:00 a.m. - 12 noon
Regency Ballroom, Second Floor, Hyatt Regency

Advances in the Treatment of Insomnia

Prevalence, Phenomenology and Consequences of Insomnia
DANIEL J. Buysee, MD
Associate Professor of Psychiatry
Western Psychiatric Institute & Clinic

Circadian Rhythm Disorders and Insomnia: Treatment with Melatonin, Phototherapy and Chronotherapy
GARY RICHARDSON, MD
Senior Research Scientist
Department of Sleep Medicine
Henry Ford Hospital

Behavioral Intervention for Chronic Insomnia
JACK EDINGER, PHD
Acting Chief, Psychology Service
VA Medical Center, Durham, NC

Pharmacotherapy for Insomnia
VAUHN McCALL, MD
Associate Professor of Psychiatry and Behavioral Medicine
Wake Forest University School of Medicine

BREAKFAST SYMPOSIUM
May 14, 2000

Hyatt Regency
Second Floor, Regency Ballroom
9:00 am - 12:00 pm
BREAKFAST: 8:00 am - 9:00 am
Chair: Vaughn McCall, MD

Sponsored by an unrestricted educational grant from Wyeth-Ayerst Pharmaceuticals

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity. The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
INDUSTRY-SUPPORTED SYMPOSIUM 13
Sunday, May 14, 9:00 a.m. - 12 noon
Grand Ballroom, Second Floor, Chicago Hilton

NOVEL TREATMENTS for DEPRESSION

Sunday, May 14, 2000
8:00 AM - 9:00 AM Breakfast
9:00 AM - 12:00 PM Symposium

Hilton Chicago & Towers
720 South Michigan Avenue
Chicago, Illinois

Grand Ballroom, Lobby Level, 2nd Floor

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the APA Physicians Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by Merck & Co., Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 14
Sunday, May 14, 9:00 a.m. - 12 noon
International Ballroom North, Second Floor, Chicago Hilton

Individualizing Management of Depressive Disorders

APA Annual Meeting
Sunday, May 14, 2000, 9:00 AM - 12:00 PM
Chicago Hilton, Second Floor, International Ballroom North
Chicago, IL
Breakfast will be served at 8:30 AM

Norman Sussman, MD
Program Chair

Sexual Dysfunction Associated With Treatment of Major Depression
Anita L.H. Clayton, MD
Elizabeth L. McGarvey, EdD
Gail Clavert, PhD

Weight Gain Associated With Long-Term Antidepressant Therapy
Norman Sussman, MD

Management of Antidepressant Nonresponders
Jerold F. Rosenbaum, MD

Linking Antidepressant Therapy to Medical Outcomes
P. Murali Doraiswamy, MD

Overall Educational Objectives: To provide a review of differences between short-term and long-term side effects of antidepressant drugs, and to offer information that will improve drug selection practices and enhance long-term compliance.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
Controversies at the Interface of Sleep and Psychiatry

EDUCATIONAL OBJECTIVE: Through debate and peer exchange, attendees will better understand the relationship of sleep disturbances to psychiatric disorders and the potential impact of sleep requirements on management strategies.

CHAIR: Thomas A. Melman, MD
PANELISTS: Rosalind Cartwright, PhD
Wallace B. Mendelson, MD
Thomas Roth, PhD

APA Annual Meeting
Sunday, May 14, 2000
1:30 to 4:30 PM
McCormick Place South
Grand Ballroom A, Level 4

PHARMACOTHERAPY OF DEPRESSION: NEW STRATEGIES
2000 APA Annual Meeting

Mechanism of Action and Clinical Response
Alan Frazer, PhD
The University of Texas Health, Sciences Center

Anxiety and Depression
Jack M. Gorman, MD
Columbia University

Sexual Dysfunction and Depression
Robert M. Hirschfeld, MD
University of Texas Medical Branch

Sleep and Depression
Michael E. Thase, MD
Western Psychiatric Institute and Clinic

Compliance and Tolerability
Steven P. Roose, MD
Columbia University

Chairperson: Michael E. Thase, MD

Sunday, May 14, 2000
1:30 pm - 4:30 pm
McCormick Place South, Grand Ballroom B
Chicago, Illinois

Reception precedes the symposium at 12:45 pm

This symposium is sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the APA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours that he/she actually spent in the educational activity.

This program is supported by an unrestricted educational grant from Pharmacia & Upjohn and Janssen Pharmaceutica, Inc.
**INDUSTRY-SUPPORTED SYMPOSIUM 19**
Sunday, May 14, 1:30 p.m. - 4:30 p.m.
Regency Ballroom, Second Floor, Hyatt Regency

*Bipolar Children and Adolescents*

Controversies in Diagnosis and Treatment
Sponsored by the American Psychiatric Association and held at the APA 2000 Annual Meeting

**Bipolar Spectrum Disorders: Genetic Hypotheses**
David M. Stueck, MD - Chairman, George Washington University Medical Center

**Controversies in Making the Diagnosis**
Peter S. Jenssen, MD, New York State Psychiatric Institute

**Controversies in the Treatment of Difficult Bipolar Adolescents**
Karen D. Wagner, MD, PhD, University of Texas Medical Branch

**Evaluation and Management of Violent Behavior in Bipolar Adolescents**
Harry Steinman, MD, Stanford University School of Medicine

**Neuroimaging and Neuropsychological Testing**
Robert L. Hendren, MD, Robert Wood Johnson Medical School

**PROGRAM OBJECTIVE**
This program will explore the genetic etiology and deficits in neurocognitive functioning. Strategies for diagnosis and innovative treatment will be reviewed.

**CREDIT DESIGNATION**
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This activity is supported by an unrestricted educational grant from Abbott Laboratories.

---

**INDUSTRY-SUPPORTED SYMPOSIUM 20**
Sunday, May 14, 1:30 p.m. - 4:30 p.m.
Grand Ballroom, Second Floor, Chicago Hilton

*complexities in the treatment of bipolar disorder*

**date, time & location**
May 14, 2000
The Chicago Hilton grand ballroom
Lunch 12:30 PM to 1:30 PM
Symposia 1:30 PM to 4:30 PM

**objectives**
Recognize risk factors for poor response to treatment in bipolar illness.
Develop a treatment plan for the complexities of bipolar disorder.

**faculties**
William Lawson, MD, PhD, EAPA
Professor of psychiatry - Indiana University School of Medicine - chief of psychiatry
John Nurnberger, Jr, MD, PhD
Joyce & Iver Small Professor of Psychiatry - Neurobiology & Medical Genetics - Director, Institute of Psychiatric Research - Associate Chairman for Research - Department of Psychiatry
Hagop S. Akiskal, MD
Professor of psychiatry - Director, International Mood Center - University of California at San Diego
Katherine Wisner, MD, MS
Professor of psychiatry & Reproductive Medicine - Director, Women's Mental Health CARE - Case Western Reserve University School of Medicine

**accreditation**
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.
The APA designates this educational activity for up to 3 hours in category 1 credit towards the APA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This program is supported by an unrestricted educational grant from Glaxo Wellcome
INDUSTRY-SUPPORTED SYMPOSIUM 21
Sunday, May 14, 1:30 p.m. - 4:30 p.m.
International Ballroom North, Second Floor, Chicago Hilton

Schizophrenia and Bipolar Disorders: Evolving Therapeutic Concepts

SUNDAY, MAY 14, 2000
Chicago Hilton and Towers
720 South Michigan Avenue
Second Floor, International Ballroom North
Chicago, Illinois

LUNCH: 12:45-1:30 p.m.
SCIENTIFIC PROGRAM: 1:30-4:30 p.m.

CHAIR: James W. Jefferson, MD
CO-CHAIR: John M. Kane, MD

FACULTY: Barbara Cornblatt, PhD
John M. Kane, MD
Lori L. Altshuler, MD
Alan J. Gelenberg, MD
James W. Jefferson, MD

Educational Objectives: After completing this activity, participants should be able to assess and safely and effectively treat bipolar disorders and schizophrenia in their earliest phases and over many years of maintenance therapy.

Accreditation: The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association
Presented in association with the American Society of Clinical Psychopharmacology
Supported by an unrestricted educational grant from Bristol-Myers Squibb

INDUSTRY-SUPPORTED SYMPOSIUM 22
Sunday, May 14, 7:00 p.m. - 10:00 p.m.
Room E450, Level 4, McCormick Place Lakeside

Neurobiology of Disease: From the Lab to the Clinic

SUNDAY, MAY 14, 2000
7:00 PM TO 10:00 PM
McCormick Place Lakeside Room E450, Level 4

Sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

SYMPOSIUM CHAIRPERSON
Charles B. Nemeroff, MD, PhD
Renéette W. Harris Professor and Chairman
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine

RECENT ADVANCES IN THE NEUROBIOLOGY OF MOOD AND ANXIETY DISORDERS
Dennis S. Charney, MD
Deputy Chairman
Academic and Scientific Affairs
Yale School of Medicine

NOVEL ACTIONS OF ANTIDEPRESSANTS
Charles B. Nemeroff, MD, PhD

USE OF FUNCTIONAL BRAIN IMAGING IN UNDERSTANDING MAJOR PSYCHIATRIC DISORDERS: PROFILES AND PROMISES
Clinton D. Kilts, PhD
Associate Professor
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine

PSYCHIATRIC SEQUELAE OF INTERFERON THERAPY AND ITS MANAGEMENT WITH ANTIDEPRESSANTS
Dominique L. Poreen, MD
Assistant Professor
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine

NEUROBIOLOGY OF THE GUT AND BRAIN: IMPLICATIONS FOR MANAGEMENT OF IRITBULIRABLE BOWEL SYNDROME
R. Bruce Lydiard, MD, PhD
Professor of Psychiatry and Behavioral Sciences
Medical University of South Carolina

* A DESSERT RECEPTION WILL FOLLOW THE PROGRAM.

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM SWEETLINE BEECHAM PHARMACEUTICALS.
INDUSTRY-SUPPORTED SYMPOSIUM 23
Sunday, May 14, 7:00 p.m. - 10:00 p.m.
Room E451, Level 4, McCormick Place Lakeside

Pharmacotherapy of Dementia
Expanding the Boundaries

INDUSTRY-SUPPORTED SYMPOSIUM 24
Sunday, May 14, 7:00 p.m. - 10:00 p.m.
Grand Ballroom A, Level 1, McCormick Place South

New Antipsychotics From Practice to Theory

OVERALL OBJECTIVES:
Demonstrate an understanding of the extent and limitations of controlled data on the new antipsychotics and how to prescribe cutting-edge treatment with them.

6:20 PM "A TASTE OF CHICAGO" DINNER
Welcome/Introductions
Stephen R. Marxer, MD and Ira D. Glick, MD Co-Chairmen

7:00 PM Subjective Response to Atypical Antipsychotic Medications
Donna A. Wellin, MD VA Greater Los Angeles

7:30 PM The Efficacy Spectrum for Atypicals in Clinical Practice
Ira D. Glick, MD Standard University School of Medicine

8:00 PM The Management of Treatment-Resistant Schizophrenia: Experiences from the Front Line
Peter F. Buckley, MD Case Western Reserve

8:30 PM Adverse Experiences with New Antipsychotics
Stephen R. Marxer, MD West Los Angeles VA Medical Center

9:00 PM Combining New Antipsychotics with Other Treatments
Hung K. Kwon, MD University of Vienna
INDUSTRY-SUPPORTED SYMPOSIUM 25
Sunday, May 14, 7:00 p.m. - 10:00 p.m.
Grand Ballroom B, Level 1, McCormick Place South

RECURRENT DEPRESSION: CHALLENGES AND SOLUTIONS

Objective: At the conclusion of the symposium, participants should be able to manage chronic recurrent depression using a combination of pharmacologic and psychotherapeutic algorithms.

Sponsored by the American Psychiatric Association (APA) and supported by an unrestricted educational grant from Forest Laboratories, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 26
Sunday, May 14, 7:00 p.m. - 10:00 p.m.
Regency Ballroom, Second Floor, Hyatt Regency
NOVEL PRECIPITANTS OF ANXIETY
SUNDAY, MAY 14, 2000
Chicago Hilton, Grand Ballroom, Second Floor, Chicago, Illinois
CHAIR: Eric Hollander, MD

6:00 PM – 7:00 PM Reception
7:00 PM – 7:10 PM Welcome and Opening Remarks ... Eric Hollander, MD
7:10 PM – 7:40 PM Precipitants of Anxiety in Response to Non-Combat Trauma ... Phoebe H. Tucker, MD
7:40 PM – 8:10 PM Precipitants of Anxiety in Children and Adolescents ... Daniel S. Pine, MD
8:10 PM – 8:40 PM Anxiety Disorders Across Cultures ... Daniel J. Stein, MD
8:40 PM – 9:10 PM Repetitive Behaviors and the Regulation of Anxiety ... Eric Hollander, MD
9:10 PM – 9:40 PM Precipitants of Anxiety in Social Situations ... Murray B. Stein, MD
9:40 PM – 10:00 PM Closing Comments ... Eric Hollander, MD
10:00 PM Meeting Conclusion

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

SPONSORED BY THE AMERICAN PSYCHIATRIC ASSOCIATION
Supported by an unrestricted educational grant provided by Solvay Pharmaceuticals, Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 30
Monday, May 15, and Tuesday, May 16, 7:00 a.m. - 8:30 a.m.
Grand Ballroom A, Level 1, McCormick Place South

"Antiepileptic Drugs in Psychiatric Disorders"
F. Moises Gaviria, MD, Chairperson  Andres M. Kanner, MD, Co-Chairperson

The American Psychiatric Association Breakfast Symposia

**Scientific Session (Part 1)**
Monday May 15, 2000

Antiepileptic Drugs in Psychiatric Disorders: An Overview
Andres M. Kanner, MD

Antiepileptic Drugs in Mood Disorders
Ovidio DeLeon, MD

Antiepileptic Drugs in Anxiety Disorders
Thomas H. Jobe, MD

**Scientific Session (Part 2)**
Tuesday May 16, 2000

Use of Antiepileptics in Drug Abuse Detoxification
Sylvia J. Dennison, MD

Negative Psychotropic Effects of Antiepileptic Drugs
F. Moises Gaviria, MD

Continental Breakfast 6:00am - 7:00am

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of the CME activity.

The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This scientific session is sponsored by the American Psychiatric Association and is supported by an unrestricted educational grant from Parke-Davis.
Evidence-Based Management of Refractory Depression

APA Annual Meeting
Hyatt Regency, Second Floor, Regency Ballroom, Chicago, IL
Breakfast will be served at 6:30 AM

Andrew A. Nierenberg, MD
Program Chair
Madhukar H. Trivedi, MD
Program Co-Chair

Monday, May 15, 2000 (Part 1) 7:00 AM - 8:30 AM
Timing and Nature of Interventions for Nonresponders
Madhukar H. Trivedi, MD

Optimizing Antidepressant Dose Will Optimize Response
James S. Ferguson, MD

The Antidepressant Pop-Out Phenomenon: A Review of the Evidence With Recommendations for Diagnosis and Treatment
Isabel T. Lagomasino, MD

At the conclusion of this symposium, the participant should be able to know the extent and limits of evidence for the treatment of resistant depression.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 32
Monday, May 15 and Tuesday, May 16, 7:00 a.m. - 8:30 a.m.
Grand Ballroom, Second Floor, Chicago Hilton.

Lengthening the Fuse
Treatment of Aggression
Sponsored by the American Psychiatric Association and held at the APA 2000 Annual Meeting

Monday, May 15, 2000
Mechanisms of Aggression
Larry Young, PhD, Emory University School of Medicine

Biologies and Treatments of Intermittent Explosive Disorder
Emil F. Coccaro, MD, The Pritzker School of Medicine at The University of Chicago

Psychopharmacology and Pharmacotherapy of Sexually Aggressive Offenders
Susan L. McElroy, MD - Symposium Chairman
University of Cincinnati College of Medicine

Tuesday, May 16, 2000
Impulsivity in Aggression: Borderline Personality Disorder and Autism
Eric Holland, MD, Minnig School of Medicine

Agitation and Aggression in the Elderly
Pierre N. Tarlow, MD, University of Rochester Medical Center

PROGRAM OBJECTIVE
This program will explore underlying mechanisms of aggression and state-of-the-art intervention and treatment strategies.

CREDIT DESIGNATION
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates each day of this educational activity for up to 5.5 hours per session in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This activity is supported by an unrestricted educational grant from Abbott Laboratories.
INDUSTRY-SUPPORTED SYMPOSIUM 35
Tuesday, May 16, 7:00 p.m. - 10:00 p.m.
Grand Ballroom A, Level 1, McCormick Place South

Neurotransmitters & Depression: New Possibilities

6:15 - 7:00 PM Dinner
7:00 - 10:00 PM Scientific Program
McCormick Place South
Grand Ballroom A, Level 1

Richard J. Metzner, MD
Symposium Chair

Neuroregulators in Depression
Jack D. Burchas, MD
Cornell Medical Center

Molecular Adaptations to Drugs Used for Depression
Chris J. Evans, PhD
University of California, Los Angeles

Deficient Neurotransmitters in Humans
Pedro I. Delgado, MD
University of Arizona

The Targeted Treatment of Depression
Richard J. Metzner, MD
University of California, Los Angeles

Sponsored by the American Psychiatric Association

Tuesday May 16
6:15 PM

Educational Objectives
The role of neurotransmitters to the etiology and treatment of depression is complex and yet generally understood. What is clear from recent studies is that clinicians who pay attention to differences between antidepressants and neuroleptics, concomitant antidepressant and other neuroregulator effects may achieve better results. Non-orthodox and combined treatments utilizing new strategies based on clinical symptoms and known neurotransmitter mechanisms will be discussed.

INDUSTRY-SUPPORTED SYMPOSIUM 36
Tuesday, May 16, 7:00 p.m. - 10:00 p.m.
Grand Ballroom B, Level 1, McCormick Place South

Psychiatry in Uncharted Territory: Assessing and Treating Psychiatric Conditions in Medical Patients

Tuesday, May 16, 2000
7:00 p.m. - 10:00 p.m.
Grand Ballroom B, Level 1
McCormick Place South
Chicago, Illinois

Reception 6:00 p.m. - 7:00 p.m.
Ellen Frank, PhD
Chairman
Wayne J. Katon, MD
Co-Chairman

Broken Hearts: Ischemic Heart Disease, Depression and Gender
Deone E. Stewart, MD
Tsunio General Hospital

Effective Treatment of Minor Depression in Primary Care
Ellen Frank, PhD
University of Pittsburgh School of Medicine

Effectiveness of an SSRI and Problem-Solving Therapy for Primary Care Patients with Depression
Wayne J. Katon, MD
University of Washington

Improving Care for Panic in Primary Care
Peter P. Roy-Byrne, MD
University of Washington

Primary Care Training Improves Depression Outcomes
Kathryn M. Rust, PhD
University of Arkansas

Psychiatric assessment and treatment no longer are confined to the consulting room and the psychiatric inpatient unit, partly as the result of the availability of easy-to-prescribe and well tolerated new pharmacotherapies, and of brief, efficacious psychotherapies. This symposium will address the challenges involved in diagnosing and treating psychiatric conditions in non-psychiatric settings, as well as the role of psychiatrists in non-psychiatric settings and the future landscape of psychiatric intervention.

This program is sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

This program is supported by an unrestricted educational grant from Forest Laboratories.
Defining Bipolar Disorder

Sponsored by the American Psychiatric Association and held at the APA 2000 Annual Meeting

A New Screening Tool for Bipolar Disorder: The Mood Disorder Questionnaire
Robert M.A. Hirschfeld, M.D. - Chairman, University of Texas Medical Branch
Cost-Effective Pathways for Bipolar Disorder
Gary S. Sachs, MD, Harvard University School of Medicine
Rapid Stabilization of Mood and Psychiatric Symptoms in Mania
Paul E. Keck, Jr., MD, University of Cincinnati College of Medicine
Pharmacologic Treatment for Women with Bipolar Disorder
Lauren Morenberg, MD, PhD, Baylor College of Medicine
Recognition and Management of Bipolar Disorder in Children and Adolescents
Neal Ryan, MD, Western Psychiatric Institute and Clinic

PROGRAM OBJECTIVE
This program will introduce a new screening tool for bipolar disorder and will emphasize accurate diagnosis, cost-effective pathways and treatment.

CREDIT DESIGNATION
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credits towards the AMA Physician Recognition Award. This activity is exempt from the CME requirement of the CN. Each physician should only claim those hours of credit which reflect actual participation in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 38
Tuesday, May 16, 7:00 p.m. - 10:00 p.m.
Grand Ballroom, Second Floor, Chicago Hilton
INDUSTRY-SUPPORTED SYMPOSIUM 39
Tuesday, May 16, 7:00 p.m. - 10:00 p.m.
International Ballroom North, Second Floor, Chicago Hilton

INDUSTRY-SUPPORTED SYMPOSIUM 40
Wednesday, May 17, and Thursday, May 18, 7:00 a.m. - 8:30 a.m.
Room E450, Level 4, McCormick Place Lakeside
INDUSTRY-SUPPORTED SYMPOSIUM 43
Wednesday, May 17, and Thursday, May 18, 7:00 a.m. - 8:30 a.m.
Regency Ballroom, Second Floor, Hyatt Regency

An educational program presented during the Year 2000 American Psychiatric Association Annual Meeting
The Interface of Neuropsychiatric Disorders in the Elderly

Diagnosis & Treatment of Psychosis & Other Behavioral Disturbances in Dementia I:
A Focus on Conventional Neuroleptics
Brian L. Swartz, MD
St. Mary's Hospital
Dublin, Ireland

Diagnosis & Treatment of Psychosis & Other Behavioral Disturbances in Dementia II:
A Focus on Atypical Neuroleptics
Stuart E. Weiner, MD, Chairman
Medical University of South Carolina
Charleston, South Carolina

Diagnosis & Treatment of Psychosis in Dementia with Lewy Bodies
Iain McKeith, MD, Consultant
Newcastle General Hospital
Newcastle upon Tyne, England

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates each day of this educational activity for up to 1.5 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Educational Objectives:
To the conclusion of this symposium, the participant should be able to:
1. Apply concepts learned in the treatment of schizophrenia to the management of psychosis and other behavioral disturbances in Alzheimer's disease and Lewy body dementia.
3. Apply concepts learned in Alzheimer's disease to the management of cognition in older adults with schizophrenia.

BREAKING THE CYCLE:
Novel Treatments in Bipolar Disorder

Wednesday, May 17
Melting Pot: Breakfast

7:00 AM - 8:30 AM
Breakfast

6:00 AM - 7:00 AM
Breakfast

7:00 AM - 8:30 AM
Symposium

Thursday, May 18
Update on the use of mood stabilizers in bipolar disorder
Andrew K. George, MD
The use of atypical antipsychotics in bipolar disorder
J. Steven Shulman, MD

Supported by an unrestricted educational grant from JANSSEN

The American Psychiatric Association, the national association representing the specialty of psychiatry, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Psychiatric Association designates this educational activity for up to 1.5 hours in category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association
INDUSTRY-SUPPORTED SYMPOSIUM 45
Wednesday, May 17, 7:00 p.m. - 10:00 p.m.
Room E450, Level 4, McCormick Place Lakeside

Why Do Anxious People Become Depressed?
The Role Of Stress Supersensitivity

Explore a new understanding of the potential misalignments of stress and depressive disorders leading to enhanced clinical skills in managing patients with complex comorbidities. Breakfast 6:30 a.m.
Wednesday, May 17, 7:00-8:30 a.m.
McCormick Place Lakeside, Level 4, Room E450

Chair: Philip T. Nieren, MD

The Genetic Epidemiology of Major Depression and the Anxiety Disorders
Scott Woods, MD

The HPA Axis and the Pathophysiology of Depression
Dominique L. Mustian, MD

Antidepressants: What Are They Achieving? Are They Effective?
Alan Finkle, MD

Seven Habits Of Highly Effective Psychopharmacologists
Identify the practice patterns for the most effective use of psychopharmacologic agents. Apply molecular and pharmacologic principles to the selection and combination of psychotropic drugs. Dinner 6:30 a.m.
Wednesday, May 17, 7:00-10:00 p.m.
McCormick Place Lakeside, Level 4, Room E450

Chair: Stephen M. Stahl, MD

Tips on How to Begin With the End in Mind, Synthesize and Sharpen the Saw
Stephen M. Stahl, MD

Clinical Pearls on How to Become Proactive, Understand and Then Be Engaged
David V. Shader, MD

Practical Psychopharmacologists: Put First Things First and Think Win-Win
John M. Zapolsky, MD

Sponsored by the American Psychiatric Association.
Supported by an unrestricted educational grant from Wyeth-Ayerst Laboratories.

INDUSTRY-SUPPORTED SYMPOSIUM 46
Wednesday, May 17, 7:00 p.m. - 10:00 p.m.
Grand Ballroom A, Level 1, McCormick Place South

Behavioral Disturbances in Dementia
Causes, Treatments, and Impact

Agenda
6:30 PM Reception
7:00 Welcome and Introduction
Pierre N. Tariot, MD — Chairman
Professor of Psychiatry
Medicine, and Neurology
University of Washington
Medical Center
Seattle, Washington

7:10 Neuroimaging in Dementia Evaluation and Research
Gary S. Small, MD
Director, UCLA Center on Aging
Professor of Psychiatry and
Behavioral Sciences
University of California at Los Angeles
Los Angeles, California

7:35 Drugs, Tips, and Atypicals
Pierre N. Tariot, MD

8:00 Psychosocial Impact of Alzheimer’s Disease on the Family
Elisabeth Smith-Boyer, MS
Administrator
MilView Adult Home
Waterford, New York

Sponsored by the American Psychiatric Association (APA) as a part of the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA bears responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates each of these educational activities for up to 3 hours of credit towards the APA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
INDUSTRY-SUPPORTED SYMPOSIUM 47
Wednesday, May 17, 7:00 p.m. - 10:00 p.m.
Grand Ballroom B, Level 1, McCormick Place South

Schizophrenia: Across the Life Cycle

6:00 p.m.-7:00 p.m., Dinner
7:00 p.m.-10:00 p.m., Symposium

Supported by an unrestricted educational grant from JANSSEN

INDUSTRY-SUPPORTED SYMPOSIUM 48
Wednesday, May 17, 7:00 p.m. - 10:00 p.m.
Regency Ballroom, Second Floor, Hyatt Regency

Advances in ADHD:
From Research to Clinical Practice

Wednesday, May 17, 2000/Hyatt Regency McCormick Place
Regency Ballroom, Second Floor; Dinner will be served at 6:00 p.m.
Program begins at 7:00 p.m. - 10:00 p.m.

Educational Objectives:
- Understand the course and presentation of ADHD from childhood to adulthood
- Appreciate relevant gender differences in ADHD
- Understand the familial and genetic nature of ADHD
- Learn pharmacological strategies in the management of ADHD in children, adolescents, and adults

Global Functioning in Boys With Persistent ADHD
Presented by Eric Mick, ScD
Instructor in Psychiatry, Harvard Medical School
Clinical Research Program in Pediatric Psychopharmacology
Massachusetts General Hospital

ADHD in Girls: Results From a Family Genetic Study
Presented by Joseph Biederman, MD

Genetics of ADHD
Presented by Stephen V. Farone, PhD
Associate Professor of Psychiatry, Harvard Medical School
Director of Research, Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital

Pharmacotherapy of Pediatric ADHD
Presented by Timothy E. Winters, MD

Pharmacotherapy of Adult ADHD
Presented by Thomas J. Spencer, MD
Associate Professor of Psychiatry, Harvard Medical School
Assistant Chief, Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA takes responsibility for the content, quality, and scientific integrity of this CME activity.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association.
Supported by an unrestricted educational grant from ALZA Pharmaceuticals.
This event will take place during the APA Annual Meeting.
Take a Look at What the American Psychiatric Association RESOURCE CENTER Has to Offer

- Apply for APA Membership Onsite
- Members can create your own APA-sponsored website ‘live’
- Learn more about the APA and its’ District Branches and Societies
- Receive your personalized CME Certificate of Attendance
- Speak with experts in your area of subspecialty [See the Daily Bulletin for Schedule]
- View the most recent Public Service Announcement on “Suicide”
- Learn about the many APA Fellowship Opportunities
- Sign up for your free Subscription to “Psychiatric Research Report”
- Write to Congress about issues of importance to you
- Join other members online via one of the APA’s Members-Only Listservs
- Submit an application on our NEW Internet-Based Job Bank
- Learn more about the online CME programs the APA offers
- View the computerized APA/Net Outcomes Quality Project
- Enter to win the recently revised “Psychiatric Self-Assessment” Kit [PSA-R]

And Obtain...

- The 2000 Annual Meeting Abstracts on Disk and the New Research Abstracts Book
- Information on the latest activities related to Underrepresented Populations
- AIDS Program Office Policy Guidelines, Training Programs, Educational and Clinical Resources
- 2000 Video Library Catalog

Plus Other Valuable Information....

**ENTER TO WIN FANTASTIC PRIZES!**

Pick Up Your 2000 Annual Meeting Lapel Pin!

**APA Resource Center**

**Convention Center Exhibit Hall**

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>May 13</td>
<td>10 am - 5 pm</td>
</tr>
<tr>
<td>Sunday</td>
<td>May 14</td>
<td>8 am - 5 pm</td>
</tr>
<tr>
<td>Monday</td>
<td>May 15</td>
<td>10 am - 6 pm</td>
</tr>
<tr>
<td>Tuesday</td>
<td>May 16</td>
<td>10 am - 6 pm</td>
</tr>
<tr>
<td>Wednesday</td>
<td>May 17</td>
<td>10 am - 3 pm</td>
</tr>
</tbody>
</table>

The APA... a professional partner dedicated to helping you build and maintain a satisfying career and successful practice.